Other Sites:
Robert J. Robbins is a biologist, an educator, a science administrator, a publisher, an information technologist, and an IT leader and manager who specializes in advancing biomedical knowledge and supporting education through the application of information technology. More About: RJR | OUR TEAM | OUR SERVICES | THIS WEBSITE
RJR: Recommended Bibliography 18 Nov 2026 at 01:44 Created:
covid-19
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS coronavirus 2, or SARS-CoV-2), a virus closely related to the SARS virus. The disease was discovered and named during the 2019-20 coronavirus outbreak. Those affected may develop a fever, dry cough, fatigue, and shortness of breath. A sore throat, runny nose or sneezing is less common. While the majority of cases result in mild symptoms, some can progress to pneumonia and multi-organ failure. The infection is spread from one person to others via respiratory droplets produced from the airways, often during coughing or sneezing. Time from exposure to onset of symptoms is generally between 2 and 14 days, with an average of 5 days. The standard method of diagnosis is by reverse transcription polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab or sputum sample, with results within a few hours to 2 days. Antibody assays can also be used, using a blood serum sample, with results within a few days. The infection can also be diagnosed from a combination of symptoms, risk factors and a chest CT scan showing features of pneumonia. Correct handwashing technique, maintaining distance from people who are coughing and not touching one's face with unwashed hands are measures recommended to prevent the disease. It is also recommended to cover one's nose and mouth with a tissue or a bent elbow when coughing. Those who suspect they carry the virus are recommended to wear a surgical face mask and seek medical advice by calling a doctor rather than visiting a clinic in person. Masks are also recommended for those who are taking care of someone with a suspected infection but not for the general public. There is no vaccine or specific antiviral treatment, with management involving treatment of symptoms, supportive care and experimental measures. The case fatality rate is estimated at between 1% and 3%. The World Health Organization (WHO) has declared the 2019-20 coronavirus outbreak a Public Health Emergency of International Concern (PHEIC). As of 29 February 2020, China, Hong Kong, Iran, Italy, Japan, Singapore, South Korea and the United States are areas having evidence of community transmission of the disease.
Created with PubMed® Query: ( SARS-CoV-2 OR COVID-19 OR (wuhan AND coronavirus) AND review[SB] ) AND (2023[PDAT] OR 2024[PDAT] OR 2025[PDAT] OR 2026[PDAT]) NOT 40982904[pmid] NOT 40982965[pmid] NOT 35908569[pmid] NOT pmcbook NOT ispreviousversion
Citations The Papers (from PubMed®)
RevDate: 2026-11-17
CmpDate: 2026-11-17
MRAs and Race in Heart Failure: An Individual Participant Data Meta-Analysis of Randomized Trials.
Circulation. Heart failure, 19(11):e014355.
BACKGROUND: There are concerns that renin-angiotensin system inhibitors are less effective in Black patients than non-Black patients with heart failure (HF). We examined the efficacy and safety of mineralocorticoid-receptor antagonists (MRAs), compared with placebo, in patients with HF and reduced ejection fraction or HF with mildly reduced/preserved ejection fraction, according to self-reported race (Black or non-Black).
METHODS: This was a post hoc individual participant data meta-analysis of the 4 large placebo-controlled trials comparing MRAs to placebo in patients with HF and reduced ejection fraction (RALES [Randomized Aldactone Evaluation Study], EMPHASIS-HF [Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure]) and HF with mildly reduced/preserved ejection fraction (TOPCAT [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist], FINEARTS-HF [Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure]). The primary outcome was a composite of cardiovascular death or first HF hospitalization.
RESULTS: Of the 13 846 patients randomized in the 4 trials, 577 (4.2%) identified as Black. Despite being younger (64 versus 70 years), rates of HF hospitalizations and death were higher in Black than non-Black patients. The hazard ratio for MRA versus placebo for the primary composite outcome was 0.87 (95% CI, 0.66-1.15) in Black patients and 0.77 (95% CI, 0.72-0.82) in non-Black patients (Pinteraction=0.34), with 3.9 and 2.7 fewer events per 100 person-years of treatment, respectively. For first HF hospitalization, the hazard ratios were 0.86 (95% CI, 0.63-1.17) and 0.73 (95% CI, 0.68-0.80) for Black and non-Black patients, respectively (Pinteraction=0.36). The corresponding hazard ratios for cardiovascular death were 0.75 (95% CI, 0.48-1.17) and 0.81 (95% CI, 0.74-0.90), respectively (Pinteraction=0.80). Adverse events with MRAs, compared with placebo, were not modified by race. The effects of MRAs in patients with HF and reduced ejection fraction and HF with preserved ejection fraction, individually, were not modified by race.
CONCLUSIONS: There was no statistically significant evidence of heterogeneity in the absolute or relative effects of MRAs on clinical outcomes between Black and non-Black patients with HF, regardless of HF phenotype.
Additional Links: PMID-42565235
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42565235,
year = {2026},
author = {Butt, JH and Jhund, PS and Henderson, AD and Talebi, A and Vardeny, O and Claggett, BL and Vaduganathan, M and Desai, AS and Pfeffer, MA and Lam, CSP and Senni, M and Shah, SJ and Voors, AA and van Veldhuisen, DJ and Verma, S and Lewis, EF and Zannad, F and Pitt, B and Solomon, SD and McMurray, JJV},
title = {MRAs and Race in Heart Failure: An Individual Participant Data Meta-Analysis of Randomized Trials.},
journal = {Circulation. Heart failure},
volume = {19},
number = {11},
pages = {e014355},
doi = {10.1161/CIRCHEARTFAILURE.125.014355},
pmid = {42565235},
issn = {1941-3297},
mesh = {Humans ; *Heart Failure/drug therapy/physiopathology/ethnology/mortality ; *Mineralocorticoid Receptor Antagonists/therapeutic use/adverse effects ; Randomized Controlled Trials as Topic ; Stroke Volume/drug effects ; Female ; Treatment Outcome ; Aged ; Middle Aged ; Hospitalization ; Male ; *Black or African American ; Treatment Effect Heterogeneity ; Risk Factors ; Ventricular Function, Left/drug effects ; },
abstract = {BACKGROUND: There are concerns that renin-angiotensin system inhibitors are less effective in Black patients than non-Black patients with heart failure (HF). We examined the efficacy and safety of mineralocorticoid-receptor antagonists (MRAs), compared with placebo, in patients with HF and reduced ejection fraction or HF with mildly reduced/preserved ejection fraction, according to self-reported race (Black or non-Black).
METHODS: This was a post hoc individual participant data meta-analysis of the 4 large placebo-controlled trials comparing MRAs to placebo in patients with HF and reduced ejection fraction (RALES [Randomized Aldactone Evaluation Study], EMPHASIS-HF [Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure]) and HF with mildly reduced/preserved ejection fraction (TOPCAT [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist], FINEARTS-HF [Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure]). The primary outcome was a composite of cardiovascular death or first HF hospitalization.
RESULTS: Of the 13 846 patients randomized in the 4 trials, 577 (4.2%) identified as Black. Despite being younger (64 versus 70 years), rates of HF hospitalizations and death were higher in Black than non-Black patients. The hazard ratio for MRA versus placebo for the primary composite outcome was 0.87 (95% CI, 0.66-1.15) in Black patients and 0.77 (95% CI, 0.72-0.82) in non-Black patients (Pinteraction=0.34), with 3.9 and 2.7 fewer events per 100 person-years of treatment, respectively. For first HF hospitalization, the hazard ratios were 0.86 (95% CI, 0.63-1.17) and 0.73 (95% CI, 0.68-0.80) for Black and non-Black patients, respectively (Pinteraction=0.36). The corresponding hazard ratios for cardiovascular death were 0.75 (95% CI, 0.48-1.17) and 0.81 (95% CI, 0.74-0.90), respectively (Pinteraction=0.80). Adverse events with MRAs, compared with placebo, were not modified by race. The effects of MRAs in patients with HF and reduced ejection fraction and HF with preserved ejection fraction, individually, were not modified by race.
CONCLUSIONS: There was no statistically significant evidence of heterogeneity in the absolute or relative effects of MRAs on clinical outcomes between Black and non-Black patients with HF, regardless of HF phenotype.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Heart Failure/drug therapy/physiopathology/ethnology/mortality
*Mineralocorticoid Receptor Antagonists/therapeutic use/adverse effects
Randomized Controlled Trials as Topic
Stroke Volume/drug effects
Female
Treatment Outcome
Aged
Middle Aged
Hospitalization
Male
*Black or African American
Treatment Effect Heterogeneity
Risk Factors
Ventricular Function, Left/drug effects
RevDate: 2026-11-16
CmpDate: 2026-11-16
Viral Infections and Dysregulation of Neurotrophin Signaling: Potential impact in the Central Nervous System.
Molecular neurobiology, 63(1):.
Viral infections can perturb neurotrophin signaling in the central nervous system, with important consequences for neuronal survival, synaptic plasticity, neurodevelopment, and long-term cognitive and neuropsychiatric outcomes. Neurotrophins, including nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4, mediate their actions primarily through tropomyosin receptor kinases (TrkA, TrkB and TrkC) and the p75 neurotrophin receptor (p75[NTR]), activating intracellular pathways such as PI3K-AKT, MAPK-ERK, and PLC-γ. Growing evidence suggests that both neurotropic/neuroinvasive and non-classically neurotropic viruses can interfere with these pathways through multiple mechanisms, including those elicited by direct infection of neural and glial cells, interference with endosomal trafficking required for sustained Trk signaling, and inflammation-driven alterations in neurotrophin expression and receptor balance. This review summarizes current knowledge on how selected viruses affect neurotrophin availability and downstream signaling in experimental models and clinical settings. Specifically, the review focuses on: 1) viruses capable of establishing life-long latent or persistent infection such as i) herpesviruses (herpes simplex virus-1; Epstein Barr virus; human cytomegalovirus), and ii) human immunodeficiency virus; 2) other neurotropic viruses driving peculiar neuropathological profiles, such West Nile virus, Japanese encephalitis virus, Zika virus, and Borna disease virus 1; 3) respiratory viruses, such as influenza A virus, human respiratory syncytial virus, and severe acute respiratory syndrome coronavirus 2. For each virus group, we discuss convergent pathogenic mechanisms and receptor-level interference with neurotrophin signaling. We further highlight some gaps in current knowledge, including limited longitudinal human data and the underexplored role of viral co-infections and reactivations, and the unclear causal directionality of neurotrophin dysregulation.
Additional Links: PMID-43037869
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43037869,
year = {2026},
author = {Miteva, MT and Protto, V and Zanzi, F and Cesta, MC and Allegretti, M and De Chiara, G},
title = {Viral Infections and Dysregulation of Neurotrophin Signaling: Potential impact in the Central Nervous System.},
journal = {Molecular neurobiology},
volume = {63},
number = {1},
pages = {},
pmid = {43037869},
issn = {1559-1182},
mesh = {Humans ; Animals ; *Signal Transduction/physiology ; *Nerve Growth Factors/metabolism ; *Virus Diseases/metabolism/pathology ; *Central Nervous System/metabolism/virology/pathology ; },
abstract = {Viral infections can perturb neurotrophin signaling in the central nervous system, with important consequences for neuronal survival, synaptic plasticity, neurodevelopment, and long-term cognitive and neuropsychiatric outcomes. Neurotrophins, including nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4, mediate their actions primarily through tropomyosin receptor kinases (TrkA, TrkB and TrkC) and the p75 neurotrophin receptor (p75[NTR]), activating intracellular pathways such as PI3K-AKT, MAPK-ERK, and PLC-γ. Growing evidence suggests that both neurotropic/neuroinvasive and non-classically neurotropic viruses can interfere with these pathways through multiple mechanisms, including those elicited by direct infection of neural and glial cells, interference with endosomal trafficking required for sustained Trk signaling, and inflammation-driven alterations in neurotrophin expression and receptor balance. This review summarizes current knowledge on how selected viruses affect neurotrophin availability and downstream signaling in experimental models and clinical settings. Specifically, the review focuses on: 1) viruses capable of establishing life-long latent or persistent infection such as i) herpesviruses (herpes simplex virus-1; Epstein Barr virus; human cytomegalovirus), and ii) human immunodeficiency virus; 2) other neurotropic viruses driving peculiar neuropathological profiles, such West Nile virus, Japanese encephalitis virus, Zika virus, and Borna disease virus 1; 3) respiratory viruses, such as influenza A virus, human respiratory syncytial virus, and severe acute respiratory syndrome coronavirus 2. For each virus group, we discuss convergent pathogenic mechanisms and receptor-level interference with neurotrophin signaling. We further highlight some gaps in current knowledge, including limited longitudinal human data and the underexplored role of viral co-infections and reactivations, and the unclear causal directionality of neurotrophin dysregulation.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Animals
*Signal Transduction/physiology
*Nerve Growth Factors/metabolism
*Virus Diseases/metabolism/pathology
*Central Nervous System/metabolism/virology/pathology
RevDate: 2026-11-16
Engineering mRNA lipid nanoparticle for protein replacement in rare genetic diseases - current advances and future challenges.
International journal of pharmaceutics pii:S0378-5173(26)01130-0 [Epub ahead of print].
Rare genetic diseases affect over 350 million patients worldwide and have long posed significant challenges in modern medicine. Although messenger RNA (mRNA) was initially considered unsuitable due to its instability, immunogenicity, and inability to cross biological barriers, the COVID-19 pandemic established mRNA as a clinically validated therapeutic. Advances in mRNA synthesis and lipid nanoparticle (LNP) design have since improved stability, translation, safety, and scalability, offering a modern strategy, alongside advances in our understanding of rare diseases. By enabling the production of functional proteins without modifying the genome, mRNA-LNP offer a flexible solution to restore proteins lost through rare genetic diseases. Despite this promise, their application for rare genetic diseases remains at early stages, with most candidates in preclinical developments or early Phase 1/2 trials. This review underlines recent advances in mRNA-based protein replacement for rare genetic disorders, integrating innovations in mRNA design combined with LNPs optimization. It also discusses current challenges, emerging innovations, and future perspectives. While early clinical programs have mainly targeted liver-based disorders, the field is expanding toward pulmonary, hematologic, and neuromuscular diseases. Continued multidisciplinary efforts may establish mRNA nanotherapies as a transformative treatment option for patients with rare genetic disorders.
Additional Links: PMID-43039124
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43039124,
year = {2026},
author = {Zarikian, L and Martin, L and Lepeltier, E},
title = {Engineering mRNA lipid nanoparticle for protein replacement in rare genetic diseases - current advances and future challenges.},
journal = {International journal of pharmaceutics},
volume = {},
number = {},
pages = {127681},
doi = {10.1016/j.ijpharm.2026.127681},
pmid = {43039124},
issn = {1873-3476},
abstract = {Rare genetic diseases affect over 350 million patients worldwide and have long posed significant challenges in modern medicine. Although messenger RNA (mRNA) was initially considered unsuitable due to its instability, immunogenicity, and inability to cross biological barriers, the COVID-19 pandemic established mRNA as a clinically validated therapeutic. Advances in mRNA synthesis and lipid nanoparticle (LNP) design have since improved stability, translation, safety, and scalability, offering a modern strategy, alongside advances in our understanding of rare diseases. By enabling the production of functional proteins without modifying the genome, mRNA-LNP offer a flexible solution to restore proteins lost through rare genetic diseases. Despite this promise, their application for rare genetic diseases remains at early stages, with most candidates in preclinical developments or early Phase 1/2 trials. This review underlines recent advances in mRNA-based protein replacement for rare genetic disorders, integrating innovations in mRNA design combined with LNPs optimization. It also discusses current challenges, emerging innovations, and future perspectives. While early clinical programs have mainly targeted liver-based disorders, the field is expanding toward pulmonary, hematologic, and neuromuscular diseases. Continued multidisciplinary efforts may establish mRNA nanotherapies as a transformative treatment option for patients with rare genetic disorders.},
}
RevDate: 2026-11-16
CmpDate: 2026-11-17
Gender differences regarding body image-related aspects in the general population during the COVID-19 pandemic: a systematic review.
BMC psychology, 14(1):.
BACKGROUND: The COVID-19 pandemic disrupted daily routines, physical activity, eating behaviors, and social interactions, all of which may have influenced body image. Previous research suggests that body image concerns differ by gender and may be particularly pronounced among sexual and gender minority (SGM) individuals, who face unique challenges due to internalized appearance ideals and societal stigma. This systematic review examined gender differences in body image-related concerns in the general adult population during the pandemic. Supported by: German Federal Ministry of Education and Research (01KX2121).
METHODS: This systematic review was preregistered (PROSPERO CRD42023421727) and conducted according to PRESS, PRISMA guidelines. Scopus, Web of Science, PubMed, PsycINFO were searched for original studies published January 2019-July 2024. Studies were eligible if they 1) examined body image-related outcomes during the COVID-19 pandemic and reported gender-specific analyses in non-clinical adult populations. Study quality was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Analytical Cross-Sectional Studies. Studies were narratively summarized according to body image-related constructs assessed and the reported gender-specific findings.
RESULTS: Sixteen studies comprising 9,813 participants were included. Across most studies, women reported greater body dissatisfaction, weight and shape concerns, body shame and guilt, and dysmorphic concerns than men. Men generally reported lower body dissatisfaction and higher body satisfaction and were more likely to perceive their bodies as slimmer or more athletic. However, three studies found no significant gender differences, and one study reported higher body dissatisfaction among men. Longitudinal evidence suggested increases in body dissatisfaction among men over the course of the pandemic, whereas weight concerns decreased among women over time. One study found higher levels of weight- and body-related shame and guilt among gender minority participants compared with cisgender men, while another study reported no association between sexual orientation and body appreciation.
CONCLUSIONS: Women generally reported greater body image-related concerns than men during the COVID-19 pandemic, although findings were not entirely consistent across studies. Evidence regarding SGM individuals remains limited due to their underrepresentation in the literature. Additional longitudinal and gender diverse research is needed to better understand body image changes during public health crises and to inform targeted prevention and intervention.
Additional Links: PMID-43040381
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43040381,
year = {2026},
author = {Laskowski, NM and Sabel, L and Ballero Reque, C and Pahlenkemper, M and Brandt, G and Zaiser, C and Paslakis, G},
title = {Gender differences regarding body image-related aspects in the general population during the COVID-19 pandemic: a systematic review.},
journal = {BMC psychology},
volume = {14},
number = {1},
pages = {},
pmid = {43040381},
issn = {2050-7283},
mesh = {Humans ; *COVID-19/psychology ; *Body Image/psychology ; Female ; Male ; Sex Factors ; Body Satisfaction ; Adult ; Pandemics ; },
abstract = {BACKGROUND: The COVID-19 pandemic disrupted daily routines, physical activity, eating behaviors, and social interactions, all of which may have influenced body image. Previous research suggests that body image concerns differ by gender and may be particularly pronounced among sexual and gender minority (SGM) individuals, who face unique challenges due to internalized appearance ideals and societal stigma. This systematic review examined gender differences in body image-related concerns in the general adult population during the pandemic. Supported by: German Federal Ministry of Education and Research (01KX2121).
METHODS: This systematic review was preregistered (PROSPERO CRD42023421727) and conducted according to PRESS, PRISMA guidelines. Scopus, Web of Science, PubMed, PsycINFO were searched for original studies published January 2019-July 2024. Studies were eligible if they 1) examined body image-related outcomes during the COVID-19 pandemic and reported gender-specific analyses in non-clinical adult populations. Study quality was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Analytical Cross-Sectional Studies. Studies were narratively summarized according to body image-related constructs assessed and the reported gender-specific findings.
RESULTS: Sixteen studies comprising 9,813 participants were included. Across most studies, women reported greater body dissatisfaction, weight and shape concerns, body shame and guilt, and dysmorphic concerns than men. Men generally reported lower body dissatisfaction and higher body satisfaction and were more likely to perceive their bodies as slimmer or more athletic. However, three studies found no significant gender differences, and one study reported higher body dissatisfaction among men. Longitudinal evidence suggested increases in body dissatisfaction among men over the course of the pandemic, whereas weight concerns decreased among women over time. One study found higher levels of weight- and body-related shame and guilt among gender minority participants compared with cisgender men, while another study reported no association between sexual orientation and body appreciation.
CONCLUSIONS: Women generally reported greater body image-related concerns than men during the COVID-19 pandemic, although findings were not entirely consistent across studies. Evidence regarding SGM individuals remains limited due to their underrepresentation in the literature. Additional longitudinal and gender diverse research is needed to better understand body image changes during public health crises and to inform targeted prevention and intervention.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*COVID-19/psychology
*Body Image/psychology
Female
Male
Sex Factors
Body Satisfaction
Adult
Pandemics
RevDate: 2026-11-17
Teletherapy for Adolescent Mental Health: A Scoping Review of Comparative Effectiveness.
Telemedicine journal and e-health : the official journal of the American Telemedicine Association [Epub ahead of print].
BACKGROUND: Teletherapy has become an increasingly common delivery format for adolescent mental healthcare, particularly since the COVID-19 pandemic. Given adolescents' distinct developmental characteristics, its effectiveness requires evaluation against in-person treatment and alternative remote formats. The objective was to map the randomized controlled trial (RCT) evidence on teletherapy for adolescent mental health and to conduct a quantitative synthesis where the evidence permits.
METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidance, six databases were searched for RCTs published from 2014 onward that evaluated therapist-delivered remote psychotherapy for adolescents (13-18 years) with diagnosed mental health conditions, compared with face-to-face treatment, an alternative teletherapy format, or a waitlist or minimal-contact control. Quantitative synthesis was stratified by comparator type.
RESULTS: Eighteen RCTs across eight diagnostic categories were included. Six compared teletherapy with face-to-face treatment, six compared two remote formats, and six used only waitlist or minimal-contact controls. Among face-to-face comparisons, two obsessive-compulsive disorder trials met noninferiority margins, two anxiety trials nonsignificantly favored face-to-face treatment (g = -0.54 and -0.45), and single tic-disorder and insomnia trials found no clear difference. Teletherapy was superior to waitlist or minimal-contact control for anxiety (k = 6, g = 1.56, 95% confidence interval [CI]: 0.75-2.38) and depression (k = 5, g = 1.14, 95% CI: 0.64-1.64). Risk of bias was low in 3 of 18 trials.
CONCLUSIONS: Teletherapy improves adolescent anxiety and depression relative to waitlist or minimal-contact controls, although the size of the benefit is uncertain. Face-to-face comparisons are few, and their findings differ by condition, so equivalence to in-person care cannot yet be established. Condition-specific trials with face-to-face comparators are needed.
Additional Links: PMID-43040836
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43040836,
year = {2026},
author = {Lee, H and Min, S and Ha, JH},
title = {Teletherapy for Adolescent Mental Health: A Scoping Review of Comparative Effectiveness.},
journal = {Telemedicine journal and e-health : the official journal of the American Telemedicine Association},
volume = {},
number = {},
pages = {15305627261506860},
doi = {10.1177/15305627261506860},
pmid = {43040836},
issn = {1556-3669},
abstract = {BACKGROUND: Teletherapy has become an increasingly common delivery format for adolescent mental healthcare, particularly since the COVID-19 pandemic. Given adolescents' distinct developmental characteristics, its effectiveness requires evaluation against in-person treatment and alternative remote formats. The objective was to map the randomized controlled trial (RCT) evidence on teletherapy for adolescent mental health and to conduct a quantitative synthesis where the evidence permits.
METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidance, six databases were searched for RCTs published from 2014 onward that evaluated therapist-delivered remote psychotherapy for adolescents (13-18 years) with diagnosed mental health conditions, compared with face-to-face treatment, an alternative teletherapy format, or a waitlist or minimal-contact control. Quantitative synthesis was stratified by comparator type.
RESULTS: Eighteen RCTs across eight diagnostic categories were included. Six compared teletherapy with face-to-face treatment, six compared two remote formats, and six used only waitlist or minimal-contact controls. Among face-to-face comparisons, two obsessive-compulsive disorder trials met noninferiority margins, two anxiety trials nonsignificantly favored face-to-face treatment (g = -0.54 and -0.45), and single tic-disorder and insomnia trials found no clear difference. Teletherapy was superior to waitlist or minimal-contact control for anxiety (k = 6, g = 1.56, 95% confidence interval [CI]: 0.75-2.38) and depression (k = 5, g = 1.14, 95% CI: 0.64-1.64). Risk of bias was low in 3 of 18 trials.
CONCLUSIONS: Teletherapy improves adolescent anxiety and depression relative to waitlist or minimal-contact controls, although the size of the benefit is uncertain. Face-to-face comparisons are few, and their findings differ by condition, so equivalence to in-person care cannot yet be established. Condition-specific trials with face-to-face comparators are needed.},
}
RevDate: 2026-11-17
EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications in Relapsed/Refractory Multiple Myeloma Patients Treated with FDA Approved Bispecific Antibodies.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research [Epub ahead of print].
Bispecific antibodies (BsAbs) are used for relapsed or refractory multiple myeloma (RRMM), but infectious complications remain an important concern. We estimated the reported proportion of all-grade and grade ≥3 infections during teclistamab, talquetamab, and elranatamab treatment.A systematic literature review was conducted with Pubmed to extract data which, included the number of patients, grade ≥ 3 infectious adverse events, and non-grade ≥ 3 infectious adverse events. Analyses were conducted using R software and the meta package. A random effect model was utilized.Eight studies (6 RCTs, 2 retrospective studies) involving 946 patients (teclistamab: 394, talquetamab: 374, elranatamab: 178) were analyzed. Pooled proportion (PP) for teclistamab was 0.517 [95% CI, 0.183-0.837], and grade ≥ 3 was 0.233 [95% CI, 0.058-0.598]. The talquetamab group had a PP of 0.636 [95% CI, 0.305-0.874], and grade ≥ 3 were 0.201 [95% CI, 0.110-0.339], with COVID-19 & pneumonia most reported. For elranatamab, the PP was 0.714 [95% CI, 0.397-0.904], with grade ≥ 3 infections at 0.344 [95% CI, 0.015-0.948]. Common infections were adenovirus, CMV, COVID-19, and pneumocystis jirovecii. Table 2 shows consistently reported AEs amongst the three bispecific antibodies for comparability.Infections were frequently reported, but substantial heterogeneity limits the precision and generalizability of a single pooled estimate. Consistent outcome definitions and follow-up are needed.
Additional Links: PMID-43041151
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041151,
year = {2026},
author = {Shah, PD and Yeremian, S and Forte, E and Park, D and Choi, E and Qi, J and Nguyen, A and Akhtari, M},
title = {EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications in Relapsed/Refractory Multiple Myeloma Patients Treated with FDA Approved Bispecific Antibodies.},
journal = {Journal of investigative medicine : the official publication of the American Federation for Clinical Research},
volume = {},
number = {},
pages = {10815589261507073},
doi = {10.1177/10815589261507073},
pmid = {43041151},
issn = {1708-8267},
abstract = {Bispecific antibodies (BsAbs) are used for relapsed or refractory multiple myeloma (RRMM), but infectious complications remain an important concern. We estimated the reported proportion of all-grade and grade ≥3 infections during teclistamab, talquetamab, and elranatamab treatment.A systematic literature review was conducted with Pubmed to extract data which, included the number of patients, grade ≥ 3 infectious adverse events, and non-grade ≥ 3 infectious adverse events. Analyses were conducted using R software and the meta package. A random effect model was utilized.Eight studies (6 RCTs, 2 retrospective studies) involving 946 patients (teclistamab: 394, talquetamab: 374, elranatamab: 178) were analyzed. Pooled proportion (PP) for teclistamab was 0.517 [95% CI, 0.183-0.837], and grade ≥ 3 was 0.233 [95% CI, 0.058-0.598]. The talquetamab group had a PP of 0.636 [95% CI, 0.305-0.874], and grade ≥ 3 were 0.201 [95% CI, 0.110-0.339], with COVID-19 & pneumonia most reported. For elranatamab, the PP was 0.714 [95% CI, 0.397-0.904], with grade ≥ 3 infections at 0.344 [95% CI, 0.015-0.948]. Common infections were adenovirus, CMV, COVID-19, and pneumocystis jirovecii. Table 2 shows consistently reported AEs amongst the three bispecific antibodies for comparability.Infections were frequently reported, but substantial heterogeneity limits the precision and generalizability of a single pooled estimate. Consistent outcome definitions and follow-up are needed.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-17
Digital health misinformation in Southeast Asia: a systematic review of susceptibility, public health consequences, and intervention evidence.
Frontiers in public health, 14:1979322.
BACKGROUND: Digital health misinformation forms part of the information environment in which people assess health risks and act on health advice. We systematically reviewed participant-level studies from Southeast Asia addressing susceptibility, public-health consequences, and intervention evidence.
METHODS: We searched PubMed, Europe PMC, Web of Science Core Collection, and Scopus, supplemented by known reports from the original manuscript and publication-version checks. Prespecified eligibility criteria required primary empirical research involving Southeast Asian populations, an explicit health-misinformation focus, a documented digital connection, and participant-level outcomes. The search and selection process was reported according to PRISMA 2020. Methodological quality was assessed using the Mixed Methods Appraisal Tool (MMAT 2018). Heterogeneity in study designs, measures, and outcomes precluded meta-analysis; findings were synthesized narratively.
RESULTS: The searches identified 2,210 database records; 1,142 remained after deduplication. Including supplementary identification, 282 reports were sought, 147 were assessed in full text, and 77 reports were included, representing 74 conservatively grouped study populations. Country-attributable evidence came from Indonesia, Malaysia, Singapore, the Philippines, Thailand, Vietnam, and Lao PDR; two further reports provided regional findings. Fifty-four reports concerned COVID-19. Appraisal and belief were associated with cognition, literacy, trust, identity, emotion, and social context, although measures and sampling differed considerably. Findings linked misinformation-related constructs with sharing, vaccine attitudes, preventive behavior, distress, and accounts of delayed care. Correction, inoculation, digital education, chatbots, and community responses produced heterogeneous findings; most interventions did not isolate a misinformation-specific behavioral effect.
DISCUSSION: Interpretation is limited by 135 unretrieved reports, a single assessment workflow without independent duplicate human screening, and predominantly observational evidence. The regional literature supports context-sensitive interpretation of exposure, appraisal, belief, and action; it does not establish a uniform causal pathway or a preferred intervention transferable across all settings.
Additional Links: PMID-43041235
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041235,
year = {2026},
author = {Zhang, L and Zhu, W and Ding, H and Liu, L},
title = {Digital health misinformation in Southeast Asia: a systematic review of susceptibility, public health consequences, and intervention evidence.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1979322},
pmid = {43041235},
issn = {2296-2565},
mesh = {Humans ; Asia, Southeastern ; Digital Health ; *Communication ; *Public Health ; Digital Media ; },
abstract = {BACKGROUND: Digital health misinformation forms part of the information environment in which people assess health risks and act on health advice. We systematically reviewed participant-level studies from Southeast Asia addressing susceptibility, public-health consequences, and intervention evidence.
METHODS: We searched PubMed, Europe PMC, Web of Science Core Collection, and Scopus, supplemented by known reports from the original manuscript and publication-version checks. Prespecified eligibility criteria required primary empirical research involving Southeast Asian populations, an explicit health-misinformation focus, a documented digital connection, and participant-level outcomes. The search and selection process was reported according to PRISMA 2020. Methodological quality was assessed using the Mixed Methods Appraisal Tool (MMAT 2018). Heterogeneity in study designs, measures, and outcomes precluded meta-analysis; findings were synthesized narratively.
RESULTS: The searches identified 2,210 database records; 1,142 remained after deduplication. Including supplementary identification, 282 reports were sought, 147 were assessed in full text, and 77 reports were included, representing 74 conservatively grouped study populations. Country-attributable evidence came from Indonesia, Malaysia, Singapore, the Philippines, Thailand, Vietnam, and Lao PDR; two further reports provided regional findings. Fifty-four reports concerned COVID-19. Appraisal and belief were associated with cognition, literacy, trust, identity, emotion, and social context, although measures and sampling differed considerably. Findings linked misinformation-related constructs with sharing, vaccine attitudes, preventive behavior, distress, and accounts of delayed care. Correction, inoculation, digital education, chatbots, and community responses produced heterogeneous findings; most interventions did not isolate a misinformation-specific behavioral effect.
DISCUSSION: Interpretation is limited by 135 unretrieved reports, a single assessment workflow without independent duplicate human screening, and predominantly observational evidence. The regional literature supports context-sensitive interpretation of exposure, appraisal, belief, and action; it does not establish a uniform causal pathway or a preferred intervention transferable across all settings.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Asia, Southeastern
Digital Health
*Communication
*Public Health
Digital Media
RevDate: 2026-11-17
CmpDate: 2026-11-17
Why emerging infectious diseases are becoming more complex in the twenty-first century.
One health (Amsterdam, Netherlands), 23:101650.
Emerging infectious diseases in the twenty-first century arise within rapidly changing biological, ecological, environmental, social, and health care systems. Recent outbreaks and antimicrobial resistance show that infectious disease threats can no longer be understood through pathogen-centered models alone. This review examines why infectious diseases are becoming more complex, with emphasis on zoonotic spillover, environmental change, climate-sensitive transmission, globalization, antimicrobial resistance, viral evolution, surveillance, and preparedness. Infectious disease complexity reflects interactions among microbial adaptation, reservoir ecology, host susceptibility, human-animal contact, land-use change, climate pressure, urbanization, mobility, health care exposure, and unequal public health capacity. Case examples including Ebola disease, severe acute respiratory syndrome (SARS), highly pathogenic avian influenza, Middle East respiratory syndrome (MERS), coronavirus disease 2019 (COVID-19), Nipah virus disease, and mpox show that containment depends on transmission biology, exposure setting, timing of infectiousness, and health system readiness. Antimicrobial resistance adds a slower but persistent crisis because resistant organisms, resistance genes, antimicrobial residues, and vulnerable hosts circulate across hospitals, communities, food systems, wastewater, and environmental reservoirs. Preparedness should move upstream of the first recognized human case. Future strategies should make ecological prevention measurable, study reservoir-host dynamics, anticipate pathogen adaptation, reduce exposure at spillover interfaces, detect silent human infection earlier, and respond rapidly through coordinated investigation. Infectious disease control in the twenty-first century will require integrated systems that connect ecological prevention, molecular insight, surveillance, health care resilience, public trust, equity, and sustained global cooperation.
Additional Links: PMID-43041772
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041772,
year = {2026},
author = {Li, YY and Tay, FR},
title = {Why emerging infectious diseases are becoming more complex in the twenty-first century.},
journal = {One health (Amsterdam, Netherlands)},
volume = {23},
number = {},
pages = {101650},
pmid = {43041772},
issn = {2352-7714},
abstract = {Emerging infectious diseases in the twenty-first century arise within rapidly changing biological, ecological, environmental, social, and health care systems. Recent outbreaks and antimicrobial resistance show that infectious disease threats can no longer be understood through pathogen-centered models alone. This review examines why infectious diseases are becoming more complex, with emphasis on zoonotic spillover, environmental change, climate-sensitive transmission, globalization, antimicrobial resistance, viral evolution, surveillance, and preparedness. Infectious disease complexity reflects interactions among microbial adaptation, reservoir ecology, host susceptibility, human-animal contact, land-use change, climate pressure, urbanization, mobility, health care exposure, and unequal public health capacity. Case examples including Ebola disease, severe acute respiratory syndrome (SARS), highly pathogenic avian influenza, Middle East respiratory syndrome (MERS), coronavirus disease 2019 (COVID-19), Nipah virus disease, and mpox show that containment depends on transmission biology, exposure setting, timing of infectiousness, and health system readiness. Antimicrobial resistance adds a slower but persistent crisis because resistant organisms, resistance genes, antimicrobial residues, and vulnerable hosts circulate across hospitals, communities, food systems, wastewater, and environmental reservoirs. Preparedness should move upstream of the first recognized human case. Future strategies should make ecological prevention measurable, study reservoir-host dynamics, anticipate pathogen adaptation, reduce exposure at spillover interfaces, detect silent human infection earlier, and respond rapidly through coordinated investigation. Infectious disease control in the twenty-first century will require integrated systems that connect ecological prevention, molecular insight, surveillance, health care resilience, public trust, equity, and sustained global cooperation.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-17
Association between sarcopenia and mortality in older adults with pneumonia: A systematic review and meta-analysis.
Pakistan journal of medical sciences, 42(10):2904-2912.
OBJECTIVE: This systematic review and meta-analysis aimed to evaluate the association between sarcopenia and mortality in adult patients with pneumonia.
METHODOLOGY: PubMed, Embase, Scopus, and Web of Science were searched from inception to 14 October 2025. Observational studies comparing outcomes between pneumonia patients with and without sarcopenia were included, excluding COVID-19-related studies. Data were pooled using a random-effects model. Subgroup analyses were performed.
RESULTS: Eleven studies (12 datasets) were included. Sarcopenia, defined using CT-based low skeletal muscle mass measures, was significantly associated with increased mortality in pneumonia (OR: 1.03 95% CI 1.02-1.05, p = 0.00001). Between-study variability was substantial: I² = 87.6%. Sensitivity analyses confirmed the stability of the results. Subgroup analyses demonstrated significant associations across most locations, study designs, and follow-up periods, although not all subgroups reached statistical significance.
CONCLUSIONS: Sarcopenia was associated with increased mortality in patients with pneumonia. Further prospective studies using standardized sarcopenia definitions are necessary for better evidence. Registration No.: PROSPERO database (CRD420251163076).
Additional Links: PMID-43041971
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041971,
year = {2026},
author = {Ma, H and Liu, C and Zhou, H and Fang, F and Wang, X},
title = {Association between sarcopenia and mortality in older adults with pneumonia: A systematic review and meta-analysis.},
journal = {Pakistan journal of medical sciences},
volume = {42},
number = {10},
pages = {2904-2912},
pmid = {43041971},
issn = {1682-024X},
abstract = {OBJECTIVE: This systematic review and meta-analysis aimed to evaluate the association between sarcopenia and mortality in adult patients with pneumonia.
METHODOLOGY: PubMed, Embase, Scopus, and Web of Science were searched from inception to 14 October 2025. Observational studies comparing outcomes between pneumonia patients with and without sarcopenia were included, excluding COVID-19-related studies. Data were pooled using a random-effects model. Subgroup analyses were performed.
RESULTS: Eleven studies (12 datasets) were included. Sarcopenia, defined using CT-based low skeletal muscle mass measures, was significantly associated with increased mortality in pneumonia (OR: 1.03 95% CI 1.02-1.05, p = 0.00001). Between-study variability was substantial: I² = 87.6%. Sensitivity analyses confirmed the stability of the results. Subgroup analyses demonstrated significant associations across most locations, study designs, and follow-up periods, although not all subgroups reached statistical significance.
CONCLUSIONS: Sarcopenia was associated with increased mortality in patients with pneumonia. Further prospective studies using standardized sarcopenia definitions are necessary for better evidence. Registration No.: PROSPERO database (CRD420251163076).},
}
RevDate: 2026-11-17
CmpDate: 2026-11-17
Prevention of alcohol relapse in post-liver transplant patients with alcohol use disorder.
Hepatology forum, 7(4):407-415.
Alcohol-associated liver disease has become the most common reason for liver transplantation (LT) in many regions, including the US. This shift reflects the declining hepatitis C-related LTs and rising prevalence of harmful alcohol use, which increased substantially, especially during COVID-19 pandemic. Post-LT alcohol relapse leads to poor clinical outcomes, including medication non-adherence, graft dysfunction (steatosis and alcohol-related hepatitis), recurrent cirrhosis, and decreased overall survival. For patients with severe alcohol-associated hepatitis, early or expedited LT can offer a survival advantage in carefully selected candidates compared with traditional approaches requiring six months of pre-LT abstinence, without a substantial increase in hazardous relapse. Pre-LT risk assessment is essential for the candidate selection and combines psychosocial factors with validated tools such as Stanford Integrated Psychosocial Assessment for Transplantation, Hopkins psychosocial scale, sustained alcohol use post-LT, harmful alcohol use post-LT, and high-risk alcoholism relapse. Post-LT monitoring utilizing direct biomarkers (e.g., phosphatidylethanol, ethyl glucuronide) with indirect markers of alcohol-use to widen the detection window and capture both low-level and heavy use should be considered. Optimal management of alcohol-use disorder (AUD) relies on combining pharmacologic and psychosocial interventions. Among pharmacologic options, naltrexone and acamprosate are considered first-line options, whereas disulfiram is less commonly used after LT given concerns about its drug interactions. Psychosocial aspects of the management are as important as the pharmacologic aspects to maintain abstinence and reduce relapse risk. Potential barriers to participation, such as hepatic decompensation, hepatic encephalopathy, or logistical challenges, should also be recognized and addressed. This narrative review summarizes current management strategies for AUD with emphasis on the post-LT setting.
Additional Links: PMID-43041983
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041983,
year = {2026},
author = {Elsawy, M and Bardak, AE and Yildiz, E and Ozturk, NB and Toruner, MD and Gurakar, M and Gangat, SA and Cindoruk, C and Gurakar, A},
title = {Prevention of alcohol relapse in post-liver transplant patients with alcohol use disorder.},
journal = {Hepatology forum},
volume = {7},
number = {4},
pages = {407-415},
pmid = {43041983},
issn = {2757-7392},
abstract = {Alcohol-associated liver disease has become the most common reason for liver transplantation (LT) in many regions, including the US. This shift reflects the declining hepatitis C-related LTs and rising prevalence of harmful alcohol use, which increased substantially, especially during COVID-19 pandemic. Post-LT alcohol relapse leads to poor clinical outcomes, including medication non-adherence, graft dysfunction (steatosis and alcohol-related hepatitis), recurrent cirrhosis, and decreased overall survival. For patients with severe alcohol-associated hepatitis, early or expedited LT can offer a survival advantage in carefully selected candidates compared with traditional approaches requiring six months of pre-LT abstinence, without a substantial increase in hazardous relapse. Pre-LT risk assessment is essential for the candidate selection and combines psychosocial factors with validated tools such as Stanford Integrated Psychosocial Assessment for Transplantation, Hopkins psychosocial scale, sustained alcohol use post-LT, harmful alcohol use post-LT, and high-risk alcoholism relapse. Post-LT monitoring utilizing direct biomarkers (e.g., phosphatidylethanol, ethyl glucuronide) with indirect markers of alcohol-use to widen the detection window and capture both low-level and heavy use should be considered. Optimal management of alcohol-use disorder (AUD) relies on combining pharmacologic and psychosocial interventions. Among pharmacologic options, naltrexone and acamprosate are considered first-line options, whereas disulfiram is less commonly used after LT given concerns about its drug interactions. Psychosocial aspects of the management are as important as the pharmacologic aspects to maintain abstinence and reduce relapse risk. Potential barriers to participation, such as hepatic decompensation, hepatic encephalopathy, or logistical challenges, should also be recognized and addressed. This narrative review summarizes current management strategies for AUD with emphasis on the post-LT setting.},
}
RevDate: 2026-11-17
Programmable nucleases for nucleic acid detection: bridging the gap between analytical sensitivity and clinical adoption.
Analytical methods : advancing methods and applications [Epub ahead of print].
Nucleic acid testing faces a persistent tension between analytical sensitivity and field deployability. Centralized qPCR relies on thermal cyclers and trained personnel, whereas isothermal amplification eliminates thermal cycling but often compromises sensitivity and stability. The COVID-19 pandemic intensified these constraints in primary care and point-of-care settings. Programmable nucleases offer a different detection logic: after guide-mediated target recognition, effector activity converts the recognition event into a detectable signal. Effector families such as CRISPR (clustered regularly interspaced short palindromic repeats), pAgo (prokaryotic Argonaute), and TnpB/Fanzor have yielded diverse assays, although TnpB has only recently been demonstrated, and Fanzor remains at the proof-of-principle stage. This review integrates effector mechanisms, engineering strategies, clinical evidence, and commercialization. It highlights three shifts: (i) an expanding effector toolbox with greater diversity in size, targeting requirements, and signal encoding; (ii) a transition from optimizing detection limits toward system-level capabilities, such as single-tube operation, multiplexing, absolute quantification, and robustness with unextracted or minimally processed samples; and (iii) a growing mismatch between analytical performance and regulatory maturity. Most CRISPR-based COVID-19 diagnostic products have been withdrawn, expired, or discontinued, likely reflecting commercial and regulatory factors rather than inherent technical limitations. In 2026, a CRISPR-based tuberculosis blood test received regulatory authorization in Colombia, extending the technology beyond respiratory virus detection. Bridging the laboratory-to-clinic gap now depends less on further sensitivity gains than on clear clinical indications, rigorous validation, and cost-controlled engineering. This review aims to guide assay selection and the development of next-generation diagnostics.
Additional Links: PMID-43042488
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43042488,
year = {2026},
author = {Ding, R and Gao, H and Li, Y and Li, Z and Mao, H and Gao, S and Long, J},
title = {Programmable nucleases for nucleic acid detection: bridging the gap between analytical sensitivity and clinical adoption.},
journal = {Analytical methods : advancing methods and applications},
volume = {},
number = {},
pages = {},
doi = {10.1039/d6ay02209j},
pmid = {43042488},
issn = {1759-9679},
abstract = {Nucleic acid testing faces a persistent tension between analytical sensitivity and field deployability. Centralized qPCR relies on thermal cyclers and trained personnel, whereas isothermal amplification eliminates thermal cycling but often compromises sensitivity and stability. The COVID-19 pandemic intensified these constraints in primary care and point-of-care settings. Programmable nucleases offer a different detection logic: after guide-mediated target recognition, effector activity converts the recognition event into a detectable signal. Effector families such as CRISPR (clustered regularly interspaced short palindromic repeats), pAgo (prokaryotic Argonaute), and TnpB/Fanzor have yielded diverse assays, although TnpB has only recently been demonstrated, and Fanzor remains at the proof-of-principle stage. This review integrates effector mechanisms, engineering strategies, clinical evidence, and commercialization. It highlights three shifts: (i) an expanding effector toolbox with greater diversity in size, targeting requirements, and signal encoding; (ii) a transition from optimizing detection limits toward system-level capabilities, such as single-tube operation, multiplexing, absolute quantification, and robustness with unextracted or minimally processed samples; and (iii) a growing mismatch between analytical performance and regulatory maturity. Most CRISPR-based COVID-19 diagnostic products have been withdrawn, expired, or discontinued, likely reflecting commercial and regulatory factors rather than inherent technical limitations. In 2026, a CRISPR-based tuberculosis blood test received regulatory authorization in Colombia, extending the technology beyond respiratory virus detection. Bridging the laboratory-to-clinic gap now depends less on further sensitivity gains than on clear clinical indications, rigorous validation, and cost-controlled engineering. This review aims to guide assay selection and the development of next-generation diagnostics.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-17
[2026 vaccination schedule for adults aged 65 years and older: towards comprehensive vaccine-based prevention in older age].
Geriatrie et psychologie neuropsychiatrie du vieillissement, 24(S2):7-16.
The 2026 French vaccination schedule redefines geriatric prevention, extending its focus beyond the prevention of infectious diseases to the preservation of independence and functional health. Yet vaccination coverage in France remains inadequate. To address immunosenescence, the strategy prioritizes comprehensive protection against respiratory infections caused by influenza viruses, SARS-CoV-2, pneumococcus and respiratory syncytial virus (RSV). For influenza, guidelines recommend the preferential use of enhanced vaccines-either high-dose or adjuvanted formulations-to improve protection in older adults and reduce hospital admissions. Covid-19 boosters remain essential for this vulnerable population, with the adjuvanted recombinant protein vaccine Nuvaxovid® available alongside mRNA vaccines. Pneumococcal prevention is considerably simplified: a single dose of the 21-valent pneumococcal conjugate vaccine (PCV21, Capvaxive®) is recommended for all adults aged 65 years and older. This vaccine covers the serotypes responsible for 83.5% of invasive pneumococcal disease cases in France in 2024. RSV vaccination is indicated for adults aged 75 years and older and for those aged 65 years and older with cardiopulmonary comorbidities, providing protection against severe disease and reducing hospital admissions during winter. Beyond respiratory infections, vaccination against herpes zoster with the adjuvanted recombinant vaccine Shingrix® is recommended for all adults aged 65 years and older. Recent data associate this vaccination not only with the prevention of postherpetic neuralgia but also with a reduced risk of stroke. Tdap-IPV boosters remain essential in the context of recent pertussis epidemics and the persistent risk of tetanus in older adults. Vaccine coadministration is safe and should be offered to improve coverage and reduce the number of visits required. When vaccination records are unavailable, the priority is to proceed with vaccination rather than delay protection. This proactive, integrated approach aims to address inadequate vaccination coverage, reduce mortality and preserve independence in older adults.
Additional Links: PMID-43042679
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43042679,
year = {2026},
author = {Corroyer-Simovic, B},
title = {[2026 vaccination schedule for adults aged 65 years and older: towards comprehensive vaccine-based prevention in older age].},
journal = {Geriatrie et psychologie neuropsychiatrie du vieillissement},
volume = {24},
number = {S2},
pages = {7-16},
doi = {10.1684/pnv.2026.1310},
pmid = {43042679},
issn = {2115-7863},
mesh = {Humans ; Aged ; France ; *Immunization Schedule ; *Vaccination ; Pneumococcal Vaccines/administration & dosage ; Aged, 80 and over ; Influenza Vaccines/administration & dosage ; Influenza, Human/prevention & control ; COVID-19/prevention & control ; Herpes Zoster Vaccine ; },
abstract = {The 2026 French vaccination schedule redefines geriatric prevention, extending its focus beyond the prevention of infectious diseases to the preservation of independence and functional health. Yet vaccination coverage in France remains inadequate. To address immunosenescence, the strategy prioritizes comprehensive protection against respiratory infections caused by influenza viruses, SARS-CoV-2, pneumococcus and respiratory syncytial virus (RSV). For influenza, guidelines recommend the preferential use of enhanced vaccines-either high-dose or adjuvanted formulations-to improve protection in older adults and reduce hospital admissions. Covid-19 boosters remain essential for this vulnerable population, with the adjuvanted recombinant protein vaccine Nuvaxovid® available alongside mRNA vaccines. Pneumococcal prevention is considerably simplified: a single dose of the 21-valent pneumococcal conjugate vaccine (PCV21, Capvaxive®) is recommended for all adults aged 65 years and older. This vaccine covers the serotypes responsible for 83.5% of invasive pneumococcal disease cases in France in 2024. RSV vaccination is indicated for adults aged 75 years and older and for those aged 65 years and older with cardiopulmonary comorbidities, providing protection against severe disease and reducing hospital admissions during winter. Beyond respiratory infections, vaccination against herpes zoster with the adjuvanted recombinant vaccine Shingrix® is recommended for all adults aged 65 years and older. Recent data associate this vaccination not only with the prevention of postherpetic neuralgia but also with a reduced risk of stroke. Tdap-IPV boosters remain essential in the context of recent pertussis epidemics and the persistent risk of tetanus in older adults. Vaccine coadministration is safe and should be offered to improve coverage and reduce the number of visits required. When vaccination records are unavailable, the priority is to proceed with vaccination rather than delay protection. This proactive, integrated approach aims to address inadequate vaccination coverage, reduce mortality and preserve independence in older adults.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Aged
France
*Immunization Schedule
*Vaccination
Pneumococcal Vaccines/administration & dosage
Aged, 80 and over
Influenza Vaccines/administration & dosage
Influenza, Human/prevention & control
COVID-19/prevention & control
Herpes Zoster Vaccine
RevDate: 2026-11-17
CmpDate: 2026-11-17
Modern Diagnostic Tools for Benign Prostatic Hyperplasia.
Current urology reports, 27(1):.
PURPOSE OF REVIEW: Management of benign prostatic hyperplasia (BPH) constitutes a major component of urologic practice. With the rise of remote healthcare from the COVID-19 pandemic, there is a shift in BPH testing to improve accessibility for patients and providers. This study aims to review modern diagnostic tests available for BPH.
METHODS: A literature review was performed with keywords including benign prostatic hyperplasia, lower urinary tract symptoms (LUTS), bladder outlet obstruction, uroflow, urocuff, penile cuff test, digital therapy, mobile health apps, and remote diagnostic and monitoring tools. Inclusion criteria included studies assessing tools for the diagnostic and perioperative work-up of patients with BPH, those assessing flow parameters, and those published within the past 6 years (2020-2026).
RECENT FINDINGS: Multiple methods for remote BPH evaluation exist including questionnaires, remote uroflow, ambulatory urodynamics (UDS), and noninvasive pressure flow studies. Remote questionnaires aid in tracking BPH symptoms but often require technological literacy and are often not validated. Remote uroflow, such as sound-based uroflow and catheter free UDS, allows for multiple data points collected in a more familiar environment but is susceptible to variations in calibration. Ambulatory urodynamics, including Glean UDS, offers a catheter-free alternative to traditional methods. Non-invasive pressure flow studies offer novel ways to measure voiding pressures. Multiple remote and noninvasive tools are emerging in the field of BPH. These tests aim to reduce discomfort, embarrassment, and variability compared to traditional testing. Further studies should be performed to improve validation and standardization of these novel techniques.
Additional Links: PMID-43043525
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43043525,
year = {2026},
author = {Zhang, K and Palasi, SF and Pham, R and da Silva, RD},
title = {Modern Diagnostic Tools for Benign Prostatic Hyperplasia.},
journal = {Current urology reports},
volume = {27},
number = {1},
pages = {},
pmid = {43043525},
issn = {1534-6285},
mesh = {Humans ; *Prostatic Hyperplasia/diagnosis/complications ; Male ; Urodynamics ; *Diagnostic Techniques, Urological ; },
abstract = {PURPOSE OF REVIEW: Management of benign prostatic hyperplasia (BPH) constitutes a major component of urologic practice. With the rise of remote healthcare from the COVID-19 pandemic, there is a shift in BPH testing to improve accessibility for patients and providers. This study aims to review modern diagnostic tests available for BPH.
METHODS: A literature review was performed with keywords including benign prostatic hyperplasia, lower urinary tract symptoms (LUTS), bladder outlet obstruction, uroflow, urocuff, penile cuff test, digital therapy, mobile health apps, and remote diagnostic and monitoring tools. Inclusion criteria included studies assessing tools for the diagnostic and perioperative work-up of patients with BPH, those assessing flow parameters, and those published within the past 6 years (2020-2026).
RECENT FINDINGS: Multiple methods for remote BPH evaluation exist including questionnaires, remote uroflow, ambulatory urodynamics (UDS), and noninvasive pressure flow studies. Remote questionnaires aid in tracking BPH symptoms but often require technological literacy and are often not validated. Remote uroflow, such as sound-based uroflow and catheter free UDS, allows for multiple data points collected in a more familiar environment but is susceptible to variations in calibration. Ambulatory urodynamics, including Glean UDS, offers a catheter-free alternative to traditional methods. Non-invasive pressure flow studies offer novel ways to measure voiding pressures. Multiple remote and noninvasive tools are emerging in the field of BPH. These tests aim to reduce discomfort, embarrassment, and variability compared to traditional testing. Further studies should be performed to improve validation and standardization of these novel techniques.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Prostatic Hyperplasia/diagnosis/complications
Male
Urodynamics
*Diagnostic Techniques, Urological
RevDate: 2026-11-17
A dose of reality: autodisable syringe supply challenges in the COVID-19 immunization response.
Vaccine, 96:129360 pii:S0264-410X(26)01169-2 [Epub ahead of print].
Autodisable (AD) syringes are vital for safe immunization, particularly in low- and middle-income countries, as they prevent reuse and reduce the risk of disease transmission. Prior to the COVID-19 pandemic, global supply was stable and met routine immunization needs. The pandemic, however, highlighted coordination challenges in aligning vaccine and injection device supply chains. The rapid rollout of COVID-19 vaccines led to a surge in demand for AD syringes, including those with nonstandard dose volumes, which required new product development and matching of syringes to specific vaccines-a synchronization that is typically not needed. Limited early information on COVID-19 vaccine dose volume specifications, long lead times, and lack of coordination between vaccine and syringe stakeholders created forecasting difficulties. Procurement agencies faced increased costs and logistical constraints and had to quickly adapt contracts and supply strategies. Although manufacturing capacity expanded, syringe shortages still emerged, increasing the risk of dosing errors and placing additional strain on health systems. As demand later declined, oversupply and market instability followed, prompting contract adjustments. This paper incorporates lessons learned from the COVID-19 response and emphasizes that syringes must not be an afterthought in immunization planning for both future outbreak preparedness and routine immunization efforts. It also outlines key strategies for strengthening syringe market resilience.
Additional Links: PMID-43044466
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044466,
year = {2026},
author = {Herrick, T and Cavazos-Luppino, L and Griffin, E and Mallins, P and Matthews, R and Ozturk, M and Pinza, R and Rajaram, S and Jarrahian, C},
title = {A dose of reality: autodisable syringe supply challenges in the COVID-19 immunization response.},
journal = {Vaccine},
volume = {96},
number = {},
pages = {129360},
doi = {10.1016/j.vaccine.2026.129360},
pmid = {43044466},
issn = {1873-2518},
abstract = {Autodisable (AD) syringes are vital for safe immunization, particularly in low- and middle-income countries, as they prevent reuse and reduce the risk of disease transmission. Prior to the COVID-19 pandemic, global supply was stable and met routine immunization needs. The pandemic, however, highlighted coordination challenges in aligning vaccine and injection device supply chains. The rapid rollout of COVID-19 vaccines led to a surge in demand for AD syringes, including those with nonstandard dose volumes, which required new product development and matching of syringes to specific vaccines-a synchronization that is typically not needed. Limited early information on COVID-19 vaccine dose volume specifications, long lead times, and lack of coordination between vaccine and syringe stakeholders created forecasting difficulties. Procurement agencies faced increased costs and logistical constraints and had to quickly adapt contracts and supply strategies. Although manufacturing capacity expanded, syringe shortages still emerged, increasing the risk of dosing errors and placing additional strain on health systems. As demand later declined, oversupply and market instability followed, prompting contract adjustments. This paper incorporates lessons learned from the COVID-19 response and emphasizes that syringes must not be an afterthought in immunization planning for both future outbreak preparedness and routine immunization efforts. It also outlines key strategies for strengthening syringe market resilience.},
}
RevDate: 2026-11-16
CmpDate: 2026-11-16
State of the global tuberculosis epidemic: burden, progress towards WHO End TB Strategy targets and systemic challenges.
The Lancet. Microbe, 7(11):101433.
Mycobacterium tuberculosis remains the leading cause of death from a single infectious pathogen globally despite decades of effective chemotherapy. In 2024, an estimated 10·7 million people developed tuberculosis, including approximately 620 000 people living with HIV (PLHIV), and tuberculosis caused an estimated 1·23 million deaths overall, including approximately 150 000 deaths among PLHIV. Men accounted for more than half of the cases, and children represented a substantial burden, reflecting ongoing transmission and diagnostic gaps. Approximately a quarter of the world's population has been infected with M tuberculosis, with immunological evidence of previous or current infection. This population includes groups at increased risk of progression to tuberculosis disease, particularly those with recent infection, HIV, undernutrition, young age, or other clinical and social vulnerabilities. Following 3 years of COVID-19-related setbacks, global tuberculosis incidence declined modestly (1%) from 2023 to 2024 but remains higher than in 2020 and far off-track to meet the 2025 WHO End TB Strategy milestones. Case detection improved to 8·3 million notifications (78% of estimated incident cases), supported by expanded molecular diagnostics; however, prevalence surveys continue to reveal substantial proportions of bacteriologically confirmed but asymptomatic tuberculosis, highlighting persistent transmission and missed diagnoses. 30 high-burden countries accounted for 87% of cases, led by India, Indonesia, the Philippines, China, Pakistan, Nigeria, the Democratic Republic of the Congo, and Bangladesh. M tuberculosis-HIV co-infection remains a major driver of mortality in sub-Saharan Africa. Drug-resistant tuberculosis threatens progress: of 390 000 estimated multidrug-resistant or rifampicin-resistant tuberculosis cases in 2024, only 42% initiated treatment, although treatment success improved to 71%. Tuberculosis-preventive treatment reached 5·3 million people, including 58% of PLHIV and 25% of eligible household contacts, well below global targets. Persistent undernutrition, poverty, HIV, diabetes, smoking, alcohol use, air pollution, migration, and conflict continue to shape tuberculosis epidemiology. With financing at only 27% of global targets, accelerated prevention, proactive case finding, social protection, and sustained political commitment are essential to eliminate tuberculosis.
Additional Links: PMID-42526488
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42526488,
year = {2026},
author = {Zenner, D and Hui, DS and Sahu, S and Ditiu, L and Yeboah-Manu, D and Ntoumi, F and Mfinanga, S and Chakaya, J and Zumla, A and Ahmed, R and Tiberi, S and Goletti, D and Walzl, G and Marais, BJ and Zumla, A},
title = {State of the global tuberculosis epidemic: burden, progress towards WHO End TB Strategy targets and systemic challenges.},
journal = {The Lancet. Microbe},
volume = {7},
number = {11},
pages = {101433},
doi = {10.1016/j.lanmic.2026.101433},
pmid = {42526488},
issn = {2666-5247},
mesh = {Humans ; *Tuberculosis/epidemiology/prevention & control/drug therapy/diagnosis ; HIV Infections/epidemiology/complications ; Global Health ; Mycobacterium tuberculosis/drug effects ; Incidence ; World Health Organization ; Antitubercular Agents/therapeutic use ; *Epidemics ; Prevalence ; COVID-19/epidemiology ; Tuberculosis, Multidrug-Resistant/epidemiology ; },
abstract = {Mycobacterium tuberculosis remains the leading cause of death from a single infectious pathogen globally despite decades of effective chemotherapy. In 2024, an estimated 10·7 million people developed tuberculosis, including approximately 620 000 people living with HIV (PLHIV), and tuberculosis caused an estimated 1·23 million deaths overall, including approximately 150 000 deaths among PLHIV. Men accounted for more than half of the cases, and children represented a substantial burden, reflecting ongoing transmission and diagnostic gaps. Approximately a quarter of the world's population has been infected with M tuberculosis, with immunological evidence of previous or current infection. This population includes groups at increased risk of progression to tuberculosis disease, particularly those with recent infection, HIV, undernutrition, young age, or other clinical and social vulnerabilities. Following 3 years of COVID-19-related setbacks, global tuberculosis incidence declined modestly (1%) from 2023 to 2024 but remains higher than in 2020 and far off-track to meet the 2025 WHO End TB Strategy milestones. Case detection improved to 8·3 million notifications (78% of estimated incident cases), supported by expanded molecular diagnostics; however, prevalence surveys continue to reveal substantial proportions of bacteriologically confirmed but asymptomatic tuberculosis, highlighting persistent transmission and missed diagnoses. 30 high-burden countries accounted for 87% of cases, led by India, Indonesia, the Philippines, China, Pakistan, Nigeria, the Democratic Republic of the Congo, and Bangladesh. M tuberculosis-HIV co-infection remains a major driver of mortality in sub-Saharan Africa. Drug-resistant tuberculosis threatens progress: of 390 000 estimated multidrug-resistant or rifampicin-resistant tuberculosis cases in 2024, only 42% initiated treatment, although treatment success improved to 71%. Tuberculosis-preventive treatment reached 5·3 million people, including 58% of PLHIV and 25% of eligible household contacts, well below global targets. Persistent undernutrition, poverty, HIV, diabetes, smoking, alcohol use, air pollution, migration, and conflict continue to shape tuberculosis epidemiology. With financing at only 27% of global targets, accelerated prevention, proactive case finding, social protection, and sustained political commitment are essential to eliminate tuberculosis.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Tuberculosis/epidemiology/prevention & control/drug therapy/diagnosis
HIV Infections/epidemiology/complications
Global Health
Mycobacterium tuberculosis/drug effects
Incidence
World Health Organization
Antitubercular Agents/therapeutic use
*Epidemics
Prevalence
COVID-19/epidemiology
Tuberculosis, Multidrug-Resistant/epidemiology
RevDate: 2026-11-16
CmpDate: 2026-11-16
Celiac disease incidence after COVID-19 infection.
Minerva medica, 117(5):300-306.
BACKGROUND: An increased incidence of auto-inflammatory diseases, such as celiac disease (CD), has been reported following coronavirus disease 2019 (COVID-19) pandemic. The aim of this systematic review and meta-analysis was to assess whether COVID-19 is associated with CD risk.
METHODS: We searched MEDLINE (PubMed), Cochrane Library and Clinicaltrial.gov databases up to October 30, 2025, for studies evaluating the incidence of CD following COVID-19 infection (PROSPERO ID: CRD420251174742). We performed qualitative and quantitative syntheses of retrospective studies to evaluate the role of COVID-19 infection in CD incidence.
RESULTS: A total of 4 studies were used in the qualitative and quantitative analysis. The studies were conducted between 2023 and 2024 and included 3,465,996 exposed and 7,044,493 non-exposed COVID-19 people. The results from the pooled synthesis showed no significant difference in CD incidence among exposed and non-exposed people with COVID-19 (risk ratio [RR] 1.25, 95% confidence interval [CI; 0.94, 1.66], P=0.12, I[2]=87%). Similarly, no difference was observed in CD incidence between COVID-19 and non-COVID-19 patients after performing a leave-one-out sensitivity analysis (RR 1.10 95% CI [1.00, 1.22], P=0.06, I[2]=0%).
CONCLUSIONS: These findings suggest that COVID-19 infection does not appear to increase the risk of developing CD.
Additional Links: PMID-42545252
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42545252,
year = {2026},
author = {Mastori-Kourmpani, C and Filippatos, TD and Agouridis, AP},
title = {Celiac disease incidence after COVID-19 infection.},
journal = {Minerva medica},
volume = {117},
number = {5},
pages = {300-306},
doi = {10.23736/S0026-4806.26.09921-0},
pmid = {42545252},
issn = {1827-1669},
mesh = {Humans ; *Celiac Disease/epidemiology/etiology ; *COVID-19/complications/epidemiology ; Incidence ; },
abstract = {BACKGROUND: An increased incidence of auto-inflammatory diseases, such as celiac disease (CD), has been reported following coronavirus disease 2019 (COVID-19) pandemic. The aim of this systematic review and meta-analysis was to assess whether COVID-19 is associated with CD risk.
METHODS: We searched MEDLINE (PubMed), Cochrane Library and Clinicaltrial.gov databases up to October 30, 2025, for studies evaluating the incidence of CD following COVID-19 infection (PROSPERO ID: CRD420251174742). We performed qualitative and quantitative syntheses of retrospective studies to evaluate the role of COVID-19 infection in CD incidence.
RESULTS: A total of 4 studies were used in the qualitative and quantitative analysis. The studies were conducted between 2023 and 2024 and included 3,465,996 exposed and 7,044,493 non-exposed COVID-19 people. The results from the pooled synthesis showed no significant difference in CD incidence among exposed and non-exposed people with COVID-19 (risk ratio [RR] 1.25, 95% confidence interval [CI; 0.94, 1.66], P=0.12, I[2]=87%). Similarly, no difference was observed in CD incidence between COVID-19 and non-COVID-19 patients after performing a leave-one-out sensitivity analysis (RR 1.10 95% CI [1.00, 1.22], P=0.06, I[2]=0%).
CONCLUSIONS: These findings suggest that COVID-19 infection does not appear to increase the risk of developing CD.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Celiac Disease/epidemiology/etiology
*COVID-19/complications/epidemiology
Incidence
RevDate: 2026-11-16
CmpDate: 2026-11-16
COVID-19 vaccine effectiveness in people on immunosuppressive therapies: a systematic review and meta-analysis.
The Lancet. Microbe, 7(11):101424.
BACKGROUND: People on immunosuppressive therapies are at increased risk of severe COVID-19, yet vaccine efficacy in these individuals has been inadequately assessed in randomised controlled trials. This systematic review and meta-analysis aims to examine vaccine effectiveness in people with medical conditions commonly treated with conventional synthetic or targeted immunosuppressive therapies.
METHODS: We searched PubMed and Scopus from database inception and Embase from Jan 1, 2020, until Dec 5, 2025. We included randomised controlled trials, cohort studies, and case-control studies of COVID-19 vaccines in adults with haematological malignancies or autoimmune and immune-mediated inflammatory disorders. Studies were eligible if they were published in English and reported vaccine effectiveness or a relative risk (RR) measure for preventing SARS-CoV-2 infection, hospitalisation, severe disease, or death. We excluded studies of organ transplant recipients and patients with other conditions (eg, HIV or non-haematologic cancers). Data were extracted by one author (SRK or ES) and verified by another author (SRK, KME, ES, CP, PH, RVH, RVJ, or SCS). Risk of bias was assessed independently by two authors (KME and EE) using the Newcastle-Ottawa Scale. Effect measures were pooled using random-effects meta-analysis with inverse variance weighting. I[2] with 95% CIs were reported as measures of between-study heterogeneity. This review was registered with PROSPERO (CRD42023434975).
FINDINGS: Our database search identified 3316 studies, and one additional study was identified from citation searching. 35 studies were eligible for inclusion in the review, of which 34 were included in the meta-analysis (one study was excluded due to no cases in all arms). Of the 34 included studies, 17 reported vaccine effectiveness against COVID-19 outcomes in people on immunosuppressive therapies compared with unvaccinated individuals, 16 reported RR measures in vaccinated individuals on immunosuppressive therapies compared with vaccinated healthy controls, and one reported both. Of the 34 included studies, risk of bias was rated as good in 21 (62%) studies, as fair in four (12%), and as poor in nine (26%). Clinical outcomes reported across the studies were: infection in 28 (82%), hospitalisation or severe disease in 16 (47%), and death in eight (24%). Vaccine effectiveness was 82·3% (95% CI 72·4-88·7, I[2]=96·8%) against SARS-CoV-2 infection with pre-omicron variants after three vaccinations and 88·4% (82·8-92·3, 73·9%) against hospitalisation. Among vaccinated individuals on immunosuppressive therapies, the RR compared with that in vaccinated healthy individuals was 1·57 (1·25-1·96, I[2]=89·7%) for SARS-CoV-2 infection, 3·72 (1·63-8·47, 85·5%) for hospitalisation, and 3·14 (1·51-6·54, 75·2%) for death.
INTERPRETATION: This analysis shows a substantial benefit of vaccination for people on immunosuppressive therapy, particularly after three vaccine doses and against severe outcomes. It also highlights a significantly higher risk of hospitalisation and death in this group than in vaccinated healthy individuals. Assessing booster vaccine effectiveness in these populations against current circulating variants and with updated vaccines remains a priority.
FUNDING: National Health and Medical Research Council (Australia).
Additional Links: PMID-42743943
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42743943,
year = {2026},
author = {Stadler, E and Khan, SR and Elias, KM and Egilmezer, E and Phetsouphanh, C and Hastak, P and Hewavisenti, RV and Joshi, RV and Turner, T and Cromer, D and Sasson, SC and Davenport, MP and Khoury, DS},
title = {COVID-19 vaccine effectiveness in people on immunosuppressive therapies: a systematic review and meta-analysis.},
journal = {The Lancet. Microbe},
volume = {7},
number = {11},
pages = {101424},
doi = {10.1016/j.lanmic.2026.101424},
pmid = {42743943},
issn = {2666-5247},
mesh = {Humans ; *Immunosuppressive Agents/therapeutic use/adverse effects ; *COVID-19/prevention & control/immunology ; *COVID-19 Vaccines/immunology/administration & dosage ; *Vaccine Efficacy ; SARS-CoV-2/immunology ; Immunocompromised Host ; Randomized Controlled Trials as Topic ; },
abstract = {BACKGROUND: People on immunosuppressive therapies are at increased risk of severe COVID-19, yet vaccine efficacy in these individuals has been inadequately assessed in randomised controlled trials. This systematic review and meta-analysis aims to examine vaccine effectiveness in people with medical conditions commonly treated with conventional synthetic or targeted immunosuppressive therapies.
METHODS: We searched PubMed and Scopus from database inception and Embase from Jan 1, 2020, until Dec 5, 2025. We included randomised controlled trials, cohort studies, and case-control studies of COVID-19 vaccines in adults with haematological malignancies or autoimmune and immune-mediated inflammatory disorders. Studies were eligible if they were published in English and reported vaccine effectiveness or a relative risk (RR) measure for preventing SARS-CoV-2 infection, hospitalisation, severe disease, or death. We excluded studies of organ transplant recipients and patients with other conditions (eg, HIV or non-haematologic cancers). Data were extracted by one author (SRK or ES) and verified by another author (SRK, KME, ES, CP, PH, RVH, RVJ, or SCS). Risk of bias was assessed independently by two authors (KME and EE) using the Newcastle-Ottawa Scale. Effect measures were pooled using random-effects meta-analysis with inverse variance weighting. I[2] with 95% CIs were reported as measures of between-study heterogeneity. This review was registered with PROSPERO (CRD42023434975).
FINDINGS: Our database search identified 3316 studies, and one additional study was identified from citation searching. 35 studies were eligible for inclusion in the review, of which 34 were included in the meta-analysis (one study was excluded due to no cases in all arms). Of the 34 included studies, 17 reported vaccine effectiveness against COVID-19 outcomes in people on immunosuppressive therapies compared with unvaccinated individuals, 16 reported RR measures in vaccinated individuals on immunosuppressive therapies compared with vaccinated healthy controls, and one reported both. Of the 34 included studies, risk of bias was rated as good in 21 (62%) studies, as fair in four (12%), and as poor in nine (26%). Clinical outcomes reported across the studies were: infection in 28 (82%), hospitalisation or severe disease in 16 (47%), and death in eight (24%). Vaccine effectiveness was 82·3% (95% CI 72·4-88·7, I[2]=96·8%) against SARS-CoV-2 infection with pre-omicron variants after three vaccinations and 88·4% (82·8-92·3, 73·9%) against hospitalisation. Among vaccinated individuals on immunosuppressive therapies, the RR compared with that in vaccinated healthy individuals was 1·57 (1·25-1·96, I[2]=89·7%) for SARS-CoV-2 infection, 3·72 (1·63-8·47, 85·5%) for hospitalisation, and 3·14 (1·51-6·54, 75·2%) for death.
INTERPRETATION: This analysis shows a substantial benefit of vaccination for people on immunosuppressive therapy, particularly after three vaccine doses and against severe outcomes. It also highlights a significantly higher risk of hospitalisation and death in this group than in vaccinated healthy individuals. Assessing booster vaccine effectiveness in these populations against current circulating variants and with updated vaccines remains a priority.
FUNDING: National Health and Medical Research Council (Australia).},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Immunosuppressive Agents/therapeutic use/adverse effects
*COVID-19/prevention & control/immunology
*COVID-19 Vaccines/immunology/administration & dosage
*Vaccine Efficacy
SARS-CoV-2/immunology
Immunocompromised Host
Randomized Controlled Trials as Topic
RevDate: 2026-11-15
CmpDate: 2026-11-15
Three-dimensional organoid and organ-on-chip models for studying human viral infections: applications across respiratory, hepatotropic, enteric, cardiac, and neurotropic virus research.
In vitro models, 5(4):893-905.
Conventional two-dimensional cell lines and animal models each present well-recognized limitations for studying human viral infection: monolayer cultures lack tissue-level architecture and cellular heterogeneity, while species differences in receptor expression and immune physiology limit the translatability of animal data to human disease. Three-dimensional in vitro models, including air-liquid interface (ALI) transwell cultures, adult stem cell- and pluripotent stem cell-derived organoids, and microfluidic organ-on-chip platforms, have emerged as physiologically relevant alternatives that better recapitulate human tissue architecture, cellular diversity, and host-pathogen interactions. This review examines the application of these three-dimensional platforms across six domains of human viral pathogenesis: respiratory viruses (influenza, SARS-CoV-2, rhinovirus, respiratory syncytial virus) studied using ALI airway cultures, airway/lung/nasal organoids, and alveolar-capillary organ-on-chip systems; hepatotropic viruses (hepatitis B and C viruses) studied using perfused microfluidic liver cultures and patient-derived liver organoids capable of supporting complete viral replication cycles; enteric viruses (rotavirus, norovirus, coxsackievirus) studied using human intestinal enteroids and gut-on-chip systems; hemorrhagic-fever viruses (Ebola, Lassa) studied using microvessel-on-chip platforms; cardiotropic SARS-CoV-2 infection studied using engineered heart tissue; and neurotropic TORCH viruses (Toxoplasma, Other agents, Rubella, Cytomegalovirus, Herpes simplex virus - here represented by Zika virus and herpes simplex virus 1) studied using human brain organoids that recapitulate virus-induced microcephaly phenotypes. We compare the architecture, quantitative performance, strengths, and limitations of twenty-one representative platforms, position six platform classes on a physiological-relevance-versus-throughput landscape, summarize demonstrated applications in antiviral drug screening (including chip-based identification of amodiaquine and nafamostat repurposing candidates and a clinically important hydroxychloroquine false-positive), and extend the discussion to the translational challenges of donor variability, cross-laboratory standardization, throughput, and immune-cell integration that currently limit broader adoption of these models in preclinical virology and drug discovery pipelines.
Additional Links: PMID-43034355
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43034355,
year = {2026},
author = {Al-Attabi, A and Mohammed, MK and Hindi, NKK},
title = {Three-dimensional organoid and organ-on-chip models for studying human viral infections: applications across respiratory, hepatotropic, enteric, cardiac, and neurotropic virus research.},
journal = {In vitro models},
volume = {5},
number = {4},
pages = {893-905},
pmid = {43034355},
issn = {2731-3441},
abstract = {Conventional two-dimensional cell lines and animal models each present well-recognized limitations for studying human viral infection: monolayer cultures lack tissue-level architecture and cellular heterogeneity, while species differences in receptor expression and immune physiology limit the translatability of animal data to human disease. Three-dimensional in vitro models, including air-liquid interface (ALI) transwell cultures, adult stem cell- and pluripotent stem cell-derived organoids, and microfluidic organ-on-chip platforms, have emerged as physiologically relevant alternatives that better recapitulate human tissue architecture, cellular diversity, and host-pathogen interactions. This review examines the application of these three-dimensional platforms across six domains of human viral pathogenesis: respiratory viruses (influenza, SARS-CoV-2, rhinovirus, respiratory syncytial virus) studied using ALI airway cultures, airway/lung/nasal organoids, and alveolar-capillary organ-on-chip systems; hepatotropic viruses (hepatitis B and C viruses) studied using perfused microfluidic liver cultures and patient-derived liver organoids capable of supporting complete viral replication cycles; enteric viruses (rotavirus, norovirus, coxsackievirus) studied using human intestinal enteroids and gut-on-chip systems; hemorrhagic-fever viruses (Ebola, Lassa) studied using microvessel-on-chip platforms; cardiotropic SARS-CoV-2 infection studied using engineered heart tissue; and neurotropic TORCH viruses (Toxoplasma, Other agents, Rubella, Cytomegalovirus, Herpes simplex virus - here represented by Zika virus and herpes simplex virus 1) studied using human brain organoids that recapitulate virus-induced microcephaly phenotypes. We compare the architecture, quantitative performance, strengths, and limitations of twenty-one representative platforms, position six platform classes on a physiological-relevance-versus-throughput landscape, summarize demonstrated applications in antiviral drug screening (including chip-based identification of amodiaquine and nafamostat repurposing candidates and a clinically important hydroxychloroquine false-positive), and extend the discussion to the translational challenges of donor variability, cross-laboratory standardization, throughput, and immune-cell integration that currently limit broader adoption of these models in preclinical virology and drug discovery pipelines.},
}
RevDate: 2026-11-16
CmpDate: 2026-11-16
Fecal microbiota transplantation for pediatric Clostridioides difficile infection: efficacy, challenges, and the path to next-generation microbiome therapies.
Gut microbes, 18(1):2761763.
Clostridioides difficile infection (CDI) is an increasing cause of morbidity in children, with recurrent disease posing substantial therapeutic challenges. Antibiotic therapy remains the cornerstone of initial management; however, up to 30% of children experience recurrence, and those with underlying comorbidities face recurrence rates as high as 65%. Fecal microbiota transplantation (FMT) has demonstrated superior efficacy over antibiotics for recurrent CDI (rCDI) in adults and has emerged as the most effective available intervention for pediatric rCDI. In this review, we synthesize current evidence on FMT efficacy, microbiome changes, and safety in children with CDI. Data from large multicenter cohort studies demonstrate cure rates exceeding 80%, with comparable efficacy observed in high-risk subpopulations, including those with inflammatory bowel disease and immunocompromising conditions. Critical research gaps remain, including the absence of randomized controlled trials and limited long-term safety data in children. Despite demonstrated effectiveness, significant barriers limit FMT accessibility for children. The COVID-19 pandemic has substantially impacted availability, and current regulatory changes have further restricted access. The lack of FDA-approved live biotherapeutic products approved for CDI in children creates additional challenges. We critically examine the emerging pipeline of next-generation microbiome-based therapies and identify the steps required to ensure children with recurrent CDI have access to safe, effective, and approved treatments.
Additional Links: PMID-43037257
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43037257,
year = {2026},
author = {Nicholson, MR and Conrad, MA and Diaz De Leon, S and Strength, R and Kelsen, JR and Kahn, SA and Hourigan, SK},
title = {Fecal microbiota transplantation for pediatric Clostridioides difficile infection: efficacy, challenges, and the path to next-generation microbiome therapies.},
journal = {Gut microbes},
volume = {18},
number = {1},
pages = {2761763},
doi = {10.1080/19490976.2026.2761763},
pmid = {43037257},
issn = {1949-0984},
mesh = {Humans ; *Fecal Microbiota Transplantation/methods/adverse effects ; *Clostridium Infections/therapy/microbiology ; Child ; Clostridioides difficile/physiology ; Treatment Outcome ; *Gastrointestinal Microbiome ; Recurrence ; Anti-Bacterial Agents/therapeutic use ; },
abstract = {Clostridioides difficile infection (CDI) is an increasing cause of morbidity in children, with recurrent disease posing substantial therapeutic challenges. Antibiotic therapy remains the cornerstone of initial management; however, up to 30% of children experience recurrence, and those with underlying comorbidities face recurrence rates as high as 65%. Fecal microbiota transplantation (FMT) has demonstrated superior efficacy over antibiotics for recurrent CDI (rCDI) in adults and has emerged as the most effective available intervention for pediatric rCDI. In this review, we synthesize current evidence on FMT efficacy, microbiome changes, and safety in children with CDI. Data from large multicenter cohort studies demonstrate cure rates exceeding 80%, with comparable efficacy observed in high-risk subpopulations, including those with inflammatory bowel disease and immunocompromising conditions. Critical research gaps remain, including the absence of randomized controlled trials and limited long-term safety data in children. Despite demonstrated effectiveness, significant barriers limit FMT accessibility for children. The COVID-19 pandemic has substantially impacted availability, and current regulatory changes have further restricted access. The lack of FDA-approved live biotherapeutic products approved for CDI in children creates additional challenges. We critically examine the emerging pipeline of next-generation microbiome-based therapies and identify the steps required to ensure children with recurrent CDI have access to safe, effective, and approved treatments.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Fecal Microbiota Transplantation/methods/adverse effects
*Clostridium Infections/therapy/microbiology
Child
Clostridioides difficile/physiology
Treatment Outcome
*Gastrointestinal Microbiome
Recurrence
Anti-Bacterial Agents/therapeutic use
RevDate: 2026-11-16
From bench to bedside: 60-year development of adenine nucleoside- and nucleotide-based antiviral drugs.
Clinical microbiology reviews [Epub ahead of print].
SUMMARYHuman pathogenic viruses, including HIV, hepatitis B virus, and hepatitis C virus, as well as recent global outbreaks and pandemics caused by RNA viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV; 2002-2003), Middle East respiratory syndrome-CoV (2012-2015 and 2019), and SARS-CoV-2 (2019-2023), have resulted in a significant loss of life. The development of antiviral drugs has provided therapeutic options, enabling more effective treatment. With the discovery of idoxuridine, the first antiviral nucleoside approved by the U.S. Food and Drug Administration in 1963, a series of antiviral nucleosides and nucleotides has been approved worldwide over the following 60 years. These drugs, with the potential to interfere with DNA/RNA synthesis, demonstrated unique therapeutic mechanisms. In this review, we focus on adenine nucleoside and nucleotide analogs as antiviral drugs, summarizing their antiviral mechanisms across the viral life cycle, representative potent small-molecule agents with diverse scaffolds, current clinical development, and combination therapies, as well as modification strategies based on the adenosine scaffold developed over the past 60 years. In addition to the development of new antiviral agents, some adenine nucleoside and nucleotide analogs have been repurposed for new indications, and some of them, such as remdesivir, exhibit broad-spectrum antiviral activity. Through the summary of past achievements, current challenges, and available opportunities in both biology and chemistry, we hope to inspire the future development of antiviral nucleosides/nucleotides.
Additional Links: PMID-43037422
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43037422,
year = {2026},
author = {Bi, C and De Clercq, E and Liu, W},
title = {From bench to bedside: 60-year development of adenine nucleoside- and nucleotide-based antiviral drugs.},
journal = {Clinical microbiology reviews},
volume = {},
number = {},
pages = {e0001826},
doi = {10.1128/cmr.00018-26},
pmid = {43037422},
issn = {1098-6618},
abstract = {SUMMARYHuman pathogenic viruses, including HIV, hepatitis B virus, and hepatitis C virus, as well as recent global outbreaks and pandemics caused by RNA viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV; 2002-2003), Middle East respiratory syndrome-CoV (2012-2015 and 2019), and SARS-CoV-2 (2019-2023), have resulted in a significant loss of life. The development of antiviral drugs has provided therapeutic options, enabling more effective treatment. With the discovery of idoxuridine, the first antiviral nucleoside approved by the U.S. Food and Drug Administration in 1963, a series of antiviral nucleosides and nucleotides has been approved worldwide over the following 60 years. These drugs, with the potential to interfere with DNA/RNA synthesis, demonstrated unique therapeutic mechanisms. In this review, we focus on adenine nucleoside and nucleotide analogs as antiviral drugs, summarizing their antiviral mechanisms across the viral life cycle, representative potent small-molecule agents with diverse scaffolds, current clinical development, and combination therapies, as well as modification strategies based on the adenosine scaffold developed over the past 60 years. In addition to the development of new antiviral agents, some adenine nucleoside and nucleotide analogs have been repurposed for new indications, and some of them, such as remdesivir, exhibit broad-spectrum antiviral activity. Through the summary of past achievements, current challenges, and available opportunities in both biology and chemistry, we hope to inspire the future development of antiviral nucleosides/nucleotides.},
}
RevDate: 2026-11-16
CmpDate: 2026-11-16
Mobile pharmacovigilance: a comprehensive review.
European journal of clinical pharmacology, 82(12):.
PURPOSE: Adverse drug reactions (ADRs) and serious adverse events (SAEs) remain major contributors to morbidity, mortality, and healthcare costs worldwide, while spontaneous reporting systems continue to suffer from substantial underreporting and incomplete documentation. The rapid advancement of mobile health (mHealth) technologies has introduced mobile pharmacovigilance as an innovative approach to improve the efficiency, accessibility, and quality of ADR reporting. This review aims to comprehensively evaluate the role of mobile applications in pharmacovigilance, with particular emphasis on ADR and SAE reporting, regulatory integration, user engagement, and future technological developments.
METHODS: A hybrid systematic-narrative review methodology was adopted using PRISMA-guided literature identification across PubMed, Embase, Scopus, Google Scholar, and grey literature from the World Health Organization (WHO), regulatory agencies, and pharmacovigilance organizations. The review synthesizes evidence from studies evaluating mobile-based pharmacovigilance platforms, including WEB-RADR, Med Safety App, MedWatcher, My eReport France, VigiBIP, and V-safe.
RESULTS: The findings demonstrate that mobile applications significantly improve both the quantity and quality of ADR reports by reducing reporting time, minimizing missing data, and enhancing report completeness through standardized digital reporting forms. Furthermore, mobile platforms have strengthened patient participation, enabled real-time safety surveillance during public health emergencies such as the COVID-19 pandemic, and facilitated bidirectional communication between healthcare professionals, patients, and regulatory authorities. Despite these advantages, challenges including digital inequality, limited regulatory harmonization, privacy concerns, low awareness, and inconsistent integration with national pharmacovigilance systems continue to hinder widespread adoption.
CONCLUSION: Emerging technologies such as artificial intelligence, electronic health record integration, blockchain, and advanced data analytics are expected to further transform mobile pharmacovigilance. Overall, mobile applications represent a promising strategy for strengthening global pharmacovigilance systems by enabling timely, accurate, patient-centered, and efficient drug safety monitoring.
Additional Links: PMID-43037704
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43037704,
year = {2026},
author = {Tadge, S and Gambhire, M and Somavanshi, DB and Sonawane, G and Patil, C},
title = {Mobile pharmacovigilance: a comprehensive review.},
journal = {European journal of clinical pharmacology},
volume = {82},
number = {12},
pages = {},
pmid = {43037704},
issn = {1432-1041},
mesh = {*Pharmacovigilance ; Humans ; *Adverse Drug Reaction Reporting Systems ; *Mobile Applications ; Telemedicine ; *Drug-Related Side Effects and Adverse Reactions/epidemiology ; Digital Health ; },
abstract = {PURPOSE: Adverse drug reactions (ADRs) and serious adverse events (SAEs) remain major contributors to morbidity, mortality, and healthcare costs worldwide, while spontaneous reporting systems continue to suffer from substantial underreporting and incomplete documentation. The rapid advancement of mobile health (mHealth) technologies has introduced mobile pharmacovigilance as an innovative approach to improve the efficiency, accessibility, and quality of ADR reporting. This review aims to comprehensively evaluate the role of mobile applications in pharmacovigilance, with particular emphasis on ADR and SAE reporting, regulatory integration, user engagement, and future technological developments.
METHODS: A hybrid systematic-narrative review methodology was adopted using PRISMA-guided literature identification across PubMed, Embase, Scopus, Google Scholar, and grey literature from the World Health Organization (WHO), regulatory agencies, and pharmacovigilance organizations. The review synthesizes evidence from studies evaluating mobile-based pharmacovigilance platforms, including WEB-RADR, Med Safety App, MedWatcher, My eReport France, VigiBIP, and V-safe.
RESULTS: The findings demonstrate that mobile applications significantly improve both the quantity and quality of ADR reports by reducing reporting time, minimizing missing data, and enhancing report completeness through standardized digital reporting forms. Furthermore, mobile platforms have strengthened patient participation, enabled real-time safety surveillance during public health emergencies such as the COVID-19 pandemic, and facilitated bidirectional communication between healthcare professionals, patients, and regulatory authorities. Despite these advantages, challenges including digital inequality, limited regulatory harmonization, privacy concerns, low awareness, and inconsistent integration with national pharmacovigilance systems continue to hinder widespread adoption.
CONCLUSION: Emerging technologies such as artificial intelligence, electronic health record integration, blockchain, and advanced data analytics are expected to further transform mobile pharmacovigilance. Overall, mobile applications represent a promising strategy for strengthening global pharmacovigilance systems by enabling timely, accurate, patient-centered, and efficient drug safety monitoring.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Pharmacovigilance
Humans
*Adverse Drug Reaction Reporting Systems
*Mobile Applications
Telemedicine
*Drug-Related Side Effects and Adverse Reactions/epidemiology
Digital Health
RevDate: 2026-11-14
Continuous Positive Airway Pressure versus High-Flow Nasal Oxygen in Adults with Pneumonia-Related Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-Analysis.
Respiratory medicine pii:S0954-6111(26)00666-9 [Epub ahead of print].
BACKGROUND: Continuous positive airway pressure (CPAP) and high-flow nasal oxygen (HFNO) are both used to avert invasive mechanical ventilation in patients with pneumonia-related acute hypoxemic respiratory failure (AHRF), but head-to-head evidence comparing these two modalities specifically, rather than each against conventional oxygen, remains fragmented.
METHODS: We searched major databases for studies enrolling adults with pneumonia-related AHRF, including COVID-19-related pneumonia, managed with CPAP versus HFNO. The prespecified primary outcome was intubation within 30 days; secondary outcomes were time to intubation, in-hospital, 30-day, and 90-day mortality, and length of hospital stay.
RESULTS: Seven studies (n=1,551), met the inclusion criteria. CPAP was associated with a significantly lower risk of intubation within 30 days than HFNO (RR 0.75 [0.65-0.86], p<0.0001; I[2]=33%; moderate certainty of evidence). This benefit was significant among patients with COVID-19 pneumonia (RR 0.75 [0.65-0.86], p<0.0001) but not among those with non-COVID-19 pneumonia (RR 0.67 [0.31-1.45]), although no significant subgroup interaction was detected (p=0.78). CPAP was also associated with a significantly longer time to intubation than HFNO (MD 22.27 hours [16.22-28.33]). No significant differences were observed between CPAP and HFNO for 30-day mortality, 90-day mortality, in-hospital mortality, or length of hospital stay. The reduction in intubation was attenuated but persisted when the analysis was restricted to the four randomized trials (RR 0.81 [0.70-0.95]; I[2]=0%).
CONCLUSIONS: In adults with pneumonia-related AHRF, CPAP probably reduces the risk of intubation compared with HFNO without conferring a mortality advantage or reducing length of stay. HFNO remains a reasonable, generally better-tolerated alternative.
Additional Links: PMID-43034002
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43034002,
year = {2026},
author = {Bokhari, SFH and Shah, SZA and Asad Ullah, H and Fatima, H and Shafi, M and Ali, W and Zahir, M and Arshad, H and Mehmood, H and Shafi, A and Nawaz, H and Muneer, M and Habib, S and Ali, H and Iqbal, A and Hasan, AH},
title = {Continuous Positive Airway Pressure versus High-Flow Nasal Oxygen in Adults with Pneumonia-Related Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-Analysis.},
journal = {Respiratory medicine},
volume = {},
number = {},
pages = {109297},
doi = {10.1016/j.rmed.2026.109297},
pmid = {43034002},
issn = {1532-3064},
abstract = {BACKGROUND: Continuous positive airway pressure (CPAP) and high-flow nasal oxygen (HFNO) are both used to avert invasive mechanical ventilation in patients with pneumonia-related acute hypoxemic respiratory failure (AHRF), but head-to-head evidence comparing these two modalities specifically, rather than each against conventional oxygen, remains fragmented.
METHODS: We searched major databases for studies enrolling adults with pneumonia-related AHRF, including COVID-19-related pneumonia, managed with CPAP versus HFNO. The prespecified primary outcome was intubation within 30 days; secondary outcomes were time to intubation, in-hospital, 30-day, and 90-day mortality, and length of hospital stay.
RESULTS: Seven studies (n=1,551), met the inclusion criteria. CPAP was associated with a significantly lower risk of intubation within 30 days than HFNO (RR 0.75 [0.65-0.86], p<0.0001; I[2]=33%; moderate certainty of evidence). This benefit was significant among patients with COVID-19 pneumonia (RR 0.75 [0.65-0.86], p<0.0001) but not among those with non-COVID-19 pneumonia (RR 0.67 [0.31-1.45]), although no significant subgroup interaction was detected (p=0.78). CPAP was also associated with a significantly longer time to intubation than HFNO (MD 22.27 hours [16.22-28.33]). No significant differences were observed between CPAP and HFNO for 30-day mortality, 90-day mortality, in-hospital mortality, or length of hospital stay. The reduction in intubation was attenuated but persisted when the analysis was restricted to the four randomized trials (RR 0.81 [0.70-0.95]; I[2]=0%).
CONCLUSIONS: In adults with pneumonia-related AHRF, CPAP probably reduces the risk of intubation compared with HFNO without conferring a mortality advantage or reducing length of stay. HFNO remains a reasonable, generally better-tolerated alternative.},
}
RevDate: 2026-11-15
CmpDate: 2026-11-14
Systemic and oral adverse effects of semaglutide reported in randomized controlled trials: a scoping review.
BMC oral health, 26(1):.
OBJECTIVES: To map the systemic and oral adverse events (AEs) of semaglutide reported in randomized controlled trials (RCTs).
DATA: This scoping review was conducted following the PRISMA-ScR guidelines. Only english-language and RCTs were considered.
SOURCES: A literature search was conducted in PubMed, Scopus, and Web of Science from 2019 until 2025.
STUDY SELECTION: Of 630 identified records (300 in PubMed, 312 in Scopus, and 18 in Web of Science), 12 studies were included after screening. The review identified systemic AEs of semaglutide, primarily gastrointestinal events like nausea (12 studies) and diarrhea (11 studies). Less frequent effects included pancreatitis (5 studies), hepatobiliary (3 studies) and gallbladder disease (3 studies), dental caries (1 study) and dry mouth (1 study). Subcutaneous administration predominating (7 studies), followed by oral (3) and mixed routes (2), over treatment durations of 21-68 weeks and 4-9 weeks of follow-up. Additionally, systemic events such as nasopharyngitis (5 studies), COVID-19 (5 studies), and metabolic or nutrition-related disorders were reported in all 12 studies. Importantly, none of the included studies directly investigated oral or dental outcomes.
CONCLUSIONS: Semaglutide demonstrated an overall favorable safety profile in the included randomized controlled trials, with adverse events predominantly gastrointestinal. However, the RCTs did not provide direct evidence regarding oral health outcomes. Therefore, the available evidence is insufficient to draw conclusions about oral adverse events associated with semaglutide, highlighting the need for randomized clinical trials specifically designed to assess oral health outcomes in patients receiving GLP-1 receptor agonists.
Additional Links: PMID-43034163
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43034163,
year = {2026},
author = {Muknickas, D and Câmara, JVF and Schestakow, A and da Silva Spinola, M and Heller, D and Hannig, M},
title = {Systemic and oral adverse effects of semaglutide reported in randomized controlled trials: a scoping review.},
journal = {BMC oral health},
volume = {26},
number = {1},
pages = {},
pmid = {43034163},
issn = {1472-6831},
mesh = {Humans ; Semaglutide ; *Glucagon-Like Peptides/adverse effects/administration & dosage ; Randomized Controlled Trials as Topic ; *Hypoglycemic Agents/adverse effects/administration & dosage ; Diabetes Mellitus, Type 2/drug therapy ; Administration, Oral ; },
abstract = {OBJECTIVES: To map the systemic and oral adverse events (AEs) of semaglutide reported in randomized controlled trials (RCTs).
DATA: This scoping review was conducted following the PRISMA-ScR guidelines. Only english-language and RCTs were considered.
SOURCES: A literature search was conducted in PubMed, Scopus, and Web of Science from 2019 until 2025.
STUDY SELECTION: Of 630 identified records (300 in PubMed, 312 in Scopus, and 18 in Web of Science), 12 studies were included after screening. The review identified systemic AEs of semaglutide, primarily gastrointestinal events like nausea (12 studies) and diarrhea (11 studies). Less frequent effects included pancreatitis (5 studies), hepatobiliary (3 studies) and gallbladder disease (3 studies), dental caries (1 study) and dry mouth (1 study). Subcutaneous administration predominating (7 studies), followed by oral (3) and mixed routes (2), over treatment durations of 21-68 weeks and 4-9 weeks of follow-up. Additionally, systemic events such as nasopharyngitis (5 studies), COVID-19 (5 studies), and metabolic or nutrition-related disorders were reported in all 12 studies. Importantly, none of the included studies directly investigated oral or dental outcomes.
CONCLUSIONS: Semaglutide demonstrated an overall favorable safety profile in the included randomized controlled trials, with adverse events predominantly gastrointestinal. However, the RCTs did not provide direct evidence regarding oral health outcomes. Therefore, the available evidence is insufficient to draw conclusions about oral adverse events associated with semaglutide, highlighting the need for randomized clinical trials specifically designed to assess oral health outcomes in patients receiving GLP-1 receptor agonists.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Semaglutide
*Glucagon-Like Peptides/adverse effects/administration & dosage
Randomized Controlled Trials as Topic
*Hypoglycemic Agents/adverse effects/administration & dosage
Diabetes Mellitus, Type 2/drug therapy
Administration, Oral
RevDate: 2026-11-15
CmpDate: 2026-11-15
Living mapping review of global research funding for high-risk pathogens-Pandemic PACT Grant Tracker.
Wellcome open research, 10:582.
BACKGROUND: The COVID-19 pandemic spurred an unprecedented global research response, highlighting the need for better coordination amid limited resources and the ongoing threat of emerging diseases. The Pandemic PACT Programme has developed a live database tracking funded research on high-risk pathogens and broader preparedness efforts to facilitate improved pandemic preparedness. This paper presents the first analysis update of this dataset, examining trends in research funding identified by the Pandemic PACT programme by disease, geography and research topic, and identifying which funders are supporting high-risk pathogen research, particularly in low- and middle-income countries (LMICs).
METHODS: As of December 6, 2025, the database includes 28,176 awards from 330 funding organisations spread across 60 different countries, representing at least $25.9 billion in financial commitments. We conducted a living mapping review to provide an open, accessible analysis of the funded research portfolio on high-risk infectious diseases. The review analyses funding trends from 2020 to 2025 across high-risk pathogens and research areas, identifying key investment priorities and potential gaps.
RESULTS: Analysis of the Pandemic PACT dataset reveals an uneven global research investment across high-risk infectious diseases. While funding has generally aligned with research priorities, research around diagnostics, health systems research, and ethics are the focus of comparatively fewer research awards. Although vaccine and therapeutic research dominate the portfolio, much of it remains focused on pre-clinical and early-phase trials. There is, however, increasing attention to vector and environmental research in comparison to prior analyses on COVID-19 research. Investments remain concentrated in high-income countries, with limited financial support for context-specific research led by institutions in LMICs. The stated inclusion of populations identified to be vulnerable in funded awards is also limited.
CONCLUSIONS: Our findings reveal critical gaps and disparities in global pandemic preparedness research funding through research awards identified and collected by Pandemic PACT. Investments remain concentrated in high-income countries, with limited funding for LMIC-led research and identifyable representation of vulnerable populations across the funded research portfolio. The relatively lower levels of investment in diagnostics, health systems research, and ethics indicate potential gaps within the current high-risk pathogen research portfolio. The living design of this review will enable ongoing monitoring of these gaps, providing real-time evidence to support funder coordination and policy decisions.
Additional Links: PMID-43034302
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43034302,
year = {2025},
author = {Furst, R and Antonio, E and Levanita, S and Kadri-Alabi, Z and Cerrado, JP and Jabin, N and Khader Ibrahim, S and Mendy, T and Bucher, A and Norton, A},
title = {Living mapping review of global research funding for high-risk pathogens-Pandemic PACT Grant Tracker.},
journal = {Wellcome open research},
volume = {10},
number = {},
pages = {582},
pmid = {43034302},
issn = {2398-502X},
mesh = {Humans ; *COVID-19/epidemiology/economics ; Pandemic Preparedness ; Global Health/economics ; SARS-CoV-2 ; Pandemics ; *Biomedical Research/economics ; *Research Support as Topic/trends ; Developing Countries ; },
abstract = {BACKGROUND: The COVID-19 pandemic spurred an unprecedented global research response, highlighting the need for better coordination amid limited resources and the ongoing threat of emerging diseases. The Pandemic PACT Programme has developed a live database tracking funded research on high-risk pathogens and broader preparedness efforts to facilitate improved pandemic preparedness. This paper presents the first analysis update of this dataset, examining trends in research funding identified by the Pandemic PACT programme by disease, geography and research topic, and identifying which funders are supporting high-risk pathogen research, particularly in low- and middle-income countries (LMICs).
METHODS: As of December 6, 2025, the database includes 28,176 awards from 330 funding organisations spread across 60 different countries, representing at least $25.9 billion in financial commitments. We conducted a living mapping review to provide an open, accessible analysis of the funded research portfolio on high-risk infectious diseases. The review analyses funding trends from 2020 to 2025 across high-risk pathogens and research areas, identifying key investment priorities and potential gaps.
RESULTS: Analysis of the Pandemic PACT dataset reveals an uneven global research investment across high-risk infectious diseases. While funding has generally aligned with research priorities, research around diagnostics, health systems research, and ethics are the focus of comparatively fewer research awards. Although vaccine and therapeutic research dominate the portfolio, much of it remains focused on pre-clinical and early-phase trials. There is, however, increasing attention to vector and environmental research in comparison to prior analyses on COVID-19 research. Investments remain concentrated in high-income countries, with limited financial support for context-specific research led by institutions in LMICs. The stated inclusion of populations identified to be vulnerable in funded awards is also limited.
CONCLUSIONS: Our findings reveal critical gaps and disparities in global pandemic preparedness research funding through research awards identified and collected by Pandemic PACT. Investments remain concentrated in high-income countries, with limited funding for LMIC-led research and identifyable representation of vulnerable populations across the funded research portfolio. The relatively lower levels of investment in diagnostics, health systems research, and ethics indicate potential gaps within the current high-risk pathogen research portfolio. The living design of this review will enable ongoing monitoring of these gaps, providing real-time evidence to support funder coordination and policy decisions.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*COVID-19/epidemiology/economics
Pandemic Preparedness
Global Health/economics
SARS-CoV-2
Pandemics
*Biomedical Research/economics
*Research Support as Topic/trends
Developing Countries
RevDate: 2026-11-14
CmpDate: 2026-11-14
Vaccinations in pregnancy: An update for a changing time.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 175(3):1124-1132.
Maternal immunization is one of the most effective public health interventions to reduce infectious morbidity and mortality in pregnant women, fetuses, and newborns. Despite robust evidence supporting vaccine safety and effectiveness in pregnancy, global uptake has declined following the COVID-19 pandemic, contributing to resurgent outbreaks of vaccine-preventable diseases. While national immunization schedules vary, there is broad international consensus recommending influenza and tetanus-diphtheria-acellular pertussis (Tdap) vaccination during pregnancy, with increasing adoption of maternal respiratory syncytial virus (RSV) immunization. This review provides an updated, globally relevant summary of recommended vaccines before, during, and after pregnancy, highlights vaccines under development, and discusses implementation challenges. Strengthening maternal immunization requires coordinated action across governments, healthcare systems, industry, and media to improve access, trust, and equity in vaccine delivery.
Additional Links: PMID-42841243
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42841243,
year = {2026},
author = {Hodge, W and Bhuinneáin, M and Goba, G and Labovsky, M and Amaral, E and Khalil, A and Lissauer, D and Divakar, H and McAuliffe, FM and Money, D and Pasupathy, D and , },
title = {Vaccinations in pregnancy: An update for a changing time.},
journal = {International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics},
volume = {175},
number = {3},
pages = {1124-1132},
doi = {10.1002/ijgo.71273},
pmid = {42841243},
issn = {1879-3479},
mesh = {Humans ; Pregnancy ; Female ; *Vaccination ; Immunization Schedule ; *Pregnancy Complications, Infectious/prevention & control ; COVID-19/prevention & control/epidemiology ; Diphtheria-Tetanus-acellular Pertussis Vaccines/administration & dosage ; Influenza Vaccines/administration & dosage ; *Vaccines/administration & dosage ; },
abstract = {Maternal immunization is one of the most effective public health interventions to reduce infectious morbidity and mortality in pregnant women, fetuses, and newborns. Despite robust evidence supporting vaccine safety and effectiveness in pregnancy, global uptake has declined following the COVID-19 pandemic, contributing to resurgent outbreaks of vaccine-preventable diseases. While national immunization schedules vary, there is broad international consensus recommending influenza and tetanus-diphtheria-acellular pertussis (Tdap) vaccination during pregnancy, with increasing adoption of maternal respiratory syncytial virus (RSV) immunization. This review provides an updated, globally relevant summary of recommended vaccines before, during, and after pregnancy, highlights vaccines under development, and discusses implementation challenges. Strengthening maternal immunization requires coordinated action across governments, healthcare systems, industry, and media to improve access, trust, and equity in vaccine delivery.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Pregnancy
Female
*Vaccination
Immunization Schedule
*Pregnancy Complications, Infectious/prevention & control
COVID-19/prevention & control/epidemiology
Diphtheria-Tetanus-acellular Pertussis Vaccines/administration & dosage
Influenza Vaccines/administration & dosage
*Vaccines/administration & dosage
RevDate: 2026-11-14
CmpDate: 2026-11-14
Vaccination for girls and women across the life course: Evidence-based recommendations for clinical practice and policy.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 175(3):1145-1151.
Vaccination across the life course is a cornerstone of preventive health care for girls and women. Although WHO recommends completion of essential vaccines by adolescence, global coverage remains suboptimal. Vaccine-preventable diseases-including HPV-related cancers, vaginal, vulvar, anal, oropharyngeal, influenza, pertussis, hepatitis B, herpes zoster, and pneumococcal disease-continue to impose a disproportionate burden on girls and women, particularly in low- and middle-income countries (LMICs) and migrant populations. Key life stages, such as childhood (early and middle), adolescence, preconception, pregnancy, postpartum, midlife, and beyond, offer critical opportunities for immunization. Obstetricians, gynecologists, midwives, and other women's healthcare providers are uniquely positioned to integrate vaccination into routine care in all settings and influence vaccine acceptance. Strengthening vaccine advocacy within women's health care is essential to reduce preventable morbidity and mortality and advance health equity for girls and women globally. This paper presents evidence-based recommendations for equitable vaccination across the life course of girls and women, synthesizing guidance from WHO, the Strategic Advisory Group of Experts on Immunization (SAGE), the Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists (ACOG), and national immunization technical advisory groups. Vaccines reviewed include HPV, tetanus-diphtheria-pertussis (Tdap), influenza, hepatitis B, measles-mumps-rubella (MMR), varicella, herpes zoster, pneumococcal, Respiratory Syncytial Virus (RSV), and COVID-19. A life-course framework is proposed, emphasizing maternal immunization, cervical cancer prevention, and integration of regular and opportune vaccination into routine obstetric and gynecologic services. Practical implementation strategies and policy recommendations are outlined to support FIGO member societies.
Additional Links: PMID-42861791
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42861791,
year = {2026},
author = {Divakar, H and McAuliffe, FM and Goba, G and Benedetto, C and Bhuinneáin, MN and Khadilkar, S and Labovsky, M and Abou-Dakn, M and Barnea, ER and da Silva-Filho, AL and Argale, E and Genazzani, A and Ramos, D and Pasupathy, D},
title = {Vaccination for girls and women across the life course: Evidence-based recommendations for clinical practice and policy.},
journal = {International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics},
volume = {175},
number = {3},
pages = {1145-1151},
doi = {10.1002/ijgo.71330},
pmid = {42861791},
issn = {1879-3479},
mesh = {Humans ; Female ; *Vaccination/standards ; Pregnancy ; Adolescent ; Child ; Health Policy ; *Vaccine-Preventable Diseases/prevention & control ; Adult ; Practice Guidelines as Topic ; Obstetricians ; Evidence-Based Practice ; Women's Health ; },
abstract = {Vaccination across the life course is a cornerstone of preventive health care for girls and women. Although WHO recommends completion of essential vaccines by adolescence, global coverage remains suboptimal. Vaccine-preventable diseases-including HPV-related cancers, vaginal, vulvar, anal, oropharyngeal, influenza, pertussis, hepatitis B, herpes zoster, and pneumococcal disease-continue to impose a disproportionate burden on girls and women, particularly in low- and middle-income countries (LMICs) and migrant populations. Key life stages, such as childhood (early and middle), adolescence, preconception, pregnancy, postpartum, midlife, and beyond, offer critical opportunities for immunization. Obstetricians, gynecologists, midwives, and other women's healthcare providers are uniquely positioned to integrate vaccination into routine care in all settings and influence vaccine acceptance. Strengthening vaccine advocacy within women's health care is essential to reduce preventable morbidity and mortality and advance health equity for girls and women globally. This paper presents evidence-based recommendations for equitable vaccination across the life course of girls and women, synthesizing guidance from WHO, the Strategic Advisory Group of Experts on Immunization (SAGE), the Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists (ACOG), and national immunization technical advisory groups. Vaccines reviewed include HPV, tetanus-diphtheria-pertussis (Tdap), influenza, hepatitis B, measles-mumps-rubella (MMR), varicella, herpes zoster, pneumococcal, Respiratory Syncytial Virus (RSV), and COVID-19. A life-course framework is proposed, emphasizing maternal immunization, cervical cancer prevention, and integration of regular and opportune vaccination into routine obstetric and gynecologic services. Practical implementation strategies and policy recommendations are outlined to support FIGO member societies.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Female
*Vaccination/standards
Pregnancy
Adolescent
Child
Health Policy
*Vaccine-Preventable Diseases/prevention & control
Adult
Practice Guidelines as Topic
Obstetricians
Evidence-Based Practice
Women's Health
RevDate: 2026-11-13
CmpDate: 2026-11-13
A Viral Revolution: Emerging Viral Infections of the Last Decade.
Dermatologic clinics, 45(1):187-202.
Multiple international outbreaks of mpox in 2022 led to the classification of new clades, the description of novel symptoms and cutaneous morphologies, and development of medications and vaccines. Coronavirus disease 2019 has a wide morphologic range that informs diagnosis, prognosis and treatment. Measles outbreaks in the United States are driven by regional trends in vaccine hesitancy. Finally, understanding underrecognized infections like borealpox and oropouche will prepare clinicians to anticipate spread to new areas.
Additional Links: PMID-43025934
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43025934,
year = {2027},
author = {Huynh, T and Leslie, K},
title = {A Viral Revolution: Emerging Viral Infections of the Last Decade.},
journal = {Dermatologic clinics},
volume = {45},
number = {1},
pages = {187-202},
doi = {10.1016/j.det.2026.09.004},
pmid = {43025934},
issn = {1558-0520},
mesh = {Humans ; *Communicable Diseases, Emerging/epidemiology/diagnosis ; *COVID-19/epidemiology/prevention & control ; *Measles/epidemiology/diagnosis ; SARS-CoV-2 ; Disease Outbreaks ; },
abstract = {Multiple international outbreaks of mpox in 2022 led to the classification of new clades, the description of novel symptoms and cutaneous morphologies, and development of medications and vaccines. Coronavirus disease 2019 has a wide morphologic range that informs diagnosis, prognosis and treatment. Measles outbreaks in the United States are driven by regional trends in vaccine hesitancy. Finally, understanding underrecognized infections like borealpox and oropouche will prepare clinicians to anticipate spread to new areas.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Communicable Diseases, Emerging/epidemiology/diagnosis
*COVID-19/epidemiology/prevention & control
*Measles/epidemiology/diagnosis
SARS-CoV-2
Disease Outbreaks
RevDate: 2026-11-13
CmpDate: 2026-11-13
The role of dental public health in patient, public and the professions' safety: insights and case studies from England.
British dental journal, 241(9):674-678.
Introduction Dental public health (DPH) is a clinical dental specialty that works across six domains and the three pillars of public health, including health protection. Across the UK, the DPH speciality workforce plays a vital role in the management of dental health protection cases, utilising their system-level knowledge and clinical leadership to address complex health protection incidents in dental setting. This paper is one of two papers dealing with health protection as part of this Themed Issue on the speciality and aims to provide insights to the systems leadership role it plays within health protection across the UK. The second paper is focussed on antimicrobial resistance, which is another key element of protecting the health of our population.Methods This paper provides a narrative overview of the role of dental public health and includes case studies focussed on the contribution of specialist leadership during the COVID-19 pandemic response and the management of a dental case involving a practice with infection prevention control concerns.Case studies Through these case studies, the proactive and wide impact the speciality has in the protection of patients, the public and the dental workforce is highlighted.Conclusions The management of complex dental incidents, with health protection concerns requires robust, timely, and evidence-informed system response. Specialists in DPH provide critical clinical and system leadership, enabling partnership working and influencing coordinated actions across organisational boundaries. Their specialist understanding of the unique combination of dentistry and public health is crucial for patients, public, and healthcare workforce protection.
Additional Links: PMID-43026250
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43026250,
year = {2026},
author = {Kaddour, S and Sibanda, L and Simon, SE and Watt, S and Patel, R},
title = {The role of dental public health in patient, public and the professions' safety: insights and case studies from England.},
journal = {British dental journal},
volume = {241},
number = {9},
pages = {674-678},
doi = {10.1038/s41415-026-0189-3},
pmid = {43026250},
issn = {1476-5373},
mesh = {Humans ; England ; *Public Health Dentistry ; *COVID-19/epidemiology/prevention & control ; Leadership ; *Public Health ; *Patient Safety ; SARS-CoV-2 ; },
abstract = {Introduction Dental public health (DPH) is a clinical dental specialty that works across six domains and the three pillars of public health, including health protection. Across the UK, the DPH speciality workforce plays a vital role in the management of dental health protection cases, utilising their system-level knowledge and clinical leadership to address complex health protection incidents in dental setting. This paper is one of two papers dealing with health protection as part of this Themed Issue on the speciality and aims to provide insights to the systems leadership role it plays within health protection across the UK. The second paper is focussed on antimicrobial resistance, which is another key element of protecting the health of our population.Methods This paper provides a narrative overview of the role of dental public health and includes case studies focussed on the contribution of specialist leadership during the COVID-19 pandemic response and the management of a dental case involving a practice with infection prevention control concerns.Case studies Through these case studies, the proactive and wide impact the speciality has in the protection of patients, the public and the dental workforce is highlighted.Conclusions The management of complex dental incidents, with health protection concerns requires robust, timely, and evidence-informed system response. Specialists in DPH provide critical clinical and system leadership, enabling partnership working and influencing coordinated actions across organisational boundaries. Their specialist understanding of the unique combination of dentistry and public health is crucial for patients, public, and healthcare workforce protection.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
England
*Public Health Dentistry
*COVID-19/epidemiology/prevention & control
Leadership
*Public Health
*Patient Safety
SARS-CoV-2
RevDate: 2026-11-14
CmpDate: 2026-11-14
Modeling the Human Stomach In Vitro: Gastric Organoids in Development, Disease, and Therapy.
Cells, 15(21):.
Gastric organoids are advanced three-dimensional models generated from adult or pluripotent stem cells. By reproducing key structural, cellular, and functional features of gastric tissue, they overcome several limitations of conventional two-dimensional cultures and animal models. Gastric organoids provide physiologically relevant platforms for studying stomach development, cellular differentiation, and the molecular mechanisms underlying gastric diseases. This review summarizes the principal cell sources and protocols used to generate gastric organoids and discusses recent advances in culture systems, including two-dimensional organoid-derived monolayers, air-liquid interface cultures, co-culture systems, and organoid-on-a-chip technologies. Particular attention is given to the application of gastric organoids in modeling Helicobacter pylori infection, SARS-CoV-2 infection, and gastric cancer, as well as in evaluating therapeutic responses. Their roles in developmental biology, the investigation of congenital disorders, drug screening, potential precision-medicine application, biobanking, and regenerative medicine are also discussed. Despite their considerable potential, current gastric organoid models remain limited: conventional epithelial organoids lack stromal, immune, neural, and vascular components; PSC-derived organoids contain only a limited mesenchymal population; and more complex engineered multicellular tissues still depend largely on in vivo engraftment for maturation. Variable maturation, dependence on poorly defined extracellular matrices, and insufficient standardization further limit their translation.
Additional Links: PMID-43027330
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43027330,
year = {2026},
author = {Enteshari Najafabadi, Z and Ryszkiel, I and Baharvand, H and Sadeghi, A and Stanek, A and Meyfour, A},
title = {Modeling the Human Stomach In Vitro: Gastric Organoids in Development, Disease, and Therapy.},
journal = {Cells},
volume = {15},
number = {21},
pages = {},
pmid = {43027330},
issn = {2073-4409},
mesh = {Humans ; *Organoids/pathology/cytology/growth & development ; *Stomach/pathology/growth & development/cytology ; *Models, Biological ; Animals ; Stomach Neoplasms/pathology/therapy ; Microphysiological Systems ; COVID-19/pathology ; Helicobacter Infections/pathology ; },
abstract = {Gastric organoids are advanced three-dimensional models generated from adult or pluripotent stem cells. By reproducing key structural, cellular, and functional features of gastric tissue, they overcome several limitations of conventional two-dimensional cultures and animal models. Gastric organoids provide physiologically relevant platforms for studying stomach development, cellular differentiation, and the molecular mechanisms underlying gastric diseases. This review summarizes the principal cell sources and protocols used to generate gastric organoids and discusses recent advances in culture systems, including two-dimensional organoid-derived monolayers, air-liquid interface cultures, co-culture systems, and organoid-on-a-chip technologies. Particular attention is given to the application of gastric organoids in modeling Helicobacter pylori infection, SARS-CoV-2 infection, and gastric cancer, as well as in evaluating therapeutic responses. Their roles in developmental biology, the investigation of congenital disorders, drug screening, potential precision-medicine application, biobanking, and regenerative medicine are also discussed. Despite their considerable potential, current gastric organoid models remain limited: conventional epithelial organoids lack stromal, immune, neural, and vascular components; PSC-derived organoids contain only a limited mesenchymal population; and more complex engineered multicellular tissues still depend largely on in vivo engraftment for maturation. Variable maturation, dependence on poorly defined extracellular matrices, and insufficient standardization further limit their translation.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Organoids/pathology/cytology/growth & development
*Stomach/pathology/growth & development/cytology
*Models, Biological
Animals
Stomach Neoplasms/pathology/therapy
Microphysiological Systems
COVID-19/pathology
Helicobacter Infections/pathology
RevDate: 2026-11-14
CmpDate: 2026-11-14
Self-Amplifying RNA Vaccines After the First Approvals: Technology, Development Landscape, and Regulatory Science Considerations.
International journal of molecular sciences, 27(21):.
Self-amplifying RNA (saRNA) is a next-generation nucleic acid vaccine platform that enhances antigen expression through intracellular amplification of replicon RNA without producing infectious virions. saRNA constructs encode an alphavirus-derived replicase comprising nonstructural proteins nsP1-nsP4 and can elicit robust immune responses at low RNA doses. Replication intermediates may activate RIG-I, MDA5, and endosomal TLR3/7/8, contributing adjuvant-like activity. Kostaive (ARCT-154; zapomeran) became the first saRNA vaccine to receive full marketing approval in Japan in 2023, followed by authorization in the European Union in 2025 and the United Kingdom in 2026, demonstrating the platform's clinical and regulatory feasibility. Development now extends beyond COVID-19 to seasonal and pandemic influenza, rabies, Crimean-Congo hemorrhagic fever, Nipah virus disease, and individualized cancer vaccines. However, the longer transcripts and additional replicase and subgenomic-promoter elements make in vitro transcription efficiency, full-length RNA content, double-stranded and truncated RNA impurities, lipid nanoparticle encapsulation, and potency testing particularly important. Regulatory assessment increasingly focuses on correct replicase and antigen expression, the magnitude and duration of self-amplification, biodistribution and persistence, and comparability. This review synthesizes the scientific basis, development landscape, manufacturing challenges, and regulatory science considerations of saRNA vaccines.
Additional Links: PMID-43027709
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43027709,
year = {2026},
author = {Yi, S and Seo, E and Hong, KJ and Park, PG},
title = {Self-Amplifying RNA Vaccines After the First Approvals: Technology, Development Landscape, and Regulatory Science Considerations.},
journal = {International journal of molecular sciences},
volume = {27},
number = {21},
pages = {},
pmid = {43027709},
issn = {1422-0067},
support = {RS-2025-02221518 and RS-2025-02213409//Ministry of Food and Drug Safety/ ; },
mesh = {Humans ; Animals ; *Nucleic Acid-Based Vaccines/immunology ; *Vaccine Development ; RNA Replication ; SARS-CoV-2/immunology ; },
abstract = {Self-amplifying RNA (saRNA) is a next-generation nucleic acid vaccine platform that enhances antigen expression through intracellular amplification of replicon RNA without producing infectious virions. saRNA constructs encode an alphavirus-derived replicase comprising nonstructural proteins nsP1-nsP4 and can elicit robust immune responses at low RNA doses. Replication intermediates may activate RIG-I, MDA5, and endosomal TLR3/7/8, contributing adjuvant-like activity. Kostaive (ARCT-154; zapomeran) became the first saRNA vaccine to receive full marketing approval in Japan in 2023, followed by authorization in the European Union in 2025 and the United Kingdom in 2026, demonstrating the platform's clinical and regulatory feasibility. Development now extends beyond COVID-19 to seasonal and pandemic influenza, rabies, Crimean-Congo hemorrhagic fever, Nipah virus disease, and individualized cancer vaccines. However, the longer transcripts and additional replicase and subgenomic-promoter elements make in vitro transcription efficiency, full-length RNA content, double-stranded and truncated RNA impurities, lipid nanoparticle encapsulation, and potency testing particularly important. Regulatory assessment increasingly focuses on correct replicase and antigen expression, the magnitude and duration of self-amplification, biodistribution and persistence, and comparability. This review synthesizes the scientific basis, development landscape, manufacturing challenges, and regulatory science considerations of saRNA vaccines.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Animals
*Nucleic Acid-Based Vaccines/immunology
*Vaccine Development
RNA Replication
SARS-CoV-2/immunology
RevDate: 2026-11-14
CmpDate: 2026-11-14
Through the Long COVID Looking-Glass: An Unremitting Conundrum of Mitochondria?.
International journal of molecular sciences, 27(21):.
Plentiful data indicate a high post-COVID risk of developing pathologies that are long-term and result from disruption of multiple cellular processes. The significance of this data becomes increasingly clear as it links the pandemic's effects to enduring health problems which could affect millions. These conditions are usually caused by different problems with mitochondria. These problems can include less efficient energy production and increased removal of damaged cells, showing how complex cell health is. Having other health problems such as high blood pressure, type 2 diabetes, brain diseases, and cancer related to renin-angiotensin-aldosterone system (RAAS) imbalance worsened COVID-19 and its lasting effects. This highlights the importance of focused treatments for these at-risk groups. This review seeks to evaluate the information on this issue, carefully studying the features and symptoms often associated with mitochondrial disorders. What happens next in the pandemic is still to be seen, but we know there is much to learn. It is important to lessen the effects of the pandemic on people with comorbidities as much as possible.
Additional Links: PMID-43028000
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43028000,
year = {2026},
author = {Kononova, S and Bobkova, N and Leonov, S and Sukhikh, G},
title = {Through the Long COVID Looking-Glass: An Unremitting Conundrum of Mitochondria?.},
journal = {International journal of molecular sciences},
volume = {27},
number = {21},
pages = {},
pmid = {43028000},
issn = {1422-0067},
support = {25-24-00872//Russian Science Foundation/ ; },
mesh = {Humans ; *COVID-19/complications/metabolism ; *Mitochondria/metabolism/pathology ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; Renin-Angiotensin System ; *Mitochondrial Diseases/metabolism/pathology ; Pandemics ; *Coronavirus Infections/complications ; *Pneumonia, Viral/complications ; },
abstract = {Plentiful data indicate a high post-COVID risk of developing pathologies that are long-term and result from disruption of multiple cellular processes. The significance of this data becomes increasingly clear as it links the pandemic's effects to enduring health problems which could affect millions. These conditions are usually caused by different problems with mitochondria. These problems can include less efficient energy production and increased removal of damaged cells, showing how complex cell health is. Having other health problems such as high blood pressure, type 2 diabetes, brain diseases, and cancer related to renin-angiotensin-aldosterone system (RAAS) imbalance worsened COVID-19 and its lasting effects. This highlights the importance of focused treatments for these at-risk groups. This review seeks to evaluate the information on this issue, carefully studying the features and symptoms often associated with mitochondrial disorders. What happens next in the pandemic is still to be seen, but we know there is much to learn. It is important to lessen the effects of the pandemic on people with comorbidities as much as possible.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*COVID-19/complications/metabolism
*Mitochondria/metabolism/pathology
Post-Acute COVID-19 Syndrome
SARS-CoV-2
Renin-Angiotensin System
*Mitochondrial Diseases/metabolism/pathology
Pandemics
*Coronavirus Infections/complications
*Pneumonia, Viral/complications
RevDate: 2026-11-14
CmpDate: 2026-11-14
Antimicrobial Resistance and Infectious Complications in Cancer Immunotherapy: CAR-T Cells, Bispecific Antibodies and Immune Checkpoint Inhibitors.
International journal of molecular sciences, 27(21):.
Cancer immunotherapies, including chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies (BsAbs), and immune checkpoint inhibitors (ICIs), have improved outcomes across hematologic and solid malignancies. Infection risk remains heterogeneous and depends on treatment platform, target antigen, lymphodepletion, immune reconstitution, concomitant immunosuppression, and supportive care. This narrative review synthesizes clinical trials, observational studies, and guidance identified through PubMed/MEDLINE, reference screening, and a targeted literature update through October 2026. It focuses on infection incidence, microbiological spectrum, antimicrobial resistance (AMR), multidrug-resistant (MDR) colonization and infection, antimicrobial exposure, prevention, and stewardship. Severe infections can be frequent with BCMA-directed BsAbs: the MagnetisMM-3 study reported grade 3-4 infections in 39.8% of elranatamab-treated patients, while a pooled global teclistamab cohort reported grade 3-4 infections in 55.3%; these estimates are study-specific and are influenced in part by COVID-19. Direct AMR evidence is concentrated in CAR-T and broader cellular-therapy cohorts, while comparable data for BsAbs and ICIs remain limited. Associations between broad-spectrum antibiotic exposure, microbiome disruption, and CAR-T outcomes are clinically important but remain vulnerable to confounding. Prevention should integrate immune status, prior microbiology, antimicrobial exposure, and local resistance patterns rather than infer resistance risk from treatment platform alone. Prospective studies using harmonized outcomes are needed to improve individualized infection prevention and antimicrobial stewardship.
Additional Links: PMID-43028152
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43028152,
year = {2026},
author = {Lasagna, A and Andreoni, M and Silvestris, N and Pedrazzoli, P},
title = {Antimicrobial Resistance and Infectious Complications in Cancer Immunotherapy: CAR-T Cells, Bispecific Antibodies and Immune Checkpoint Inhibitors.},
journal = {International journal of molecular sciences},
volume = {27},
number = {21},
pages = {},
pmid = {43028152},
issn = {1422-0067},
mesh = {Humans ; *Immune Checkpoint Inhibitors/therapeutic use/adverse effects ; *Neoplasms/therapy/immunology/complications ; *Antibodies, Bispecific/therapeutic use/adverse effects ; *Immunotherapy, Adoptive/adverse effects/methods ; *Immunotherapy/adverse effects/methods ; *Drug Resistance, Microbial ; },
abstract = {Cancer immunotherapies, including chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies (BsAbs), and immune checkpoint inhibitors (ICIs), have improved outcomes across hematologic and solid malignancies. Infection risk remains heterogeneous and depends on treatment platform, target antigen, lymphodepletion, immune reconstitution, concomitant immunosuppression, and supportive care. This narrative review synthesizes clinical trials, observational studies, and guidance identified through PubMed/MEDLINE, reference screening, and a targeted literature update through October 2026. It focuses on infection incidence, microbiological spectrum, antimicrobial resistance (AMR), multidrug-resistant (MDR) colonization and infection, antimicrobial exposure, prevention, and stewardship. Severe infections can be frequent with BCMA-directed BsAbs: the MagnetisMM-3 study reported grade 3-4 infections in 39.8% of elranatamab-treated patients, while a pooled global teclistamab cohort reported grade 3-4 infections in 55.3%; these estimates are study-specific and are influenced in part by COVID-19. Direct AMR evidence is concentrated in CAR-T and broader cellular-therapy cohorts, while comparable data for BsAbs and ICIs remain limited. Associations between broad-spectrum antibiotic exposure, microbiome disruption, and CAR-T outcomes are clinically important but remain vulnerable to confounding. Prevention should integrate immune status, prior microbiology, antimicrobial exposure, and local resistance patterns rather than infer resistance risk from treatment platform alone. Prospective studies using harmonized outcomes are needed to improve individualized infection prevention and antimicrobial stewardship.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Immune Checkpoint Inhibitors/therapeutic use/adverse effects
*Neoplasms/therapy/immunology/complications
*Antibodies, Bispecific/therapeutic use/adverse effects
*Immunotherapy, Adoptive/adverse effects/methods
*Immunotherapy/adverse effects/methods
*Drug Resistance, Microbial
RevDate: 2026-11-14
CmpDate: 2026-11-14
Compartmentalization of Host Multi-Omics Responses in Lower Respiratory Tract Infection: Discordance Between Airway-Local and Systemic Molecular Profiles-A Narrative Review.
Diagnostics (Basel, Switzerland), 16(21):.
Lower respiratory tract infection (LRTI) remains a leading cause of infection-related mortality. Peripheral blood multi-omics shows promise for pathogen discrimination and severity prediction, yet how well blood reflects airway-local responses in LRTI other than coronavirus disease 2019 (COVID-19) is unclear. We searched PubMed, Web of Science Core Collection, and Europe PMC (January 2021 to August 2026); after de-duplication and dual screening, 29 of 817 unique records were included (Layer A: ≥2 host functional omics layers, n = 23; Layer B: single omics platform with paired airway-blood specimens, n = 6), plus four COVID-19 benchmarks. Blood-based multi-omics distinguished bacterial, viral, and Mycoplasma pneumoniae (M. pneumoniae) LRTI; severity models performed promisingly within their discovery cohorts. In the two studies reporting airway-versus-blood protein inventories, the airway showed more differentially expressed proteins (DEPs) than blood (airway-to-blood DEP count ratios ≈ 3.6-9.3; descriptive study-specific measures), and cross-compartment correlations were predominantly weak (r ≈ -0.3 to +0.3) in the only paired viral LRTI study; interferon-stimulated gene 15 (ISG15; r = 0.79) was a notable exception. Paired evidence derives mostly from a pediatric cohort, hospital-acquired pneumonia, and acute respiratory distress syndrome (ARDS); adult community-acquired LRTI remains under-represented. Current evidence suggests that peripheral blood provides an incomplete, context-dependent representation of airway-local responses; closing this gap requires adult longitudinal paired cohorts, non-invasive airway sampling, improved integration algorithms, and multimodal data fusion.
Additional Links: PMID-43028362
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43028362,
year = {2026},
author = {Tang, S and Hao, A and Su, B and Liu, B},
title = {Compartmentalization of Host Multi-Omics Responses in Lower Respiratory Tract Infection: Discordance Between Airway-Local and Systemic Molecular Profiles-A Narrative Review.},
journal = {Diagnostics (Basel, Switzerland)},
volume = {16},
number = {21},
pages = {},
pmid = {43028362},
issn = {2075-4418},
support = {TJYXZDXK-3-001D//the Tianjin Key Medical Discipline Construction Project/ ; TJWJ2026XK038//the Tianjin Municipal Health Commission Research Project/ ; },
abstract = {Lower respiratory tract infection (LRTI) remains a leading cause of infection-related mortality. Peripheral blood multi-omics shows promise for pathogen discrimination and severity prediction, yet how well blood reflects airway-local responses in LRTI other than coronavirus disease 2019 (COVID-19) is unclear. We searched PubMed, Web of Science Core Collection, and Europe PMC (January 2021 to August 2026); after de-duplication and dual screening, 29 of 817 unique records were included (Layer A: ≥2 host functional omics layers, n = 23; Layer B: single omics platform with paired airway-blood specimens, n = 6), plus four COVID-19 benchmarks. Blood-based multi-omics distinguished bacterial, viral, and Mycoplasma pneumoniae (M. pneumoniae) LRTI; severity models performed promisingly within their discovery cohorts. In the two studies reporting airway-versus-blood protein inventories, the airway showed more differentially expressed proteins (DEPs) than blood (airway-to-blood DEP count ratios ≈ 3.6-9.3; descriptive study-specific measures), and cross-compartment correlations were predominantly weak (r ≈ -0.3 to +0.3) in the only paired viral LRTI study; interferon-stimulated gene 15 (ISG15; r = 0.79) was a notable exception. Paired evidence derives mostly from a pediatric cohort, hospital-acquired pneumonia, and acute respiratory distress syndrome (ARDS); adult community-acquired LRTI remains under-represented. Current evidence suggests that peripheral blood provides an incomplete, context-dependent representation of airway-local responses; closing this gap requires adult longitudinal paired cohorts, non-invasive airway sampling, improved integration algorithms, and multimodal data fusion.},
}
RevDate: 2026-11-14
CmpDate: 2026-11-14
Job Satisfaction Among Healthcare Professionals During and Directly After the COVID-19 Pandemic: A Systematic Review of Psychosocial, Organizational and System-Level Factors.
Healthcare (Basel, Switzerland), 14(21):.
BACKGROUND/OBJECTIVES: The COVID-19 pandemic substantially changed working conditions in healthcare and increased the workload of healthcare professionals. This systematic review aimed to identify factors associated with job satisfaction among physicians, nurses, and paramedics during the COVID-19 pandemic, with particular emphasis on psychosocial, organizational, and system-level factors.
METHODS: A systematic review was conducted in accordance with PRISMA guidelines. Searches were performed in ScienceDirect (10 January 2026), PubMed (16 January 2026), and Scopus (22 January 2026). Original studies published between 2020 and 2025 in English or Polish were eligible. Three researchers independently conducted the study selection and methodological assessment. Methodological quality was assessed using JBI critical appraisal tools. Fifteen studies involving physicians, nurses, and paramedics were included. Findings were synthesized narratively because of substantial heterogeneity among the included studies. The review was registered in the Open Science Framework.
CONCLUSIONS: Higher job satisfaction was associated with older age, longer length of service and higher remuneration. In contrast, lower job satisfaction was associated with direct work with patients infected with SARS-CoV-2, higher levels of stress and burnout, and poor work organization.
LIMITATIONS: The main limitations were related to the fact that only three databases were searched, the heterogeneity of the studies, and a language restriction, as only articles in Polish and English were included in the search.
Additional Links: PMID-43028837
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43028837,
year = {2026},
author = {Makowicz, D and Dziubaszewska, R and Bryniarski, K and Lisowicz, K and Zarzycka, D},
title = {Job Satisfaction Among Healthcare Professionals During and Directly After the COVID-19 Pandemic: A Systematic Review of Psychosocial, Organizational and System-Level Factors.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {21},
pages = {},
pmid = {43028837},
issn = {2227-9032},
abstract = {BACKGROUND/OBJECTIVES: The COVID-19 pandemic substantially changed working conditions in healthcare and increased the workload of healthcare professionals. This systematic review aimed to identify factors associated with job satisfaction among physicians, nurses, and paramedics during the COVID-19 pandemic, with particular emphasis on psychosocial, organizational, and system-level factors.
METHODS: A systematic review was conducted in accordance with PRISMA guidelines. Searches were performed in ScienceDirect (10 January 2026), PubMed (16 January 2026), and Scopus (22 January 2026). Original studies published between 2020 and 2025 in English or Polish were eligible. Three researchers independently conducted the study selection and methodological assessment. Methodological quality was assessed using JBI critical appraisal tools. Fifteen studies involving physicians, nurses, and paramedics were included. Findings were synthesized narratively because of substantial heterogeneity among the included studies. The review was registered in the Open Science Framework.
CONCLUSIONS: Higher job satisfaction was associated with older age, longer length of service and higher remuneration. In contrast, lower job satisfaction was associated with direct work with patients infected with SARS-CoV-2, higher levels of stress and burnout, and poor work organization.
LIMITATIONS: The main limitations were related to the fact that only three databases were searched, the heterogeneity of the studies, and a language restriction, as only articles in Polish and English were included in the search.},
}
RevDate: 2026-11-14
CmpDate: 2026-11-14
An Artificial Intelligence-Assisted Umbrella Review of Eating Disorder Meta-Analyses (2020-2025): Mapping Treatment Efficacy, Comorbidity, and Persistent Gaps in Sample Diversity.
Nutrients, 18(21):.
Background/Objectives: Eating disorders (EDs) are serious psychiatric illnesses that result in physical and mental-health impairments. A unifying summary of the broad collection of ED research findings is lacking. This umbrella review leveraged artificial intelligence (AI) to summarize ED-focused meta-analyses, to identify directions for future research and treatment. Methods: PubMed, PsycINFO, Web of Science, Embase, and ProQuest were searched for meta-analyses of human ED research published between 1 June 2020 and 31 May 2025 (inclusive). A large language model (LLM) conducted risk of bias assessment and data extraction for studies meeting all inclusion criteria. Neural topic modeling (BERTopic) identified the themes present across included meta-analyses, and an LLM summarized findings of articles in each category. Results: 220 meta-analyses were included. AI tools demonstrated good accuracy in quality appraisal, data extraction, and data synthesis (97%, 93%, and 96%, respectively). Most meta-analyses had at least one critical flaw (per AMSTAR 2 quality appraisal). Neural topic modeling identified 16 themes within the set of included articles: Neurocognition, Treatment Effectiveness, Intervention Efficacy, Biomarkers, Premorbid Conditions, Clinical Features, Epidemiology, Psychiatric Comorbidity, Behavioral Addictions, Long-Term Outcomes, Prevention, Psychological Factors, Treatment Gaps, COVID-19, Pharmacotherapy, and Avoidant Restrictive Food Intake Disorder. Article summaries collectively identified ED prevalence of 1.69% and associations of EDs with mortality and disability. Studies covered a range of illness mechanisms and treatments, though disproportionately included Western females. Conclusions: This review highlights the broad scope but limited generalizability of ED research, as well as the potential of AI to accelerate systematic review workflows.
Additional Links: PMID-43030277
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43030277,
year = {2026},
author = {Lloyd, EC and Calderon, PDS and Morales, C and Lee, E and Maharajh, S and Moorman, B and Le Grange, D and Hagan, K and Gorrell, S},
title = {An Artificial Intelligence-Assisted Umbrella Review of Eating Disorder Meta-Analyses (2020-2025): Mapping Treatment Efficacy, Comorbidity, and Persistent Gaps in Sample Diversity.},
journal = {Nutrients},
volume = {18},
number = {21},
pages = {},
pmid = {43030277},
issn = {2072-6643},
support = {1K01MH139904-01A1/NH/NIH HHS/United States ; 5T32MH096679-13A1/NH/NIH HHS/United States ; 1K23MH137567-01A1/NH/NIH HHS/United States ; //Fundación Alfonso Martín Escudero/ ; },
mesh = {Humans ; *Feeding and Eating Disorders/therapy/epidemiology/psychology ; *Artificial Intelligence ; Meta-Analysis as Topic ; Comorbidity ; Treatment Outcome ; Large Language Models ; Female ; Evidence Gaps ; },
abstract = {Background/Objectives: Eating disorders (EDs) are serious psychiatric illnesses that result in physical and mental-health impairments. A unifying summary of the broad collection of ED research findings is lacking. This umbrella review leveraged artificial intelligence (AI) to summarize ED-focused meta-analyses, to identify directions for future research and treatment. Methods: PubMed, PsycINFO, Web of Science, Embase, and ProQuest were searched for meta-analyses of human ED research published between 1 June 2020 and 31 May 2025 (inclusive). A large language model (LLM) conducted risk of bias assessment and data extraction for studies meeting all inclusion criteria. Neural topic modeling (BERTopic) identified the themes present across included meta-analyses, and an LLM summarized findings of articles in each category. Results: 220 meta-analyses were included. AI tools demonstrated good accuracy in quality appraisal, data extraction, and data synthesis (97%, 93%, and 96%, respectively). Most meta-analyses had at least one critical flaw (per AMSTAR 2 quality appraisal). Neural topic modeling identified 16 themes within the set of included articles: Neurocognition, Treatment Effectiveness, Intervention Efficacy, Biomarkers, Premorbid Conditions, Clinical Features, Epidemiology, Psychiatric Comorbidity, Behavioral Addictions, Long-Term Outcomes, Prevention, Psychological Factors, Treatment Gaps, COVID-19, Pharmacotherapy, and Avoidant Restrictive Food Intake Disorder. Article summaries collectively identified ED prevalence of 1.69% and associations of EDs with mortality and disability. Studies covered a range of illness mechanisms and treatments, though disproportionately included Western females. Conclusions: This review highlights the broad scope but limited generalizability of ED research, as well as the potential of AI to accelerate systematic review workflows.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Feeding and Eating Disorders/therapy/epidemiology/psychology
*Artificial Intelligence
Meta-Analysis as Topic
Comorbidity
Treatment Outcome
Large Language Models
Female
Evidence Gaps
RevDate: 2026-11-14
CmpDate: 2026-11-14
Navigating the Pharma 4.0 revolution: how AI-enabled applications and predictive modelling shaped pharmaceutical development in the post-pandemic era: a systematic review.
Frontiers in artificial intelligence, 9:1976101.
Pharma 4.0 is touted to make processes more efficient and resilient to unforeseen circumstances, boosting productivity, speed and accuracy of pharmaceutical systems. Besides operational stability, these technological implementations could potentially improve clinical outcomes. AI-enabled Pharma 4.0 applications and predictive modelling are utilised in pharmaceutical development for the discovery of new compounds that could potentially be used as drugs for COVID-19. This systematic review examined how contemporary Pharma 4.0 technologies have impacted pharmaceutical development in the post COVID-19 pandemic. A systematic review following the "Preferred Reporting Items for Systematic Review and Meta-Analyses" (PRISMA) method was carried out on scientific peer-reviewed literature, covering the period from 2023 to 2025. From the PubMed and Scopus databases, 593 articles were identified and 57 were included for further analysis. Performance metrics describing the reported predictive models used in research areas were identified and descriptive statistics were used to present the findings. We found that predictive models of Pharma 4.0 technologies were predominantly concentrated in early-stage drug discovery and computational research, with reported benefits of more efficient and accurate processes. Our current findings on the nonclinical performance metrics observed good use cases for drug discovery, but limited insights on the clinical applications that these recent technological developments had on the pharmacological effects. These technologies enhanced complex processes, facilitated predictive models to optimise product development in the early phase of the product life cycle.
Additional Links: PMID-43032471
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43032471,
year = {2026},
author = {Chang, XY and Teo, C and Goh, CH},
title = {Navigating the Pharma 4.0 revolution: how AI-enabled applications and predictive modelling shaped pharmaceutical development in the post-pandemic era: a systematic review.},
journal = {Frontiers in artificial intelligence},
volume = {9},
number = {},
pages = {1976101},
doi = {10.3389/frai.2026.1976101},
pmid = {43032471},
issn = {2624-8212},
abstract = {Pharma 4.0 is touted to make processes more efficient and resilient to unforeseen circumstances, boosting productivity, speed and accuracy of pharmaceutical systems. Besides operational stability, these technological implementations could potentially improve clinical outcomes. AI-enabled Pharma 4.0 applications and predictive modelling are utilised in pharmaceutical development for the discovery of new compounds that could potentially be used as drugs for COVID-19. This systematic review examined how contemporary Pharma 4.0 technologies have impacted pharmaceutical development in the post COVID-19 pandemic. A systematic review following the "Preferred Reporting Items for Systematic Review and Meta-Analyses" (PRISMA) method was carried out on scientific peer-reviewed literature, covering the period from 2023 to 2025. From the PubMed and Scopus databases, 593 articles were identified and 57 were included for further analysis. Performance metrics describing the reported predictive models used in research areas were identified and descriptive statistics were used to present the findings. We found that predictive models of Pharma 4.0 technologies were predominantly concentrated in early-stage drug discovery and computational research, with reported benefits of more efficient and accurate processes. Our current findings on the nonclinical performance metrics observed good use cases for drug discovery, but limited insights on the clinical applications that these recent technological developments had on the pharmacological effects. These technologies enhanced complex processes, facilitated predictive models to optimise product development in the early phase of the product life cycle.},
}
RevDate: 2026-11-14
CmpDate: 2026-11-14
From prophylactic mRNA vaccines against viral infections to therapeutic applications: regulatory science considerations for expanding mRNA platforms.
Frontiers in immunology, 17:2007961.
Conventional non-amplifying messenger RNA (mRNA) and self-amplifying RNA (saRNA) medicines generally share a core linear RNA architecture-including a 5' cap, untranslated regions, one or more open reading frames, and a poly(A) tail-and are commonly formulated with delivery systems such as lipid nanoparticles (LNPs) to enable transient intracellular expression of a target protein. Prophylactic mRNA vaccines are designed primarily to express infectious-disease antigens and generate protective immune memory, whereas mRNA therapeutics exert pharmacological effects intended to treat disease, suppress recurrence, replace proteins, modulate immunity, or deliver gene-editing enzymes. Thus, even products based on similar mRNA-LNP technology may have different regulatory classifications and evidence requirements according to their intended use and mechanism of action. The clinical and regulatory landscape has expanded beyond the first coronavirus disease 2019 vaccines to include respiratory syncytial virus and influenza mRNA vaccines, an influenza-coronavirus disease 2019 combination vaccine, an authorized saRNA vaccine, personalized cancer immunotherapies, protein-replacement therapies, in vivo cell programming, and gene-editing delivery systems. This review examines which prophylactic-vaccine evidence can support therapeutic development and where product-specific quality, nonclinical, clinical, and lifecycle evidence remains necessary. For prophylactic mRNA vaccines, major regulatory considerations include quality, immunogenicity, preventive efficacy, lot release, and safety surveillance after large-scale vaccination. For mRNA therapeutics, the principal issues include delivery to target tissues, function of the expressed product, repeat-dose safety, biodistribution, off-target risk, long-term follow-up, and patient-specific manufacture and traceability. In particular, although personalized mRNA cancer vaccines are commonly described as vaccines, they are closer in regulatory purpose to therapeutics that act on the basis of each patient's tumor characteristics than to vaccines that prevent infectious disease. Antigen-selection algorithms, patient-specific sequence design, small-batch and multi-product manufacture, product-patient matching, clinical evaluation of combination strategies, manufacturing delays and analysis populations, and risk-based long-term postauthorization follow-up therefore require explicit regulatory consideration. Platform-level knowledge from prophylactic mRNA vaccine authorization can support therapeutic development, but regulatory questions may vary with each new product type; developers will need to track evolving regulatory instruments across jurisdictions and engage regulatory authorities early.
Additional Links: PMID-43032544
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43032544,
year = {2026},
author = {Yi, S and Seo, E and Park, PG and Hong, KJ},
title = {From prophylactic mRNA vaccines against viral infections to therapeutic applications: regulatory science considerations for expanding mRNA platforms.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {2007961},
pmid = {43032544},
issn = {1664-3224},
mesh = {Humans ; *mRNA Vaccines/immunology/therapeutic use ; Animals ; *Virus Diseases/prevention & control/immunology/therapy ; *RNA, Messenger/immunology/genetics ; Cancer Vaccines/immunology ; *Viral Vaccines/immunology ; },
abstract = {Conventional non-amplifying messenger RNA (mRNA) and self-amplifying RNA (saRNA) medicines generally share a core linear RNA architecture-including a 5' cap, untranslated regions, one or more open reading frames, and a poly(A) tail-and are commonly formulated with delivery systems such as lipid nanoparticles (LNPs) to enable transient intracellular expression of a target protein. Prophylactic mRNA vaccines are designed primarily to express infectious-disease antigens and generate protective immune memory, whereas mRNA therapeutics exert pharmacological effects intended to treat disease, suppress recurrence, replace proteins, modulate immunity, or deliver gene-editing enzymes. Thus, even products based on similar mRNA-LNP technology may have different regulatory classifications and evidence requirements according to their intended use and mechanism of action. The clinical and regulatory landscape has expanded beyond the first coronavirus disease 2019 vaccines to include respiratory syncytial virus and influenza mRNA vaccines, an influenza-coronavirus disease 2019 combination vaccine, an authorized saRNA vaccine, personalized cancer immunotherapies, protein-replacement therapies, in vivo cell programming, and gene-editing delivery systems. This review examines which prophylactic-vaccine evidence can support therapeutic development and where product-specific quality, nonclinical, clinical, and lifecycle evidence remains necessary. For prophylactic mRNA vaccines, major regulatory considerations include quality, immunogenicity, preventive efficacy, lot release, and safety surveillance after large-scale vaccination. For mRNA therapeutics, the principal issues include delivery to target tissues, function of the expressed product, repeat-dose safety, biodistribution, off-target risk, long-term follow-up, and patient-specific manufacture and traceability. In particular, although personalized mRNA cancer vaccines are commonly described as vaccines, they are closer in regulatory purpose to therapeutics that act on the basis of each patient's tumor characteristics than to vaccines that prevent infectious disease. Antigen-selection algorithms, patient-specific sequence design, small-batch and multi-product manufacture, product-patient matching, clinical evaluation of combination strategies, manufacturing delays and analysis populations, and risk-based long-term postauthorization follow-up therefore require explicit regulatory consideration. Platform-level knowledge from prophylactic mRNA vaccine authorization can support therapeutic development, but regulatory questions may vary with each new product type; developers will need to track evolving regulatory instruments across jurisdictions and engage regulatory authorities early.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*mRNA Vaccines/immunology/therapeutic use
Animals
*Virus Diseases/prevention & control/immunology/therapy
*RNA, Messenger/immunology/genetics
Cancer Vaccines/immunology
*Viral Vaccines/immunology
RevDate: 2026-11-14
CmpDate: 2026-11-14
Low-dose aripiprazole for long COVID symptom management: A retrospective observational study.
Brain, behavior, & immunity - health, 58:101379 pii:S2666-3546(26)00212-7.
BACKGROUND: Long COVID (LC) is defined as the persistence of new or worsened symptoms for 3 or more months following acute SARS-CoV-2 infection, affecting multiple organ systems. Currently, there are no approved drugs for treating LC. We reported the effect of low-dose Aripiprazole (LDA) on the management of LC symptoms in a retrospective study.
METHODS: A retrospective study was done using electronic health records from 50 adult patients from the Stanford LC clinic with a history of SARS-CoV-2 and subsequent LC who received LDA between 5/2021 and 10/2023. LDA was prescribed with dose titration (0.1-2.0 mg oral daily). The assessment include 29 symptoms, (ii) severity of each symptom on the Likert-scale 1 (mild) to 5 (very severe), and (iii) the Functional Status Scale (FSS) from asymptomatic (level I), symptomatic without limitations (level II), symptomatic with reduced daily activity (level III), symptomatic with a struggle to perform daily activities (level IV), or incapacitated and bedridden (level V). An improvement was defined as a reduction in the ordinal scale (V, IV, III, II, and I) from higher to lower before and after exposure to LDA. A composite score of the severity of the seven most common symptoms (headache, fatigue, brain fog, unrefreshing sleep, sleep difficulty, post-exertional malaise, and lightheadedness) was calculated to assess the effect of LDA pre- and post-treatment, using Wilcoxon Signed-Rank Tests.
RESULTS: Within the cohort of 50 patients, the median patient age was 46.5 years, 62% were female, and the mean body mass index (BMI) was 27.5 kg/m[2] The median duration of symptoms was 566.5 days (range 153-1457). The FSS improved significantly from 3.78 to 3.28 (p = 0.001). There were no statistically significant differences in reductions in symptom severity, symptom count, or composite scores across the seven selected symptoms. Symptom duration before treatment, and course of the illness before and after the aripiprazole period did not significantly affect treatment associated changes. The median dose of Aripiprazole was 1 mg. Aripiprazole was generally well tolerated in our study cohort, with no severe adverse effects reported.
CONCLUSION: In our cohort study, LDA was associated with improved FSS. These retrospective observational results suggest that LDA warrants further investigation in a randomized controlled trial as a therapeutic option for LC. Exploring the mechanism of action for LDA in LC may also provide new insights into pathogenesis.
Additional Links: PMID-43032818
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43032818,
year = {2026},
author = {Cui, JL and Kalaycioglu, M and Ricciardiello Mejia, GC and Tian, L and Geng, LN and McComsey, G and Macorni, V and Ballon, J and Chopra, A and Quach, TC and Grewal, M and Paleru, AM and Xin, V and Robinson, ML and Grossman, L and Shafer, R and Bonilla, H},
title = {Low-dose aripiprazole for long COVID symptom management: A retrospective observational study.},
journal = {Brain, behavior, & immunity - health},
volume = {58},
number = {},
pages = {101379},
doi = {10.1016/j.bbih.2026.101379},
pmid = {43032818},
issn = {2666-3546},
abstract = {BACKGROUND: Long COVID (LC) is defined as the persistence of new or worsened symptoms for 3 or more months following acute SARS-CoV-2 infection, affecting multiple organ systems. Currently, there are no approved drugs for treating LC. We reported the effect of low-dose Aripiprazole (LDA) on the management of LC symptoms in a retrospective study.
METHODS: A retrospective study was done using electronic health records from 50 adult patients from the Stanford LC clinic with a history of SARS-CoV-2 and subsequent LC who received LDA between 5/2021 and 10/2023. LDA was prescribed with dose titration (0.1-2.0 mg oral daily). The assessment include 29 symptoms, (ii) severity of each symptom on the Likert-scale 1 (mild) to 5 (very severe), and (iii) the Functional Status Scale (FSS) from asymptomatic (level I), symptomatic without limitations (level II), symptomatic with reduced daily activity (level III), symptomatic with a struggle to perform daily activities (level IV), or incapacitated and bedridden (level V). An improvement was defined as a reduction in the ordinal scale (V, IV, III, II, and I) from higher to lower before and after exposure to LDA. A composite score of the severity of the seven most common symptoms (headache, fatigue, brain fog, unrefreshing sleep, sleep difficulty, post-exertional malaise, and lightheadedness) was calculated to assess the effect of LDA pre- and post-treatment, using Wilcoxon Signed-Rank Tests.
RESULTS: Within the cohort of 50 patients, the median patient age was 46.5 years, 62% were female, and the mean body mass index (BMI) was 27.5 kg/m[2] The median duration of symptoms was 566.5 days (range 153-1457). The FSS improved significantly from 3.78 to 3.28 (p = 0.001). There were no statistically significant differences in reductions in symptom severity, symptom count, or composite scores across the seven selected symptoms. Symptom duration before treatment, and course of the illness before and after the aripiprazole period did not significantly affect treatment associated changes. The median dose of Aripiprazole was 1 mg. Aripiprazole was generally well tolerated in our study cohort, with no severe adverse effects reported.
CONCLUSION: In our cohort study, LDA was associated with improved FSS. These retrospective observational results suggest that LDA warrants further investigation in a randomized controlled trial as a therapeutic option for LC. Exploring the mechanism of action for LDA in LC may also provide new insights into pathogenesis.},
}
RevDate: 2025-08-05
CmpDate: 2025-03-25
Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.
JAMA, 333(12):1062-1073.
IMPORTANCE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors improve hyperglycemia, and SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACEs) among individuals with type 2 diabetes. It is not clear whether efficacy varies by age or sex.
OBJECTIVE: To assess whether age or sex are associated with differences in the efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and DPP4 inhibitors.
The MEDLINE and Embase databases and US and Chinese clinical trial registries were searched for articles published from inception to November 2022; in August 2024, the search was updated to capture the trial results. Two reviewers screened for randomized clinical trials of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP4 inhibitors vs a placebo or active comparator in adults with type 2 diabetes.
DATA EXTRACTION AND SYNTHESIS: Individual participant data and aggregate data were used to estimate age × treatment interactions and sex × treatment interactions in multilevel network meta-regression models.
MAIN OUTCOME AND MEASURES: Hemoglobin A1c (HbA1c) and MACEs.
RESULTS: Of the 601 eligible trials identified (592 trials with 309 503 participants reported HbA1c; mean age, 58.9 [SD, 10.8] years; 42.3% were female and 23 trials with 168 489 participants reported MACEs; mean age, 64.0 [SD, 8.6] years; 35.3% were female), individual participant data were obtained for 103 trials (103 reported HbA1c and 6 reported MACEs). The use of SGLT2 inhibitors (vs placebo) was associated with less HbA1c lowering with increasing age for monotherapy (absolute reduction [AR], 0.24% [95% credible interval {CrI}, 0.10% to 0.38%] per 30-year increment in age), for dual therapy (AR, 0.17% [95% CrI, 0.10% to 0.24%]), and for triple therapy (AR, 0.25% [95% CrI, 0.20% to 0.30%]). The use of GLP-1 receptor agonists was associated with greater HbA1c lowering with increasing age for monotherapy (AR, -0.18% [95% CrI, -0.31% to -0.05%] per 30-year increment in age) and for dual therapy (AR, -0.24% [95% CrI, -0.40% to -0.07%]), but not for triple therapy (AR, 0.04% [95% CrI, -0.02% to 0.11%]). The use of DPP4 inhibitors was associated with slightly better HbA1c lowering in older people for dual therapy (AR, -0.09% [95% CrI, -0.15% to -0.03%] per 30-year increment in age), but not for monotherapy (AR, -0.08% [95% CrI, -0.18% to 0.01%]) or triple therapy (AR, -0.01% [95% CrI, -0.06% to 0.05%]). The relative reduction in MACEs with use of SGLT2 inhibitors was greater in older vs younger participants per 30-year increment in age (hazard ratio, 0.76 [95% CrI, 0.62 to 0.93]), and the relative reduction in MACEs with use of GLP-1 receptor agonists was less in older vs younger participants (hazard ratio, 1.47 [95% CrI, 1.07 to 2.02]). There was no consistent evidence for sex × treatment interactions with use of SGLT2 inhibitors and GLP-1 receptor agonists.
CONCLUSIONS AND RELEVANCE: The SGLT2 inhibitors and GLP-1 receptor agonists were associated with lower risk of MACEs. Analysis of age × treatment interactions suggested that SGLT2 inhibitors were more cardioprotective in older than in younger people despite smaller reductions in HbA1c; GLP-1 receptor agonists were more cardioprotective in younger people.
Additional Links: PMID-39899304
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid39899304,
year = {2025},
author = {Hanlon, P and Butterly, E and Wei, L and Wightman, H and Almazam, SAM and Alsallumi, K and Crowther, J and McChrystal, R and Rennison, H and Hughes, K and Lewsey, J and Lindsay, R and McGurnaghan, S and Petrie, J and Tomlinson, LA and Wild, S and Adler, A and Sattar, N and Phillippo, DM and Dias, S and Welton, NJ and McAllister, DA},
title = {Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.},
journal = {JAMA},
volume = {333},
number = {12},
pages = {1062-1073},
pmid = {39899304},
issn = {1538-3598},
support = {MR/W016648/1/MRC_/Medical Research Council/United Kingdom ; },
mesh = {Aged ; Female ; Humans ; Male ; Middle Aged ; Age Factors ; Cardiovascular Diseases/epidemiology/etiology/prevention & control ; *Diabetes Mellitus, Type 2/blood/complications/drug therapy ; *Dipeptidyl-Peptidase IV Inhibitors/administration & dosage/adverse effects ; *Glucagon-Like Peptide-1 Receptor Agonists/administration & dosage/adverse effects ; Glycated Hemoglobin/analysis ; Randomized Controlled Trials as Topic ; Sex Factors ; *Sodium-Glucose Transporter 2 Inhibitors/administration & dosage/adverse effects ; Treatment Outcome ; Glycemic Control/adverse effects/methods/statistics & numerical data ; Adult ; Aged, 80 and over ; Drug Therapy, Combination/adverse effects/methods ; Incidence ; },
abstract = {IMPORTANCE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors improve hyperglycemia, and SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACEs) among individuals with type 2 diabetes. It is not clear whether efficacy varies by age or sex.
OBJECTIVE: To assess whether age or sex are associated with differences in the efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and DPP4 inhibitors.
The MEDLINE and Embase databases and US and Chinese clinical trial registries were searched for articles published from inception to November 2022; in August 2024, the search was updated to capture the trial results. Two reviewers screened for randomized clinical trials of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP4 inhibitors vs a placebo or active comparator in adults with type 2 diabetes.
DATA EXTRACTION AND SYNTHESIS: Individual participant data and aggregate data were used to estimate age × treatment interactions and sex × treatment interactions in multilevel network meta-regression models.
MAIN OUTCOME AND MEASURES: Hemoglobin A1c (HbA1c) and MACEs.
RESULTS: Of the 601 eligible trials identified (592 trials with 309 503 participants reported HbA1c; mean age, 58.9 [SD, 10.8] years; 42.3% were female and 23 trials with 168 489 participants reported MACEs; mean age, 64.0 [SD, 8.6] years; 35.3% were female), individual participant data were obtained for 103 trials (103 reported HbA1c and 6 reported MACEs). The use of SGLT2 inhibitors (vs placebo) was associated with less HbA1c lowering with increasing age for monotherapy (absolute reduction [AR], 0.24% [95% credible interval {CrI},
0.10% to 0.38%] per 30-year increment in age), for dual therapy (AR, 0.17% [95% CrI, 0.10% to 0.24%]), and for triple therapy (AR, 0.25% [95% CrI, 0.20% to 0.30%]). The use of GLP-1 receptor agonists was associated with greater HbA1c lowering with increasing age for monotherapy (AR, -0.18% [95% CrI, -0.31% to -0.05%] per 30-year increment in age) and for dual therapy (AR, -0.24% [95% CrI, -0.40% to -0.07%]), but not for triple therapy (AR, 0.04% [95% CrI, -0.02% to 0.11%]). The use of DPP4 inhibitors was associated with slightly better HbA1c lowering in older people for dual therapy (AR, -0.09% [95% CrI, -0.15% to -0.03%] per 30-year increment in age), but not for monotherapy (AR, -0.08% [95% CrI, -0.18% to 0.01%]) or triple therapy (AR, -0.01% [95% CrI, -0.06% to 0.05%]). The relative reduction in MACEs with use of SGLT2 inhibitors was greater in older vs younger participants per 30-year increment in age (hazard ratio, 0.76 [95% CrI, 0.62 to 0.93]), and the relative reduction in MACEs with use of GLP-1 receptor agonists was less in older vs younger participants (hazard ratio, 1.47 [95% CrI, 1.07 to 2.02]). There was no consistent evidence for sex × treatment interactions with use of SGLT2 inhibitors and GLP-1 receptor agonists.
CONCLUSIONS AND RELEVANCE: The SGLT2 inhibitors and GLP-1 receptor agonists were associated with lower risk of MACEs. Analysis of age × treatment interactions suggested that SGLT2 inhibitors were more cardioprotective in older than in younger people despite smaller reductions in HbA1c; GLP-1 receptor agonists were more cardioprotective in younger people.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Aged
Female
Humans
Male
Middle Aged
Age Factors
Cardiovascular Diseases/epidemiology/etiology/prevention & control
*Diabetes Mellitus, Type 2/blood/complications/drug therapy
*Dipeptidyl-Peptidase IV Inhibitors/administration & dosage/adverse effects
*Glucagon-Like Peptide-1 Receptor Agonists/administration & dosage/adverse effects
Glycated Hemoglobin/analysis
Randomized Controlled Trials as Topic
Sex Factors
*Sodium-Glucose Transporter 2 Inhibitors/administration & dosage/adverse effects
Treatment Outcome
Glycemic Control/adverse effects/methods/statistics & numerical data
Adult
Aged, 80 and over
Drug Therapy, Combination/adverse effects/methods
Incidence
RevDate: 2026-11-13
CmpDate: 2026-11-13
The Application of Reiki Therapy on Stress, Anxiety, and Well-Being in Health care Workers During the COVID-19 Pandemic: An Integrative Review.
Holistic nursing practice, 41(1):27-35.
The Coronavirus 2019 (COVID-19) pandemic changed the way health care workers manage working with patients globally by increasing demands and resulting in burnout. With limited access to interventions targeting stress, anxiety, and well-being in health care workers, Reiki is a promising intervention that can be conducted virtually with a Reiki practitioner and even be used to treat oneself (self-Reiki). This integrative review highlights Reiki's opportunity to help health care workers combat stress and anxiety and promote healthy well-being. Further research using Reiki with large sample sizes, multi-sites, and outcome evaluation is needed.
Additional Links: PMID-41433417
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid41433417,
year = {2027},
author = {DiBenedetto, JK and Godzik, CM and Stahl, JE},
title = {The Application of Reiki Therapy on Stress, Anxiety, and Well-Being in Health care Workers During the COVID-19 Pandemic: An Integrative Review.},
journal = {Holistic nursing practice},
volume = {41},
number = {1},
pages = {27-35},
pmid = {41433417},
issn = {1550-5138},
mesh = {Humans ; *Reiki/methods ; COVID-19/psychology ; *Anxiety/therapy/psychology ; *Health Personnel/psychology ; Pandemics ; *Stress, Psychological/therapy ; Psychological Well-Being ; *Pneumonia, Viral/epidemiology/psychology ; *Coronavirus Infections/epidemiology/psychology ; Burnout, Professional ; Frontline Workers ; *Therapeutic Touch ; },
abstract = {The Coronavirus 2019 (COVID-19) pandemic changed the way health care workers manage working with patients globally by increasing demands and resulting in burnout. With limited access to interventions targeting stress, anxiety, and well-being in health care workers, Reiki is a promising intervention that can be conducted virtually with a Reiki practitioner and even be used to treat oneself (self-Reiki). This integrative review highlights Reiki's opportunity to help health care workers combat stress and anxiety and promote healthy well-being. Further research using Reiki with large sample sizes, multi-sites, and outcome evaluation is needed.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Reiki/methods
COVID-19/psychology
*Anxiety/therapy/psychology
*Health Personnel/psychology
Pandemics
*Stress, Psychological/therapy
Psychological Well-Being
*Pneumonia, Viral/epidemiology/psychology
*Coronavirus Infections/epidemiology/psychology
Burnout, Professional
Frontline Workers
*Therapeutic Touch
RevDate: 2026-11-13
CmpDate: 2026-11-13
Lipidation and Stapled Peptides: Enhancing Stability and Pharmacokinetics.
Current protein & peptide science, 27(10):904-925.
The potential of peptide therapeutics is high because the targeting is highly specific, toxicity is low, and also the ability to affect complex biological determinants. These things are, however, hampered by issues like low stability, faster corrosion, low bioavailability, and low cell permeability, which limit their effectiveness in clinical conditions. This is why lipidation and peptide stapling approaches to balancing, which are highlighted in this review, are collaborators in challenging these questions. Lipidation is a covalent bonding of fatty acids or hydrophobic components, which increases the pharmacokinetics through better binding to albumin and enhancing half-life and through greater membrane interaction. Stapling also fixes α-helical structures with hydrocarbon or alternative linkers to improve resistance to proteolysis, structural stability, and intracellular transport. The sum of these changes results in a dual functionality peptide with an unexpected increased stability, bioavailability, and therapeutic effect. Other major case studies are antiviral agents targeted at SARS-CoV-2, antimicrobial peptides that include SLP-51, and stapled degraders targeting protein-protein interactions that are oncogenic. The balanced design frameworks, strategic placement of changes, linker techniques, and useful computational tools such as StaPep and Length LogD are also discussed in the review. Although issues of immunogenicity, scalability in manufacturing, and non-invasive delivery still remain, advances in peptide engineering and AI-inspired designing are also assisting in the future of dual-modified therapeutics. The combination of lipidation and stapling is a revolutionary technology that can revolutionize the development of peptide drugs in infectious diseases, cancer, and metabolic diseases.
Additional Links: PMID-41863453
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid41863453,
year = {2026},
author = {Rajesh, RP and Selvam, M and Palaniselvam, S and Ramachandran, S},
title = {Lipidation and Stapled Peptides: Enhancing Stability and Pharmacokinetics.},
journal = {Current protein & peptide science},
volume = {27},
number = {10},
pages = {904-925},
pmid = {41863453},
issn = {1875-5550},
mesh = {Humans ; *Peptides/chemistry/pharmacokinetics/pharmacology ; *Antiviral Agents/chemistry/pharmacokinetics/pharmacology ; Animals ; Protein Stability ; SARS-CoV-2/drug effects ; *COVID-19 Drug Treatment ; Biological Availability ; Hydrophobic and Hydrophilic Interactions ; Antimicrobial Peptides/chemistry/pharmacokinetics ; *Lipids/chemistry ; },
abstract = {The potential of peptide therapeutics is high because the targeting is highly specific, toxicity is low, and also the ability to affect complex biological determinants. These things are, however, hampered by issues like low stability, faster corrosion, low bioavailability, and low cell permeability, which limit their effectiveness in clinical conditions. This is why lipidation and peptide stapling approaches to balancing, which are highlighted in this review, are collaborators in challenging these questions. Lipidation is a covalent bonding of fatty acids or hydrophobic components, which increases the pharmacokinetics through better binding to albumin and enhancing half-life and through greater membrane interaction. Stapling also fixes α-helical structures with hydrocarbon or alternative linkers to improve resistance to proteolysis, structural stability, and intracellular transport. The sum of these changes results in a dual functionality peptide with an unexpected increased stability, bioavailability, and therapeutic effect. Other major case studies are antiviral agents targeted at SARS-CoV-2, antimicrobial peptides that include SLP-51, and stapled degraders targeting protein-protein interactions that are oncogenic. The balanced design frameworks, strategic placement of changes, linker techniques, and useful computational tools such as StaPep and Length LogD are also discussed in the review. Although issues of immunogenicity, scalability in manufacturing, and non-invasive delivery still remain, advances in peptide engineering and AI-inspired designing are also assisting in the future of dual-modified therapeutics. The combination of lipidation and stapling is a revolutionary technology that can revolutionize the development of peptide drugs in infectious diseases, cancer, and metabolic diseases.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Peptides/chemistry/pharmacokinetics/pharmacology
*Antiviral Agents/chemistry/pharmacokinetics/pharmacology
Animals
Protein Stability
SARS-CoV-2/drug effects
*COVID-19 Drug Treatment
Biological Availability
Hydrophobic and Hydrophilic Interactions
Antimicrobial Peptides/chemistry/pharmacokinetics
*Lipids/chemistry
RevDate: 2026-11-13
CmpDate: 2026-11-13
Incremental Net Benefit of COVID-19 Booster Vaccination: A Systematic Review and Meta-Analysis.
Value in health regional issues, 56:101633.
OBJECTIVES: The COVID-19 booster vaccination is recommended to maintain immunity. However, few cost-effectiveness studies of booster vaccinations exist. This meta-analysis was conducted to quantitatively pool the incremental net benefit (INB) of using COVID-19 booster vaccination.
METHODS: We searched PubMed, Embase, EconLit, and the Cost-effectiveness Analysis Registry by Tufts Medical Center to identify studies from inception to December 2024. Studies were eligible if they included cost-effectiveness analyses, reporting cost per quality-adjusted life-year of COVID-19 messenger RNA or adapted booster vaccines compared with primary series or no booster vaccination. Various monetary units were converted to 2023 US dollars. The INBs were pooled across studies using a random-effects model, stratified by country income level, vaccination frequency, study perspective, and age-risk groups. The risk of bias was assessed using the Economic Evaluation Bias checklist. Heterogeneity was assessed using the I[2] statistic.
RESULTS: A total of 8 studies were identified, and 7 were included in the meta-analysis. In the general population, the pooled INB indicated annual booster vaccination was significantly cost-effective from a societal perspective (INB: $210; 95% confidence intervals [CI]: 46-373) but not significant from a payer perspective (INB: $45; 95% CI: -21 to 110). The pooled INB was not cost-effective in the high-risk group from either perspective. For the mixed-risk group, it was cost-effective only from a payer perspective.
CONCLUSION: Compared with no booster vaccination, annual messenger RNA booster vaccination was cost-effective from a societal perspective in the general population. Our findings may facilitate decision making in settings where country-specific studies are unavailable.
Additional Links: PMID-42053479
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42053479,
year = {2026},
author = {Kissi-Twum, K and Cho, JY and Awalime, DK and Chaiyakunapruk, N},
title = {Incremental Net Benefit of COVID-19 Booster Vaccination: A Systematic Review and Meta-Analysis.},
journal = {Value in health regional issues},
volume = {56},
number = {},
pages = {101633},
doi = {10.1016/j.vhri.2026.101633},
pmid = {42053479},
issn = {2212-1102},
mesh = {Humans ; *COVID-19 Vaccines/economics/administration & dosage ; *Immunization, Secondary/economics ; Cost-Benefit Analysis ; *COVID-19/prevention & control ; Cost-Effectiveness Analysis ; },
abstract = {OBJECTIVES: The COVID-19 booster vaccination is recommended to maintain immunity. However, few cost-effectiveness studies of booster vaccinations exist. This meta-analysis was conducted to quantitatively pool the incremental net benefit (INB) of using COVID-19 booster vaccination.
METHODS: We searched PubMed, Embase, EconLit, and the Cost-effectiveness Analysis Registry by Tufts Medical Center to identify studies from inception to December 2024. Studies were eligible if they included cost-effectiveness analyses, reporting cost per quality-adjusted life-year of COVID-19 messenger RNA or adapted booster vaccines compared with primary series or no booster vaccination. Various monetary units were converted to 2023 US dollars. The INBs were pooled across studies using a random-effects model, stratified by country income level, vaccination frequency, study perspective, and age-risk groups. The risk of bias was assessed using the Economic Evaluation Bias checklist. Heterogeneity was assessed using the I[2] statistic.
RESULTS: A total of 8 studies were identified, and 7 were included in the meta-analysis. In the general population, the pooled INB indicated annual booster vaccination was significantly cost-effective from a societal perspective (INB: $210; 95% confidence intervals [CI]: 46-373) but not significant from a payer perspective (INB: $45; 95% CI: -21 to 110). The pooled INB was not cost-effective in the high-risk group from either perspective. For the mixed-risk group, it was cost-effective only from a payer perspective.
CONCLUSION: Compared with no booster vaccination, annual messenger RNA booster vaccination was cost-effective from a societal perspective in the general population. Our findings may facilitate decision making in settings where country-specific studies are unavailable.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*COVID-19 Vaccines/economics/administration & dosage
*Immunization, Secondary/economics
Cost-Benefit Analysis
*COVID-19/prevention & control
Cost-Effectiveness Analysis
RevDate: 2026-11-13
CmpDate: 2026-11-13
In the shadow of crisis: A systematic review and meta-analysis on the impact of the COVID-19 pandemic on children's social-emotional skills, behavioral adjustment, and psychological well-being.
Child development, 97(6):2289-2307.
This meta-analysis synthesizes 157 longitudinal studies from 33 countries, involving demographically diverse samples from a wide range of cultural contexts, to examine COVID-19-related changes in social-emotional development, psychological well-being, and behavioral adjustment among children aged 0-12, and the moderating role of political restrictions. Results showed significant declines in children's social-emotional skills and well-being, and increases in behavioral problems in studies comparing pre-pandemic and during-pandemic data. No further declines emerged in studies comparing multiple time points during the pandemic. Political restrictions moderated the effects: Increases in restriction stringency were associated with stronger declines in well-being and greater increases in externalizing problems, whereas higher restriction levels were associated with stronger increases in internalizing problems. These findings underscore the costs of crisis-related disruptions for child development.
Additional Links: PMID-42119003
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42119003,
year = {2026},
author = {Stacheder, M and Oppermann, E and Anders, Y},
title = {In the shadow of crisis: A systematic review and meta-analysis on the impact of the COVID-19 pandemic on children's social-emotional skills, behavioral adjustment, and psychological well-being.},
journal = {Child development},
volume = {97},
number = {6},
pages = {2289-2307},
doi = {10.1093/chidev/aacag090},
pmid = {42119003},
issn = {1467-8624},
mesh = {Humans ; *COVID-19/psychology ; Psychological Well-Being ; Child ; *Social Adjustment ; *Social Skills ; *Emotional Adjustment ; *Child Behavior/psychology ; Child, Preschool ; *Child Development ; Infant ; },
abstract = {This meta-analysis synthesizes 157 longitudinal studies from 33 countries, involving demographically diverse samples from a wide range of cultural contexts, to examine COVID-19-related changes in social-emotional development, psychological well-being, and behavioral adjustment among children aged 0-12, and the moderating role of political restrictions. Results showed significant declines in children's social-emotional skills and well-being, and increases in behavioral problems in studies comparing pre-pandemic and during-pandemic data. No further declines emerged in studies comparing multiple time points during the pandemic. Political restrictions moderated the effects: Increases in restriction stringency were associated with stronger declines in well-being and greater increases in externalizing problems, whereas higher restriction levels were associated with stronger increases in internalizing problems. These findings underscore the costs of crisis-related disruptions for child development.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*COVID-19/psychology
Psychological Well-Being
Child
*Social Adjustment
*Social Skills
*Emotional Adjustment
*Child Behavior/psychology
Child, Preschool
*Child Development
Infant
RevDate: 2026-11-13
CmpDate: 2026-11-13
High-pressure macromolecular crystallography as a tool for studying protein flexibility.
IUCrJ, 13(Pt 6):766-777 pii:S2052252526008468.
Protein function depends on their conformational flexibility. Complementary to temperature-dependent studies, high-pressure (HP) macromolecular crystallography is well suited to exploring the conformational space of proteins at atomic resolution. We have developed a new HP cell concept for macromolecular X-ray crystallography that overcomes the limitations of current devices. It consists of a single-crystalline sapphire capillary, which is loaded with multiple crystals and pressurized with helium at freely adjustable gas pressures of up to 120 MPa. Studying five different proteins, we generally observed a compression of the protein structures and a decrease in thermal displacement parameters at high pressure. Structurally, observations included the compression of a central tunnel of a biotechnologically relevant enzyme and the stabilization of ligand binding in the membrane protein photosynthetic reaction center of Cereibacter sphaeroides. For two pharmaceutically relevant proteins, the human kinase DRAK2 and SARS-CoV-2 main protease, we identified concerted movements of subdomains. Such knowledge is essential for predictions of protein dynamics and defined conformational states, offering the potential for improved structure-based drug development.
Additional Links: PMID-42895459
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42895459,
year = {2026},
author = {Lieske, J and Saouane, S and Reinke, PYA and Falke, S and Ewert, W and Meyer, J and Pakendorf, T and Burkhardt, A and Crosas, E and Hakanpää, J and Stachnik, K and Sieg, J and Rarey, M and Aßmann, M and Zaun, H and Kuballa, J and Selikhanov, GK and Gabdulkhakov, AG and Chapman, HN and Günther, S and Meents, A},
title = {High-pressure macromolecular crystallography as a tool for studying protein flexibility.},
journal = {IUCrJ},
volume = {13},
number = {Pt 6},
pages = {766-777},
doi = {10.1107/S2052252526008468},
pmid = {42895459},
issn = {2052-2525},
support = {031B0405A/B//Bundesministerium für Bildung und Forschung/ ; 16GW0277//Bundesministerium für Bildung und Forschung/ ; FISCOV//Helmholtz-Gemeinschaft/ ; SFragX//Helmholtz-Gemeinschaft/ ; HIR3X//Helmholtz-Gemeinschaft/ ; },
mesh = {Crystallography, X-Ray/methods/instrumentation ; Protein Conformation ; Pressure ; Humans ; *Proteins/chemistry ; },
abstract = {Protein function depends on their conformational flexibility. Complementary to temperature-dependent studies, high-pressure (HP) macromolecular crystallography is well suited to exploring the conformational space of proteins at atomic resolution. We have developed a new HP cell concept for macromolecular X-ray crystallography that overcomes the limitations of current devices. It consists of a single-crystalline sapphire capillary, which is loaded with multiple crystals and pressurized with helium at freely adjustable gas pressures of up to 120 MPa. Studying five different proteins, we generally observed a compression of the protein structures and a decrease in thermal displacement parameters at high pressure. Structurally, observations included the compression of a central tunnel of a biotechnologically relevant enzyme and the stabilization of ligand binding in the membrane protein photosynthetic reaction center of Cereibacter sphaeroides. For two pharmaceutically relevant proteins, the human kinase DRAK2 and SARS-CoV-2 main protease, we identified concerted movements of subdomains. Such knowledge is essential for predictions of protein dynamics and defined conformational states, offering the potential for improved structure-based drug development.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Crystallography, X-Ray/methods/instrumentation
Protein Conformation
Pressure
Humans
*Proteins/chemistry
RevDate: 2026-11-12
Moral distress among nursing academics: What do we know and what do we need to know? A scoping review.
Nurse education today, 169:107499 pii:S0260-6917(26)00527-7 [Epub ahead of print].
BACKGROUND: Nursing academics navigate competing institutional, educational and professional obligations that may give rise to moral distress when ethically appropriate action is constrained. Although extensively examined in clinical settings, moral distress in higher education remains insufficiently understood.
OBJECTIVES: To map empirical evidence on the sources, experiences, consequences and responses to moral distress among higher education academics, particularly nursing academics, and identify implications for nursing education and future research.
DESIGN: Scoping review.
DATA SOURCES: Electronic database searches were conducted between January and December 2025, supplemented by Google, Google Scholar, grey literature and backward and forward citation searching.
REVIEW METHODS: Guided by the Arksey and O'Malley framework and reported with reference to PRISMA-ScR, the review included English-language empirical studies without publication-year restrictions. Two reviewers screened records and charted study findings. Evidence was organised using descriptive thematic synthesis.
RESULTS: Database searches identified 2310 records; 1980 records were screened and 77 full texts assessed. Six studies met the inclusion criteria, five involving nursing academics. Seven themes were identified: institutional constraints; emotional and physical consequences; compromised professional identity; student-related ethical challenges; faculty and peer conflict; resistance and withdrawal as coping responses; and concerns about professional standards and public safety. COVID-19-related experiences were reported in one study and considered within institutional constraints.
CONCLUSIONS: The evidence suggests that moral distress in nursing academia arises when organisational conditions and competing obligations constrain professional and ethical judgement. Reported consequences include psychological strain, threats to professional identity and disengagement, although causal relationships and workforce effects remain unestablished.
IMPLICATIONS FOR PRACTICE: Schools of nursing and universities should recognise moral distress as a significant occupational and ethical issue, address avoidable sources of distress, strengthen ethical and psychologically safe work environments, and support educators to navigate unavoidable ethical tensions to protect educator wellbeing, educational quality and patient safety.
Additional Links: PMID-43020002
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43020002,
year = {2026},
author = {Ng, L and Burston, A and Chaichana, J and Singh, JKN and Eley, R},
title = {Moral distress among nursing academics: What do we know and what do we need to know? A scoping review.},
journal = {Nurse education today},
volume = {169},
number = {},
pages = {107499},
doi = {10.1016/j.nedt.2026.107499},
pmid = {43020002},
issn = {1532-2793},
abstract = {BACKGROUND: Nursing academics navigate competing institutional, educational and professional obligations that may give rise to moral distress when ethically appropriate action is constrained. Although extensively examined in clinical settings, moral distress in higher education remains insufficiently understood.
OBJECTIVES: To map empirical evidence on the sources, experiences, consequences and responses to moral distress among higher education academics, particularly nursing academics, and identify implications for nursing education and future research.
DESIGN: Scoping review.
DATA SOURCES: Electronic database searches were conducted between January and December 2025, supplemented by Google, Google Scholar, grey literature and backward and forward citation searching.
REVIEW METHODS: Guided by the Arksey and O'Malley framework and reported with reference to PRISMA-ScR, the review included English-language empirical studies without publication-year restrictions. Two reviewers screened records and charted study findings. Evidence was organised using descriptive thematic synthesis.
RESULTS: Database searches identified 2310 records; 1980 records were screened and 77 full texts assessed. Six studies met the inclusion criteria, five involving nursing academics. Seven themes were identified: institutional constraints; emotional and physical consequences; compromised professional identity; student-related ethical challenges; faculty and peer conflict; resistance and withdrawal as coping responses; and concerns about professional standards and public safety. COVID-19-related experiences were reported in one study and considered within institutional constraints.
CONCLUSIONS: The evidence suggests that moral distress in nursing academia arises when organisational conditions and competing obligations constrain professional and ethical judgement. Reported consequences include psychological strain, threats to professional identity and disengagement, although causal relationships and workforce effects remain unestablished.
IMPLICATIONS FOR PRACTICE: Schools of nursing and universities should recognise moral distress as a significant occupational and ethical issue, address avoidable sources of distress, strengthen ethical and psychologically safe work environments, and support educators to navigate unavoidable ethical tensions to protect educator wellbeing, educational quality and patient safety.},
}
RevDate: 2026-11-13
CmpDate: 2026-11-13
Vitamin D binding protein gene polymorphisms and the risk of respiratory diseases: a meta-analysis and systematic review.
BMC medical genomics, 19(1):.
BACKGROUND: Recent studies have found that VDBP gene polymorphism is closely related to the pathogenesis of some respiratory diseases. Rs7041 and rs4588 are two major single-nucleotide polymorphisms(SNPs) in the GC gene encoding VDBP. Different combinations of these variants give rise to three major haplotypic isoforms, GC*1F, GC*1S, and GC*2, which may influence pulmonary immune-inflammatory responses and immune regulation. This systematic review and meta-analysis aimed to clarify the associations between VDBP gene polymorphisms and respiratory diseases including chronic obstructive pulmonary disease(COPD), asthma, Corona Virus Disease-2019(COVID-19) and tuberculosis, so as to provide evidence for the formulation of individualized prevention and therapeutic strategies in the future.
METHODS: We searched the Pubmed, web of science, Wanfang, Embase and China National Knowledge Infrastructure(CNKI) to find the eligible case-control studies. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Forest plots were generated using Review Manager version 5.4, and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.
RESULTS: A total of 30 studies involving 8,844 participants were included. No significant associations were observed between the rs7041 or rs4588 polymorphism and COPD susceptibility (both P > 0.05). In the analysis of GC variants, GC*1F-related genetic models were associated with an increased risk of COPD. The ORs for GC*1F/1F versus GC*1F/1S and for GC*1F/1F versus GC*1S/1S group were 1.73 and 2.17, respectively. The OR for the GC*1F/1F homozygous comparison was 1.96, and the GC*1F allele analysis was also statistically significant (P = 0.0003). Ethnicity-based subgroup analyses suggested that GC*1F may be primarily associated with increased COPD susceptibility in East Asian populations. In non-East Asian populations, GC*2 showed a trend toward a reduced risk of COPD, although this association did not reach statistical significance (OR = 0.52, P = 0.09). In the asthma analysis, GC*2 may be associated with an increased risk of asthma (P ≤ 0.001). However, because relatively few studies were available for asthma, COVID-19, and tuberculosis, and substantial heterogeneity was present in some analyses, the current evidence remains insufficient to draw definitive conclusions regarding the associations between GC variants and these diseases.
CONCLUSION: The GC*1F allele and GC*1F/1F diplotype may be associated with increased susceptibility to COPD, particularly in East Asian populations, whereas no significant associations were observed between rs7041 or rs4588 and COPD risk. GC*2 may show a potentially protective trend against COPD in non-East Asian populations but may be associated with increased asthma susceptibility. Given the limited and highly heterogeneous evidence regarding asthma, COVID-19, and tuberculosis, further high-quality studies are needed to validate these findings.
Additional Links: PMID-43021259
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43021259,
year = {2026},
author = {Zhang, J and Li, H and Chi, X and Zhang, G and Jiang, H},
title = {Vitamin D binding protein gene polymorphisms and the risk of respiratory diseases: a meta-analysis and systematic review.},
journal = {BMC medical genomics},
volume = {19},
number = {1},
pages = {},
pmid = {43021259},
issn = {1755-8794},
mesh = {*Vitamin D-Binding Protein/genetics ; Humans ; *Polymorphism, Single Nucleotide ; *Genetic Predisposition to Disease ; Pulmonary Disease, Chronic Obstructive/genetics ; Asthma/genetics ; COVID-19/genetics ; },
abstract = {BACKGROUND: Recent studies have found that VDBP gene polymorphism is closely related to the pathogenesis of some respiratory diseases. Rs7041 and rs4588 are two major single-nucleotide polymorphisms(SNPs) in the GC gene encoding VDBP. Different combinations of these variants give rise to three major haplotypic isoforms, GC*1F, GC*1S, and GC*2, which may influence pulmonary immune-inflammatory responses and immune regulation. This systematic review and meta-analysis aimed to clarify the associations between VDBP gene polymorphisms and respiratory diseases including chronic obstructive pulmonary disease(COPD), asthma, Corona Virus Disease-2019(COVID-19) and tuberculosis, so as to provide evidence for the formulation of individualized prevention and therapeutic strategies in the future.
METHODS: We searched the Pubmed, web of science, Wanfang, Embase and China National Knowledge Infrastructure(CNKI) to find the eligible case-control studies. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Forest plots were generated using Review Manager version 5.4, and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.
RESULTS: A total of 30 studies involving 8,844 participants were included. No significant associations were observed between the rs7041 or rs4588 polymorphism and COPD susceptibility (both P > 0.05). In the analysis of GC variants, GC*1F-related genetic models were associated with an increased risk of COPD. The ORs for GC*1F/1F versus GC*1F/1S and for GC*1F/1F versus GC*1S/1S group were 1.73 and 2.17, respectively. The OR for the GC*1F/1F homozygous comparison was 1.96, and the GC*1F allele analysis was also statistically significant (P = 0.0003). Ethnicity-based subgroup analyses suggested that GC*1F may be primarily associated with increased COPD susceptibility in East Asian populations. In non-East Asian populations, GC*2 showed a trend toward a reduced risk of COPD, although this association did not reach statistical significance (OR = 0.52, P = 0.09). In the asthma analysis, GC*2 may be associated with an increased risk of asthma (P ≤ 0.001). However, because relatively few studies were available for asthma, COVID-19, and tuberculosis, and substantial heterogeneity was present in some analyses, the current evidence remains insufficient to draw definitive conclusions regarding the associations between GC variants and these diseases.
CONCLUSION: The GC*1F allele and GC*1F/1F diplotype may be associated with increased susceptibility to COPD, particularly in East Asian populations, whereas no significant associations were observed between rs7041 or rs4588 and COPD risk. GC*2 may show a potentially protective trend against COPD in non-East Asian populations but may be associated with increased asthma susceptibility. Given the limited and highly heterogeneous evidence regarding asthma, COVID-19, and tuberculosis, further high-quality studies are needed to validate these findings.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Vitamin D-Binding Protein/genetics
Humans
*Polymorphism, Single Nucleotide
*Genetic Predisposition to Disease
Pulmonary Disease, Chronic Obstructive/genetics
Asthma/genetics
COVID-19/genetics
RevDate: 2026-11-13
Pericarditis in COVID-19: a focus on the paediatric population.
Cardiology in the young pii:S1047951126124688 [Epub ahead of print].
BACKGROUND: COVID-19, caused by SARS-CoV-2, is primarily a respiratory illness but may cause cardiovascular complications, including pericarditis. Pediatric SARS-CoV-2-associated pericarditis remains uncommon and likely underreported. This review summarizes the epidemiology, pathophysiology, clinical presentation, diagnosis, management, and outcomes of pericarditis associated with SARS-CoV-2 infection in children.
METHODS: We narratively reviewed the available literature on SARS-CoV-2-associated pericarditis in the pediatric population, including isolated acute pericarditis, myopericarditis, pericardial effusion, cardiac tamponade, and pericardial involvement in multisystem inflammatory syndrome in children (MIS-C).
RESULTS: The true incidence of pediatric SARS-CoV-2-associated pericarditis remains unclear. Reported cases suggest that older children and adolescents are more commonly affected, typically presenting with chest pain, fever, dyspnea, or tachycardia, whereas younger children may exhibit nonspecific symptoms. Diagnosis relies on clinical criteria supported by electrocardiography, echocardiography, inflammatory markers, and cardiac biomarkers, with cardiac magnetic resonance imaging useful when myocardial involvement is suspected. Available evidence suggests a predominantly immune-mediated pathophysiology involving cytokine dysregulation and systemic inflammation, with limited evidence of direct viral invasion. Management is largely extrapolated from established pediatric pericarditis principles and adult data. Nonsteroidal anti-inflammatory drugs and colchicine are first-line therapies, while corticosteroids or intravenous immunoglobulin may be considered in selected inflammatory or MIS-C-associated cases, and interleukin-1 blockade in refractory or recurrent disease. Most affected children recover, although severe pericardial effusion, tamponade, and recurrence have been reported.
CONCLUSION: Pediatric SARS-CoV-2-associated pericarditis encompasses a spectrum of clinical presentations and generally carries a favorable prognosis. Nevertheless, potentially serious complications emphasize the importance of early recognition, differentiation from myocarditis and MIS-C, and structured follow-up.
Additional Links: PMID-43021480
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43021480,
year = {2026},
author = {Bou Jaoude, CR and Yassine, F and Sleem, B and Awada, A and Bitar, FF and Arabi, M},
title = {Pericarditis in COVID-19: a focus on the paediatric population.},
journal = {Cardiology in the young},
volume = {},
number = {},
pages = {1-9},
doi = {10.1017/S1047951126124688},
pmid = {43021480},
issn = {1467-1107},
abstract = {BACKGROUND: COVID-19, caused by SARS-CoV-2, is primarily a respiratory illness but may cause cardiovascular complications, including pericarditis. Pediatric SARS-CoV-2-associated pericarditis remains uncommon and likely underreported. This review summarizes the epidemiology, pathophysiology, clinical presentation, diagnosis, management, and outcomes of pericarditis associated with SARS-CoV-2 infection in children.
METHODS: We narratively reviewed the available literature on SARS-CoV-2-associated pericarditis in the pediatric population, including isolated acute pericarditis, myopericarditis, pericardial effusion, cardiac tamponade, and pericardial involvement in multisystem inflammatory syndrome in children (MIS-C).
RESULTS: The true incidence of pediatric SARS-CoV-2-associated pericarditis remains unclear. Reported cases suggest that older children and adolescents are more commonly affected, typically presenting with chest pain, fever, dyspnea, or tachycardia, whereas younger children may exhibit nonspecific symptoms. Diagnosis relies on clinical criteria supported by electrocardiography, echocardiography, inflammatory markers, and cardiac biomarkers, with cardiac magnetic resonance imaging useful when myocardial involvement is suspected. Available evidence suggests a predominantly immune-mediated pathophysiology involving cytokine dysregulation and systemic inflammation, with limited evidence of direct viral invasion. Management is largely extrapolated from established pediatric pericarditis principles and adult data. Nonsteroidal anti-inflammatory drugs and colchicine are first-line therapies, while corticosteroids or intravenous immunoglobulin may be considered in selected inflammatory or MIS-C-associated cases, and interleukin-1 blockade in refractory or recurrent disease. Most affected children recover, although severe pericardial effusion, tamponade, and recurrence have been reported.
CONCLUSION: Pediatric SARS-CoV-2-associated pericarditis encompasses a spectrum of clinical presentations and generally carries a favorable prognosis. Nevertheless, potentially serious complications emphasize the importance of early recognition, differentiation from myocarditis and MIS-C, and structured follow-up.},
}
RevDate: 2026-11-13
CmpDate: 2026-11-13
Prevalence of burnout in physiotherapists during the COVID-19 pandemic: systematic review and meta-analysis.
Frontiers in public health, 14:1978417.
UNLABELLED: This study aimed to obtain a pooled estimate of the prevalence of burnout in physiotherapists during the COVID-19 pandemic and to explore differences between low- and middle-income countries (LMICs) and high-income countries (HICs). A systematic search was conducted on six databases, from December 2019 to June 2026. Two reviewers independently extracted data from the included studies and assessed the risk of bias using a modified version of the Newcastle-Ottawa Scale. The pooled prevalence was calculated through meta-analysis of proportions with 95% confidence interval (CI). Prevalence of overall burnout and of its three dimensions of emotional exhaustion (EE), depersonalization (DP), and reduced personal accomplishment (PA) was estimated. A total of 23 studies was included and 19 was used for meta-analyses. Pooled prevalence (95% CI) estimate of 18% (9-35), higher than usually observed pre-COVID. The pooled prevalence of the three MBI components was: EE, 46% (35-57); DP, 46% (21-73), and low PA, 34% (13-64), and tended to be higher in LMICs, although the difference between LMICs and HICs were statistically significant only for EE. The findings indicate a substantial prevalence of burnout among physiotherapists during the COVID-19 pandemic. However, substantial heterogeneity and differences in burnout definitions across studies should be considered when interpreting these estimates. To prevent burnout, special attention should be given to healthcare professionals' wellbeing during exceptional events such as the COVID-19 pandemic.
PROSPERO, CRD420251029422.
Additional Links: PMID-43021887
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43021887,
year = {2026},
author = {Paci, M and Berbenni, N and Ugolini, A and Bianchi, L and Chessa, L and Giusti, M and Di Bari, M},
title = {Prevalence of burnout in physiotherapists during the COVID-19 pandemic: systematic review and meta-analysis.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1978417},
pmid = {43021887},
issn = {2296-2565},
mesh = {Humans ; *Burnout, Professional/epidemiology ; *COVID-19/epidemiology/psychology ; *Physical Therapists/psychology/statistics & numerical data ; Prevalence ; Emotional Exhaustion ; Pandemics ; SARS-CoV-2 ; Developing Countries ; },
abstract = {UNLABELLED: This study aimed to obtain a pooled estimate of the prevalence of burnout in physiotherapists during the COVID-19 pandemic and to explore differences between low- and middle-income countries (LMICs) and high-income countries (HICs). A systematic search was conducted on six databases, from December 2019 to June 2026. Two reviewers independently extracted data from the included studies and assessed the risk of bias using a modified version of the Newcastle-Ottawa Scale. The pooled prevalence was calculated through meta-analysis of proportions with 95% confidence interval (CI). Prevalence of overall burnout and of its three dimensions of emotional exhaustion (EE), depersonalization (DP), and reduced personal accomplishment (PA) was estimated. A total of 23 studies was included and 19 was used for meta-analyses. Pooled prevalence (95% CI) estimate of 18% (9-35), higher than usually observed pre-COVID. The pooled prevalence of the three MBI components was: EE, 46% (35-57); DP, 46% (21-73), and low PA, 34% (13-64), and tended to be higher in LMICs, although the difference between LMICs and HICs were statistically significant only for EE. The findings indicate a substantial prevalence of burnout among physiotherapists during the COVID-19 pandemic. However, substantial heterogeneity and differences in burnout definitions across studies should be considered when interpreting these estimates. To prevent burnout, special attention should be given to healthcare professionals' wellbeing during exceptional events such as the COVID-19 pandemic.
PROSPERO, CRD420251029422.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Burnout, Professional/epidemiology
*COVID-19/epidemiology/psychology
*Physical Therapists/psychology/statistics & numerical data
Prevalence
Emotional Exhaustion
Pandemics
SARS-CoV-2
Developing Countries
RevDate: 2026-11-13
CmpDate: 2026-11-13
Design and applications of engineering coronavirus vaccines with virus-like particles.
Clinical and experimental vaccine research, 15(4):255-265.
Coronavirus vaccine development must accommodate antigenic evolution, diverse host species, and the distinct immune demands of respiratory and enteric disease. Virus-like particles (VLPs) are genome-free particulate immunogens that present coronavirus antigens in a defined structural context without productive infection. This review differentiates authentic coronavirus-mimetic VLPs containing spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins; simplified envelope-based VLPs; and heterologous scaffolds displaying S-derived antigens. We examine how production platforms shape product attributes, how preassembled particles can complement messenger RNA vaccines, and how antigen composition, adjuvant, and administration route influence humoral, cellular, and mucosal immunity. Severe acute respiratory syndrome coronavirus (SARS-CoV-2) provides the most advanced translational evidence, including protective animal studies, phase III efficacy, and regulatory authorization of a plant-derived VLP vaccine. Evidence from SARS-CoV, Middle East respiratory syndrome coronavirus, and veterinary coronaviruses extends the rationale, especially for multivalent coverage, maternal immunity, and repeated vaccination. The key question is whether VLP complexity provides a measurable immunological or deployment advantage for a defined use case. Progress will require scalable manufacture, rigorous structural characterization, comparability after antigen updates, and efficacy endpoints aligned with host and virus biology.
Additional Links: PMID-43022064
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43022064,
year = {2026},
author = {Choi, KS},
title = {Design and applications of engineering coronavirus vaccines with virus-like particles.},
journal = {Clinical and experimental vaccine research},
volume = {15},
number = {4},
pages = {255-265},
pmid = {43022064},
issn = {2287-3651},
abstract = {Coronavirus vaccine development must accommodate antigenic evolution, diverse host species, and the distinct immune demands of respiratory and enteric disease. Virus-like particles (VLPs) are genome-free particulate immunogens that present coronavirus antigens in a defined structural context without productive infection. This review differentiates authentic coronavirus-mimetic VLPs containing spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins; simplified envelope-based VLPs; and heterologous scaffolds displaying S-derived antigens. We examine how production platforms shape product attributes, how preassembled particles can complement messenger RNA vaccines, and how antigen composition, adjuvant, and administration route influence humoral, cellular, and mucosal immunity. Severe acute respiratory syndrome coronavirus (SARS-CoV-2) provides the most advanced translational evidence, including protective animal studies, phase III efficacy, and regulatory authorization of a plant-derived VLP vaccine. Evidence from SARS-CoV, Middle East respiratory syndrome coronavirus, and veterinary coronaviruses extends the rationale, especially for multivalent coverage, maternal immunity, and repeated vaccination. The key question is whether VLP complexity provides a measurable immunological or deployment advantage for a defined use case. Progress will require scalable manufacture, rigorous structural characterization, comparability after antigen updates, and efficacy endpoints aligned with host and virus biology.},
}
RevDate: 2026-11-13
CmpDate: 2026-11-13
Messenger RNA vaccines and beyond: Molecular design, delivery platforms, and emerging therapeutic applications.
Molecular therapy. Nucleic acids, 37(4):103140.
Messenger RNA (mRNA) medicine has progressed from a conceptual nucleic acid modality to a clinically validated platform for transient protein expression, with SARS-CoV-2 vaccines providing population-scale proof of maturity. This review synthesizes the molecular and translational principles underlying this transition, emphasizing two determinants of mRNA performance: transcript engineering and delivery formulation. Transcript engineering integrates cap structure, untranslated regions, coding-sequence optimization, nucleoside chemistry, and poly(A) design, whereas formulation controls encapsulation, tissue tropism, cytosolic release, stability, and route-dependent biodistribution. We examine how this platform logic extends beyond vaccination to protein replacement, lung-directed gene complementation, regenerative signaling, in vivo antibody production, local tumor immunomodulation, genome editing, and transient ex vivo cell engineering. We also compare conventional mRNA, self-amplifying RNA, and circular RNA as complementary architectures with distinct dose requirements, expression durability, immunogenicity, and manufacturability. Across preventive and therapeutic settings, translation is constrained by extrahepatic delivery specificity, productive endosomal escape, innate and carrier-driven immune responses during repeat dosing, and scalable manufacturing with robust analytical quality control. The future of mRNA medicine will depend on platform matching: aligning RNA architecture, formulation, administration route, and disease context with clinical settings in which transient expression offers a genuine therapeutic advantage.
Additional Links: PMID-43022281
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43022281,
year = {2026},
author = {Lee, KS and Park, JY and Kim, CU},
title = {Messenger RNA vaccines and beyond: Molecular design, delivery platforms, and emerging therapeutic applications.},
journal = {Molecular therapy. Nucleic acids},
volume = {37},
number = {4},
pages = {103140},
pmid = {43022281},
issn = {2162-2531},
abstract = {Messenger RNA (mRNA) medicine has progressed from a conceptual nucleic acid modality to a clinically validated platform for transient protein expression, with SARS-CoV-2 vaccines providing population-scale proof of maturity. This review synthesizes the molecular and translational principles underlying this transition, emphasizing two determinants of mRNA performance: transcript engineering and delivery formulation. Transcript engineering integrates cap structure, untranslated regions, coding-sequence optimization, nucleoside chemistry, and poly(A) design, whereas formulation controls encapsulation, tissue tropism, cytosolic release, stability, and route-dependent biodistribution. We examine how this platform logic extends beyond vaccination to protein replacement, lung-directed gene complementation, regenerative signaling, in vivo antibody production, local tumor immunomodulation, genome editing, and transient ex vivo cell engineering. We also compare conventional mRNA, self-amplifying RNA, and circular RNA as complementary architectures with distinct dose requirements, expression durability, immunogenicity, and manufacturability. Across preventive and therapeutic settings, translation is constrained by extrahepatic delivery specificity, productive endosomal escape, innate and carrier-driven immune responses during repeat dosing, and scalable manufacturing with robust analytical quality control. The future of mRNA medicine will depend on platform matching: aligning RNA architecture, formulation, administration route, and disease context with clinical settings in which transient expression offers a genuine therapeutic advantage.},
}
RevDate: 2026-11-13
CmpDate: 2026-11-13
Post-COVID Cardiac Symptoms in the Absence of Epicardial Stenoses: Potential Association with Persistent Coronary Microvascular Dysfunction.
European cardiology, 21:e58.
Additional Links: PMID-43022470
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43022470,
year = {2026},
author = {Ong, P and Safdar, B and Heusch, G},
title = {Post-COVID Cardiac Symptoms in the Absence of Epicardial Stenoses: Potential Association with Persistent Coronary Microvascular Dysfunction.},
journal = {European cardiology},
volume = {21},
number = {},
pages = {e58},
pmid = {43022470},
issn = {1758-3764},
}
RevDate: 2026-11-13
CmpDate: 2026-11-13
Obstructive sleep apnea and long COVID syndrome: a scoping review of current evidence in adults.
Frontiers in sleep, 5:1990528.
BACKGROUND: Obstructive Sleep Apnea (OSA) is a prevalent sleep disorder characterized by intermittent hypoxia and sleep fragmentation, contributing to systemic inflammation and autonomic dysfunction. Long COVID refers to persistent symptoms following acute COVID-19 infection. Emerging evidence suggests an association between OSA and persistent post-COVID-19 symptoms, potentially mediated by overlapping biological pathways; however, the direction and causality of this relationship remain uncertain.
AIM: This scoping review aimed to examine the current evidence regarding the different associations between OSA and Long COVID in adults, summarize the reported clinical findings, and explore the proposed pathophysiological mechanisms linking OSA and Long COVID.
METHODS: Following PRISMA-ScR guidelines, PubMed, Embase, Scopus, Web of Science, Cochrane Library, Google Scholar, and ClinicalTrials.gov were searched for studies published between 2020 and 2026. Eligible studies included observational studies, clinical trials, and reviews involving adults with OSAand/or Long COVID syndrome. Two independent reviewers screened studies, extracted data, and synthesized findings thematically.
RESULTS: Of 184 identified records, 11 studies met the inclusion criteria. Evidence suggested different associations between OSA and Long COVID across the included studies. Proposed mechanisms included intermittent hypoxia, systemic inflammation, autonomic dysregulation, sleep fragmentation, and circadian disturbance; however, these mechanisms were not consistently measured across studies. Reported Long COVID manifestations among patients with OSA included fatigue, respiratory impairment, cognitive dysfunction, and cardiovascular complications. Evidence regarding the impact of OSA treatment on Long COVID outcomes was limited.
CONCLUSIONS: Current evidence suggests an association between OSA and Long COVID, although the nature and direction of this association vary across studies. However, the evidence remains limited and heterogeneous. Further longitudinal studies are needed to clarify this relationship and determine whether effective OSA management can improve Long COVID outcomes.
Additional Links: PMID-43022529
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43022529,
year = {2026},
author = {Alhotye, MI and Alotaibi, TF and Alotaibi, MM and Alojyri, RM and Almutairi, AG and Almutairi, HA and Alghuraibi, RS and Alrashdi, AM and Alruwaili, AH and Alqahtani, MK},
title = {Obstructive sleep apnea and long COVID syndrome: a scoping review of current evidence in adults.},
journal = {Frontiers in sleep},
volume = {5},
number = {},
pages = {1990528},
pmid = {43022529},
issn = {2813-2890},
abstract = {BACKGROUND: Obstructive Sleep Apnea (OSA) is a prevalent sleep disorder characterized by intermittent hypoxia and sleep fragmentation, contributing to systemic inflammation and autonomic dysfunction. Long COVID refers to persistent symptoms following acute COVID-19 infection. Emerging evidence suggests an association between OSA and persistent post-COVID-19 symptoms, potentially mediated by overlapping biological pathways; however, the direction and causality of this relationship remain uncertain.
AIM: This scoping review aimed to examine the current evidence regarding the different associations between OSA and Long COVID in adults, summarize the reported clinical findings, and explore the proposed pathophysiological mechanisms linking OSA and Long COVID.
METHODS: Following PRISMA-ScR guidelines, PubMed, Embase, Scopus, Web of Science, Cochrane Library, Google Scholar, and ClinicalTrials.gov were searched for studies published between 2020 and 2026. Eligible studies included observational studies, clinical trials, and reviews involving adults with OSAand/or Long COVID syndrome. Two independent reviewers screened studies, extracted data, and synthesized findings thematically.
RESULTS: Of 184 identified records, 11 studies met the inclusion criteria. Evidence suggested different associations between OSA and Long COVID across the included studies. Proposed mechanisms included intermittent hypoxia, systemic inflammation, autonomic dysregulation, sleep fragmentation, and circadian disturbance; however, these mechanisms were not consistently measured across studies. Reported Long COVID manifestations among patients with OSA included fatigue, respiratory impairment, cognitive dysfunction, and cardiovascular complications. Evidence regarding the impact of OSA treatment on Long COVID outcomes was limited.
CONCLUSIONS: Current evidence suggests an association between OSA and Long COVID, although the nature and direction of this association vary across studies. However, the evidence remains limited and heterogeneous. Further longitudinal studies are needed to clarify this relationship and determine whether effective OSA management can improve Long COVID outcomes.},
}
RevDate: 2026-11-13
CmpDate: 2026-11-13
Exosomes in infectious diseases: From pathogenic exploitation to next-generation diagnostics and therapeutics.
Infectious medicine, 5(4):100291.
Exosomes (30-150 nm extracellular vesicles of endosomal origin) have redefined our understanding of intercellular communication during infection. This review provides a comprehensive, updated analysis of how exosomes function as double-edged swords in infectious diseases, mediating both host protective immunity and pathogen dissemination. We focus on recently discovered mechanisms (2020-2026) in bacterial, viral, parasitic, and fungal infections, including Mycobacterium tuberculosis, human immunodeficiency virus -1, severe acute respiratory syndrome coronavirus 2, Leishmania, Trypanosoma cruzi, and Candida albicans. We systematically compare shared versus unique host-pathogen interaction nodes across major pathogen groups, with particular emphasis on ESCRT-dependent versus endosomal sorting complex required for transport (ESCRT)-independent biogenesis pathways and their differential exploitation by pathogens. We identify a clear dichotomy: viruses predominantly co-opt ESCRT-dependent machinery, whereas intracellular bacteria and parasites show greater reliance on ESCRT-independent pathways involving tetraspanins and lipid rafts, likely reflecting their distinct intracellular vacuolar lifestyles. Furthermore, we critically evaluate host protective exosome functions, distinguishing mechanistic evidence from correlative findings, and we provide a balanced assessment of diagnostic and therapeutic translational hurdles. We further highlight the emergence of exosome-based liquid biopsies for early diagnosis and exosome-engineered platforms for vaccine and therapeutic delivery, while addressing critical limitations including isolation standardization, the distinction between association and causation in biomarker studies, and the absence of multi-center clinical validation. By integrating new insights into exosomal cargo sorting, organotropism, and pathogen-driven reprogramming, this review proposes a roadmap for translating exosome biology into clinical practice against infectious diseases.
Additional Links: PMID-43023074
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43023074,
year = {2026},
author = {Khosrojerdi, M and Hashemi, SA and Besharati, R and Azimian, A},
title = {Exosomes in infectious diseases: From pathogenic exploitation to next-generation diagnostics and therapeutics.},
journal = {Infectious medicine},
volume = {5},
number = {4},
pages = {100291},
pmid = {43023074},
issn = {2772-431X},
abstract = {Exosomes (30-150 nm extracellular vesicles of endosomal origin) have redefined our understanding of intercellular communication during infection. This review provides a comprehensive, updated analysis of how exosomes function as double-edged swords in infectious diseases, mediating both host protective immunity and pathogen dissemination. We focus on recently discovered mechanisms (2020-2026) in bacterial, viral, parasitic, and fungal infections, including Mycobacterium tuberculosis, human immunodeficiency virus -1, severe acute respiratory syndrome coronavirus 2, Leishmania, Trypanosoma cruzi, and Candida albicans. We systematically compare shared versus unique host-pathogen interaction nodes across major pathogen groups, with particular emphasis on ESCRT-dependent versus endosomal sorting complex required for transport (ESCRT)-independent biogenesis pathways and their differential exploitation by pathogens. We identify a clear dichotomy: viruses predominantly co-opt ESCRT-dependent machinery, whereas intracellular bacteria and parasites show greater reliance on ESCRT-independent pathways involving tetraspanins and lipid rafts, likely reflecting their distinct intracellular vacuolar lifestyles. Furthermore, we critically evaluate host protective exosome functions, distinguishing mechanistic evidence from correlative findings, and we provide a balanced assessment of diagnostic and therapeutic translational hurdles. We further highlight the emergence of exosome-based liquid biopsies for early diagnosis and exosome-engineered platforms for vaccine and therapeutic delivery, while addressing critical limitations including isolation standardization, the distinction between association and causation in biomarker studies, and the absence of multi-center clinical validation. By integrating new insights into exosomal cargo sorting, organotropism, and pathogen-driven reprogramming, this review proposes a roadmap for translating exosome biology into clinical practice against infectious diseases.},
}
RevDate: 2026-11-13
CmpDate: 2026-11-13
Stress Granules in Respiratory Infections Linking Host Defence to Pathogen Adaptation and Therapeutic Opportunities.
Journal of cellular and molecular medicine, 30(21):.
Stress granules (SGs) are dynamic, membrane-less ribonucleoprotein condensates that assemble via liquid-liquid phase separation in the cytoplasm when translation initiation is impaired. SG formation commonly accompanies translational repression and may subsequently redistribute selected RNAs and signalling proteins, thereby linking cellular stress to innate immunity. Many viruses have been reported to inhibit SG assembly or recruit SG-associated proteins, whereas bacterial and mycobacterial infections can activate eIF2α phosphorylation and are associated with SG-like responses. Respiratory pathogens exhibit diverse SG phenotypes: coronaviruses and influenza viruses generally limit canonical SG assembly, although individual SARS-CoV-2 proteins have been reported to exert opposing effects; respiratory syncytial virus replication correlates with G3BP1 and SG-positive cells, but an SG-specific mechanism remains unresolved; and Mycobacterium tuberculosis induces persistent G3BP1-positive granules together with translational and metabolic suppression. Studies in bacterial model systems also suggest that pathogen-intrinsic protein condensates may influence dormancy and antibiotic tolerance, but whether analogous condensates form during respiratory infection remains unknown. Understanding how respiratory pathogens alter the ISR, translation and SG-associated pathways may reveal pathogen- and context-specific therapeutic opportunities. This review summarizes mechanistic advances in coronavirus-G3BP interactions, SG biology and pathogen-specific observations; critically distinguishes causal evidence from correlation, as well as SG-dependent from SG-independent functions of commonly manipulated proteins; and discusses antibiotic tolerance and therapeutic hypotheses in light of their current evidentiary limitations.
Additional Links: PMID-43023630
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43023630,
year = {2026},
author = {Jo, S and Kim, J and Song, CH},
title = {Stress Granules in Respiratory Infections Linking Host Defence to Pathogen Adaptation and Therapeutic Opportunities.},
journal = {Journal of cellular and molecular medicine},
volume = {30},
number = {21},
pages = {},
doi = {10.1111/jcmm.71457},
pmid = {43023630},
issn = {1582-4934},
support = {RS-2025-02263643//National Research Foundation of Korea/ ; RS-2025-00523465//National Research Foundation of Korea/ ; 2024//BK21 Four Program by Chungnam National University/ ; 2026//BK21 Four Program by Chungnam National University/ ; },
mesh = {Humans ; *Stress Granules/metabolism/immunology/virology ; *Host-Pathogen Interactions/immunology ; RNA Helicases/metabolism ; *Respiratory Tract Infections/virology/immunology/drug therapy/metabolism/microbiology/pathology ; Immunity, Innate ; Mycobacterium tuberculosis/pathogenicity ; Animals ; SARS-CoV-2/pathogenicity ; RNA Recognition Motif Proteins/metabolism ; COVID-19/virology/immunology ; DNA Helicases/metabolism ; Poly-ADP-Ribose Binding Proteins ; },
abstract = {Stress granules (SGs) are dynamic, membrane-less ribonucleoprotein condensates that assemble via liquid-liquid phase separation in the cytoplasm when translation initiation is impaired. SG formation commonly accompanies translational repression and may subsequently redistribute selected RNAs and signalling proteins, thereby linking cellular stress to innate immunity. Many viruses have been reported to inhibit SG assembly or recruit SG-associated proteins, whereas bacterial and mycobacterial infections can activate eIF2α phosphorylation and are associated with SG-like responses. Respiratory pathogens exhibit diverse SG phenotypes: coronaviruses and influenza viruses generally limit canonical SG assembly, although individual SARS-CoV-2 proteins have been reported to exert opposing effects; respiratory syncytial virus replication correlates with G3BP1 and SG-positive cells, but an SG-specific mechanism remains unresolved; and Mycobacterium tuberculosis induces persistent G3BP1-positive granules together with translational and metabolic suppression. Studies in bacterial model systems also suggest that pathogen-intrinsic protein condensates may influence dormancy and antibiotic tolerance, but whether analogous condensates form during respiratory infection remains unknown. Understanding how respiratory pathogens alter the ISR, translation and SG-associated pathways may reveal pathogen- and context-specific therapeutic opportunities. This review summarizes mechanistic advances in coronavirus-G3BP interactions, SG biology and pathogen-specific observations; critically distinguishes causal evidence from correlation, as well as SG-dependent from SG-independent functions of commonly manipulated proteins; and discusses antibiotic tolerance and therapeutic hypotheses in light of their current evidentiary limitations.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Stress Granules/metabolism/immunology/virology
*Host-Pathogen Interactions/immunology
RNA Helicases/metabolism
*Respiratory Tract Infections/virology/immunology/drug therapy/metabolism/microbiology/pathology
Immunity, Innate
Mycobacterium tuberculosis/pathogenicity
Animals
SARS-CoV-2/pathogenicity
RNA Recognition Motif Proteins/metabolism
COVID-19/virology/immunology
DNA Helicases/metabolism
Poly-ADP-Ribose Binding Proteins
RevDate: 2026-11-13
CmpDate: 2026-11-13
Molecular epidemiology, spike-protein evolution, antigenic variation, and experimental pathogenicity of G2c porcine epidemic diarrhea virus: a systematic review.
Veterinary research communications, 51(1):.
Porcine epidemic diarrhea virus (PEDV) is a major cause of severe enteric disease and mortality in neonatal piglets. This systematic review aimed to synthesize current evidence on the molecular epidemiology, spike-protein variation, experimental pathogenicity, and control-related applications of the G2c lineage. Web of Science Core Collection, PubMed, and ScienceDirect were searched for peer-reviewed original studies published from 1 January 2020 to 31 May 2026. Of 78 records identified, 26 studies met the eligibility criteria. G2c was the most frequently assigned lineage in several national, multi-provincial, and regional PEDV datasets in China, particularly in Sichuan and Guangdong. However, its distribution was geographically heterogeneous, and G2a remained predominant in Guangxi. Contemporary G2c viruses exhibited extensive spike-protein variation, including substitutions, insertions, deletions, and predicted glycosylation changes in antigenically relevant regions. Cross-neutralization studies demonstrated strain-dependent antigenic differences, but consistent lineage-wide immune escape was not established. Experimental infections showed that natural G2c isolates caused acute watery diarrhea, dehydration, intestinal villous atrophy, high viral shedding, and, in some studies, substantial mortality in neonatal or suckling piglets. Heterogeneity in experimental design prevented reliable comparison of virulence among strains. Current evidence also supports the development of G2c-specific molecular diagnostics and several vaccine approaches, including cell-adapted candidates, maternal-immunity strategies, messenger RNA vaccines, and autogenous inactivated vaccines. Overall, G2c is an epidemiologically important and pathogenic PEDV lineage. Standardized classification, whole-genome surveillance, functional antigenic studies, matched challenge experiments, and heterologous vaccine-efficacy evaluations are needed to improve disease control.
Additional Links: PMID-43024095
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43024095,
year = {2026},
author = {Tang, J and Pei, J and Lu, X and Chen, Z and Wei, S and Xia, Z and Cui, K},
title = {Molecular epidemiology, spike-protein evolution, antigenic variation, and experimental pathogenicity of G2c porcine epidemic diarrhea virus: a systematic review.},
journal = {Veterinary research communications},
volume = {51},
number = {1},
pages = {},
pmid = {43024095},
issn = {1573-7446},
mesh = {Animals ; *Porcine epidemic diarrhea virus/pathogenicity/genetics/immunology ; *Coronavirus Infections/veterinary/epidemiology/virology ; *Swine Diseases/virology/epidemiology ; Swine ; *Spike Glycoprotein, Coronavirus/genetics/immunology ; *Antigenic Variation ; Molecular Epidemiology ; *Evolution, Molecular ; Virulence ; },
abstract = {Porcine epidemic diarrhea virus (PEDV) is a major cause of severe enteric disease and mortality in neonatal piglets. This systematic review aimed to synthesize current evidence on the molecular epidemiology, spike-protein variation, experimental pathogenicity, and control-related applications of the G2c lineage. Web of Science Core Collection, PubMed, and ScienceDirect were searched for peer-reviewed original studies published from 1 January 2020 to 31 May 2026. Of 78 records identified, 26 studies met the eligibility criteria. G2c was the most frequently assigned lineage in several national, multi-provincial, and regional PEDV datasets in China, particularly in Sichuan and Guangdong. However, its distribution was geographically heterogeneous, and G2a remained predominant in Guangxi. Contemporary G2c viruses exhibited extensive spike-protein variation, including substitutions, insertions, deletions, and predicted glycosylation changes in antigenically relevant regions. Cross-neutralization studies demonstrated strain-dependent antigenic differences, but consistent lineage-wide immune escape was not established. Experimental infections showed that natural G2c isolates caused acute watery diarrhea, dehydration, intestinal villous atrophy, high viral shedding, and, in some studies, substantial mortality in neonatal or suckling piglets. Heterogeneity in experimental design prevented reliable comparison of virulence among strains. Current evidence also supports the development of G2c-specific molecular diagnostics and several vaccine approaches, including cell-adapted candidates, maternal-immunity strategies, messenger RNA vaccines, and autogenous inactivated vaccines. Overall, G2c is an epidemiologically important and pathogenic PEDV lineage. Standardized classification, whole-genome surveillance, functional antigenic studies, matched challenge experiments, and heterologous vaccine-efficacy evaluations are needed to improve disease control.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Porcine epidemic diarrhea virus/pathogenicity/genetics/immunology
*Coronavirus Infections/veterinary/epidemiology/virology
*Swine Diseases/virology/epidemiology
Swine
*Spike Glycoprotein, Coronavirus/genetics/immunology
*Antigenic Variation
Molecular Epidemiology
*Evolution, Molecular
Virulence
RevDate: 2026-11-13
CmpDate: 2026-11-13
Children's Psychological Reactions to Quarantine During Pandemics, Epidemics, and Other Disease Outbreaks.
Current psychiatry reports, 28(1):.
PURPOSE OF REVIEW: This review synthesizes evidence on children's psychological reactions to quarantine, and physical distancing during pandemics, epidemics, and other disease outbreaks. It also examines the risk and protective factors underlying the substantial heterogeneity in outcomes.
RECENT FINDINGS: Across outbreak contexts, depression emerged as the most consistently reported psychological reaction. The anxiety findings varied by subtype, with health- and uncertainty-related anxiety rising and social/performance anxiety often declining. Traumatic stress, externalizing behavior, and suicidality showed mixed but concerning trends. Pre-existing mental health vulnerabilities, parental mental health, and socioeconomic disadvantage were the strongest risk factors. On the other hand, positive coping, emotion regulation, family cohesion, social connectedness, and maternal mentalization consistently protected against adverse outcomes. Children''s psychological reactions to quarantine are shaped relatively less by restriction itself and more by individual, familial, and structural context. Findings support integrating emotion-regulation and family-functioning screening into routine care, strengthening family- and policy-level supports, and prioritizing longitudinal, Low-and-Middle-Income-Countries (LMIC) -inclusive research to disentangle policy stringency from outbreak severity for future public health emergencies.
Additional Links: PMID-43024126
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43024126,
year = {2026},
author = {Imran, N and Ayub, M and Aamer, I},
title = {Children's Psychological Reactions to Quarantine During Pandemics, Epidemics, and Other Disease Outbreaks.},
journal = {Current psychiatry reports},
volume = {28},
number = {1},
pages = {},
pmid = {43024126},
issn = {1535-1645},
mesh = {Humans ; *Quarantine/psychology ; Child ; *Disease Outbreaks ; *Pandemics ; Anxiety/psychology ; *Epidemics ; COVID-19/psychology ; Depression/psychology ; },
abstract = {PURPOSE OF REVIEW: This review synthesizes evidence on children's psychological reactions to quarantine, and physical distancing during pandemics, epidemics, and other disease outbreaks. It also examines the risk and protective factors underlying the substantial heterogeneity in outcomes.
RECENT FINDINGS: Across outbreak contexts, depression emerged as the most consistently reported psychological reaction. The anxiety findings varied by subtype, with health- and uncertainty-related anxiety rising and social/performance anxiety often declining. Traumatic stress, externalizing behavior, and suicidality showed mixed but concerning trends. Pre-existing mental health vulnerabilities, parental mental health, and socioeconomic disadvantage were the strongest risk factors. On the other hand, positive coping, emotion regulation, family cohesion, social connectedness, and maternal mentalization consistently protected against adverse outcomes. Children''s psychological reactions to quarantine are shaped relatively less by restriction itself and more by individual, familial, and structural context. Findings support integrating emotion-regulation and family-functioning screening into routine care, strengthening family- and policy-level supports, and prioritizing longitudinal, Low-and-Middle-Income-Countries (LMIC) -inclusive research to disentangle policy stringency from outbreak severity for future public health emergencies.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Quarantine/psychology
Child
*Disease Outbreaks
*Pandemics
Anxiety/psychology
*Epidemics
COVID-19/psychology
Depression/psychology
RevDate: 2026-11-13
CmpDate: 2026-11-13
Interpretive Frames to Understand the Contribution of Digital Exclusion to Health Inequalities: Hermeneutic Review.
Online journal of public health informatics, 18:e98204 pii:v18i1e98204.
BACKGROUND: Digital exclusion is a multidimensional and relational process shaped by interactions among individuals, technologies, institutions, and wider social structures. Research on digital exclusion has expanded significantly in recent years, largely due to the COVID-19 pandemic and the rapid digitalization of health, welfare, and public services. Yet, despite this growth, conceptualizations of digital exclusion remain fragmented, limiting a comprehensive understanding of how digital exclusion contributes to the creation or intensification of health inequalities.
OBJECTIVE: This hermeneutic review aims to develop an interpretive understanding of how digital exclusion has been conceptualized across diverse bodies of literature in relation to health inequalities.
METHODS: We conducted a hermeneutic review using keyword searches and snowballing across PubMed, Scopus, and supplementary sources published between January 2020 and July 2025. Analysis involved repeated reading, note-taking, and comparative interpretation of each text's disciplinary field, theoretical orientation, and underlying assumptions about how digital exclusion is framed in relation to health inequalities. Knowledge users contributed throughout to ensure the developing interpretations remained relevant to policy, practice, and lived experience.
RESULTS: Thirty-one publications were included, spanning multiple disciplines and theoretical orientations. Five interpretive frames were identified: (1) inequality, which conceptualizes digital exclusion as arising from unequal social, economic, and material conditions; (2) power and social injustice, which highlights how institutional rules, governance arrangements, cultural norms, and service pathways condition who is recognized or supported, showing how digital systems can reproduce existing social hierarchies; (3) life transitions, which illustrates how exclusion shifts during periods of disruption or change, emphasizing the fluctuating conditions and vulnerabilities associated with major life changes; (4) psychobehavioral, which focuses on psychological, cognitive, and emotional responses to digital demands; and (5) sociotechnical misalignment, which frames exclusion as arising when digital systems do not align with people's routines or everyday contexts. These interpretive frames show how digital exclusion is understood through different yet overlapping explanations that emphasize structural conditions, institutional practices, life circumstances, individual experiences, and service and system design.
CONCLUSIONS: This hermeneutic review identifies 5 interpretive frames that integrate diverse disciplinary perspectives on how digital exclusion contributes to health inequalities. The frames clarify the multiple, intersecting processes through which exclusion is produced and reproduced, helping to explain its persistence and uneven impacts. Our findings highlight the need for future research that examines structural and institutional mechanisms alongside lived experience and for digital health policy and practice to move beyond access- and skill-focused solutions toward approaches that address the multiple and interacting causes of digital exclusion.
Additional Links: PMID-43024865
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43024865,
year = {2026},
author = {Bright, D and Tuveri, C and Papoutsi, C and Shaw, S and van Dael, J and Swann, N and Tandy, S and Naamani, C and Lovell, J and Davies, A},
title = {Interpretive Frames to Understand the Contribution of Digital Exclusion to Health Inequalities: Hermeneutic Review.},
journal = {Online journal of public health informatics},
volume = {18},
number = {},
pages = {e98204},
doi = {10.2196/98204},
pmid = {43024865},
issn = {1947-2579},
abstract = {BACKGROUND: Digital exclusion is a multidimensional and relational process shaped by interactions among individuals, technologies, institutions, and wider social structures. Research on digital exclusion has expanded significantly in recent years, largely due to the COVID-19 pandemic and the rapid digitalization of health, welfare, and public services. Yet, despite this growth, conceptualizations of digital exclusion remain fragmented, limiting a comprehensive understanding of how digital exclusion contributes to the creation or intensification of health inequalities.
OBJECTIVE: This hermeneutic review aims to develop an interpretive understanding of how digital exclusion has been conceptualized across diverse bodies of literature in relation to health inequalities.
METHODS: We conducted a hermeneutic review using keyword searches and snowballing across PubMed, Scopus, and supplementary sources published between January 2020 and July 2025. Analysis involved repeated reading, note-taking, and comparative interpretation of each text's disciplinary field, theoretical orientation, and underlying assumptions about how digital exclusion is framed in relation to health inequalities. Knowledge users contributed throughout to ensure the developing interpretations remained relevant to policy, practice, and lived experience.
RESULTS: Thirty-one publications were included, spanning multiple disciplines and theoretical orientations. Five interpretive frames were identified: (1) inequality, which conceptualizes digital exclusion as arising from unequal social, economic, and material conditions; (2) power and social injustice, which highlights how institutional rules, governance arrangements, cultural norms, and service pathways condition who is recognized or supported, showing how digital systems can reproduce existing social hierarchies; (3) life transitions, which illustrates how exclusion shifts during periods of disruption or change, emphasizing the fluctuating conditions and vulnerabilities associated with major life changes; (4) psychobehavioral, which focuses on psychological, cognitive, and emotional responses to digital demands; and (5) sociotechnical misalignment, which frames exclusion as arising when digital systems do not align with people's routines or everyday contexts. These interpretive frames show how digital exclusion is understood through different yet overlapping explanations that emphasize structural conditions, institutional practices, life circumstances, individual experiences, and service and system design.
CONCLUSIONS: This hermeneutic review identifies 5 interpretive frames that integrate diverse disciplinary perspectives on how digital exclusion contributes to health inequalities. The frames clarify the multiple, intersecting processes through which exclusion is produced and reproduced, helping to explain its persistence and uneven impacts. Our findings highlight the need for future research that examines structural and institutional mechanisms alongside lived experience and for digital health policy and practice to move beyond access- and skill-focused solutions toward approaches that address the multiple and interacting causes of digital exclusion.},
}
RevDate: 2026-11-13
COVID-19 vaccination and non-pharmaceutical interventions in selected European settings: a systematic review.
Vaccine, 96:129337 pii:S0264-410X(26)01146-1 [Epub ahead of print].
BACKGROUND: COVID-19 pandemic responses in European countries relied on both vaccination campaigns and non-pharmaceutical interventions (NPIs). While vaccination reduced severe disease, NPIs remained necessary to limit transmission, particularly during periods of variant emergence. However, the effectiveness of these strategies depended on social trust, communication clarity, and behavioural adaptation.
OBJECTIVE: To synthesize empirical evidence on shared determinants of vaccination and NPI-related behaviours, behavioural relationships between these strategies, and evidence concerning their joint epidemiological effects.
METHODS: PubMed and Scopus were searched on 11 February 2025 using free-text terms for COVID-19, vaccination, and social or non-pharmaceutical measures. Eligible studies were peer-reviewed, empirical (quantitative, qualitative, or mixed-methods), conducted by authors affiliated with selected European institutions, and examined relationships between vaccination and NPIs. Studies based solely on modelling or secondary data were excluded. Data were synthesized narratively due to heterogeneity of study designs and outcomes.
RESULTS: Twelve studies met inclusion criteria. Trust in scientific and governmental authorities consistently predicted adherence to NPIs and willingness to vaccinate. Sweden's reliance on voluntary measures was effective where institutional trust was high. In contrast, inconsistent communication in the United Kingdom contributed to reduced adherence and public frustration. Vaccinated individuals tended to increase social contacts, an association compatible with behavioural adaptation. A conjoint experiment examined stated vaccination preferences in relation to NPI attributes. Younger populations experienced notable psychological strain during prolonged restrictions.
CONCLUSIONS: The synthesis primarily informs social and behavioural relationships involving vaccination and NPIs. Shared determinants and behavioural associations should not be interpreted as evidence of synergistic effects on infection, hospitalisation, or mortality. Future pandemic preparedness should prioritize trust-building, consistent messaging, and targeted psychosocial support for vulnerable groups.
Additional Links: PMID-43025126
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43025126,
year = {2026},
author = {Kravvari, CM and Tsiakiri, A and Plakias, S and Paraskevis, D and Kokkotis, C},
title = {COVID-19 vaccination and non-pharmaceutical interventions in selected European settings: a systematic review.},
journal = {Vaccine},
volume = {96},
number = {},
pages = {129337},
doi = {10.1016/j.vaccine.2026.129337},
pmid = {43025126},
issn = {1873-2518},
abstract = {BACKGROUND: COVID-19 pandemic responses in European countries relied on both vaccination campaigns and non-pharmaceutical interventions (NPIs). While vaccination reduced severe disease, NPIs remained necessary to limit transmission, particularly during periods of variant emergence. However, the effectiveness of these strategies depended on social trust, communication clarity, and behavioural adaptation.
OBJECTIVE: To synthesize empirical evidence on shared determinants of vaccination and NPI-related behaviours, behavioural relationships between these strategies, and evidence concerning their joint epidemiological effects.
METHODS: PubMed and Scopus were searched on 11 February 2025 using free-text terms for COVID-19, vaccination, and social or non-pharmaceutical measures. Eligible studies were peer-reviewed, empirical (quantitative, qualitative, or mixed-methods), conducted by authors affiliated with selected European institutions, and examined relationships between vaccination and NPIs. Studies based solely on modelling or secondary data were excluded. Data were synthesized narratively due to heterogeneity of study designs and outcomes.
RESULTS: Twelve studies met inclusion criteria. Trust in scientific and governmental authorities consistently predicted adherence to NPIs and willingness to vaccinate. Sweden's reliance on voluntary measures was effective where institutional trust was high. In contrast, inconsistent communication in the United Kingdom contributed to reduced adherence and public frustration. Vaccinated individuals tended to increase social contacts, an association compatible with behavioural adaptation. A conjoint experiment examined stated vaccination preferences in relation to NPI attributes. Younger populations experienced notable psychological strain during prolonged restrictions.
CONCLUSIONS: The synthesis primarily informs social and behavioural relationships involving vaccination and NPIs. Shared determinants and behavioural associations should not be interpreted as evidence of synergistic effects on infection, hospitalisation, or mortality. Future pandemic preparedness should prioritize trust-building, consistent messaging, and targeted psychosocial support for vulnerable groups.},
}
RevDate: 2026-11-13
A scoping review of food insecurity in U.S. higher education by state's congressional delegation majority.
Advances in nutrition (Bethesda, Md.) pii:S2161-8313(26)00185-7 [Epub ahead of print].
Since the COVID-19 pandemic, the literature on U.S. college student food insecurity has expanded, warranting an updated review. The pandemic represented a unique period in which emergency aid may have influenced students' food security status, highlighting the importance of examining the prevalence of food insecurity before, during, and after the pandemic. Additionally, introduced federal legislation aimed at addressing student food insecurity has yet to be enacted. Because congressional delegates help shape the federal policy landscape, examining food insecurity in relation to states' congressional delegations may offer new insight. This scoping review aimed to critically synthesize peer-reviewed publications and grey literature (i.e., institutional reports) on the prevalence of food insecurity among college students attending U.S. four-year public institutions by pre-pandemic, pandemic, and post-pandemic periods, and to document the prevalence by U.S. states' congressional delegation majorities. MEDLINE-PubMed, Web of Science, ProQuest, and EBSCO Host Academic Search Complete were searched for articles published between September 1995 and July 2026. Search terms included "food security" or "food insecurity", "university" or "college" or "students", and "prevalence" or "rate". A hand search was conducted to identify institutional reports on student food insecurity. A total of 48 studies were eligible for full-text analysis. The mean prevalence of food insecurity was 39% pre-pandemic (n=18), 36% during the pandemic (n=12), and 41% post-pandemic (n=18). Higher proportions of food insecurity were observed in states with Republican-majority congressional delegations (43%) compared to those with Democratic-majority (35%) or split delegations (35%). College student food insecurity remains high across the U.S., regardless of state congressional delegation majority, suggesting federal action is needed, such as expanding student access to federal food assistance programs.
Additional Links: PMID-43025605
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43025605,
year = {2026},
author = {Martinez, SM and Chodur, G and Singh, S and Esaryk, E and Nystrom, C and Nazmi, A},
title = {A scoping review of food insecurity in U.S. higher education by state's congressional delegation majority.},
journal = {Advances in nutrition (Bethesda, Md.)},
volume = {},
number = {},
pages = {100771},
doi = {10.1016/j.advnut.2026.100771},
pmid = {43025605},
issn = {2156-5376},
abstract = {Since the COVID-19 pandemic, the literature on U.S. college student food insecurity has expanded, warranting an updated review. The pandemic represented a unique period in which emergency aid may have influenced students' food security status, highlighting the importance of examining the prevalence of food insecurity before, during, and after the pandemic. Additionally, introduced federal legislation aimed at addressing student food insecurity has yet to be enacted. Because congressional delegates help shape the federal policy landscape, examining food insecurity in relation to states' congressional delegations may offer new insight. This scoping review aimed to critically synthesize peer-reviewed publications and grey literature (i.e., institutional reports) on the prevalence of food insecurity among college students attending U.S. four-year public institutions by pre-pandemic, pandemic, and post-pandemic periods, and to document the prevalence by U.S. states' congressional delegation majorities. MEDLINE-PubMed, Web of Science, ProQuest, and EBSCO Host Academic Search Complete were searched for articles published between September 1995 and July 2026. Search terms included "food security" or "food insecurity", "university" or "college" or "students", and "prevalence" or "rate". A hand search was conducted to identify institutional reports on student food insecurity. A total of 48 studies were eligible for full-text analysis. The mean prevalence of food insecurity was 39% pre-pandemic (n=18), 36% during the pandemic (n=12), and 41% post-pandemic (n=18). Higher proportions of food insecurity were observed in states with Republican-majority congressional delegations (43%) compared to those with Democratic-majority (35%) or split delegations (35%). College student food insecurity remains high across the U.S., regardless of state congressional delegation majority, suggesting federal action is needed, such as expanding student access to federal food assistance programs.},
}
RevDate: 2026-11-12
CmpDate: 2026-11-12
Progress in Synthesis and Therapeutic Applications of Mefloquine: A Review.
Current topics in medicinal chemistry, 26(19):2060-2077.
Mefloquine is a synthetic antimalarial drug known for its effectiveness in the treatment and prevention of malaria. This belongs to the amino alcohol group of compounds. Its structure consists of a quinoline and piperidine ring, along with two chiral centers, which give rise to four distinct stereoisomers. There are various synthetic methods for preparing this compound from starting materials such as p-trifluoromethylaniline, 4-bromoquinoline, and trifluoroacetimidoyl iodide. In recent years, mefloquine has gained attention for its potential therapeutic applications beyond malaria, with research exploring its use in cancer therapy, parasitic infections, neurological disorders, tuberculosis, and COVID-19. This article covers its synthetic approaches, established application as an antimalarial compound, as well as repurposed therapeutic applications.
Additional Links: PMID-40965021
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid40965021,
year = {2026},
author = {Yadav, N and Singh, D and Singh, R and Tyagi, YK},
title = {Progress in Synthesis and Therapeutic Applications of Mefloquine: A Review.},
journal = {Current topics in medicinal chemistry},
volume = {26},
number = {19},
pages = {2060-2077},
pmid = {40965021},
issn = {1873-4294},
mesh = {*Mefloquine/chemical synthesis/therapeutic use/pharmacology/chemistry ; Humans ; *Antimalarials/chemical synthesis/therapeutic use/pharmacology/chemistry ; Malaria/drug therapy ; Animals ; *Antineoplastic Agents/chemical synthesis/pharmacology/chemistry/therapeutic use ; Neoplasms/drug therapy ; COVID-19 Drug Treatment ; },
abstract = {Mefloquine is a synthetic antimalarial drug known for its effectiveness in the treatment and prevention of malaria. This belongs to the amino alcohol group of compounds. Its structure consists of a quinoline and piperidine ring, along with two chiral centers, which give rise to four distinct stereoisomers. There are various synthetic methods for preparing this compound from starting materials such as p-trifluoromethylaniline, 4-bromoquinoline, and trifluoroacetimidoyl iodide. In recent years, mefloquine has gained attention for its potential therapeutic applications beyond malaria, with research exploring its use in cancer therapy, parasitic infections, neurological disorders, tuberculosis, and COVID-19. This article covers its synthetic approaches, established application as an antimalarial compound, as well as repurposed therapeutic applications.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Mefloquine/chemical synthesis/therapeutic use/pharmacology/chemistry
Humans
*Antimalarials/chemical synthesis/therapeutic use/pharmacology/chemistry
Malaria/drug therapy
Animals
*Antineoplastic Agents/chemical synthesis/pharmacology/chemistry/therapeutic use
Neoplasms/drug therapy
COVID-19 Drug Treatment
RevDate: 2026-11-12
CmpDate: 2026-11-12
Mapping resilience and co-occurring theoretical constructs in nurses: a scoping review.
JBI evidence synthesis, 24(11):2264-2321.
OBJECTIVE: The aim of this scoping review was to map the concept of resilience, and its definition and measurement, along with co-occurring theoretical constructs within nursing research, using the COVID-19 pandemic as a critical date range for the current evidence.
INTRODUCTION: The research literature offers a wide range of definitions of resilience, and the concept is frequently examined in conjunction with related theoretical constructs. Nurse resilience is a key element in interventions targeting nurse well-being and has been tied to burnout and mental health. Resilience is influential in workforce stabilization and impactful for nurse retention both within facilities and within the field of nursing. This is significant given the worldwide nursing shortage and the attrition from the field.
ELIGIBILITY CRITERIA: This review considered published and unpublished quantitative studies that investigated resilience and co-occurring theoretical constructs in nurses from the onset of the COVID-19 pandemic, taken as January 10, 2020, to the present. Studies published in English or Spanish were eligible, without restriction of the setting or geographic location. All instruments that measure resilience were considered and mapped in conjunction with the co-occurring constructs.
METHODS: This review was guided by the JBI methodology for scoping reviews and the published a priori protocol. CINAHL (EBSCOhost), PubMed, Embase (Embase.com), APA PsycINFO (EBSCOhost), Scopus, and LILACS were searched for evidence from January 10, 2020, to May 17, 2024. A search for unpublished studies and gray literature was conducted in ProQuest Dissertation and Theses. Titles and abstracts, followed by full texts, were screened against the eligibility criteria independently by 2 or more reviewers. Data were extracted using a piloted extraction tool, and findings are presented as a narrative summary supported by figures and tables, including a cluster analysis and qualitative coding of co-occurring constructs into theoretical domains.
RESULTS: A total of 337 records met the eligibility criteria. Research on nurse resilience was conducted in 52 countries. Most of the evidence was cross-sectional in design (n = 277), of which 23 were interventional studies. Hospital-based nurses were represented in 70% of studies (n = 238). COVID-19 was a key element in the research for 65% of studies (n = 220), with only 3% of evidence published during 2020. Resilience was measured by 39 different validated tools, with the Connor-Davidson Resilience Scales accounting for more than half of the studies. There were 193 theoretical constructs studied alongside resilience: burnout (n = 73), stress (n = 69), anxiety (n = 48), and depression (n = 44) were the most prevalent. A total of 175 constructs were measured fewer than 10 times, while 118 constructs appeared only once. Exploration of the co-occurring theoretical constructs included a cluster analysis, which identified 5 thematic clusters, and qualitative coding of the theoretical constructs into 13 domains to capture broad thematic categories.
CONCLUSION: This scoping review maps the quantitative evidence on nurse resilience during and after the COVID-19 pandemic. The literature demonstrates notable methodological gaps and limited attention to organizational factors and culture beyond the level of the individual, highlighting the need for more rigorous, context-sensitive research to inform effective interventions.
REVIEW REGISTRATION: OSF https://osf.io/n2uge/.
SUPPLEMENTAL DIGITAL CONTENT: A Spanish-language version of the abstract is available: https://links.lww.com/SRX/A193.
Additional Links: PMID-42714222
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42714222,
year = {2026},
author = {Rosenblatt, A and Dominguez-Cancino, K and Chung, C and Mecham, K and Bennett, M and Davis-Sandfoss, T and Palmieri, P},
title = {Mapping resilience and co-occurring theoretical constructs in nurses: a scoping review.},
journal = {JBI evidence synthesis},
volume = {24},
number = {11},
pages = {2264-2321},
pmid = {42714222},
issn = {2689-8381},
mesh = {*COVID-19/psychology ; Humans ; *Resilience, Psychological ; Pandemics ; SARS-CoV-2 ; *Nurses/psychology ; Burnout, Professional/psychology ; },
abstract = {OBJECTIVE: The aim of this scoping review was to map the concept of resilience, and its definition and measurement, along with co-occurring theoretical constructs within nursing research, using the COVID-19 pandemic as a critical date range for the current evidence.
INTRODUCTION: The research literature offers a wide range of definitions of resilience, and the concept is frequently examined in conjunction with related theoretical constructs. Nurse resilience is a key element in interventions targeting nurse well-being and has been tied to burnout and mental health. Resilience is influential in workforce stabilization and impactful for nurse retention both within facilities and within the field of nursing. This is significant given the worldwide nursing shortage and the attrition from the field.
ELIGIBILITY CRITERIA: This review considered published and unpublished quantitative studies that investigated resilience and co-occurring theoretical constructs in nurses from the onset of the COVID-19 pandemic, taken as January 10, 2020, to the present. Studies published in English or Spanish were eligible, without restriction of the setting or geographic location. All instruments that measure resilience were considered and mapped in conjunction with the co-occurring constructs.
METHODS: This review was guided by the JBI methodology for scoping reviews and the published a priori protocol. CINAHL (EBSCOhost), PubMed, Embase (Embase.com), APA PsycINFO (EBSCOhost), Scopus, and LILACS were searched for evidence from January 10, 2020, to May 17, 2024. A search for unpublished studies and gray literature was conducted in ProQuest Dissertation and Theses. Titles and abstracts, followed by full texts, were screened against the eligibility criteria independently by 2 or more reviewers. Data were extracted using a piloted extraction tool, and findings are presented as a narrative summary supported by figures and tables, including a cluster analysis and qualitative coding of co-occurring constructs into theoretical domains.
RESULTS: A total of 337 records met the eligibility criteria. Research on nurse resilience was conducted in 52 countries. Most of the evidence was cross-sectional in design (n = 277), of which 23 were interventional studies. Hospital-based nurses were represented in 70% of studies (n = 238). COVID-19 was a key element in the research for 65% of studies (n = 220), with only 3% of evidence published during 2020. Resilience was measured by 39 different validated tools, with the Connor-Davidson Resilience Scales accounting for more than half of the studies. There were 193 theoretical constructs studied alongside resilience: burnout (n = 73), stress (n = 69), anxiety (n = 48), and depression (n = 44) were the most prevalent. A total of 175 constructs were measured fewer than 10 times, while 118 constructs appeared only once. Exploration of the co-occurring theoretical constructs included a cluster analysis, which identified 5 thematic clusters, and qualitative coding of the theoretical constructs into 13 domains to capture broad thematic categories.
CONCLUSION: This scoping review maps the quantitative evidence on nurse resilience during and after the COVID-19 pandemic. The literature demonstrates notable methodological gaps and limited attention to organizational factors and culture beyond the level of the individual, highlighting the need for more rigorous, context-sensitive research to inform effective interventions.
REVIEW REGISTRATION: OSF https://osf.io/n2uge/.
SUPPLEMENTAL DIGITAL CONTENT: A Spanish-language version of the abstract is available: https://links.lww.com/SRX/A193.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*COVID-19/psychology
Humans
*Resilience, Psychological
Pandemics
SARS-CoV-2
*Nurses/psychology
Burnout, Professional/psychology
RevDate: 2026-11-11
CmpDate: 2026-11-12
The evolution of biocontainment unit care for high-consequence infectious diseases: progress, lessons learned, and future directions.
Critical care (London, England), 30(1):.
Biocontainment units (BCUs) are specialized facilities designed to treat patients with high-consequence infectious diseases (HCIDs) which are pathogens with high mortality rates, limited treatment options, and significant potential for healthcare-associated transmission. Since the opening of the first modern BCU in 1971, these units have evolved from simple isolation environments into advanced centers capable of delivering comprehensive critical care while maintaining rigorous infection control. This evolution has been driven from the lessons learned from past outbreaks of Ebola, Marburg, Middle Eastern Respiratory Syndrome (MERS), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), among other emerging infectious threats. Four key domains contribute to the care of patients with HCIDs - laboratory capabilities, critical care delivery, healthcare workforce readiness, and safe patient transport. Improvements in diagnostic capabilities have allowed for earlier disease recognition while greater access to routine laboratory tests better inform clinical decision making. Clinical care capabilities now match those seen in intensive care units while maintaining infection control standards. Training of specialized workforce and multidisciplinary staffing models have improved bedside care and operational readiness. Meanwhile, innovations in ground and air transport have enhanced the ability to safely transfer HCID patients to facilities best suited to provide care. This review synthesizes the evolution of BCU capabilities globally, examining advances in critical care, diagnostics, investigational therapeutics, workforce models, and patient transport.
Additional Links: PMID-43015819
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43015819,
year = {2026},
author = {Chasen, E and Biswas, I and Lo Piccolo, A and Leone, R and McGuire, E and Mukherjee, V and Postelnicu, R},
title = {The evolution of biocontainment unit care for high-consequence infectious diseases: progress, lessons learned, and future directions.},
journal = {Critical care (London, England)},
volume = {30},
number = {1},
pages = {},
pmid = {43015819},
issn = {1466-609X},
mesh = {Humans ; *Containment of Biohazards/trends/methods ; *Infection Control/methods/trends ; COVID-19 ; Intensive Care Units/organization & administration ; *Communicable Diseases/therapy ; Coronavirus Infections/prevention & control ; Pandemics/prevention & control ; *Cross Infection/prevention & control ; *Critical Care ; },
abstract = {Biocontainment units (BCUs) are specialized facilities designed to treat patients with high-consequence infectious diseases (HCIDs) which are pathogens with high mortality rates, limited treatment options, and significant potential for healthcare-associated transmission. Since the opening of the first modern BCU in 1971, these units have evolved from simple isolation environments into advanced centers capable of delivering comprehensive critical care while maintaining rigorous infection control. This evolution has been driven from the lessons learned from past outbreaks of Ebola, Marburg, Middle Eastern Respiratory Syndrome (MERS), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), among other emerging infectious threats. Four key domains contribute to the care of patients with HCIDs - laboratory capabilities, critical care delivery, healthcare workforce readiness, and safe patient transport. Improvements in diagnostic capabilities have allowed for earlier disease recognition while greater access to routine laboratory tests better inform clinical decision making. Clinical care capabilities now match those seen in intensive care units while maintaining infection control standards. Training of specialized workforce and multidisciplinary staffing models have improved bedside care and operational readiness. Meanwhile, innovations in ground and air transport have enhanced the ability to safely transfer HCID patients to facilities best suited to provide care. This review synthesizes the evolution of BCU capabilities globally, examining advances in critical care, diagnostics, investigational therapeutics, workforce models, and patient transport.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Containment of Biohazards/trends/methods
*Infection Control/methods/trends
COVID-19
Intensive Care Units/organization & administration
*Communicable Diseases/therapy
Coronavirus Infections/prevention & control
Pandemics/prevention & control
*Cross Infection/prevention & control
*Critical Care
RevDate: 2026-11-12
CmpDate: 2026-11-12
Canadian guidelines for post COVID-19 condition (CAN-PCC): A summary for general practitioners.
The European journal of general practice, 32(1):2748765.
BACKGROUND: Post COVID-19 condition (PCC), also known as Long COVID is associated with a substantial global burden. The Canadian Guidelines for Post COVID-19 Condition (CAN-PCC), developed by the CAN-PCC Collaborative, led by McMaster University's Cochrane Canada and GRADE Centres with support from the Public Health Agency of Canada, synthesised over 100 recommendations across prevention, diagnosis, clinical interventions and individualised care, neurological and psychiatric care, paediatric considerations, and health system supports.
OBJECTIVES: This summary highlights key, actionable recommendations for general practitioners and outlines their relevance across diverse healthcare contexts.
METHODS: We extracted recommendations from the CAN‑PCC guidelines and organized them into four domains.
RESULTS: Across the four domains, several priority recommendations for general practitioners were identified: [1] testing, identification and diagnosis (conditional recommendation for symptom‑guided work‑up; strong recommendation to screen adults for depression); [2] clinical interventions (conditional recommendation for patient‑centred goals, functional recovery, targeted pharmacotherapy, and non-pharmacological strategies); [3] prevention (conditional recommendation for vaccination, masking, indoor air quality improvement, early outpatient pharmacotherapy where indicated, including metformin and nirmatrelvir/ritonavir); and [4] paediatric considerations (conditional recommendation for vaccination and mental‑health screening; strong recommendation against cannabidiol/CBD).
CONCLUSION: As evidence evolves, the CAN‑PCC guidelines provide a comprehensive, patient‑centred framework to support general practitioners in the prevention, identification, and management of PCC. Its recommendations can be adapted across varied healthcare settings to support consistent, safe, and effective care delivery.
Additional Links: PMID-43016329
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43016329,
year = {2026},
author = {Aloosh, M and Hopkins, JP and Nieuwlaat, R and Darzi, AJ and Schünemann, HJ and Piggott, T and , },
title = {Canadian guidelines for post COVID-19 condition (CAN-PCC): A summary for general practitioners.},
journal = {The European journal of general practice},
volume = {32},
number = {1},
pages = {2748765},
doi = {10.1080/13814788.2026.2748765},
pmid = {43016329},
issn = {1751-1402},
mesh = {Humans ; *COVID-19/complications/therapy ; Post-Acute COVID-19 Syndrome ; Canada ; SARS-CoV-2 ; *Practice Guidelines as Topic ; Pandemics ; *General Practitioners ; *General Practice/standards ; },
abstract = {BACKGROUND: Post COVID-19 condition (PCC), also known as Long COVID is associated with a substantial global burden. The Canadian Guidelines for Post COVID-19 Condition (CAN-PCC), developed by the CAN-PCC Collaborative, led by McMaster University's Cochrane Canada and GRADE Centres with support from the Public Health Agency of Canada, synthesised over 100 recommendations across prevention, diagnosis, clinical interventions and individualised care, neurological and psychiatric care, paediatric considerations, and health system supports.
OBJECTIVES: This summary highlights key, actionable recommendations for general practitioners and outlines their relevance across diverse healthcare contexts.
METHODS: We extracted recommendations from the CAN‑PCC guidelines and organized them into four domains.
RESULTS: Across the four domains, several priority recommendations for general practitioners were identified: [1] testing, identification and diagnosis (conditional recommendation for symptom‑guided work‑up; strong recommendation to screen adults for depression); [2] clinical interventions (conditional recommendation for patient‑centred goals, functional recovery, targeted pharmacotherapy, and non-pharmacological strategies); [3] prevention (conditional recommendation for vaccination, masking, indoor air quality improvement, early outpatient pharmacotherapy where indicated, including metformin and nirmatrelvir/ritonavir); and [4] paediatric considerations (conditional recommendation for vaccination and mental‑health screening; strong recommendation against cannabidiol/CBD).
CONCLUSION: As evidence evolves, the CAN‑PCC guidelines provide a comprehensive, patient‑centred framework to support general practitioners in the prevention, identification, and management of PCC. Its recommendations can be adapted across varied healthcare settings to support consistent, safe, and effective care delivery.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*COVID-19/complications/therapy
Post-Acute COVID-19 Syndrome
Canada
SARS-CoV-2
*Practice Guidelines as Topic
Pandemics
*General Practitioners
*General Practice/standards
RevDate: 2026-11-12
CmpDate: 2026-11-12
Lifecourse immunization and adaptation to changing needs of India's universal immunization program: theory to practice.
Frontiers in public health, 14:1938980.
The Expanded Program on Immunization, introduced in 1974, marks a pivotal milestone in public health and celebrates its 50th anniversary in 2024. Originally targeting childhood immunization, the program has expanded to include adolescents and adults, driven by the evolving epidemiology of vaccine-preventable diseases and age-related immunosenescence. The COVID-19 pandemic highlighted the vulnerabilities of older populations, reinforcing the need for a lifecourse approach (LCA) to immunization. The article explores the integration of LCA into global health systems, focusing on low-and middle-income countries (LMICs) and India. The article discusses the critical factors and policy-level efforts that India and countries with similar contexts need to consider in expanding immunization programs across the lifecourse.
Additional Links: PMID-43017030
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43017030,
year = {2026},
author = {Dhalaria, P and Kumar, P and Kapur, S and Priyadarshini, P and Singh, AK and Jain, P and Tripathi, B and Ray, A},
title = {Lifecourse immunization and adaptation to changing needs of India's universal immunization program: theory to practice.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1938980},
pmid = {43017030},
issn = {2296-2565},
mesh = {Humans ; *Immunization Programs/organization & administration ; India ; COVID-19/epidemiology/prevention & control ; Developing Countries ; Vaccine-Preventable Diseases/prevention & control ; },
abstract = {The Expanded Program on Immunization, introduced in 1974, marks a pivotal milestone in public health and celebrates its 50th anniversary in 2024. Originally targeting childhood immunization, the program has expanded to include adolescents and adults, driven by the evolving epidemiology of vaccine-preventable diseases and age-related immunosenescence. The COVID-19 pandemic highlighted the vulnerabilities of older populations, reinforcing the need for a lifecourse approach (LCA) to immunization. The article explores the integration of LCA into global health systems, focusing on low-and middle-income countries (LMICs) and India. The article discusses the critical factors and policy-level efforts that India and countries with similar contexts need to consider in expanding immunization programs across the lifecourse.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Immunization Programs/organization & administration
India
COVID-19/epidemiology/prevention & control
Developing Countries
Vaccine-Preventable Diseases/prevention & control
RevDate: 2026-11-12
CmpDate: 2026-11-12
Quantifying the Digital Ecosystem of Commercial Technologies for Decentralized Clinical Trial Operations: Scoping Review.
JMIR medical informatics, 14:e86011 pii:v14i1e86011.
BACKGROUND: Decentralized clinical trials (DCTs) are reshaping clinical research through digital technologies such as telemedicine, mobile apps, wearable and sensor-based tools, and digital platforms. These technologies can support participation, safety, accessibility, data collection, monitoring, and trial operations. Although DCT adoption accelerated during the COVID-19 pandemic, the commercial technology landscape remains fragmented and continues to evolve rapidly. There is limited understanding of how commercial technologies align with operational activities across the DCT life cycle. The Basic Building Block (BBB) framework used in this review divides the DCT life cycle into 7 functional areas: setup and design; recruitment and enrollment; data acquisition and processing; operation and coordination; patient engagement; intervention and follow-up; and close-out and reporting.
OBJECTIVE: This scoping review aimed to map commercial technologies supporting DCT operations and assess their availability and functional alignment with clinical trial processes.
METHODS: A scoping review of commercial technologies was conducted from January 2024 to June 2025 to update a previous 2020 technology scan, with a search rerun in June 2026 for update and verification purposes. Eligible technologies were commercially available, publicly documented, and relevant to at least 1 BBB. The review was reported in accordance with PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews), with search reporting guided by PRISMA-S (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Literature Search extension) where applicable. Seven 2-person reviewer groups reassessed previously identified technologies and identified additional technologies by analyzing publicly available English-language sources, including vendor and company websites, product documentation, public reports, case studies, company announcements, and relevant academic literature. Technologies were categorized by BBB coverage, classified as single-BBB if they supported 1 BBB and multiple-BBB if they supported more than 1 BBB, and analyzed using a co-occurrence matrix.
RESULTS: The final catalog included 329 commercial technologies, spanning the DCT life cycle. Most were multiple-BBB technologies, with 293 multiple-BBB and 36 single-BBB technologies. Operation and coordination was the most frequently covered BBB (n=220), followed by data acquisition and processing (n=212), setup and design (n=189), patient engagement (n=165), close-out and reporting (n=125), intervention and follow-up (n=122), and recruitment and enrollment (n=120). The strongest co-occurrence pairings were data acquisition and processing with operation and coordination; setup and design with operation and coordination; and setup and design with data acquisition and processing. The weakest pairings involved close-out and reporting with intervention and follow-up, with recruitment and enrollment, and with patient engagement.
CONCLUSIONS: This scoping review provides an updated structured mapping of 329 commercial technologies supporting DCT operations. By combining a commercial technology scan with the BBB framework, the review quantifies functional coverage and co-occurrence across the DCT life cycle. The findings can support technology selection for decentralized and hybrid trials while highlighting operational areas where technology coverage seems to be less commonly combined.
Additional Links: PMID-43019549
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43019549,
year = {2026},
author = {Mpaltadoros, L and Huber, S and Stavropoulos, TG and Buchgraber-Schnalzer, B and Fons-Martínez, J and Murciano-Gamborino, C and Alcalde, B and Pérez-Breva, L and Nikolopoulos, S and Kompatsiaris, I and Hanke, S},
title = {Quantifying the Digital Ecosystem of Commercial Technologies for Decentralized Clinical Trial Operations: Scoping Review.},
journal = {JMIR medical informatics},
volume = {14},
number = {},
pages = {e86011},
doi = {10.2196/86011},
pmid = {43019549},
issn = {2291-9694},
mesh = {Humans ; *Clinical Trials as Topic/methods ; Digital Health ; *Telemedicine ; *Digital Technology ; COVID-19/epidemiology ; Mobile Applications ; },
abstract = {BACKGROUND: Decentralized clinical trials (DCTs) are reshaping clinical research through digital technologies such as telemedicine, mobile apps, wearable and sensor-based tools, and digital platforms. These technologies can support participation, safety, accessibility, data collection, monitoring, and trial operations. Although DCT adoption accelerated during the COVID-19 pandemic, the commercial technology landscape remains fragmented and continues to evolve rapidly. There is limited understanding of how commercial technologies align with operational activities across the DCT life cycle. The Basic Building Block (BBB) framework used in this review divides the DCT life cycle into 7 functional areas: setup and design; recruitment and enrollment; data acquisition and processing; operation and coordination; patient engagement; intervention and follow-up; and close-out and reporting.
OBJECTIVE: This scoping review aimed to map commercial technologies supporting DCT operations and assess their availability and functional alignment with clinical trial processes.
METHODS: A scoping review of commercial technologies was conducted from January 2024 to June 2025 to update a previous 2020 technology scan, with a search rerun in June 2026 for update and verification purposes. Eligible technologies were commercially available, publicly documented, and relevant to at least 1 BBB. The review was reported in accordance with PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews), with search reporting guided by PRISMA-S (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Literature Search extension) where applicable. Seven 2-person reviewer groups reassessed previously identified technologies and identified additional technologies by analyzing publicly available English-language sources, including vendor and company websites, product documentation, public reports, case studies, company announcements, and relevant academic literature. Technologies were categorized by BBB coverage, classified as single-BBB if they supported 1 BBB and multiple-BBB if they supported more than 1 BBB, and analyzed using a co-occurrence matrix.
RESULTS: The final catalog included 329 commercial technologies, spanning the DCT life cycle. Most were multiple-BBB technologies, with 293 multiple-BBB and 36 single-BBB technologies. Operation and coordination was the most frequently covered BBB (n=220), followed by data acquisition and processing (n=212), setup and design (n=189), patient engagement (n=165), close-out and reporting (n=125), intervention and follow-up (n=122), and recruitment and enrollment (n=120). The strongest co-occurrence pairings were data acquisition and processing with operation and coordination; setup and design with operation and coordination; and setup and design with data acquisition and processing. The weakest pairings involved close-out and reporting with intervention and follow-up, with recruitment and enrollment, and with patient engagement.
CONCLUSIONS: This scoping review provides an updated structured mapping of 329 commercial technologies supporting DCT operations. By combining a commercial technology scan with the BBB framework, the review quantifies functional coverage and co-occurrence across the DCT life cycle. The findings can support technology selection for decentralized and hybrid trials while highlighting operational areas where technology coverage seems to be less commonly combined.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Clinical Trials as Topic/methods
Digital Health
*Telemedicine
*Digital Technology
COVID-19/epidemiology
Mobile Applications
RevDate: 2026-11-12
How vaccine platforms are shaping preparedness for emerging and re-emerging viruses alike.
Current opinion in virology, 77:101595 pii:S1879-6257(26)00087-8 [Epub ahead of print].
Vaccine platforms are validated, adaptable technologies designed to enable a 'plug-and-play' approach to vaccine development and deployment, and have emerged as a cornerstone for epidemic and pandemic preparedness due to their capacity to be rapidly tailored to emerging pathogens. This capability was demonstrated during the COVID-19 pandemic, when the first clinical trial of a SARS-CoV-2 vaccine was initiated just 66 days after the viral genome was published. However, outbreaks caused by novel emerging viruses like SARS-CoV-2 are less common than those caused by known, re-emerging pathogens, including Marburg, Nipah and Lassa viruses. Unlike SARS-CoV-2, these pathogens have been recognised as public health threats for decades, yet licensed vaccines against them have yet to be realised. While this gap is partly attributable to scientific shortfalls, a more significant factor has arguably been the combination of economic, regulatory and epidemiological challenges that have impeded vaccine licensure and stockpile establishment. This review discusses how vaccine platforms are addressing some of these challenges, potentially providing the foundation for much-needed vaccine stockpiling approaches against re-emerging pathogens.
Additional Links: PMID-43019871
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43019871,
year = {2026},
author = {Jones, DM and Gilbert, SC},
title = {How vaccine platforms are shaping preparedness for emerging and re-emerging viruses alike.},
journal = {Current opinion in virology},
volume = {77},
number = {},
pages = {101595},
doi = {10.1016/j.coviro.2026.101595},
pmid = {43019871},
issn = {1879-6265},
abstract = {Vaccine platforms are validated, adaptable technologies designed to enable a 'plug-and-play' approach to vaccine development and deployment, and have emerged as a cornerstone for epidemic and pandemic preparedness due to their capacity to be rapidly tailored to emerging pathogens. This capability was demonstrated during the COVID-19 pandemic, when the first clinical trial of a SARS-CoV-2 vaccine was initiated just 66 days after the viral genome was published. However, outbreaks caused by novel emerging viruses like SARS-CoV-2 are less common than those caused by known, re-emerging pathogens, including Marburg, Nipah and Lassa viruses. Unlike SARS-CoV-2, these pathogens have been recognised as public health threats for decades, yet licensed vaccines against them have yet to be realised. While this gap is partly attributable to scientific shortfalls, a more significant factor has arguably been the combination of economic, regulatory and epidemiological challenges that have impeded vaccine licensure and stockpile establishment. This review discusses how vaccine platforms are addressing some of these challenges, potentially providing the foundation for much-needed vaccine stockpiling approaches against re-emerging pathogens.},
}
RevDate: 2026-11-10
CmpDate: 2026-11-11
Cost-effectiveness of digital health in primary care: a systematic review.
BMC health services research, 26(1):.
BACKGROUND: Digital health has rapidly expanded, accelerated by the COVID-19 pandemic, and is widely used for consultations, disease management, and efficiency improvements in primary care. While it is considered clinically effective and potentially cost-effective, evidence on economic impact remains limited. Previous reviews have been condition-specific, highlighting the need for a systematic review focused on cost-effectiveness of digital health within primary care.
OBJECTIVES: The aim of this systematic review was to summarize and investigate the cost-effectiveness of digital health among adult primary care patients.
METHODS: A systematic literature search was conducted using the PICO framework. Studies were included if they involved adult primary care patients (≥18 years), evaluated digital health interventions versus usual care, and reported cost‑effectiveness based on economic evaluations. PubMed, Scopus, and Health Business Elite were searched in January 2025. An updated search was conducted in September 2026. Results were reported in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. Methodological quality was assessed using the Joanna Briggs Institute Checklist for Economic Evaluations. A narrative synthesis was performed.
RESULTS: The initial search identified 4,091 records and resulted in 47 included studies. The updated search in September 2026 identified an additional 658 records, of which seven additional studies met the eligibility criteria, resulting in a total of 54 included studies. Most were trial‑based full economic evaluations focusing on digital interventions for depression and anxiety, adopting a healthcare perspective. Overall, digital health interventions were frequently associated with favourable economic outcomes, although results varied by intervention, population, economic evaluation method, and time horizon.
DISCUSSION: This review is innovative in its focus on the cost‑effectiveness of digital health interventions in primary care. Unlike previous reviews, it systematically synthesises trial‑ and model‑based economic evaluations. The review advances the field by clarifying the economic evidence base and has practical implications for decision‑makers considering the implementation of digital health in primary care. The review is limited by rapidly evolving digital health terminology, the exclusion of grey literature, and substantial methodological heterogeneity between trial‑based and model‑based economic evaluations. Potential selection bias related to digital literacy may limit generalisability.
CONCLUSIONS: Digital health in primary care demonstrated favourable economic outcomes across a broad range of clinical areas, with the majority of studies reporting cost-effective results. However, despite this positive pattern, methodological heterogeneity limits comparability between studies. Greater standardization of economic evaluation methods and reporting is therefore needed to strengthen the evidence base and support implementation decisions.
TRIAL REGISTRATION: PROSPERO registration no. CRD42025644904; [https://www.crd.york.ac.uk/PROSPERO/view/CRD42025644904].
Additional Links: PMID-43009961
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43009961,
year = {2026},
author = {Stern, S and Johansson, A and Nilsson, E and Nilsson, L},
title = {Cost-effectiveness of digital health in primary care: a systematic review.},
journal = {BMC health services research},
volume = {26},
number = {1},
pages = {},
pmid = {43009961},
issn = {1472-6963},
mesh = {Humans ; *Primary Health Care/economics ; Cost-Benefit Analysis ; *Digital Health/economics ; Cost-Effectiveness Analysis ; COVID-19 ; Pandemics ; SARS-CoV-2 ; Digital Media ; },
abstract = {BACKGROUND: Digital health has rapidly expanded, accelerated by the COVID-19 pandemic, and is widely used for consultations, disease management, and efficiency improvements in primary care. While it is considered clinically effective and potentially cost-effective, evidence on economic impact remains limited. Previous reviews have been condition-specific, highlighting the need for a systematic review focused on cost-effectiveness of digital health within primary care.
OBJECTIVES: The aim of this systematic review was to summarize and investigate the cost-effectiveness of digital health among adult primary care patients.
METHODS: A systematic literature search was conducted using the PICO framework. Studies were included if they involved adult primary care patients (≥18 years), evaluated digital health interventions versus usual care, and reported cost‑effectiveness based on economic evaluations. PubMed, Scopus, and Health Business Elite were searched in January 2025. An updated search was conducted in September 2026. Results were reported in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. Methodological quality was assessed using the Joanna Briggs Institute Checklist for Economic Evaluations. A narrative synthesis was performed.
RESULTS: The initial search identified 4,091 records and resulted in 47 included studies. The updated search in September 2026 identified an additional 658 records, of which seven additional studies met the eligibility criteria, resulting in a total of 54 included studies. Most were trial‑based full economic evaluations focusing on digital interventions for depression and anxiety, adopting a healthcare perspective. Overall, digital health interventions were frequently associated with favourable economic outcomes, although results varied by intervention, population, economic evaluation method, and time horizon.
DISCUSSION: This review is innovative in its focus on the cost‑effectiveness of digital health interventions in primary care. Unlike previous reviews, it systematically synthesises trial‑ and model‑based economic evaluations. The review advances the field by clarifying the economic evidence base and has practical implications for decision‑makers considering the implementation of digital health in primary care. The review is limited by rapidly evolving digital health terminology, the exclusion of grey literature, and substantial methodological heterogeneity between trial‑based and model‑based economic evaluations. Potential selection bias related to digital literacy may limit generalisability.
CONCLUSIONS: Digital health in primary care demonstrated favourable economic outcomes across a broad range of clinical areas, with the majority of studies reporting cost-effective results. However, despite this positive pattern, methodological heterogeneity limits comparability between studies. Greater standardization of economic evaluation methods and reporting is therefore needed to strengthen the evidence base and support implementation decisions.
TRIAL REGISTRATION: PROSPERO registration no. CRD42025644904; [https://www.crd.york.ac.uk/PROSPERO/view/CRD42025644904].},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Primary Health Care/economics
Cost-Benefit Analysis
*Digital Health/economics
Cost-Effectiveness Analysis
COVID-19
Pandemics
SARS-CoV-2
Digital Media
RevDate: 2026-11-11
Conceptualization, measurement, and factors associated with moral courage in nursing: A scoping review.
Nursing ethics [Epub ahead of print].
BackgroundFrequent exposure to ethically challenging situations can lead to moral distress and, over time, moral injury among nurses. Moral courage, acting in accordance with ethical convictions despite personal or professional risk, has been proposed as a protective factor, though the concept remains fragmented.ObjectivesTo identify, map, and summarize existing research on moral courage among nurses, focusing on its conceptualization, measurement, associated factors, and implications for practice, education, and research.Research designThis scoping review followed Joanna Briggs Institute methodology and PRISMA-ScR reporting guidelines, using a Population-Concept-Context framework: registered nurses in clinical settings; the concept of moral courage (definition, measurement, factors); any clinical context.Search strategyWeb of Science, PubMed/MEDLINE, Scopus, and the University of Toronto Library datasets were searched on 14 April 2026, for articles published from January 2000, limited to English and French. Two independent reviewers screened titles, abstracts, and full texts in Rayyan and extracted data using a piloted tool.Findings/resultsSixty-five studies (2019-2026) across eleven countries were included; 52% from Iran and 22% from China, with only three from Europe. Most (87%) used a cross-sectional design. Six instruments were identified, most commonly the Professional Moral Courage Scale (49%) and Nurses' Moral Courage Scale (33%), with clear geographic variation in instrument selection. Moral courage was conceptualized either as a stable Aristotelian virtue or a learnable ethical competence. Age, experience, ethical climate, and ethical leadership were consistently positively associated with moral courage, whereas its associations with some constructs, including moral distress and burnout, varied across studies. Structured ethics education consistently improved moral courage.ConclusionsMoral courage research in nursing has grown rapidly since the COVID-19 pandemic, yet the evidence base remains geographically concentrated, instrument-divided, and conceptually unsettled. Longitudinal and mediation-based research across diverse geographic settings is needed to clarify how moral courage develops and can be strengthened.
Additional Links: PMID-43010181
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43010181,
year = {2026},
author = {Gložinić, T and Singbo, OG and Čivljak, M},
title = {Conceptualization, measurement, and factors associated with moral courage in nursing: A scoping review.},
journal = {Nursing ethics},
volume = {},
number = {},
pages = {9697330261503762},
doi = {10.1177/09697330261503762},
pmid = {43010181},
issn = {1477-0989},
abstract = {BackgroundFrequent exposure to ethically challenging situations can lead to moral distress and, over time, moral injury among nurses. Moral courage, acting in accordance with ethical convictions despite personal or professional risk, has been proposed as a protective factor, though the concept remains fragmented.ObjectivesTo identify, map, and summarize existing research on moral courage among nurses, focusing on its conceptualization, measurement, associated factors, and implications for practice, education, and research.Research designThis scoping review followed Joanna Briggs Institute methodology and PRISMA-ScR reporting guidelines, using a Population-Concept-Context framework: registered nurses in clinical settings; the concept of moral courage (definition, measurement, factors); any clinical context.Search strategyWeb of Science, PubMed/MEDLINE, Scopus, and the University of Toronto Library datasets were searched on 14 April 2026, for articles published from January 2000, limited to English and French. Two independent reviewers screened titles, abstracts, and full texts in Rayyan and extracted data using a piloted tool.Findings/resultsSixty-five studies (2019-2026) across eleven countries were included; 52% from Iran and 22% from China, with only three from Europe. Most (87%) used a cross-sectional design. Six instruments were identified, most commonly the Professional Moral Courage Scale (49%) and Nurses' Moral Courage Scale (33%), with clear geographic variation in instrument selection. Moral courage was conceptualized either as a stable Aristotelian virtue or a learnable ethical competence. Age, experience, ethical climate, and ethical leadership were consistently positively associated with moral courage, whereas its associations with some constructs, including moral distress and burnout, varied across studies. Structured ethics education consistently improved moral courage.ConclusionsMoral courage research in nursing has grown rapidly since the COVID-19 pandemic, yet the evidence base remains geographically concentrated, instrument-divided, and conceptually unsettled. Longitudinal and mediation-based research across diverse geographic settings is needed to clarify how moral courage develops and can be strengthened.},
}
RevDate: 2026-11-11
CmpDate: 2026-11-11
Efficacy and safety of sivelestat in sepsis-induced acute respiratory distress syndrome: an updated meta-analysis based on disease severity and treatment strategy subgroups.
Frontiers in medicine, 13:1986111.
OBJECTIVE: Sivelestat sodium hydrate is a selective neutrophil elastase inhibitor that attenuates neutrophil-mediated alveolar-capillary injury and is used in some East Asian countries for acute lung injury/ARDS. We evaluated the efficacy and safety of sivelestat in sepsis-induced acute respiratory distress syndrome (ARDS) and explored whether disease severity, baseline mortality risk, and treatment background modify the mortality effect.
METHODS: We searched PubMed/MEDLINE, Embase, Cochrane CENTRAL, Web of Science, CNKI, Wanfang, and ClinicalTrials.gov from database inception to August 27, 2026. Eligible studies were adult studies of sepsis-induced ARDS comparing a sivelestat-containing regimen with an otherwise comparable regimen without sivelestat. COVID-19-only cohorts, non-septic ARDS, mixed-etiology studies without a separable sepsis subgroup, and comparisons in which both groups received sivelestat were excluded. The primary outcome was all-cause mortality; secondary outcomes included P/F ratio, duration of mechanical ventilation, ICU length of stay, organ-function scores, inflammatory markers, and adverse events. Mortality was pooled as odds ratios (ORs) using a random-effects model with restricted maximum likelihood; Hartung-Knapp intervals were used for the primary and study-design analyses. This review was prospectively registered in PROSPERO.
RESULTS: Fourteen studies were eligible for qualitative synthesis, and 10 studies (943 patients) provided extractable 2 × 2 mortality data. Deaths occurred in 73/431 patients receiving sivelestat and 125/512 controls. Sivelestat was associated with lower mortality (OR=0.55, 95% CI 0.36-0.84; I[2] = 0%). The signal persisted in randomized trials (OR=0.37, 95% CI 0.16-0.86; I[2] = 0%). Study-level point estimates appeared more favorable in cohorts with baseline P/F < 100 mmHg and control mortality >30%; however, interaction tests were not statistically significant and severity analyses were ecological. Leave-one-out analyses were stable. Egger testing did not detect significant small-study asymmetry (P = 0.197), although power was limited. Baseline-stratified treatment effects by IL-6, PCT, CRP, or neutrophil elastase were unavailable for quantitative effect-modification analyses.
CONCLUSIONS: In an updated and etiologically strict evidence synthesis, sivelestat was associated with lower mortality in sepsis-induced ARDS, including in randomized trials. Severe hypoxemia and high baseline risk remain plausible enrichment factors, but current aggregate evidence is insufficient to support a validated phenotype-guided prescribing rule. Co-intervention reporting was sparse, and residual confounding by prone positioning, sedation, neuromuscular blockade, and steroid background cannot be excluded.
PROSPERO CRD420261541158.
Additional Links: PMID-43011073
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43011073,
year = {2026},
author = {Haibier, A and Ma, J and Wang, Y and Wu, T},
title = {Efficacy and safety of sivelestat in sepsis-induced acute respiratory distress syndrome: an updated meta-analysis based on disease severity and treatment strategy subgroups.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1986111},
pmid = {43011073},
issn = {2296-858X},
abstract = {OBJECTIVE: Sivelestat sodium hydrate is a selective neutrophil elastase inhibitor that attenuates neutrophil-mediated alveolar-capillary injury and is used in some East Asian countries for acute lung injury/ARDS. We evaluated the efficacy and safety of sivelestat in sepsis-induced acute respiratory distress syndrome (ARDS) and explored whether disease severity, baseline mortality risk, and treatment background modify the mortality effect.
METHODS: We searched PubMed/MEDLINE, Embase, Cochrane CENTRAL, Web of Science, CNKI, Wanfang, and ClinicalTrials.gov from database inception to August 27, 2026. Eligible studies were adult studies of sepsis-induced ARDS comparing a sivelestat-containing regimen with an otherwise comparable regimen without sivelestat. COVID-19-only cohorts, non-septic ARDS, mixed-etiology studies without a separable sepsis subgroup, and comparisons in which both groups received sivelestat were excluded. The primary outcome was all-cause mortality; secondary outcomes included P/F ratio, duration of mechanical ventilation, ICU length of stay, organ-function scores, inflammatory markers, and adverse events. Mortality was pooled as odds ratios (ORs) using a random-effects model with restricted maximum likelihood; Hartung-Knapp intervals were used for the primary and study-design analyses. This review was prospectively registered in PROSPERO.
RESULTS: Fourteen studies were eligible for qualitative synthesis, and 10 studies (943 patients) provided extractable 2 × 2 mortality data. Deaths occurred in 73/431 patients receiving sivelestat and 125/512 controls. Sivelestat was associated with lower mortality (OR=0.55, 95% CI 0.36-0.84; I[2] = 0%). The signal persisted in randomized trials (OR=0.37, 95% CI 0.16-0.86; I[2] = 0%). Study-level point estimates appeared more favorable in cohorts with baseline P/F < 100 mmHg and control mortality >30%; however, interaction tests were not statistically significant and severity analyses were ecological. Leave-one-out analyses were stable. Egger testing did not detect significant small-study asymmetry (P = 0.197), although power was limited. Baseline-stratified treatment effects by IL-6, PCT, CRP, or neutrophil elastase were unavailable for quantitative effect-modification analyses.
CONCLUSIONS: In an updated and etiologically strict evidence synthesis, sivelestat was associated with lower mortality in sepsis-induced ARDS, including in randomized trials. Severe hypoxemia and high baseline risk remain plausible enrichment factors, but current aggregate evidence is insufficient to support a validated phenotype-guided prescribing rule. Co-intervention reporting was sparse, and residual confounding by prone positioning, sedation, neuromuscular blockade, and steroid background cannot be excluded.
PROSPERO CRD420261541158.},
}
RevDate: 2026-11-11
CmpDate: 2026-11-11
Management of community-associated bacterial skin and soft tissue infections in children and prevention of recurrence.
Paediatrics & child health, 31(7):818-838.
Skin and soft tissue infections (SSTIs) are among the most common infectious diseases encountered in children. Severity of SSTIs range from simple infections that resolve spontaneously to severe necrotizing syndromes requiring intravenous antibiotics, surgical intervention, and intensive care. Inadequate skin barrier resulting from common paediatric conditions such as eczema and skin abrasions predisposes to infection. When antibiotics are needed, their choice and duration should be guided by the most probable organisms involved, their likely susceptibility profiles, and geographical epidemiologic differences. Inappropriate treatment with overly broad-spectrum antibiotics and/or for prolonged durations is detrimental to the microbiomes of patients, increases antimicrobial-related side effects, and perpetuates colonization of resistant organisms, precipitating antimicrobial resistance. This statement provides health care providers with a toolkit for optimal management of bacterial SSTIs, including recurrent episodes. It does not comprehensively examine SSTI treatment principles in immunocompromised or burn patients due to the management complexities of both settings.
Additional Links: PMID-43011318
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43011318,
year = {2026},
author = {Penner, J and Fanella, S},
title = {Management of community-associated bacterial skin and soft tissue infections in children and prevention of recurrence.},
journal = {Paediatrics & child health},
volume = {31},
number = {7},
pages = {818-838},
pmid = {43011318},
issn = {1205-7088},
abstract = {Skin and soft tissue infections (SSTIs) are among the most common infectious diseases encountered in children. Severity of SSTIs range from simple infections that resolve spontaneously to severe necrotizing syndromes requiring intravenous antibiotics, surgical intervention, and intensive care. Inadequate skin barrier resulting from common paediatric conditions such as eczema and skin abrasions predisposes to infection. When antibiotics are needed, their choice and duration should be guided by the most probable organisms involved, their likely susceptibility profiles, and geographical epidemiologic differences. Inappropriate treatment with overly broad-spectrum antibiotics and/or for prolonged durations is detrimental to the microbiomes of patients, increases antimicrobial-related side effects, and perpetuates colonization of resistant organisms, precipitating antimicrobial resistance. This statement provides health care providers with a toolkit for optimal management of bacterial SSTIs, including recurrent episodes. It does not comprehensively examine SSTI treatment principles in immunocompromised or burn patients due to the management complexities of both settings.},
}
RevDate: 2026-11-11
CmpDate: 2026-11-11
Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects.
MedComm, 7(11):e71024.
Viral diseases remain a major global health challenge despite substantial advances in vaccination, antiviral therapeutics, and public-health interventions. However, current antiviral strategies are still constrained by important gaps, including rapid viral evolution, limited broad-spectrum efficacy, immune escape, antiviral resistance, incomplete durability of protection, and inequitable global access to prevention and treatment. This review provides a comprehensive and integrated overview of contemporary antiviral prevention and therapeutic strategies, spanning vaccines, monoclonal antibodies, direct-acting antivirals, host-targeted therapies, immunomodulators, RNA-based therapeutics, gene-editing technologies, and cellular immunotherapies. We discuss the mechanistic foundations, clinical applications, pharmacologic considerations, and translational challenges associated with each modality across major human viral pathogens, including HIV, HBV, HCV, influenza, SARS-CoV-2, RSV, Ebola virus, arboviruses, and herpesviruses. Particular emphasis is placed on emerging innovations such as long-acting prophylaxis, Fc-engineered monoclonal antibodies, nanoparticle and mucosal vaccine platforms, CRISPR-based antiviral systems, and broadly protective host-directed approaches designed to overcome resistance and enhance pandemic preparedness. In addition, we highlight the growing importance of real-time genomic surveillance and equitable global deployment strategies in shaping future antiviral responses, collectively underscoring that the next generation of antiviral medicine will depend on the convergence of universal immunization strategies, durable therapeutics, precision immune modulation, and rapidly deployable platform technologies capable of addressing both endemic and emerging viral threats.
Additional Links: PMID-43011527
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43011527,
year = {2026},
author = {Khan, S and Nisar, A and Li, X and Yu, H and Qadeer, A and Mehmood, SA and Lamraoui, I and Liu, S and Zhu, L and Deng, X and Kong, B and Zhong, K and Xia, Z},
title = {Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects.},
journal = {MedComm},
volume = {7},
number = {11},
pages = {e71024},
pmid = {43011527},
issn = {2688-2663},
abstract = {Viral diseases remain a major global health challenge despite substantial advances in vaccination, antiviral therapeutics, and public-health interventions. However, current antiviral strategies are still constrained by important gaps, including rapid viral evolution, limited broad-spectrum efficacy, immune escape, antiviral resistance, incomplete durability of protection, and inequitable global access to prevention and treatment. This review provides a comprehensive and integrated overview of contemporary antiviral prevention and therapeutic strategies, spanning vaccines, monoclonal antibodies, direct-acting antivirals, host-targeted therapies, immunomodulators, RNA-based therapeutics, gene-editing technologies, and cellular immunotherapies. We discuss the mechanistic foundations, clinical applications, pharmacologic considerations, and translational challenges associated with each modality across major human viral pathogens, including HIV, HBV, HCV, influenza, SARS-CoV-2, RSV, Ebola virus, arboviruses, and herpesviruses. Particular emphasis is placed on emerging innovations such as long-acting prophylaxis, Fc-engineered monoclonal antibodies, nanoparticle and mucosal vaccine platforms, CRISPR-based antiviral systems, and broadly protective host-directed approaches designed to overcome resistance and enhance pandemic preparedness. In addition, we highlight the growing importance of real-time genomic surveillance and equitable global deployment strategies in shaping future antiviral responses, collectively underscoring that the next generation of antiviral medicine will depend on the convergence of universal immunization strategies, durable therapeutics, precision immune modulation, and rapidly deployable platform technologies capable of addressing both endemic and emerging viral threats.},
}
RevDate: 2026-11-11
CmpDate: 2026-11-11
Immunopathogenesis of MEWDS and the white dot syndromes: anatomical specificity and mechanistic heterogeneity.
Frontiers in medicine, 13:1979898.
The white dot syndromes (WDS) are an umbrella term for a heterogeneous group of idiopathic inflammatory chorioretinopathies-including multiple evanescent white dot syndrome (MEWDS), acute posterior multifocal placoid pigment epitheliopathy (APMPPE), birdshot chorioretinopathy, multifocal choroiditis (MFC), and punctate inner choroidopathy (PIC). MEWDS is the subtype in which the debate over the primary anatomical site of disease initiation has been most intense: three competing hypotheses-choriocapillaritis, photoreceptoritis, and retinal pigment epithelium (RPE) dysfunction-remain unresolved. MEWDS has also accumulated substantial evidence for viral triggers, including SARS-CoV-2 infection and COVID-19 vaccination, whereas other WDS subtypes exhibit distinct mechanistic signatures (HLA-A29 in birdshot, choriocapillaris ischemia in APMPPE, Bruch's membrane disruption in MFC/PIC). This narrative review synthesizes the three MEWDS-specific hypotheses against multimodal imaging, genetic, and immunological evidence published through 2026, and contrasts them with disease-specific mechanisms across the WDS spectrum. Indocyanine green angiography (ICGA) findings support primary choriocapillaritis, whereas optical coherence tomography angiography (OCT-A) has yielded paradoxically preserved flow maps; RPE dysfunction remains plausible given fundus autofluorescence patterns and the RPE's immunoregulatory role. The Multimodal Imaging in Uveitis (MUV) Task Force Report 11 (2026) proposes an anatomical reclassification that assigns MEWDS to the photoreceptor/RPE group. Across WDS, the evidence supports mechanistically distinct diseases and motivates disease-specific, mechanism-driven nomenclature.
Additional Links: PMID-43011577
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43011577,
year = {2026},
author = {Wang, X and Li, Z and Kong, W and Yin, T and Cui, Z},
title = {Immunopathogenesis of MEWDS and the white dot syndromes: anatomical specificity and mechanistic heterogeneity.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1979898},
pmid = {43011577},
issn = {2296-858X},
abstract = {The white dot syndromes (WDS) are an umbrella term for a heterogeneous group of idiopathic inflammatory chorioretinopathies-including multiple evanescent white dot syndrome (MEWDS), acute posterior multifocal placoid pigment epitheliopathy (APMPPE), birdshot chorioretinopathy, multifocal choroiditis (MFC), and punctate inner choroidopathy (PIC). MEWDS is the subtype in which the debate over the primary anatomical site of disease initiation has been most intense: three competing hypotheses-choriocapillaritis, photoreceptoritis, and retinal pigment epithelium (RPE) dysfunction-remain unresolved. MEWDS has also accumulated substantial evidence for viral triggers, including SARS-CoV-2 infection and COVID-19 vaccination, whereas other WDS subtypes exhibit distinct mechanistic signatures (HLA-A29 in birdshot, choriocapillaris ischemia in APMPPE, Bruch's membrane disruption in MFC/PIC). This narrative review synthesizes the three MEWDS-specific hypotheses against multimodal imaging, genetic, and immunological evidence published through 2026, and contrasts them with disease-specific mechanisms across the WDS spectrum. Indocyanine green angiography (ICGA) findings support primary choriocapillaritis, whereas optical coherence tomography angiography (OCT-A) has yielded paradoxically preserved flow maps; RPE dysfunction remains plausible given fundus autofluorescence patterns and the RPE's immunoregulatory role. The Multimodal Imaging in Uveitis (MUV) Task Force Report 11 (2026) proposes an anatomical reclassification that assigns MEWDS to the photoreceptor/RPE group. Across WDS, the evidence supports mechanistically distinct diseases and motivates disease-specific, mechanism-driven nomenclature.},
}
RevDate: 2026-11-11
CmpDate: 2026-11-11
[Differential diagnosis of aseptic meningitis in Central Europe: An overview of less common infectious etiologies].
Klinicka mikrobiologie a infekcni lekarstvi, 32(3):104-110.
Aseptic meningoencephalitis in immunocompetent adults in Central Europe is most commonly attributed to Borrelia burgdorferi, enteroviruses, herpesviruses (HSV, VZV), and tick-borne encephalitis virus. While these agents retain diagnostic priority, a range of less common yet clinically relevant etiologies are frequently overlooked in differential diagnosis, potentially affecting disease course and patient prognosis. This narrative review focuses on such underrecognized infectious agents in patients without a travel history outside Central Europe and adjacent regions. Discussed pathogens include hepatitis E virus (particularly genotype HEV-3, with its neurological manifestations such as neuralgicamyotrophy and Guillain-Barré syndrome), acute HIV infection, neurosyphilis, leptospirosis, bartonellosis, tularemia,Rickettsia, Anaplasma, and Coxiella infections, Mycoplasma pneumoniae, and Tropheryma whipplei. Particular attention is given to vector-borne neurotropic viruses relevant to the Central European region (West Nile virus, Usutu virus, Tahyna virus, Borna disease virus 1, Toscana virus, Sindbis virus, and Crimean-Congo hemorrhagic fever virus), respiratory viruses (influenza, SARS-CoV-2, measles, mumps, etc.), and opportunistic pathogens in immunocompromised patients. For each pathogen, key epidemiological associations, typical clinical presentation, and recommended diagnostic approach are summarized, including limitations of serological methods (notably cross-reactivity among flaviviruses) and the potential role of next-generation metagenomic sequencing. The aim of this review is to provide clinicians with a practical tool for broadening the differential diagnosis of aseptic meningoencephalitis and to highlight epidemiological and clinical clues that may facilitate earlier recognition of these overlooked, yet treatable or prognostically significant, etiologies. Keywords: aseptic meningitis, meningoencephalitis, differential diagnosis, neuroinfection, Central Europe.
Additional Links: PMID-43012855
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43012855,
year = {2026},
author = {Mihalčin, M and Fašaneková, L and Kašpárková, B},
title = {[Differential diagnosis of aseptic meningitis in Central Europe: An overview of less common infectious etiologies].},
journal = {Klinicka mikrobiologie a infekcni lekarstvi},
volume = {32},
number = {3},
pages = {104-110},
pmid = {43012855},
issn = {1211-264X},
mesh = {Humans ; Diagnosis, Differential ; *Meningitis, Aseptic/diagnosis/etiology/virology/microbiology ; Europe ; },
abstract = {Aseptic meningoencephalitis in immunocompetent adults in Central Europe is most commonly attributed to Borrelia burgdorferi, enteroviruses, herpesviruses (HSV, VZV), and tick-borne encephalitis virus. While these agents retain diagnostic priority, a range of less common yet clinically relevant etiologies are frequently overlooked in differential diagnosis, potentially affecting disease course and patient prognosis. This narrative review focuses on such underrecognized infectious agents in patients without a travel history outside Central Europe and adjacent regions. Discussed pathogens include hepatitis E virus (particularly genotype HEV-3, with its neurological manifestations such as neuralgicamyotrophy and Guillain-Barré syndrome), acute HIV infection, neurosyphilis, leptospirosis, bartonellosis, tularemia,Rickettsia, Anaplasma, and Coxiella infections, Mycoplasma pneumoniae, and Tropheryma whipplei. Particular attention is given to vector-borne neurotropic viruses relevant to the Central European region (West Nile virus, Usutu virus, Tahyna virus, Borna disease virus 1, Toscana virus, Sindbis virus, and Crimean-Congo hemorrhagic fever virus), respiratory viruses (influenza, SARS-CoV-2, measles, mumps, etc.), and opportunistic pathogens in immunocompromised patients. For each pathogen, key epidemiological associations, typical clinical presentation, and recommended diagnostic approach are summarized, including limitations of serological methods (notably cross-reactivity among flaviviruses) and the potential role of next-generation metagenomic sequencing. The aim of this review is to provide clinicians with a practical tool for broadening the differential diagnosis of aseptic meningoencephalitis and to highlight epidemiological and clinical clues that may facilitate earlier recognition of these overlooked, yet treatable or prognostically significant, etiologies. Keywords: aseptic meningitis, meningoencephalitis, differential diagnosis, neuroinfection, Central Europe.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Diagnosis, Differential
*Meningitis, Aseptic/diagnosis/etiology/virology/microbiology
Europe
RevDate: 2026-11-11
CmpDate: 2026-11-11
Antidepressants in postural orthostatic tachycardia syndrome (POTS): A scoping review.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 47(12):.
BACKGROUND: Postural orthostatic tachycardia syndrome (POTS) is one of the most common autonomic disorders with increasing prevalence and incidence after COVID-19 pandemic. Despite standard treatment of POTS consisting of nonpharmacologic and pharmacologic therapies that decrease heart rate and increase blood pressure and plasma volume, antidepressant medications are widely utilized in patients with POTS.
METHODS: We conducted a scoping review of literature to examine the published studies on the use of antidepressants and their efficacy in patients with POTS.
RESULTS: We found only 2 studies, one retrospective chart review involving bupropion and second study of a randomized placebo-controlled crossover trial of a single dose of sertraline 50 mg. Both studies showed no benefits of these medications on orthostatic vital signs or orthostatic symptoms. A third study involving retrospective chart review did not examine medication efficacy, but found that nearly half of 120 patients with POTS were taking some type of antidepressant or antianxiety medication while only 15.7% were taking cardiovascular medications for treatment of POTS.
CONCLUSIONS: Based on very limited available data, we conclude that antidepressants show no efficacy for treatment of POTS despite being widely utilized. Education of healthcare professionals regarding proper diagnosis and appropriate treatment of POTS is essential to instituting the right treatment and avoiding inappropriate use of antidepressants in this patient population.
Additional Links: PMID-43013113
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43013113,
year = {2026},
author = {Blitshteyn, S and Reiersen, AM and Weinstock, LB and Speed, TJ and Treisman, GJ},
title = {Antidepressants in postural orthostatic tachycardia syndrome (POTS): A scoping review.},
journal = {Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology},
volume = {47},
number = {12},
pages = {},
pmid = {43013113},
issn = {1590-3478},
mesh = {Humans ; *Postural Orthostatic Tachycardia Syndrome/drug therapy ; *Antidepressive Agents/therapeutic use ; },
abstract = {BACKGROUND: Postural orthostatic tachycardia syndrome (POTS) is one of the most common autonomic disorders with increasing prevalence and incidence after COVID-19 pandemic. Despite standard treatment of POTS consisting of nonpharmacologic and pharmacologic therapies that decrease heart rate and increase blood pressure and plasma volume, antidepressant medications are widely utilized in patients with POTS.
METHODS: We conducted a scoping review of literature to examine the published studies on the use of antidepressants and their efficacy in patients with POTS.
RESULTS: We found only 2 studies, one retrospective chart review involving bupropion and second study of a randomized placebo-controlled crossover trial of a single dose of sertraline 50 mg. Both studies showed no benefits of these medications on orthostatic vital signs or orthostatic symptoms. A third study involving retrospective chart review did not examine medication efficacy, but found that nearly half of 120 patients with POTS were taking some type of antidepressant or antianxiety medication while only 15.7% were taking cardiovascular medications for treatment of POTS.
CONCLUSIONS: Based on very limited available data, we conclude that antidepressants show no efficacy for treatment of POTS despite being widely utilized. Education of healthcare professionals regarding proper diagnosis and appropriate treatment of POTS is essential to instituting the right treatment and avoiding inappropriate use of antidepressants in this patient population.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Postural Orthostatic Tachycardia Syndrome/drug therapy
*Antidepressive Agents/therapeutic use
RevDate: 2026-11-11
CmpDate: 2026-11-11
Intimate partner violence against women in Ethiopia: An umbrella review of systematic reviews and meta-analyses.
PloS one, 21(11):e0362748 pii:PONE-D-26-16616.
INTRODUCTION: Intimate partner violence is a major global public health concern and a serious human rights violation, involving physical, sexual, and psychological abuse within intimate relationships. Worldwide, about one in three women experiences intimate partner violence during their lifetime. Accordingly, this study aims to estimate the overall prevalence and identify the key predictors of intimate partner violence in Ethiopia.
METHODS: A comprehensive systematic search was carried out in PubMed, Web of Science, Google Scholar, and African Journals Online to identify relevant systematic reviews and meta-analyses on the prevalence and predictors of intimate partner violence against women in Ethiopia. The methodological quality of the included studies was assessed using the AMSTAR-2. A random-effects meta-analysis was conducted using STATA version 18 to generate pooled estimates.
RESULTS: This umbrella review synthesized evidence from six systematic reviews and meta-analyses comprising 80 primary studies involving 43,785 women. The overall prevalence of intimate partner violence was 35% (95% CI: 28-42%), with substantial heterogeneity across reviews (I2 = 83.48%). It also revealed a prevalence of 32% (95% CI: 26-37%) among pregnant women and 33% (95% CI: 25-40%) during the COVID-19 pandemic. The prevalence of specific forms of violence was estimated at 18% (95% CI: 14-22%) for sexual violence, 19% (95% CI: 15-23%) for physical violence, and 27% (95% CI: 23-31%) for psychological violence. Key predictors of IPV included both partners' and women's educational status, partner alcohol consumption, women's decision-making power, substance use, and income loss during the COVID-19 pandemic, with all associations found to be statistically significant.
CONCLUSION: This umbrella review shows that intimate partner violence remains a major public health issue in Ethiopia, affecting over one-third of women. Strengthening policy implementation and expanding survivor-centered services are essential to reduce IPV and advance Sustainable Development Goal 5.
Additional Links: PMID-43013531
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43013531,
year = {2026},
author = {Haile, TG and Asres, N and Gebregziabher, D and Fissahaye, B and Leake, Y and Teklay, G and Gebru, HB},
title = {Intimate partner violence against women in Ethiopia: An umbrella review of systematic reviews and meta-analyses.},
journal = {PloS one},
volume = {21},
number = {11},
pages = {e0362748},
doi = {10.1371/journal.pone.0362748},
pmid = {43013531},
issn = {1932-6203},
mesh = {Humans ; Ethiopia/epidemiology ; Female ; *Intimate Partner Violence/statistics & numerical data/psychology ; Systematic Reviews as Topic ; Prevalence ; COVID-19/epidemiology ; Pregnancy ; },
abstract = {INTRODUCTION: Intimate partner violence is a major global public health concern and a serious human rights violation, involving physical, sexual, and psychological abuse within intimate relationships. Worldwide, about one in three women experiences intimate partner violence during their lifetime. Accordingly, this study aims to estimate the overall prevalence and identify the key predictors of intimate partner violence in Ethiopia.
METHODS: A comprehensive systematic search was carried out in PubMed, Web of Science, Google Scholar, and African Journals Online to identify relevant systematic reviews and meta-analyses on the prevalence and predictors of intimate partner violence against women in Ethiopia. The methodological quality of the included studies was assessed using the AMSTAR-2. A random-effects meta-analysis was conducted using STATA version 18 to generate pooled estimates.
RESULTS: This umbrella review synthesized evidence from six systematic reviews and meta-analyses comprising 80 primary studies involving 43,785 women. The overall prevalence of intimate partner violence was 35% (95% CI: 28-42%), with substantial heterogeneity across reviews (I2 = 83.48%). It also revealed a prevalence of 32% (95% CI: 26-37%) among pregnant women and 33% (95% CI: 25-40%) during the COVID-19 pandemic. The prevalence of specific forms of violence was estimated at 18% (95% CI: 14-22%) for sexual violence, 19% (95% CI: 15-23%) for physical violence, and 27% (95% CI: 23-31%) for psychological violence. Key predictors of IPV included both partners' and women's educational status, partner alcohol consumption, women's decision-making power, substance use, and income loss during the COVID-19 pandemic, with all associations found to be statistically significant.
CONCLUSION: This umbrella review shows that intimate partner violence remains a major public health issue in Ethiopia, affecting over one-third of women. Strengthening policy implementation and expanding survivor-centered services are essential to reduce IPV and advance Sustainable Development Goal 5.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Ethiopia/epidemiology
Female
*Intimate Partner Violence/statistics & numerical data/psychology
Systematic Reviews as Topic
Prevalence
COVID-19/epidemiology
Pregnancy
RevDate: 2026-11-11
Defining the druggability of viral macrodomains in coronaviruses and alphaviruses.
Pharmacological reviews, 78(6):100162 pii:S0031-6997(26)00050-5 [Epub ahead of print].
Viral macrodomains are ADP-ribosylhydrolases encoded within the nonstructural proteins of coronaviruses and alphaviruses-2 RNA virus families with pandemic potential. Genetic studies demonstrate that ADP-ribose binding and ADP-ribosylhydrolase activity are critical for replication in alphaviruses and select coronaviruses, such as Middle East respiratory syndrome coronavirus and murine hepatitis virus. In contrast, for severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2, this domain primarily enhances in vivo fitness by modulating the innate immune response, establishing the macrodomain as a validated antiviral target. Structure-guided and high-throughput efforts have identified selective inhibitors for SARS-CoV-2 and, more recently, early-stage inhibitors of the alphavirus chikungunya virus. Both exploit a conserved active-site architecture that organizes ligand recognition into adenine, phosphate, ribose, and oxyanion subsites. Despite screening of extensive chemical libraries, inhibitor discovery has repeatedly converged on adenine-anchored scaffolds requiring polar engagement of the oxyanion region to achieve potency. This convergence defines a structurally confined druggable corridor but reveals a persistent permeability-potency tradeoff imposed by the polarity required for catalytic engagement. Cross-family comparisons further demonstrate localized divergence that shapes selectivity and constrains straightforward scaffold portability. Here, we synthesize structural, biochemical, and antiviral advances across SARS-CoV-2 and chikungunya virus, define the current boundaries of macrodomain chemical space, and delineate the chemical and biological constraints that now govern translation of catalytic inhibition into predictable antiviral efficacy. SIGNIFICANCE STATEMENT: Viral macrodomains have emerged as compelling antiviral targets in 2 pandemic-potential virus families, coronaviruses and alphaviruses, owing to their conservation and role in virulence. This review defines the chemical space and druggability of the severe acute respiratory syndrome coronavirus 2 and chikungunya virus macrodomains and the structural and biological constraints that must be overcome to translate catalytic inhibition into next-generation antivirals.
Additional Links: PMID-43014236
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43014236,
year = {2026},
author = {Biswas, B and Abraham, R and Bosch, J and Leung, AKL},
title = {Defining the druggability of viral macrodomains in coronaviruses and alphaviruses.},
journal = {Pharmacological reviews},
volume = {78},
number = {6},
pages = {100162},
doi = {10.1016/j.pharmr.2026.100162},
pmid = {43014236},
issn = {1521-0081},
abstract = {Viral macrodomains are ADP-ribosylhydrolases encoded within the nonstructural proteins of coronaviruses and alphaviruses-2 RNA virus families with pandemic potential. Genetic studies demonstrate that ADP-ribose binding and ADP-ribosylhydrolase activity are critical for replication in alphaviruses and select coronaviruses, such as Middle East respiratory syndrome coronavirus and murine hepatitis virus. In contrast, for severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2, this domain primarily enhances in vivo fitness by modulating the innate immune response, establishing the macrodomain as a validated antiviral target. Structure-guided and high-throughput efforts have identified selective inhibitors for SARS-CoV-2 and, more recently, early-stage inhibitors of the alphavirus chikungunya virus. Both exploit a conserved active-site architecture that organizes ligand recognition into adenine, phosphate, ribose, and oxyanion subsites. Despite screening of extensive chemical libraries, inhibitor discovery has repeatedly converged on adenine-anchored scaffolds requiring polar engagement of the oxyanion region to achieve potency. This convergence defines a structurally confined druggable corridor but reveals a persistent permeability-potency tradeoff imposed by the polarity required for catalytic engagement. Cross-family comparisons further demonstrate localized divergence that shapes selectivity and constrains straightforward scaffold portability. Here, we synthesize structural, biochemical, and antiviral advances across SARS-CoV-2 and chikungunya virus, define the current boundaries of macrodomain chemical space, and delineate the chemical and biological constraints that now govern translation of catalytic inhibition into predictable antiviral efficacy. SIGNIFICANCE STATEMENT: Viral macrodomains have emerged as compelling antiviral targets in 2 pandemic-potential virus families, coronaviruses and alphaviruses, owing to their conservation and role in virulence. This review defines the chemical space and druggability of the severe acute respiratory syndrome coronavirus 2 and chikungunya virus macrodomains and the structural and biological constraints that must be overcome to translate catalytic inhibition into next-generation antivirals.},
}
RevDate: 2026-11-10
CmpDate: 2026-11-10
The role of the JAK/STAT pathway in the pathogenesis and treatment of post-COVID autoimmune syndromes.
Frontiers in pharmacology, 17:1939700.
The coronavirus disease 2019 (COVID-19) pandemic has not only resulted in acute respiratory illness but has also led to a growing population of individuals affected by persistent, debilitating symptoms, collectively known as post-COVID syndrome or "Long COVID". This condition presents with a variety of manifestations, including fatigue, joint pain, cognitive disturbances, and dysautonomia, often mimicking autoimmune and neuroinflammatory disorders. Recent research highlights the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway as a central mediator in the inflammatory cascade triggered by SARS-CoV-2 infection. This review explores the dual role of the JAK/STAT pathway in both the acute phase of COVID-19 and its potential contribution to post-infectious autoimmune phenomena. We summarize the current understanding of JAK inhibitors (JAKi) as therapeutic agents for mitigating hyperinflammation during active infection and examine their emerging role in the management of post-COVID syndromes, particularly in cases with pulmonary involvement and features overlapping with fibromyalgia and chronic fatigue syndrome. Moreover, we discuss the safety profile of JAKi, their impact on vaccine immunogenicity, and the implications of autoantibody formation targeting the autonomic nervous system. Understanding the immunopathological mechanisms underpinning post-COVID may not only inform therapeutic strategies but also illuminate broader pathways involved in chronic autoimmune conditions.
Additional Links: PMID-43005306
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43005306,
year = {2026},
author = {Bruno, L and Di Berardino, M and Cafaro, G and Pozzolo, RD and Ceccarelli, F and Shoenfeld, Y and Gerli, R and Bartoloni, E and Perricone, C},
title = {The role of the JAK/STAT pathway in the pathogenesis and treatment of post-COVID autoimmune syndromes.},
journal = {Frontiers in pharmacology},
volume = {17},
number = {},
pages = {1939700},
pmid = {43005306},
issn = {1663-9812},
abstract = {The coronavirus disease 2019 (COVID-19) pandemic has not only resulted in acute respiratory illness but has also led to a growing population of individuals affected by persistent, debilitating symptoms, collectively known as post-COVID syndrome or "Long COVID". This condition presents with a variety of manifestations, including fatigue, joint pain, cognitive disturbances, and dysautonomia, often mimicking autoimmune and neuroinflammatory disorders. Recent research highlights the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway as a central mediator in the inflammatory cascade triggered by SARS-CoV-2 infection. This review explores the dual role of the JAK/STAT pathway in both the acute phase of COVID-19 and its potential contribution to post-infectious autoimmune phenomena. We summarize the current understanding of JAK inhibitors (JAKi) as therapeutic agents for mitigating hyperinflammation during active infection and examine their emerging role in the management of post-COVID syndromes, particularly in cases with pulmonary involvement and features overlapping with fibromyalgia and chronic fatigue syndrome. Moreover, we discuss the safety profile of JAKi, their impact on vaccine immunogenicity, and the implications of autoantibody formation targeting the autonomic nervous system. Understanding the immunopathological mechanisms underpinning post-COVID may not only inform therapeutic strategies but also illuminate broader pathways involved in chronic autoimmune conditions.},
}
RevDate: 2026-11-10
CmpDate: 2026-11-10
Common barriers and facilitators to the implementation of digital medicine in chronic respiratory diseases: a systematic review of reviews.
Frontiers in digital health, 8:1927835.
Digital Medicine offers significant potential for improving care in Respiratory Medicine, yet its full uptake remains limited. Barriers and facilitators involve multiple stakeholders and are likely shared across diseases and technologies. This study had the following research question: What are the common barriers, facilitators, and transferable concepts for implementing Digital Medicine in respiratory diseases, exemplified by bronchial asthma, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and COVID-19?
STUDY DESIGN AND METHODS: Systematic review of reviews. Three electronic databases (PubMed, Scopus, and Web of Science), as well as Cochrane Library were searched for review publications from September 2019 through May 2026. Nine included reviews were appraised using AMSTAR-2. Original publications referenced within these reviews were additionally screened for suitability for data extraction, leading to inclusion of 18 original publications. Extracted barriers and facilitators were visualized as disease- and actor-stratified co-occurrence networks and mapped to two implementation frameworks (CFIR and Chaudoir et al. 2013).
RESULTS: No COVID-19 publication met inclusion criteria. Asthma and, partially, CF evidence was rich and included institution-level data, while COPD evidence was less diverse. One CF program survey had structured its data according to the CFIR framework, enabling uniquely complete mapping of barriers and facilitators.
CONCLUSION: High-quality, framework-structured, network-visualizable evidence on barriers and facilitators to Digital Medicine exists in bronchial asthma and, partially, CF. In contrast, evidence on barriers and facilitators in COPD is not yet systematic. Future studies should be anchored in frameworks for sufficient comprehensiveness and facilitated knowledge translation into implementability.
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251070944, PROSPERO, CRD420251070944.
Additional Links: PMID-43005442
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43005442,
year = {2026},
author = {Korel, J and Kuhn, S and Gloeckl, R and Koczulla, R and Dreher, M and Müller, BS and Hirschbrich, R and Junker, E and Hastenteufel, T and Llauradó, X and Haddi, Z and Vogelmeier, CF and Rohde, G and Dauletbaev, N},
title = {Common barriers and facilitators to the implementation of digital medicine in chronic respiratory diseases: a systematic review of reviews.},
journal = {Frontiers in digital health},
volume = {8},
number = {},
pages = {1927835},
pmid = {43005442},
issn = {2673-253X},
abstract = {Digital Medicine offers significant potential for improving care in Respiratory Medicine, yet its full uptake remains limited. Barriers and facilitators involve multiple stakeholders and are likely shared across diseases and technologies. This study had the following research question: What are the common barriers, facilitators, and transferable concepts for implementing Digital Medicine in respiratory diseases, exemplified by bronchial asthma, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and COVID-19?
STUDY DESIGN AND METHODS: Systematic review of reviews. Three electronic databases (PubMed, Scopus, and Web of Science), as well as Cochrane Library were searched for review publications from September 2019 through May 2026. Nine included reviews were appraised using AMSTAR-2. Original publications referenced within these reviews were additionally screened for suitability for data extraction, leading to inclusion of 18 original publications. Extracted barriers and facilitators were visualized as disease- and actor-stratified co-occurrence networks and mapped to two implementation frameworks (CFIR and Chaudoir et al. 2013).
RESULTS: No COVID-19 publication met inclusion criteria. Asthma and, partially, CF evidence was rich and included institution-level data, while COPD evidence was less diverse. One CF program survey had structured its data according to the CFIR framework, enabling uniquely complete mapping of barriers and facilitators.
CONCLUSION: High-quality, framework-structured, network-visualizable evidence on barriers and facilitators to Digital Medicine exists in bronchial asthma and, partially, CF. In contrast, evidence on barriers and facilitators in COPD is not yet systematic. Future studies should be anchored in frameworks for sufficient comprehensiveness and facilitated knowledge translation into implementability.
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251070944, PROSPERO, CRD420251070944.},
}
RevDate: 2026-11-10
CmpDate: 2026-11-10
Changes in Training Quality and Workload Among Radiology Trainees Pre- and Post-COVID-19 Pandemic: A Systematic Review.
Cureus, 18(10):e117741.
This review aimed to systematically review changes in radiology trainee training quality and workload before, during, and after the COVID-19 pandemic, assessing its impact on educational experiences, clinical and procedural exposure, workload demands, trainee wellbeing, and the adoption of adaptive educational strategies such as virtual learning and simulation-based training. A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Electronic databases, including PubMed, Elsevier ScienceDirect and Web of Science, were searched for studies evaluating the impact of the COVID-19 pandemic on radiology trainee workload, education, and training quality. Supplementary searches of Google Scholar and relevant professional organisation websites, including the Royal College of Radiologists, were conducted, alongside targeted searches of Clinical Radiology and other relevant radiology publications. Although studies from multiple countries were included, findings were interpreted in the context of the UK radiology training curriculum and changes to radiology training and service provision during the COVID-19 pandemic. Eligible studies were analysed using narrative synthesis. The COVID-19 pandemic significantly affected radiology trainee workload and training quality across multiple domains. Common findings included reduced clinical exposure, decreased reporting opportunities, loss of face-to-face teaching, reduced procedural experience, and concerns regarding competency attainment. Imaging volumes declined substantially because of the postponement of elective imaging and outpatient services, resulting in reduced exposure to radiographs, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and interventional radiology procedures. Training progression was further affected by examination delays, rota disruptions, redeployment, and reduced consultant supervision. Increased psychological burden, including stress, anxiety, and burnout, was also reported across multiple studies. Despite these challenges, radiology training programmes demonstrated adaptability through the rapid adoption of virtual learning, remote reporting, simulation-based teaching, and digital educational platforms, improving accessibility and flexibility. These adaptations contributed to the development of increasingly hybrid training models combining virtual and face-to-face learning. The COVID-19 pandemic substantially disrupted radiology trainee workload, training quality, clinical exposure, and procedural experience. However, it also accelerated the adoption of virtual learning, digital platforms, remote working, and simulation-based education. The post-pandemic period has therefore seen continued integration of these approaches alongside traditional apprenticeship-based training, with potential implications for the future delivery of radiology education and training.
Additional Links: PMID-43005702
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43005702,
year = {2026},
author = {Chan, S and Koo, A},
title = {Changes in Training Quality and Workload Among Radiology Trainees Pre- and Post-COVID-19 Pandemic: A Systematic Review.},
journal = {Cureus},
volume = {18},
number = {10},
pages = {e117741},
pmid = {43005702},
issn = {2168-8184},
abstract = {This review aimed to systematically review changes in radiology trainee training quality and workload before, during, and after the COVID-19 pandemic, assessing its impact on educational experiences, clinical and procedural exposure, workload demands, trainee wellbeing, and the adoption of adaptive educational strategies such as virtual learning and simulation-based training. A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Electronic databases, including PubMed, Elsevier ScienceDirect and Web of Science, were searched for studies evaluating the impact of the COVID-19 pandemic on radiology trainee workload, education, and training quality. Supplementary searches of Google Scholar and relevant professional organisation websites, including the Royal College of Radiologists, were conducted, alongside targeted searches of Clinical Radiology and other relevant radiology publications. Although studies from multiple countries were included, findings were interpreted in the context of the UK radiology training curriculum and changes to radiology training and service provision during the COVID-19 pandemic. Eligible studies were analysed using narrative synthesis. The COVID-19 pandemic significantly affected radiology trainee workload and training quality across multiple domains. Common findings included reduced clinical exposure, decreased reporting opportunities, loss of face-to-face teaching, reduced procedural experience, and concerns regarding competency attainment. Imaging volumes declined substantially because of the postponement of elective imaging and outpatient services, resulting in reduced exposure to radiographs, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and interventional radiology procedures. Training progression was further affected by examination delays, rota disruptions, redeployment, and reduced consultant supervision. Increased psychological burden, including stress, anxiety, and burnout, was also reported across multiple studies. Despite these challenges, radiology training programmes demonstrated adaptability through the rapid adoption of virtual learning, remote reporting, simulation-based teaching, and digital educational platforms, improving accessibility and flexibility. These adaptations contributed to the development of increasingly hybrid training models combining virtual and face-to-face learning. The COVID-19 pandemic substantially disrupted radiology trainee workload, training quality, clinical exposure, and procedural experience. However, it also accelerated the adoption of virtual learning, digital platforms, remote working, and simulation-based education. The post-pandemic period has therefore seen continued integration of these approaches alongside traditional apprenticeship-based training, with potential implications for the future delivery of radiology education and training.},
}
RevDate: 2026-11-10
CmpDate: 2026-11-10
Pharmacological inhibition of coronavirus replication via modulation of host lipid metabolism.
The Journal of general virology, 107(11):.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 and the subsequent coronavirus disease 2019 pandemic highlighted the urgent need for novel therapeutic approaches. Coronaviruses rely extensively on host cell metabolic pathways to support their propagation, and efficient viral replication requires the extensive remodelling of host cell membranes. This includes the formation of specialized membranous structures known as replication organelles that accommodate viral RNA synthesis in the cytoplasm of the infected cell. Other processes depending on host membranes are viral entry, the acquisition of the coronavirus envelope from intracellular membrane compartments and the post-translational conjugation of lipids to certain viral proteins. The endogenous pathways involved in these pivotal steps of coronavirus replication represent attractive targets for host-directed antiviral therapy, which may also reduce the emergence of resistance that often limits the efficacy of direct-acting antiviral drug treatment. Accordingly, recent studies have identified a range of small-molecule inhibitors that target lipid metabolism pathways and display promising antiviral activity against coronaviruses. In this review, we examine the pharmacological modulation of lipid metabolism with small-molecule inhibitors as an antiviral strategy against SARS-CoV-2 and other coronaviruses and discuss the strengths, limitations and translational challenges associated with these compounds. We further consider how advances in our understanding of such virus-host metabolic interactions may facilitate the development of broadly active host-directed antivirals, contributing to pandemic preparedness against known and newly emerging coronaviruses.
Additional Links: PMID-43007712
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43007712,
year = {2026},
author = {Soultsioti, M and Bárcena, M and Giera, M and Snijder, EJ},
title = {Pharmacological inhibition of coronavirus replication via modulation of host lipid metabolism.},
journal = {The Journal of general virology},
volume = {107},
number = {11},
pages = {},
pmid = {43007712},
issn = {1465-2099},
mesh = {*Lipid Metabolism/drug effects ; *Virus Replication/drug effects ; Humans ; *Antiviral Agents/pharmacology/therapeutic use ; *SARS-CoV-2/drug effects/physiology ; Host-Directed Therapy ; *Coronavirus/drug effects/physiology ; Animals ; COVID-19/virology ; *Coronavirus Infections/drug therapy/virology/metabolism ; Host-Pathogen Interactions/drug effects ; Virus Internalization/drug effects ; *Betacoronavirus/drug effects/physiology ; },
abstract = {The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 and the subsequent coronavirus disease 2019 pandemic highlighted the urgent need for novel therapeutic approaches. Coronaviruses rely extensively on host cell metabolic pathways to support their propagation, and efficient viral replication requires the extensive remodelling of host cell membranes. This includes the formation of specialized membranous structures known as replication organelles that accommodate viral RNA synthesis in the cytoplasm of the infected cell. Other processes depending on host membranes are viral entry, the acquisition of the coronavirus envelope from intracellular membrane compartments and the post-translational conjugation of lipids to certain viral proteins. The endogenous pathways involved in these pivotal steps of coronavirus replication represent attractive targets for host-directed antiviral therapy, which may also reduce the emergence of resistance that often limits the efficacy of direct-acting antiviral drug treatment. Accordingly, recent studies have identified a range of small-molecule inhibitors that target lipid metabolism pathways and display promising antiviral activity against coronaviruses. In this review, we examine the pharmacological modulation of lipid metabolism with small-molecule inhibitors as an antiviral strategy against SARS-CoV-2 and other coronaviruses and discuss the strengths, limitations and translational challenges associated with these compounds. We further consider how advances in our understanding of such virus-host metabolic interactions may facilitate the development of broadly active host-directed antivirals, contributing to pandemic preparedness against known and newly emerging coronaviruses.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Lipid Metabolism/drug effects
*Virus Replication/drug effects
Humans
*Antiviral Agents/pharmacology/therapeutic use
*SARS-CoV-2/drug effects/physiology
Host-Directed Therapy
*Coronavirus/drug effects/physiology
Animals
COVID-19/virology
*Coronavirus Infections/drug therapy/virology/metabolism
Host-Pathogen Interactions/drug effects
Virus Internalization/drug effects
*Betacoronavirus/drug effects/physiology
RevDate: 2026-11-10
Pooled prevalence of infectious diseases among first responders in the prehospital setting: A systematic review with meta-analysis by occupation.
Prehospital emergency care [Epub ahead of print].
OBJECTIVES: First responders often work in unpredictable, uncontrolled environments, where exposure to infected patients and contaminated environments heighten the risk of communicable disease transmission. Their higher infection prevalence compared with the general population has driven the implementation of personal protective equipment, vaccination requirements, safety protocols, and infection prevention education. The aim of this systematic review and meta-analysis was to estimate the pooled prevalence of infections among first responders in the prehospital workers including paramedics, emergency medical technicians, patient transport staff, firefighters, police, and police officers.
METHODS: Embase, CINAHL, Web of Science and PUBMED/Medline were systematically searched. Pooled prevalence estimates were calculated using random-effects models with restricted maximum likelihood estimation, with Freeman-Tukey double-arcsine transformation and back-transformation to the original prevalence scale. Heterogeneity was assessed using I², τ², and 95% prediction intervals. Meta-regression was used to examine potential sources of between-study heterogeneity, and small-study effects and potential publication bias were assessed using funnel plots and Egger's regression test. Risk of bias was investigated using the AXIS tool.
RESULTS: Following the initial search, 34,874 articles were identified, of which 88 were full-text screened. Of these, 22 studies representing 19,188 first responders were included in this systematic review. The pooled prevalences of hepatitis B and C were 6.2% (95% CI 4.5%-8.2%) and 1.8% (95% CI 0.9%-2.9%), respectively. Around 4% (95% CI 2.6%- 5.9%) of the first responders had MRSA colonisation. Current or past infection with COVID-19 among non-vaccinated first responders was 13.6% (95% CI 4.8%- 25.9%), which reduced to 7.3% (95% CI 3.6%- 12%) after exclusion of studies with high risk of bias. Of the known study characteristics, geographic region significantly contributed to heterogeneity, explaining 36.7% of between-study variance, p = 0.039.
CONCLUSIONS: Infectious disease prevalence varied across pathogens, occupations, and geographical settings among first responders. These findings should be interpreted in light of substantial heterogeneity and limitations in the available evidence but may help inform infection prevention, occupational health policy, vaccination strategies, and future research in first responder services.
Additional Links: PMID-43008211
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43008211,
year = {2026},
author = {Alahmari, H and Hanson, L and Kelley, P and Harris, K and Spong, J and Milazzo, A and Mnatzaganian, G},
title = {Pooled prevalence of infectious diseases among first responders in the prehospital setting: A systematic review with meta-analysis by occupation.},
journal = {Prehospital emergency care},
volume = {},
number = {},
pages = {1-18},
doi = {10.1080/10903127.2026.2759763},
pmid = {43008211},
issn = {1545-0066},
abstract = {OBJECTIVES: First responders often work in unpredictable, uncontrolled environments, where exposure to infected patients and contaminated environments heighten the risk of communicable disease transmission. Their higher infection prevalence compared with the general population has driven the implementation of personal protective equipment, vaccination requirements, safety protocols, and infection prevention education. The aim of this systematic review and meta-analysis was to estimate the pooled prevalence of infections among first responders in the prehospital workers including paramedics, emergency medical technicians, patient transport staff, firefighters, police, and police officers.
METHODS: Embase, CINAHL, Web of Science and PUBMED/Medline were systematically searched. Pooled prevalence estimates were calculated using random-effects models with restricted maximum likelihood estimation, with Freeman-Tukey double-arcsine transformation and back-transformation to the original prevalence scale. Heterogeneity was assessed using I², τ², and 95% prediction intervals. Meta-regression was used to examine potential sources of between-study heterogeneity, and small-study effects and potential publication bias were assessed using funnel plots and Egger's regression test. Risk of bias was investigated using the AXIS tool.
RESULTS: Following the initial search, 34,874 articles were identified, of which 88 were full-text screened. Of these, 22 studies representing 19,188 first responders were included in this systematic review. The pooled prevalences of hepatitis B and C were 6.2% (95% CI 4.5%-8.2%) and 1.8% (95% CI 0.9%-2.9%), respectively. Around 4% (95% CI 2.6%- 5.9%) of the first responders had MRSA colonisation. Current or past infection with COVID-19 among non-vaccinated first responders was 13.6% (95% CI 4.8%- 25.9%), which reduced to 7.3% (95% CI 3.6%- 12%) after exclusion of studies with high risk of bias. Of the known study characteristics, geographic region significantly contributed to heterogeneity, explaining 36.7% of between-study variance, p = 0.039.
CONCLUSIONS: Infectious disease prevalence varied across pathogens, occupations, and geographical settings among first responders. These findings should be interpreted in light of substantial heterogeneity and limitations in the available evidence but may help inform infection prevention, occupational health policy, vaccination strategies, and future research in first responder services.},
}
RevDate: 2026-11-10
Beyond ACE2 downregulation: daphnetin as a multi-target agent for COVID-19 and rheumatic comorbidities.
European journal of pharmacology pii:S0014-2999(26)01012-5 [Epub ahead of print].
The continuous emergence of SARS-CoV-2 variants (e.g., JN.1, KP.3) and the significantly elevated risk of severe COVID-19 in patients with rheumatic autoimmune diseases highlight an urgent unmet clinical need for dual-targeted therapeutics. Daphnetin (7,8-dihydroxycoumarin), a natural coumarin compound with a long history of clinical use in China, prevents SARS-CoV-2 infection by downregulating the viral entry receptor ACE2 through inhibition of HIF-1α and JAK2/STAT3 signaling. This review synthesizes the pleiotropic pharmacological mechanisms of daphnetin, including anti-inflammatory (NF-κB, JAK/STAT, NLRP3), antioxidant (Nrf2/Keap1), immunomodulatory (Th17/Treg balance), and mitochondrial protective pathways. These pathways are critically involved in the pathogenesis of both severe COVID-19 and rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). We propose that daphnetin represents a novel "one agent, dual protection" strategy: it not only blocks viral entry by reducing ACE2 but also mitigates the hyperinflammatory and oxidative stress states that exacerbate both COVID-19 severity and rheumatic disease activity. Given its established safety, oral activity, and low cost, daphnetin is a promising candidate for clinical translation in high-risk comorbid populations. Key unresolved questions and future research directions are also discussed.
Additional Links: PMID-43009037
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43009037,
year = {2026},
author = {Chen, M and Zhang, N and Wu, Q and Cao, Y and Zhang, Z and Tang, X and Zhao, B and Zhu, C and Li, Y and Qiu, X and Chu, Z and Bao, K and Xu, X and Hu, L},
title = {Beyond ACE2 downregulation: daphnetin as a multi-target agent for COVID-19 and rheumatic comorbidities.},
journal = {European journal of pharmacology},
volume = {},
number = {},
pages = {179530},
doi = {10.1016/j.ejphar.2026.179530},
pmid = {43009037},
issn = {1879-0712},
abstract = {The continuous emergence of SARS-CoV-2 variants (e.g., JN.1, KP.3) and the significantly elevated risk of severe COVID-19 in patients with rheumatic autoimmune diseases highlight an urgent unmet clinical need for dual-targeted therapeutics. Daphnetin (7,8-dihydroxycoumarin), a natural coumarin compound with a long history of clinical use in China, prevents SARS-CoV-2 infection by downregulating the viral entry receptor ACE2 through inhibition of HIF-1α and JAK2/STAT3 signaling. This review synthesizes the pleiotropic pharmacological mechanisms of daphnetin, including anti-inflammatory (NF-κB, JAK/STAT, NLRP3), antioxidant (Nrf2/Keap1), immunomodulatory (Th17/Treg balance), and mitochondrial protective pathways. These pathways are critically involved in the pathogenesis of both severe COVID-19 and rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). We propose that daphnetin represents a novel "one agent, dual protection" strategy: it not only blocks viral entry by reducing ACE2 but also mitigates the hyperinflammatory and oxidative stress states that exacerbate both COVID-19 severity and rheumatic disease activity. Given its established safety, oral activity, and low cost, daphnetin is a promising candidate for clinical translation in high-risk comorbid populations. Key unresolved questions and future research directions are also discussed.},
}
RevDate: 2026-11-09
CmpDate: 2026-11-09
A scoping review of resilience among intensive care nurses: Exploring strengths that mitigate secondary trauma.
Psychological trauma : theory, research, practice and policy, 18(Suppl 1):S246-S254.
OBJECTIVE: The stressful and traumatic nature of nursing jobs, especially in specialized units such as the intensive care unit (ICU), puts nurses at higher risk for psychological distress or more severe diagnoses like posttraumatic stress disorder. The purpose of this study is to conduct a scoping review on resilience among ICU nurses, using the resilience portfolio model as a framework.
METHOD: We searched PubMed and APA PsycInfo for articles that included the terms "ICU nurses" and "resilience," which resulted in 302 articles. After excluding duplicates and articles that focused only on workplace performance, lacked data, or focused on the COVID-19 pandemic, 43 articles remained.
RESULTS: Mindfulness, spirituality/religion, and social support were frequently mentioned as sources of resilience. The importance of social leisure-simply relaxing with friends and family outside of work-emerged as distinct from social support in terms of comfort during times of stress. Support from leadership and mentors was also an important interpersonal resource.
CONCLUSIONS: One important adversity among ICU nurses is moral injury, which occurs when people are faced with demands that conflict with their ethical principles (Burton et al., 2020). In the ICU context, nurses can experience moral injury when hospitals, insurers, and patients' loved ones have different desires or expectations. The adversity of moral injury needs more consideration in research on trauma and resilience. Interventions such as a sacred pause after a death hold promise for supporting ICU nurses. This review indicates that a variety of ongoing supports are needed to sustain nurses working in highly stressful environments. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
Additional Links: PMID-40758268
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid40758268,
year = {2026},
author = {Piercy, S and Hamby, S},
title = {A scoping review of resilience among intensive care nurses: Exploring strengths that mitigate secondary trauma.},
journal = {Psychological trauma : theory, research, practice and policy},
volume = {18},
number = {Suppl 1},
pages = {S246-S254},
doi = {10.1037/tra0002017},
pmid = {40758268},
issn = {1942-969X},
mesh = {Humans ; *Resilience, Psychological ; Social Support ; *Critical Care Nursing ; *Nursing Staff, Hospital/psychology ; Mindfulness ; Intensive Care Units ; Spirituality ; },
abstract = {OBJECTIVE: The stressful and traumatic nature of nursing jobs, especially in specialized units such as the intensive care unit (ICU), puts nurses at higher risk for psychological distress or more severe diagnoses like posttraumatic stress disorder. The purpose of this study is to conduct a scoping review on resilience among ICU nurses, using the resilience portfolio model as a framework.
METHOD: We searched PubMed and APA PsycInfo for articles that included the terms "ICU nurses" and "resilience," which resulted in 302 articles. After excluding duplicates and articles that focused only on workplace performance, lacked data, or focused on the COVID-19 pandemic, 43 articles remained.
RESULTS: Mindfulness, spirituality/religion, and social support were frequently mentioned as sources of resilience. The importance of social leisure-simply relaxing with friends and family outside of work-emerged as distinct from social support in terms of comfort during times of stress. Support from leadership and mentors was also an important interpersonal resource.
CONCLUSIONS: One important adversity among ICU nurses is moral injury, which occurs when people are faced with demands that conflict with their ethical principles (Burton et al., 2020). In the ICU context, nurses can experience moral injury when hospitals, insurers, and patients' loved ones have different desires or expectations. The adversity of moral injury needs more consideration in research on trauma and resilience. Interventions such as a sacred pause after a death hold promise for supporting ICU nurses. This review indicates that a variety of ongoing supports are needed to sustain nurses working in highly stressful environments. (PsycInfo Database Record (c) 2026 APA, all rights reserved).},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Resilience, Psychological
Social Support
*Critical Care Nursing
*Nursing Staff, Hospital/psychology
Mindfulness
Intensive Care Units
Spirituality
RevDate: 2026-11-09
SARS-CoV-2 variants and cardiovascular complications - Implications for surveillance and vaccination: A narrative review.
Biomolecules & biomedicine [Epub ahead of print].
COVID-19, caused by SARS-CoV-2, is linked to both acute and lasting cardiovascular complications. This review synthesizes 165 studies from MEDLINE, Embase, and the Cochrane Library to summarize cardiovascular outcomes, underlying mechanisms, and implications for variant surveillance and vaccination. Clinical evidence reveals increased risks of arrhythmias, ischemic and inflammatory heart disease, heart failure, cerebrovascular events, and thromboembolic disorders even after the acute phase, including in non-hospitalized patients. These risks are higher following more severe infections. Proposed mechanisms include direct viral injury, endothelial dysfunction, complement activation, dysregulated inflammation and coagulation, and disruption of the renin-angiotensin-aldosterone system. Experimental studies show spike mutations alter viral entry and antibody escape, though their impact on cardiovascular outcomes is still unclear. Vaccination is associated with fewer cardiovascular events and post-acute sequelae, despite offering incomplete protection. Ongoing genomic surveillance, vaccination efforts, and cardiovascular follow-up are crucial to inform preventive strategies and manage the long-term cardiovascular burden of SARS-CoV-2 infection.
Additional Links: PMID-43002775
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43002775,
year = {2026},
author = {Nappi, F},
title = {SARS-CoV-2 variants and cardiovascular complications - Implications for surveillance and vaccination: A narrative review.},
journal = {Biomolecules & biomedicine},
volume = {},
number = {},
pages = {},
doi = {10.17305/bb.2026.14201},
pmid = {43002775},
issn = {2831-090X},
abstract = {COVID-19, caused by SARS-CoV-2, is linked to both acute and lasting cardiovascular complications. This review synthesizes 165 studies from MEDLINE, Embase, and the Cochrane Library to summarize cardiovascular outcomes, underlying mechanisms, and implications for variant surveillance and vaccination. Clinical evidence reveals increased risks of arrhythmias, ischemic and inflammatory heart disease, heart failure, cerebrovascular events, and thromboembolic disorders even after the acute phase, including in non-hospitalized patients. These risks are higher following more severe infections. Proposed mechanisms include direct viral injury, endothelial dysfunction, complement activation, dysregulated inflammation and coagulation, and disruption of the renin-angiotensin-aldosterone system. Experimental studies show spike mutations alter viral entry and antibody escape, though their impact on cardiovascular outcomes is still unclear. Vaccination is associated with fewer cardiovascular events and post-acute sequelae, despite offering incomplete protection. Ongoing genomic surveillance, vaccination efforts, and cardiovascular follow-up are crucial to inform preventive strategies and manage the long-term cardiovascular burden of SARS-CoV-2 infection.},
}
RevDate: 2026-11-09
CmpDate: 2026-11-09
The COVID-19 Pandemic as a Stress Test of the Intensive Care Unit Workforce.
Critical care clinics, 43(1):135-151.
The COVID-19 pandemic monumentally strained the intensive care unit (ICU) workforce and revealed both the strengths and vulnerabilities in contemporary critical care delivery. In this review, we briefly describe the composition of the US ICU workforce and the organizational features most relevant to staffing. Next, we examine how the pandemic disrupted critical care delivery, specifically health care workers. Finally, we discuss the lasting psychological toll and workforce attrition; highlight adaptations that emerged, such as tele-ICU expansion, virtual family engagement, tiered staffing models, rapid-onboarding curricula, and peer support programs; and outline priorities for policy, practice, and research to strengthen workforce resilience.
Additional Links: PMID-43003539
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43003539,
year = {2027},
author = {Connell, KA and Vranas, KC and Yu, H and Kerlin, MP},
title = {The COVID-19 Pandemic as a Stress Test of the Intensive Care Unit Workforce.},
journal = {Critical care clinics},
volume = {43},
number = {1},
pages = {135-151},
doi = {10.1016/j.ccc.2026.07.004},
pmid = {43003539},
issn = {1557-8232},
mesh = {Humans ; *COVID-19/epidemiology ; *Intensive Care Units/organization & administration ; Pandemics ; United States/epidemiology ; *Critical Care/organization & administration/psychology ; Frontline Workers ; SARS-CoV-2 ; *Pneumonia, Viral/epidemiology ; *Coronavirus Infections/epidemiology ; },
abstract = {The COVID-19 pandemic monumentally strained the intensive care unit (ICU) workforce and revealed both the strengths and vulnerabilities in contemporary critical care delivery. In this review, we briefly describe the composition of the US ICU workforce and the organizational features most relevant to staffing. Next, we examine how the pandemic disrupted critical care delivery, specifically health care workers. Finally, we discuss the lasting psychological toll and workforce attrition; highlight adaptations that emerged, such as tele-ICU expansion, virtual family engagement, tiered staffing models, rapid-onboarding curricula, and peer support programs; and outline priorities for policy, practice, and research to strengthen workforce resilience.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*COVID-19/epidemiology
*Intensive Care Units/organization & administration
Pandemics
United States/epidemiology
*Critical Care/organization & administration/psychology
Frontline Workers
SARS-CoV-2
*Pneumonia, Viral/epidemiology
*Coronavirus Infections/epidemiology
RevDate: 2026-10-19
CmpDate: 2026-07-06
The Emerging Global Threat of Candida auris: A Call for Enhanced Public Health Policy and Regional Coordination.
Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki), 47(2):73-83 pii:prilozi-2026-0020.
Antimicrobial resistance represents a paramount challenge to global public health in the 21st century. The multidrug-resistant fungal pathogen Candida auris poses a critical and escalating threat to global public health. Characterized by rapid nosocomial transmission, persistent environmental contamination, and resistance to multiple antifungal classes, C. auris challenges healthcare systems worldwide. Its independent emergence across distinct geographic clades and exponential rise in cases, exacerbated by the COVID-19 pandemic, underscore the urgent need for robust, coordinated response. This review synthesizes the current knowledge on C. auris with a focus on its implications for public health policy, particularly in the European and Balkan healthcare settings, where surveillance gaps and cross-border transmission risks remain pronounced. We analyze the key drivers of spread, including diagnostic misidentification, extensive antifungal resistance, and lapses in infection control, and evaluate the strain on surveillance and hospital preparedness. Effective mitigation is fundamentally dependent on implementing comprehensive, multi-faceted infection prevention and control strategies, guided by antifungal stewardship and rapid diagnostics. We conclude that addressing the C. auris threat requires an urgent, coordinated international and regional response focused on strengthening surveillance networks, standardizing diagnostic and infection prevention and control protocols, and fostering data sharing across borders to contain this resilient pathogen.
Additional Links: PMID-42406015
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42406015,
year = {2026},
author = {Mirchevska, G},
title = {The Emerging Global Threat of Candida auris: A Call for Enhanced Public Health Policy and Regional Coordination.},
journal = {Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)},
volume = {47},
number = {2},
pages = {73-83},
doi = {10.2478/prilozi-2026-0020},
pmid = {42406015},
issn = {1857-8985},
mesh = {Humans ; Antifungal Agents/therapeutic use ; *Candida auris/drug effects ; *Candidiasis/epidemiology/prevention & control/diagnosis/drug therapy ; *Cross Infection/prevention & control/epidemiology/microbiology ; Drug Resistance, Fungal ; Global Health ; *Health Policy ; Infection Control ; *Public Health ; Candidiasis, Invasive ; },
abstract = {Antimicrobial resistance represents a paramount challenge to global public health in the 21st century. The multidrug-resistant fungal pathogen Candida auris poses a critical and escalating threat to global public health. Characterized by rapid nosocomial transmission, persistent environmental contamination, and resistance to multiple antifungal classes, C. auris challenges healthcare systems worldwide. Its independent emergence across distinct geographic clades and exponential rise in cases, exacerbated by the COVID-19 pandemic, underscore the urgent need for robust, coordinated response. This review synthesizes the current knowledge on C. auris with a focus on its implications for public health policy, particularly in the European and Balkan healthcare settings, where surveillance gaps and cross-border transmission risks remain pronounced. We analyze the key drivers of spread, including diagnostic misidentification, extensive antifungal resistance, and lapses in infection control, and evaluate the strain on surveillance and hospital preparedness. Effective mitigation is fundamentally dependent on implementing comprehensive, multi-faceted infection prevention and control strategies, guided by antifungal stewardship and rapid diagnostics. We conclude that addressing the C. auris threat requires an urgent, coordinated international and regional response focused on strengthening surveillance networks, standardizing diagnostic and infection prevention and control protocols, and fostering data sharing across borders to contain this resilient pathogen.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Antifungal Agents/therapeutic use
*Candida auris/drug effects
*Candidiasis/epidemiology/prevention & control/diagnosis/drug therapy
*Cross Infection/prevention & control/epidemiology/microbiology
Drug Resistance, Fungal
Global Health
*Health Policy
Infection Control
*Public Health
Candidiasis, Invasive
RevDate: 2026-07-30
CmpDate: 2026-07-06
Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review.
Journal of medical economics, 29(1):1875-1897.
AIMS: Nirmatrelvir/ritonavir (NMV/r)[i] is an antiviral drug indicated for the treatment of patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk of progressing to severe disease. We performed an updated economic systematic literature review (eSLR) of NMV/r to build upon evidence reported in our previous eSLR and additionally examine the health-related outcomes associated with NMV/r and any potential effect of long COVID.
METHODS: A systematic search of Embase, PubMed, Cochrane, and EconLit and of conference and health technology assessment agency websites was performed to identify economic analyses published between January 2022 and October 2025.
RESULTS: Of the 33 included economic evaluations, most were cost-utility analyses (n = 16) and used an analysis of a short-term decision tree with a long-term Markov model (n = 11). Several types of health-related endpoints were reported by studies, with most including hospital-related endpoints (n = 20), quality-adjusted life-years (QALYs) (n = 18), and death-related endpoints (n = 18). Positive health-related outcomes were associated with NMV/r treatment, including reductions in hospitalizations and deaths and an increase in QALYs. NMV/r treatment was also associated with a reduced number of patients with long COVID complications.
LIMITATIONS: Most studies were conducted in high-income countries, were based on different COVID-19 variants, and were limited in data on the long COVID population.
CONCLUSION: In addition to monetary benefits, NMV/r provides short-term and long-term health-related benefits to patients with mild to moderate COVID-19. This study provides further support for NMV/r as a cost-effective treatment option.
Additional Links: PMID-42406565
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42406565,
year = {2026},
author = {Mugwagwa, T and Marcano Belisario, J and Hartley, L and Phan, NTN and Mokgokong, R},
title = {Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review.},
journal = {Journal of medical economics},
volume = {29},
number = {1},
pages = {1875-1897},
doi = {10.1080/13696998.2026.2695551},
pmid = {42406565},
issn = {1941-837X},
mesh = {*Ritonavir/therapeutic use/economics ; Humans ; *COVID-19 Drug Treatment ; Cost-Benefit Analysis ; Quality-Adjusted Life Years ; *Antiviral Agents/economics/therapeutic use ; Cost-Effectiveness Analysis ; Drug Combinations ; COVID-19 ; SARS-CoV-2 ; Lopinavir ; },
abstract = {AIMS: Nirmatrelvir/ritonavir (NMV/r)[i] is an antiviral drug indicated for the treatment of patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk of progressing to severe disease. We performed an updated economic systematic literature review (eSLR) of NMV/r to build upon evidence reported in our previous eSLR and additionally examine the health-related outcomes associated with NMV/r and any potential effect of long COVID.
METHODS: A systematic search of Embase, PubMed, Cochrane, and EconLit and of conference and health technology assessment agency websites was performed to identify economic analyses published between January 2022 and October 2025.
RESULTS: Of the 33 included economic evaluations, most were cost-utility analyses (n = 16) and used an analysis of a short-term decision tree with a long-term Markov model (n = 11). Several types of health-related endpoints were reported by studies, with most including hospital-related endpoints (n = 20), quality-adjusted life-years (QALYs) (n = 18), and death-related endpoints (n = 18). Positive health-related outcomes were associated with NMV/r treatment, including reductions in hospitalizations and deaths and an increase in QALYs. NMV/r treatment was also associated with a reduced number of patients with long COVID complications.
LIMITATIONS: Most studies were conducted in high-income countries, were based on different COVID-19 variants, and were limited in data on the long COVID population.
CONCLUSION: In addition to monetary benefits, NMV/r provides short-term and long-term health-related benefits to patients with mild to moderate COVID-19. This study provides further support for NMV/r as a cost-effective treatment option.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Ritonavir/therapeutic use/economics
Humans
*COVID-19 Drug Treatment
Cost-Benefit Analysis
Quality-Adjusted Life Years
*Antiviral Agents/economics/therapeutic use
Cost-Effectiveness Analysis
Drug Combinations
COVID-19
SARS-CoV-2
Lopinavir
RevDate: 2026-08-11
CmpDate: 2026-08-11
Safeguarding nanovesicles and their payload: A framework for stable storage.
Colloids and surfaces. B, Biointerfaces, 267:115956.
Recent advances in biomedical science have shifted therapeutic strategies toward biologics, nucleic acid-based medicines, and precision gene regulation, demanding equally sophisticated delivery and preservation vehicles. This shift is epitomized by the breakthrough of RNA therapeutics during the COVID-19 pandemic, which are now advancing into oncology, autoimmune disorders, and inflammatory diseases, alongside powerful gene-editing, and gene-regulation tools. Biological nanoparticles and, in particular, (EVs) are uniquely positioned to enable targeted delivery of these advanced strategies. Their favorable biodistribution, biocompatibility, biodegradability, and high loading capacity make them an ideal delivery platform. However, a critical translational gap remains: while experimental innovation accelerates, the practical knowledge of selecting appropriate dosage forms, storage conditions, and necessary stabilizers is lacking. This challenge extends beyond maintaining vehicle integrity to the crucial preservation of the therapeutic payload's activity. This review examines current advancements in EVs storage methods and conditions, highlighting the challenges for preserving functional activity of the payload. By evaluating preservation strategies and their effects on EV integrity and cargo stability, we discuss critical insights to enhance storage, ensuring both structural preservation of EVs and functionality of bioactive cargo.
Additional Links: PMID-42407372
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42407372,
year = {2026},
author = {Kachanov, A and Brezgin, S and Kostyusheva, A and Ponomareva, N and Chulanov, V and Parodi, A and Kostyushev, D},
title = {Safeguarding nanovesicles and their payload: A framework for stable storage.},
journal = {Colloids and surfaces. B, Biointerfaces},
volume = {267},
number = {},
pages = {115956},
doi = {10.1016/j.colsurfb.2026.115956},
pmid = {42407372},
issn = {1873-4367},
mesh = {Humans ; *Nanoparticles/chemistry ; Animals ; *Drug Storage/methods ; Freeze Drying ; SARS-CoV-2 ; Drug Delivery Systems/methods ; },
abstract = {Recent advances in biomedical science have shifted therapeutic strategies toward biologics, nucleic acid-based medicines, and precision gene regulation, demanding equally sophisticated delivery and preservation vehicles. This shift is epitomized by the breakthrough of RNA therapeutics during the COVID-19 pandemic, which are now advancing into oncology, autoimmune disorders, and inflammatory diseases, alongside powerful gene-editing, and gene-regulation tools. Biological nanoparticles and, in particular, (EVs) are uniquely positioned to enable targeted delivery of these advanced strategies. Their favorable biodistribution, biocompatibility, biodegradability, and high loading capacity make them an ideal delivery platform. However, a critical translational gap remains: while experimental innovation accelerates, the practical knowledge of selecting appropriate dosage forms, storage conditions, and necessary stabilizers is lacking. This challenge extends beyond maintaining vehicle integrity to the crucial preservation of the therapeutic payload's activity. This review examines current advancements in EVs storage methods and conditions, highlighting the challenges for preserving functional activity of the payload. By evaluating preservation strategies and their effects on EV integrity and cargo stability, we discuss critical insights to enhance storage, ensuring both structural preservation of EVs and functionality of bioactive cargo.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Nanoparticles/chemistry
Animals
*Drug Storage/methods
Freeze Drying
SARS-CoV-2
Drug Delivery Systems/methods
RevDate: 2026-08-13
CmpDate: 2026-07-07
Respiratory Support in the Emergency Department: An Updated Systematic Review and Meta-Analysis.
Worldviews on evidence-based nursing, 23(4):e70165.
BACKGROUND: An estimated 20% of emergency department (ED) patients require respiratory support (RS). Evidence suggests that nasal high flow (NHF) reduces RS need.
AIMS: This is an update of a published review comparing NHF to non-invasive ventilation (NIV) or to conventional oxygen therapy (COT) in adult ED patients.
METHOD: This updated systematic review (SR) and meta-analysis (MA) methods reflect the Cochrane Collaboration's methodology. The search of six databases was first completed in July 2023 and then repeated in November 2025. Databases were searched for randomized controlled trials (RCTs) comparing NHF to COT or NIV in the ED. Three summary estimates were reported: (1) need to escalate care, (2) mortality, and (3) adverse events (AEs).
RESULTS: The updated search identified three new studies, bringing the total to 21 eligible RCTs (n = 2158). One of the six MA conclusions was statistically significant. Compared with COT, NHF showed no SS difference in the risk of escalation (RR 0.65; 95% CI [0.41, 1.04]; p = 0.07), mortality (RR 1.05; 95% CI [0.74, 1.51]; p = 0.77), and AE (RR was 0.98; 95% CI [0.6, 1.6]; p = 0.94) outcomes were found. Compared with NIV, NHF increased the risk of escalation by 86% (RR 1.86; 95% CI [1.26, 2.75]; p = 0.001), but mortality risk was not SS (RR 1.33; 95% CI [0.86, 2.06]; p = 0.20).
LINKING EVIDENCE TO ACTION: Evidence suggests NHF therapy may be an alternative to COT in managing RS in EDs. While NHF may not be as effective as NIV at preventing escalation, it does not increase mortality risk, offering a nuanced approach to RS tailored to patient-specific needs. This evidence-informed decision-making can enhance patient outcomes. However, further research is needed, especially given the COVID-19 pandemic's impact on ED research.
Additional Links: PMID-42410869
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42410869,
year = {2026},
author = {O'Donnell, J and Fenn, R},
title = {Respiratory Support in the Emergency Department: An Updated Systematic Review and Meta-Analysis.},
journal = {Worldviews on evidence-based nursing},
volume = {23},
number = {4},
pages = {e70165},
pmid = {42410869},
issn = {1741-6787},
mesh = {Humans ; *Emergency Service, Hospital/organization & administration/statistics & numerical data ; Noninvasive Ventilation ; *Oxygen Inhalation Therapy/methods ; *Respiratory Therapy/methods ; },
abstract = {BACKGROUND: An estimated 20% of emergency department (ED) patients require respiratory support (RS). Evidence suggests that nasal high flow (NHF) reduces RS need.
AIMS: This is an update of a published review comparing NHF to non-invasive ventilation (NIV) or to conventional oxygen therapy (COT) in adult ED patients.
METHOD: This updated systematic review (SR) and meta-analysis (MA) methods reflect the Cochrane Collaboration's methodology. The search of six databases was first completed in July 2023 and then repeated in November 2025. Databases were searched for randomized controlled trials (RCTs) comparing NHF to COT or NIV in the ED. Three summary estimates were reported: (1) need to escalate care, (2) mortality, and (3) adverse events (AEs).
RESULTS: The updated search identified three new studies, bringing the total to 21 eligible RCTs (n = 2158). One of the six MA conclusions was statistically significant. Compared with COT, NHF showed no SS difference in the risk of escalation (RR 0.65; 95% CI [0.41, 1.04]; p = 0.07), mortality (RR 1.05; 95% CI [0.74, 1.51]; p = 0.77), and AE (RR was 0.98; 95% CI [0.6, 1.6]; p = 0.94) outcomes were found. Compared with NIV, NHF increased the risk of escalation by 86% (RR 1.86; 95% CI [1.26, 2.75]; p = 0.001), but mortality risk was not SS (RR 1.33; 95% CI [0.86, 2.06]; p = 0.20).
LINKING EVIDENCE TO ACTION: Evidence suggests NHF therapy may be an alternative to COT in managing RS in EDs. While NHF may not be as effective as NIV at preventing escalation, it does not increase mortality risk, offering a nuanced approach to RS tailored to patient-specific needs. This evidence-informed decision-making can enhance patient outcomes. However, further research is needed, especially given the COVID-19 pandemic's impact on ED research.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Emergency Service, Hospital/organization & administration/statistics & numerical data
Noninvasive Ventilation
*Oxygen Inhalation Therapy/methods
*Respiratory Therapy/methods
RevDate: 2026-07-07
Prevalence of anxiety and depressive symptoms among older adults during COVID-19 lockdowns: a systematic review and meta-analysis.
Aging & mental health [Epub ahead of print].
BACKGROUND: The COVID-19 lockdowns presented an unprecedented challenge to public mental health. The impact of these lockdowns on older adults remains unclear. To quantify the prevalence of anxiety and depressive symptoms among older adults during COVID-19 lockdowns, we conducted this systematic review and meta-analysis.
METHODS: We systematically searched nine electronic databases for relevant literature published in English or Chinese, covering the period from January 1, 2020, to November 29, 2024. The Joanna Briggs Institute Critical Appraisal tool was used to assess the risk of bias. A random-effects model was used to calculate the overall pooled prevalence.
RESULTS: A total of 51 articles, encompassing 57 studies, satisfied the inclusion criteria and included data from 26,616 participants across 23 countries. The estimated prevalence of anxiety and depressive symptoms was 12.82% (95% CI: 9.13-17.72) and 15.01% (95% CI:11.61-19.19), respectively. Factors significantly associated with anxiety symptom prevalence included the proportion of females, study quality, lockdown duration, international travel control policies, workplace closure policies, and changes in human mobility across six categories of location. Factors significantly associated with depressive symptom prevalence included study quality, international travel control policies, and public transport closure policies.
CONCLUSIONS: This study enhances our understanding of anxiety and depression symptoms among older adults during COVID-19 lockdowns, notably revealing the moderating effects of human mobility on anxiety symptoms. The findings offer tentative insights for comprehending and addressing the psychological impact of major public health emergencies on older adults.
Additional Links: PMID-42410924
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42410924,
year = {2026},
author = {Liu, W and Wang, B and Cosco, TD and Cai, Z and Tang, X and Zhou, Z and Ren, Z},
title = {Prevalence of anxiety and depressive symptoms among older adults during COVID-19 lockdowns: a systematic review and meta-analysis.},
journal = {Aging & mental health},
volume = {},
number = {},
pages = {1-14},
doi = {10.1080/13607863.2026.2690401},
pmid = {42410924},
issn = {1364-6915},
abstract = {BACKGROUND: The COVID-19 lockdowns presented an unprecedented challenge to public mental health. The impact of these lockdowns on older adults remains unclear. To quantify the prevalence of anxiety and depressive symptoms among older adults during COVID-19 lockdowns, we conducted this systematic review and meta-analysis.
METHODS: We systematically searched nine electronic databases for relevant literature published in English or Chinese, covering the period from January 1, 2020, to November 29, 2024. The Joanna Briggs Institute Critical Appraisal tool was used to assess the risk of bias. A random-effects model was used to calculate the overall pooled prevalence.
RESULTS: A total of 51 articles, encompassing 57 studies, satisfied the inclusion criteria and included data from 26,616 participants across 23 countries. The estimated prevalence of anxiety and depressive symptoms was 12.82% (95% CI: 9.13-17.72) and 15.01% (95% CI:11.61-19.19), respectively. Factors significantly associated with anxiety symptom prevalence included the proportion of females, study quality, lockdown duration, international travel control policies, workplace closure policies, and changes in human mobility across six categories of location. Factors significantly associated with depressive symptom prevalence included study quality, international travel control policies, and public transport closure policies.
CONCLUSIONS: This study enhances our understanding of anxiety and depression symptoms among older adults during COVID-19 lockdowns, notably revealing the moderating effects of human mobility on anxiety symptoms. The findings offer tentative insights for comprehending and addressing the psychological impact of major public health emergencies on older adults.},
}
RevDate: 2026-09-10
CmpDate: 2026-07-31
Increased Insulin Resistance and Hyperglycaemia in Long COVID: A Systematic Review and Meta-Analysis.
Expert reviews in molecular medicine, 28:e38.
BACKGROUND: Accumulating evidence suggests that long COVID (LC) is mediated by chronic immune activation, oxidative stress and metabolic dysregulation. These processes may impair glucose homeostasis and promote insulin resistance (IR). However, no prior meta-analysis has systematically and quantitatively evaluated IR indices and related biomarkers in LC compared with normal controls.
OBJECTIVES: To systematically review and meta-analyse IR indices including HOMA-IR, HOMA-%B, HOMA-%S, insulin, fasting and random blood sugar (FBG, RBS), glycated haemoglobin (HbA1c), C-peptide and adipokine levels in individuals with LC compared with normal controls.
METHODS: PubMed, SCOPUS, SciFinder and Google Scholar databases were searched for relevant studies from inception to September 2025. Fifty-six eligible studies were included, comprising 9623 participants, 5340 LC patients and 4283 normal controls.
RESULTS: LC disease is characterized by elevated HOMA-IR (standardized mean difference, SMD = 0.539; 95% confidence interval, CI: 0.311; 0.766), insulin (SMD = 0.424; 95% CI: 0.113; 0.735), FBG and RBS (SMD = 0.734; 95% CI: 0.190; 1.277, SMD = 0.325; 95% CI: 0.133; 0.517). Furthermore, reduced HOMA-%S was observed in LC patients versus normal controls. Publication bias was generally low, though evidence of small-study effects was observed for several outcomes. The Immunological Confounder Scale was employed to evaluate study quality, revealing an overall intermediate methodological quality.
CONCLUSIONS: Our results show that LC is associated with multiple abnormalities in glucose homeostasis, including increased HOMA-IR, hyperglycaemia and impaired insulin sensitivity indices, sustained metabolic disturbances beyond the acute phase.
Additional Links: PMID-42410961
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42410961,
year = {2026},
author = {Almulla, AF and Zhang, Y and Tunvirachaisakul, C and Carvalho, AF and Maes, M},
title = {Increased Insulin Resistance and Hyperglycaemia in Long COVID: A Systematic Review and Meta-Analysis.},
journal = {Expert reviews in molecular medicine},
volume = {28},
number = {},
pages = {e38},
pmid = {42410961},
issn = {1462-3994},
mesh = {Humans ; *Insulin Resistance ; *Hyperglycemia/blood/metabolism/virology/etiology ; *COVID-19/complications/metabolism/virology ; Post-Acute COVID-19 Syndrome ; Insulin/blood ; SARS-CoV-2 ; Blood Glucose/analysis/metabolism ; Biomarkers/blood ; Glycated Hemoglobin/metabolism/analysis ; },
abstract = {BACKGROUND: Accumulating evidence suggests that long COVID (LC) is mediated by chronic immune activation, oxidative stress and metabolic dysregulation. These processes may impair glucose homeostasis and promote insulin resistance (IR). However, no prior meta-analysis has systematically and quantitatively evaluated IR indices and related biomarkers in LC compared with normal controls.
OBJECTIVES: To systematically review and meta-analyse IR indices including HOMA-IR, HOMA-%B, HOMA-%S, insulin, fasting and random blood sugar (FBG, RBS), glycated haemoglobin (HbA1c), C-peptide and adipokine levels in individuals with LC compared with normal controls.
METHODS: PubMed, SCOPUS, SciFinder and Google Scholar databases were searched for relevant studies from inception to September 2025. Fifty-six eligible studies were included, comprising 9623 participants, 5340 LC patients and 4283 normal controls.
RESULTS: LC disease is characterized by elevated HOMA-IR (standardized mean difference, SMD = 0.539; 95% confidence interval, CI: 0.311; 0.766), insulin (SMD = 0.424; 95% CI: 0.113; 0.735), FBG and RBS (SMD = 0.734; 95% CI: 0.190; 1.277, SMD = 0.325; 95% CI: 0.133; 0.517). Furthermore, reduced HOMA-%S was observed in LC patients versus normal controls. Publication bias was generally low, though evidence of small-study effects was observed for several outcomes. The Immunological Confounder Scale was employed to evaluate study quality, revealing an overall intermediate methodological quality.
CONCLUSIONS: Our results show that LC is associated with multiple abnormalities in glucose homeostasis, including increased HOMA-IR, hyperglycaemia and impaired insulin sensitivity indices, sustained metabolic disturbances beyond the acute phase.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Insulin Resistance
*Hyperglycemia/blood/metabolism/virology/etiology
*COVID-19/complications/metabolism/virology
Post-Acute COVID-19 Syndrome
Insulin/blood
SARS-CoV-2
Blood Glucose/analysis/metabolism
Biomarkers/blood
Glycated Hemoglobin/metabolism/analysis
RevDate: 2026-10-05
CmpDate: 2026-10-05
Advances in Antiviral Drug Development Targeting Viral Proteases.
Medicinal research reviews, 46(6):1871-1896.
Viral proteases are critical targets in antiviral drug development due to their essential role in the viral lifecycle and high conservation across viral strains. This review summarizes the recent progress of antiviral drugs based on protease structures, with a focus on the structural characteristics and inhibitor design strategies targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Enterovirus 71 (EV71), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV). Based on the three-dimensional structure of proteases, various types of protease inhibitors such as peptidomimetic, non-peptidic, and natural product-derived inhibitors are discussed. Given the critical challenge of drug resistance in antiviral therapies, we address the mechanisms of protease inhibitor resistance and explore advanced strategies, including allosteric inhibition, dual-target inhibition, and Proteolysis-Targeting Chimeras (PROTAC) to overcome drug resistance. This review also explores the cutting-edge applications of artificial intelligence (AI) for viral protease-based antiviral drug discovery, providing valuable insights for the rational design and development of antiviral drugs.
Additional Links: PMID-42411042
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42411042,
year = {2026},
author = {Zhang, Y and Chen, J and Li, J and Xu, Z and Wang, J and Shang, L},
title = {Advances in Antiviral Drug Development Targeting Viral Proteases.},
journal = {Medicinal research reviews},
volume = {46},
number = {6},
pages = {1871-1896},
doi = {10.1002/med.70075},
pmid = {42411042},
issn = {1098-1128},
support = {22177055//National Natural Science Foundation of China/ ; U23A20147//National Natural Science Foundation of China/ ; GZNL2023A01002//R&D Program of Guangzhou Laboratory/ ; 63243133//Fundamental Research Funds for the Central Universities, Nankai University/ ; },
mesh = {Humans ; *Antiviral Agents/pharmacology/chemistry ; *Drug Development ; Drug Resistance, Viral ; *Protease Inhibitors/pharmacology/chemistry ; *Viral Proteases ; *Viral Protease Inhibitors/pharmacology/chemistry ; Animals ; },
abstract = {Viral proteases are critical targets in antiviral drug development due to their essential role in the viral lifecycle and high conservation across viral strains. This review summarizes the recent progress of antiviral drugs based on protease structures, with a focus on the structural characteristics and inhibitor design strategies targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Enterovirus 71 (EV71), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV). Based on the three-dimensional structure of proteases, various types of protease inhibitors such as peptidomimetic, non-peptidic, and natural product-derived inhibitors are discussed. Given the critical challenge of drug resistance in antiviral therapies, we address the mechanisms of protease inhibitor resistance and explore advanced strategies, including allosteric inhibition, dual-target inhibition, and Proteolysis-Targeting Chimeras (PROTAC) to overcome drug resistance. This review also explores the cutting-edge applications of artificial intelligence (AI) for viral protease-based antiviral drug discovery, providing valuable insights for the rational design and development of antiviral drugs.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Antiviral Agents/pharmacology/chemistry
*Drug Development
Drug Resistance, Viral
*Protease Inhibitors/pharmacology/chemistry
*Viral Proteases
*Viral Protease Inhibitors/pharmacology/chemistry
Animals
RevDate: 2026-08-28
CmpDate: 2026-08-07
Ivabradine in the Treatment of POTS Before and After COVID-19 Pandemic: A Systematic Review and Meta-Analysis.
Journal of cardiovascular pharmacology, 88(2):115-122.
Postural orthostatic tachycardia syndrome (POTS) is a debilitating autonomic disorder characterized by excessive orthostatic tachycardia and significant functional impairment. Conventional therapies, including beta-blockers, often provide incomplete relief or are poorly tolerated. Ivabradine, a selective If channel inhibitor, reduces heart rate without affecting blood pressure or myocardial contractility, making it a promising option, particularly in post-COVID-19 POTS. This systematic review and meta-analysis evaluated the efficacy and safety of ivabradine in patients with POTS. PubMed, Embase, and the Cochrane Library were searched through August 2025 in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD420251073600). Eligible studies included randomized controlled trials, observational studies, and case series reporting ivabradine outcomes in POTS. Primary outcomes were changes in standing and supine heart rate; secondary outcomes included symptom burden, quality of life, and adverse events. A random-effects model was used, heterogeneity was assessed through sensitivity analyses, and certainty of evidence was evaluated using Grading of Recommendations, Assessment, Development, and Evaluation. Nine studies involving 245 patients were included. Ivabradine significantly reduced standing heart rate (-18.5 bpm; 95% confidence interval -23.3 to -13.8) and supine heart rate (-9.7 bpm; 95% confidence interval -13.4 to -6.1). Symptom improvement particularly palpitations, lightheadedness, and exercise intolerance was consistently reported across classic, pediatric, hyperadrenergic, and post-COVID-19 subgroups. Adverse events were infrequent and mild, most commonly transient visual disturbances, with no reports of severe bradycardia or hypotension. Heterogeneity was high, largely driven by pediatric and post-COVID-19 cohorts. In conclusion, ivabradine seems to provide meaningful heart rate reduction and symptomatic improvement in POTS with a favorable safety profile. However, evidence is limited by small, heterogeneous, predominantly observational studies, underscoring the need for large, multicenter randomized controlled trials.
Additional Links: PMID-42411507
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42411507,
year = {2026},
author = {Kumar, V and Qadri, SH and Nardelli da Silva, AB and Malaj, A and Qadri, SF and Wajeeha, F and Kasina, P and Jumani, MM and Muhammad, H},
title = {Ivabradine in the Treatment of POTS Before and After COVID-19 Pandemic: A Systematic Review and Meta-Analysis.},
journal = {Journal of cardiovascular pharmacology},
volume = {88},
number = {2},
pages = {115-122},
pmid = {42411507},
issn = {1533-4023},
mesh = {Humans ; *Ivabradine/therapeutic use/adverse effects ; *Postural Orthostatic Tachycardia Syndrome/drug therapy/physiopathology/diagnosis/epidemiology ; *COVID-19/epidemiology ; Heart Rate/drug effects ; Treatment Outcome ; *Cardiovascular Agents/therapeutic use/adverse effects ; Female ; Male ; Adult ; },
abstract = {Postural orthostatic tachycardia syndrome (POTS) is a debilitating autonomic disorder characterized by excessive orthostatic tachycardia and significant functional impairment. Conventional therapies, including beta-blockers, often provide incomplete relief or are poorly tolerated. Ivabradine, a selective If channel inhibitor, reduces heart rate without affecting blood pressure or myocardial contractility, making it a promising option, particularly in post-COVID-19 POTS. This systematic review and meta-analysis evaluated the efficacy and safety of ivabradine in patients with POTS. PubMed, Embase, and the Cochrane Library were searched through August 2025 in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD420251073600). Eligible studies included randomized controlled trials, observational studies, and case series reporting ivabradine outcomes in POTS. Primary outcomes were changes in standing and supine heart rate; secondary outcomes included symptom burden, quality of life, and adverse events. A random-effects model was used, heterogeneity was assessed through sensitivity analyses, and certainty of evidence was evaluated using Grading of Recommendations, Assessment, Development, and Evaluation. Nine studies involving 245 patients were included. Ivabradine significantly reduced standing heart rate (-18.5 bpm; 95% confidence interval -23.3 to -13.8) and supine heart rate (-9.7 bpm; 95% confidence interval -13.4 to -6.1). Symptom improvement particularly palpitations, lightheadedness, and exercise intolerance was consistently reported across classic, pediatric, hyperadrenergic, and post-COVID-19 subgroups. Adverse events were infrequent and mild, most commonly transient visual disturbances, with no reports of severe bradycardia or hypotension. Heterogeneity was high, largely driven by pediatric and post-COVID-19 cohorts. In conclusion, ivabradine seems to provide meaningful heart rate reduction and symptomatic improvement in POTS with a favorable safety profile. However, evidence is limited by small, heterogeneous, predominantly observational studies, underscoring the need for large, multicenter randomized controlled trials.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Ivabradine/therapeutic use/adverse effects
*Postural Orthostatic Tachycardia Syndrome/drug therapy/physiopathology/diagnosis/epidemiology
*COVID-19/epidemiology
Heart Rate/drug effects
Treatment Outcome
*Cardiovascular Agents/therapeutic use/adverse effects
Female
Male
Adult
RevDate: 2026-09-10
CmpDate: 2026-08-26
[Otorhinolaryngologic infections in the post-pandemic context: What can we learn from the literature?].
HNO, 74(9):590-598.
BACKGROUND: The epidemiology of various respiratory infections changed due to the impact of the COVID-19 pandemic. Lockdowns and other containment measures (nonpharmacologic interventions, NPI) led to a decline in virus circulation, resulting in fewer cases at hospitals and practices. Once restrictions were eased, a rebound effect was observed worldwide, resulting in an increase in viral and severe invasive bacterial infections.
OBJECTIVE: Various case series on different ear, nose, and throat (ENT) infections have been conducted in the context of the pandemic in Germany. These studies should be summarized and interpreted in the context of currently available data.
MATERIALS AND METHODS: The literature review focuses particularly on studies from Germany before, during, and after the pandemic, supplemented by European and international data.
RESULTS: Following the lifting of NPIs, a general increase in severe bacterial ENT infections was observed worldwide, particularly among children. Evidence from the underlying retrospective data from Germany is limited. For mastoiditis and complicated sinus infections, cohort studies showed no change in the bacterial spectrum or in the complication rate. Microbiological data for peritonsillar abscesses are currently lacking. Necrotizing fasciitis in the head and neck region increased globally. Reliable data from Germany are currently unavailable.
CONCLUSION: The increased susceptibility due to low exposure to pathogens during the pandemic and the simultaneous surge in post-pandemic virus circulation is believed to be the main cause of the rise in infections. The current data do not prove a direct influence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vaccinations, strict hygiene measures, patient education, and monitoring could help to mitigate the severity of such phenomena in the future.
Additional Links: PMID-42412197
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42412197,
year = {2026},
author = {Goldberg-Bockhorn, E and Reich, A and Vahl, JM and Hoffmann, TK and Hahn, J},
title = {[Otorhinolaryngologic infections in the post-pandemic context: What can we learn from the literature?].},
journal = {HNO},
volume = {74},
number = {9},
pages = {590-598},
pmid = {42412197},
issn = {1433-0458},
mesh = {Humans ; *COVID-19/epidemiology ; Germany/epidemiology ; *Pandemics ; *Otorhinolaryngologic Diseases/epidemiology/microbiology ; SARS-CoV-2 ; Bacterial Infections/epidemiology ; },
abstract = {BACKGROUND: The epidemiology of various respiratory infections changed due to the impact of the COVID-19 pandemic. Lockdowns and other containment measures (nonpharmacologic interventions, NPI) led to a decline in virus circulation, resulting in fewer cases at hospitals and practices. Once restrictions were eased, a rebound effect was observed worldwide, resulting in an increase in viral and severe invasive bacterial infections.
OBJECTIVE: Various case series on different ear, nose, and throat (ENT) infections have been conducted in the context of the pandemic in Germany. These studies should be summarized and interpreted in the context of currently available data.
MATERIALS AND METHODS: The literature review focuses particularly on studies from Germany before, during, and after the pandemic, supplemented by European and international data.
RESULTS: Following the lifting of NPIs, a general increase in severe bacterial ENT infections was observed worldwide, particularly among children. Evidence from the underlying retrospective data from Germany is limited. For mastoiditis and complicated sinus infections, cohort studies showed no change in the bacterial spectrum or in the complication rate. Microbiological data for peritonsillar abscesses are currently lacking. Necrotizing fasciitis in the head and neck region increased globally. Reliable data from Germany are currently unavailable.
CONCLUSION: The increased susceptibility due to low exposure to pathogens during the pandemic and the simultaneous surge in post-pandemic virus circulation is believed to be the main cause of the rise in infections. The current data do not prove a direct influence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vaccinations, strict hygiene measures, patient education, and monitoring could help to mitigate the severity of such phenomena in the future.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*COVID-19/epidemiology
Germany/epidemiology
*Pandemics
*Otorhinolaryngologic Diseases/epidemiology/microbiology
SARS-CoV-2
Bacterial Infections/epidemiology
RevDate: 2026-08-13
CmpDate: 2026-07-07
Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
Virulence, 17(1):2696653.
Coronavirus helicase NSP13 is essential for viral replication and transcription and is a promising target for broad-spectrum anti-coronavirus drugs due to its high sequence conservation and structural homology. This review summarizes NSP13 sequence features, structural organization, and functional activities across the seven human-infecting coronaviruses. We outline key enzymatic properties, including duplex RNA/DNA unwinding and NTP hydrolysis, and describe how NSP13 cooperates with other nonstructural proteins to drive replication and transcription. Beyond canonical helicase roles, we discuss the genomic distribution of G-quadruplex (G4) elements in coronaviruses and potential functional connections between G4 structures and NSP13 in regulating the viral life cycle. Finally, we highlight recent progress in developing NSP13-targeting inhibitors and consider their potential utility against COVID-19 and other emerging coronaviruses, providing a rationale for broad-spectrum antiviral design.
Additional Links: PMID-42412629
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42412629,
year = {2026},
author = {Dai, Y and Li, S and He, X and Lu, K and Tian, J and Huang, Y and Wei, D and He, X and Duan, X and Liu, Y and Zhang, B},
title = {Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.},
journal = {Virulence},
volume = {17},
number = {1},
pages = {2696653},
pmid = {42412629},
issn = {2150-5608},
mesh = {Humans ; *Viral Nonstructural Proteins/metabolism/antagonists & inhibitors/chemistry/genetics ; *Antiviral Agents/pharmacology ; *RNA Helicases/metabolism/antagonists & inhibitors/genetics/chemistry ; Virus Replication/drug effects ; *Coronavirus/enzymology/drug effects/genetics ; G-Quadruplexes ; SARS-CoV-2/enzymology/drug effects/genetics ; COVID-19 Drug Treatment ; Methyltransferases ; },
abstract = {Coronavirus helicase NSP13 is essential for viral replication and transcription and is a promising target for broad-spectrum anti-coronavirus drugs due to its high sequence conservation and structural homology. This review summarizes NSP13 sequence features, structural organization, and functional activities across the seven human-infecting coronaviruses. We outline key enzymatic properties, including duplex RNA/DNA unwinding and NTP hydrolysis, and describe how NSP13 cooperates with other nonstructural proteins to drive replication and transcription. Beyond canonical helicase roles, we discuss the genomic distribution of G-quadruplex (G4) elements in coronaviruses and potential functional connections between G4 structures and NSP13 in regulating the viral life cycle. Finally, we highlight recent progress in developing NSP13-targeting inhibitors and consider their potential utility against COVID-19 and other emerging coronaviruses, providing a rationale for broad-spectrum antiviral design.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Viral Nonstructural Proteins/metabolism/antagonists & inhibitors/chemistry/genetics
*Antiviral Agents/pharmacology
*RNA Helicases/metabolism/antagonists & inhibitors/genetics/chemistry
Virus Replication/drug effects
*Coronavirus/enzymology/drug effects/genetics
G-Quadruplexes
SARS-CoV-2/enzymology/drug effects/genetics
COVID-19 Drug Treatment
Methyltransferases
RevDate: 2026-11-05
CmpDate: 2026-07-29
Implications of RNA virus persistence for post-acute sequelae and chronic inflammatory syndromes.
Nature immunology, 27(8):1553-1562.
Viral persistence refers to the ability of a virus to remain in its host for an extended period. Although most non-retroviral RNA viruses are traditionally known for causing acute, self-limiting infections, accumulating evidence of the detection of viral products long after the infectious virus is cleared suggests that RNA viruses can establish persistent infections. Persistent viral products include replication-competent viral genomes, viral proteins, mutated viruses or non-standard viral genomes. The persistence of viral products entails a continuous interaction with the host and is often associated with prolonged tissue inflammation and chronic disease. Here, we discuss emerging evidence of the persistence of viral products from viruses commonly considered to cause acute infections. We explore the known requirements for virus persistence and the implications for the development of post-acute sequelae and predisposition to chronic inflammatory syndromes.
Additional Links: PMID-42414623
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42414623,
year = {2026},
author = {Vidal, D and Castro, ÍA and López, CB},
title = {Implications of RNA virus persistence for post-acute sequelae and chronic inflammatory syndromes.},
journal = {Nature immunology},
volume = {27},
number = {8},
pages = {1553-1562},
pmid = {42414623},
issn = {1529-2916},
mesh = {Humans ; *Inflammation/virology/immunology ; *RNA Viruses/immunology/physiology/genetics ; Animals ; *RNA Virus Infections/immunology/virology/complications ; *Persistent Infection/immunology/virology ; Chronic Disease ; Post-Acute COVID-19 Syndrome ; Genome, Viral ; Host-Pathogen Interactions/immunology ; Virus Replication ; },
abstract = {Viral persistence refers to the ability of a virus to remain in its host for an extended period. Although most non-retroviral RNA viruses are traditionally known for causing acute, self-limiting infections, accumulating evidence of the detection of viral products long after the infectious virus is cleared suggests that RNA viruses can establish persistent infections. Persistent viral products include replication-competent viral genomes, viral proteins, mutated viruses or non-standard viral genomes. The persistence of viral products entails a continuous interaction with the host and is often associated with prolonged tissue inflammation and chronic disease. Here, we discuss emerging evidence of the persistence of viral products from viruses commonly considered to cause acute infections. We explore the known requirements for virus persistence and the implications for the development of post-acute sequelae and predisposition to chronic inflammatory syndromes.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Inflammation/virology/immunology
*RNA Viruses/immunology/physiology/genetics
Animals
*RNA Virus Infections/immunology/virology/complications
*Persistent Infection/immunology/virology
Chronic Disease
Post-Acute COVID-19 Syndrome
Genome, Viral
Host-Pathogen Interactions/immunology
Virus Replication
RevDate: 2026-10-20
CmpDate: 2026-09-30
Teleworking and its impact on health and well-being: a systematic review of longitudinal studies considering the psychosocial work environment (2005-2024).
BMC public health, 26(1):.
BACKGROUND: Teleworking expanded dramatically during the COVID-19 pandemic and is expected to remain widespread. While it offers benefits such as greater autonomy and improved work-life balance, teleworking also poses challenges related to workload, social isolation, and blurred boundaries between work and personal life, shaped by the psychosocial work environment. These contrasting effects raise questions about whether teleworking promotes or undermines workers' health. This systematic review synthesizes longitudinal evidence on the relationship between teleworking and workers' health, with particular attention to the role of the psychosocial work environment as an explanatory framework. Specifically, it addresses two questions: (1) What is the impact of teleworking on health (physical and mental) when psychosocial work environment factors are considered? (2) How have longitudinal studies examined the relationship between teleworking and health, including direct, mediation, and moderation effects, and how the role of teleworking in these relationships has been studied?
METHODS: This systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024599518). We searched five electronic databases (Embase, Medline, PsycInfo, Web of Science, CINAHL Plus) and bibliographies for longitudinal studies published between 2005 and 2024 in OECD countries. Eligible studies examined teleworking and workers' health (physical and/or psychological) in combination with psychosocial work environment factors. Study quality was assessed using the National Heart, Lung, and Blood Institute (NHLBI) Quality Assessment Tool. Data from 20 studies published between 2017 and 2024 were extracted and synthesized based on study and psychosocial work environment characteristics, as well as the nature of the association between telework and health outcomes.
RESULTS: All 20 studies were rated fair or good in methodological quality. Teleworking effects on health were heterogeneous and context-dependent, increasing psychological distress, exhaustion, and anxiety under high psychosocial risk (i.e., adverse work conditions such as high workload or work intensification, low autonomy, limited social support, job insecurity, reduced psychological detachment, and blurred work-nonwork boundaries) or mandatory arrangements, but protective with autonomy, supportive psychosocial conditions, or individual resources. Psychosocial work environment factors such as autonomy, job security, workload, and social support emerged as central determinants of health outcomes. Effects operated through moderation and mediation involving psychosocial work environment factors. Important gaps remain, particularly the limited investigation of physical health outcomes.
CONCLUSIONS: Teleworking is neither uniformly beneficial nor harmful. Its health impact depends on psychosocial work environment factors, individual characteristics, and contextual conditions. Longitudinal research should expand the range of psychosocial work environment factors examined, consider physical health outcomes, and investigate effects across pre-, during-, and post-pandemic periods. These insights are critical to inform evidence-based workplace interventions and organizational policies that promote employee health.
Additional Links: PMID-42414952
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42414952,
year = {2026},
author = {Parent-Lamarche, A and Beauregard, N and Blanc, MÈ and Cadieux, N and Dextras-Gauthier, J and Afota, MC and Merkouche, W and Hamouche, S and R'biaa, O and Garneau, J},
title = {Teleworking and its impact on health and well-being: a systematic review of longitudinal studies considering the psychosocial work environment (2005-2024).},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {42414952},
issn = {1471-2458},
support = {IRSST 2024-0004//Institut de Recherche Robert-Sauvé en Santé et en Sécurité du Travail/ ; },
mesh = {Humans ; *Health Status ; Longitudinal Studies ; *Occupational Health ; Psychological Well-Being ; *Teleworking ; Working Conditions ; *Workplace/psychology ; },
abstract = {BACKGROUND: Teleworking expanded dramatically during the COVID-19 pandemic and is expected to remain widespread. While it offers benefits such as greater autonomy and improved work-life balance, teleworking also poses challenges related to workload, social isolation, and blurred boundaries between work and personal life, shaped by the psychosocial work environment. These contrasting effects raise questions about whether teleworking promotes or undermines workers' health. This systematic review synthesizes longitudinal evidence on the relationship between teleworking and workers' health, with particular attention to the role of the psychosocial work environment as an explanatory framework. Specifically, it addresses two questions: (1) What is the impact of teleworking on health (physical and mental) when psychosocial work environment factors are considered? (2) How have longitudinal studies examined the relationship between teleworking and health, including direct, mediation, and moderation effects, and how the role of teleworking in these relationships has been studied?
METHODS: This systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024599518). We searched five electronic databases (Embase, Medline, PsycInfo, Web of Science, CINAHL Plus) and bibliographies for longitudinal studies published between 2005 and 2024 in OECD countries. Eligible studies examined teleworking and workers' health (physical and/or psychological) in combination with psychosocial work environment factors. Study quality was assessed using the National Heart, Lung, and Blood Institute (NHLBI) Quality Assessment Tool. Data from 20 studies published between 2017 and 2024 were extracted and synthesized based on study and psychosocial work environment characteristics, as well as the nature of the association between telework and health outcomes.
RESULTS: All 20 studies were rated fair or good in methodological quality. Teleworking effects on health were heterogeneous and context-dependent, increasing psychological distress, exhaustion, and anxiety under high psychosocial risk (i.e., adverse work conditions such as high workload or work intensification, low autonomy, limited social support, job insecurity, reduced psychological detachment, and blurred work-nonwork boundaries) or mandatory arrangements, but protective with autonomy, supportive psychosocial conditions, or individual resources. Psychosocial work environment factors such as autonomy, job security, workload, and social support emerged as central determinants of health outcomes. Effects operated through moderation and mediation involving psychosocial work environment factors. Important gaps remain, particularly the limited investigation of physical health outcomes.
CONCLUSIONS: Teleworking is neither uniformly beneficial nor harmful. Its health impact depends on psychosocial work environment factors, individual characteristics, and contextual conditions. Longitudinal research should expand the range of psychosocial work environment factors examined, consider physical health outcomes, and investigate effects across pre-, during-, and post-pandemic periods. These insights are critical to inform evidence-based workplace interventions and organizational policies that promote employee health.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Health Status
Longitudinal Studies
*Occupational Health
Psychological Well-Being
*Teleworking
Working Conditions
*Workplace/psychology
RevDate: 2026-10-09
CmpDate: 2026-10-01
Prevalence and associated risk factors of malaria in Amhara National Regional State: a systematic review and meta-analyses.
Malaria journal, 25(1):.
BACKGROUND: Malaria is a major parasitic infectious disease caused by Plasmodium species and remains a significant public health challenge in sub-Saharan African, including Ethiopia. The Amhara National Regional State is among the most malaria-affected region in Ethiopia. However, comprehensive evidence on the pooled prevalence of malaria and its associated risks in the region has been limited. Therefore, this systematic review and meta-analysis aimed to estimate the pooled prevalence of malaria and identify its associated risk factors in Amhara National Regional State.
METHODS: A systematic search of studies published between 2013 to March 3, 2023, was conducted using PubMed, Springer nature, Science Direct, and Google Scholar. Eligible studies were selected based on predefined inclusion criteria. Data were extracted using Microsoft Excel and analysed with Stata version 17. Heterogeneity among studies was assessed using the inverse variance (I[2]) statistic, while publication bias was evaluated using Egger's regression test and funnel plot.
RESULTS: Out of 2,743 records initially identified, 43 studies met the inclusion criteria. The pooled prevalence of malaria in the Amhara National Regional State was 14% (95% CI 12.0-17.0%). Subgroup analysis showed that the highest (17%, 95% CI 4.0-30.0%) pooled prevalence was from South and North Gonder Zones, whereas the lowest (8%, 95% CI 5.0-11.0%) prevalence was observed in East Gojjam Zone. Malaria prevalence estimate varied according to the diagnostic methods; with microscopy reporting a prevalence of 16%; 95% CI 13.0-18% and combination of microscopy with RDT reporting 9%; 95% CI 4.0-14.0%. The prevalence increased from 13% (95% CI 10.0-17%) before the onset of COVID-19 pandemic to 15% (95% CI 14.0-10.0%) after the onset. Plasmodium falciparum was the predominant species, accounting 9% (95% CI 6-11%) of the infection followed by P. vivax at 5% (95% CI 4-5%). Significant predictors of malarial infection included, the presence of stagnant water near residences (OR = 2.64; 95% CI 2.09-3.34), engagement in outdoor night activities (OR = 1.69; 95% CI 1.33-2.16), and lack of insecticide treated net (ITN) utilization (OR = 2.05; 95% CI 1.71-2.46).
CONCLUSION: This systematic review and meta-analysis revealed that malaria remained a considerable public health burden in the Amhara National Regional State with Plasmodium falciparum as the dominant species. Malaria prevalence varied across administrative zones, diagnostic methods, study seasons, and study periods. Environmental and behavioural factors significantly contributed to malaria transmission, highlighting the need for a strengthened and targeted malaria prevention and controlled interventions in the region.
Additional Links: PMID-42415007
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42415007,
year = {2026},
author = {Tsehay, A and Menkir, S and Hailegebriel, T},
title = {Prevalence and associated risk factors of malaria in Amhara National Regional State: a systematic review and meta-analyses.},
journal = {Malaria journal},
volume = {25},
number = {1},
pages = {},
pmid = {42415007},
issn = {1475-2875},
mesh = {Prevalence ; Risk Factors ; Humans ; Ethiopia/epidemiology ; *Malaria/epidemiology/parasitology ; *Malaria, Falciparum/epidemiology/parasitology ; },
abstract = {BACKGROUND: Malaria is a major parasitic infectious disease caused by Plasmodium species and remains a significant public health challenge in sub-Saharan African, including Ethiopia. The Amhara National Regional State is among the most malaria-affected region in Ethiopia. However, comprehensive evidence on the pooled prevalence of malaria and its associated risks in the region has been limited. Therefore, this systematic review and meta-analysis aimed to estimate the pooled prevalence of malaria and identify its associated risk factors in Amhara National Regional State.
METHODS: A systematic search of studies published between 2013 to March 3, 2023, was conducted using PubMed, Springer nature, Science Direct, and Google Scholar. Eligible studies were selected based on predefined inclusion criteria. Data were extracted using Microsoft Excel and analysed with Stata version 17. Heterogeneity among studies was assessed using the inverse variance (I[2]) statistic, while publication bias was evaluated using Egger's regression test and funnel plot.
RESULTS: Out of 2,743 records initially identified, 43 studies met the inclusion criteria. The pooled prevalence of malaria in the Amhara National Regional State was 14% (95% CI 12.0-17.0%). Subgroup analysis showed that the highest (17%, 95% CI 4.0-30.0%) pooled prevalence was from South and North Gonder Zones, whereas the lowest (8%, 95% CI 5.0-11.0%) prevalence was observed in East Gojjam Zone. Malaria prevalence estimate varied according to the diagnostic methods; with microscopy reporting a prevalence of 16%; 95% CI 13.0-18% and combination of microscopy with RDT reporting 9%; 95% CI 4.0-14.0%. The prevalence increased from 13% (95% CI 10.0-17%) before the onset of COVID-19 pandemic to 15% (95% CI 14.0-10.0%) after the onset. Plasmodium falciparum was the predominant species, accounting 9% (95% CI 6-11%) of the infection followed by P. vivax at 5% (95% CI 4-5%). Significant predictors of malarial infection included, the presence of stagnant water near residences (OR = 2.64; 95% CI 2.09-3.34), engagement in outdoor night activities (OR = 1.69; 95% CI 1.33-2.16), and lack of insecticide treated net (ITN) utilization (OR = 2.05; 95% CI 1.71-2.46).
CONCLUSION: This systematic review and meta-analysis revealed that malaria remained a considerable public health burden in the Amhara National Regional State with Plasmodium falciparum as the dominant species. Malaria prevalence varied across administrative zones, diagnostic methods, study seasons, and study periods. Environmental and behavioural factors significantly contributed to malaria transmission, highlighting the need for a strengthened and targeted malaria prevention and controlled interventions in the region.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Prevalence
Risk Factors
Humans
Ethiopia/epidemiology
*Malaria/epidemiology/parasitology
*Malaria, Falciparum/epidemiology/parasitology
RevDate: 2026-10-09
CmpDate: 2026-10-08
Clinical rationale for thymic restoration in adult immunosenescence.
Immunity & ageing : I & A, 23(1):.
Age-related thymic involution is a central feature of immunosenescence and intersects with multiple "hallmarks of aging", including genomic instability, telomere attrition, mitochondrial dysfunction, and chronic inflammation. The decline in thymic epithelial integrity and FOXN1-driven thymopoiesis reduces naïve T-cell output, contracts TCR repertoire diversity, and perturbs central tolerance, contributing to increased susceptibility to infection, cancer, and autoimmunity. These changes occur alongside broader immune-aging phenomena such as inflammaging and frailty and are reflected in poorer vaccine responses and altered outcomes to novel pathogens such as SARS-CoV‑2. This review integrates mechanistic, preclinical, and human data to reassess the adult thymus as a therapeutic target. Higher-confidence domains for thymic restoration include cancer immunosurveillance, infectious disease vulnerability, vaccine responsiveness, and post-treatment immune reconstitution, supported by modeling of age-related disease incidence, transplant and HIV cohorts, and new observational links between radiographic thymic health, mortality, and immunotherapy outcomes. High-plausibility but less directly validated domains include autoimmunity, chronic herpesvirus control, HIV immunological non-responders, and post-acute infection syndromes such as long COVID, which share convergent patterns of T-cell dysfunction and persistent immune activation. The translational landscape spans hormonal and somatotropic modulation (sex steroid ablation, growth hormone/ghrelin), cytokine and growth-factor strategies (IL‑7, IL‑22, KGF/BMP4, FGF21), cell- and tissue-engineering approaches leveraging thymic epithelial stem cells and FOXN1-reprogrammed stromal cells, and gene-therapy concepts such as intrathymic AAV delivery of FOXN1, AIRE, chemokines, and stromal-support pathways. Collectively, these data support the biological plausibility of adult thymus restoration but highlight that robust, domain-specific clinical benefits have not yet been demonstrated in controlled trials. Future work should prioritize harmonized structural and functional biomarkers, domain-focused interventional studies in high-risk populations, and combined strategies that situate thymus-directed interventions within broader efforts to modify immune and organismal aging.
Additional Links: PMID-42415124
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42415124,
year = {2026},
author = {Sewell, PE and Jensen, C},
title = {Clinical rationale for thymic restoration in adult immunosenescence.},
journal = {Immunity & ageing : I & A},
volume = {23},
number = {1},
pages = {},
pmid = {42415124},
issn = {1742-4933},
abstract = {Age-related thymic involution is a central feature of immunosenescence and intersects with multiple "hallmarks of aging", including genomic instability, telomere attrition, mitochondrial dysfunction, and chronic inflammation. The decline in thymic epithelial integrity and FOXN1-driven thymopoiesis reduces naïve T-cell output, contracts TCR repertoire diversity, and perturbs central tolerance, contributing to increased susceptibility to infection, cancer, and autoimmunity. These changes occur alongside broader immune-aging phenomena such as inflammaging and frailty and are reflected in poorer vaccine responses and altered outcomes to novel pathogens such as SARS-CoV‑2. This review integrates mechanistic, preclinical, and human data to reassess the adult thymus as a therapeutic target. Higher-confidence domains for thymic restoration include cancer immunosurveillance, infectious disease vulnerability, vaccine responsiveness, and post-treatment immune reconstitution, supported by modeling of age-related disease incidence, transplant and HIV cohorts, and new observational links between radiographic thymic health, mortality, and immunotherapy outcomes. High-plausibility but less directly validated domains include autoimmunity, chronic herpesvirus control, HIV immunological non-responders, and post-acute infection syndromes such as long COVID, which share convergent patterns of T-cell dysfunction and persistent immune activation. The translational landscape spans hormonal and somatotropic modulation (sex steroid ablation, growth hormone/ghrelin), cytokine and growth-factor strategies (IL‑7, IL‑22, KGF/BMP4, FGF21), cell- and tissue-engineering approaches leveraging thymic epithelial stem cells and FOXN1-reprogrammed stromal cells, and gene-therapy concepts such as intrathymic AAV delivery of FOXN1, AIRE, chemokines, and stromal-support pathways. Collectively, these data support the biological plausibility of adult thymus restoration but highlight that robust, domain-specific clinical benefits have not yet been demonstrated in controlled trials. Future work should prioritize harmonized structural and functional biomarkers, domain-focused interventional studies in high-risk populations, and combined strategies that situate thymus-directed interventions within broader efforts to modify immune and organismal aging.},
}
RevDate: 2026-10-20
CmpDate: 2026-07-08
Chemokines in Alzheimer's Disease: Early Defence, Late Damage and the Impact of Sex and Infection.
Basic & clinical pharmacology & toxicology, 139(2):e70273.
Chemokines constitute a versatile signalling network maintaining homeostasis and glia-neuron communication in the healthy brain but become progressively dysregulated during aging and Alzheimer's disease (AD). This review examines how chemokine systems transition from tightly regulated homeostatic signals to drivers of chronic neuroinflammation in AD. We describe the major chemokine families (CC, CXC, CX3C) and their dominant central nervous system (CNS) receptors (CCR2, CXCR3, CX3CR1), which activate canonical inflammatory pathways including NF-κB, JAK/STAT and PI3K-AKT. In AD, chemokine dysregulation occurs in a coordinated manner across multiple functional modules, including recruitment-associated (CCL2, CXCL1), interferon-inducible (CXCL10), loss-of-restraint (CX3CL1) and vascular-associated chemokines. These alterations shift the network from regulated immune communication to self-sustaining inflammatory circuits perpetuating chronic neuroinflammation. These networks reprogram microglia and astrocytes into disease-associated phenotypes, amplify peripheral immune cell infiltration and destabilise synaptic function. Biological sex profoundly influences neuroinflammatory trajectories, with females exhibiting enhanced microglial senescence and interferon signalling, while males show accelerated complement activation. Viral pathogens, particularly neurotropic viruses (HSV-1, HHV-6, VZV) and SARS-CoV-2, actively reprogram chemokine networks, linking infection to amyloid-β accumulation, tau pathology and neurodegeneration. Therapeutically, chemokine axes represent precision targets requiring stage-matched, sex-stratified interventions rather than broad anti-inflammatory approaches. Understanding chemokine network dynamics offers mechanistic insights into AD pathogenesis and could provide pointers for therapeutic strategies.
Additional Links: PMID-42415281
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42415281,
year = {2026},
author = {Aldana, BI and Freude, K},
title = {Chemokines in Alzheimer's Disease: Early Defence, Late Damage and the Impact of Sex and Infection.},
journal = {Basic & clinical pharmacology & toxicology},
volume = {139},
number = {2},
pages = {e70273},
pmid = {42415281},
issn = {1742-7843},
support = {R434-2023-242//Lundbeck Foundation/ ; N/A//Alzheimersfonden/ ; },
mesh = {Animals ; Female ; Humans ; Male ; *Alzheimer Disease/immunology/metabolism ; Brain/immunology/metabolism ; *Chemokines/metabolism/immunology ; Neuroinflammatory Diseases/immunology ; Receptors, Chemokine/metabolism ; Sex Characteristics ; Sex Factors ; Signal Transduction ; Virus Diseases/immunology ; },
abstract = {Chemokines constitute a versatile signalling network maintaining homeostasis and glia-neuron communication in the healthy brain but become progressively dysregulated during aging and Alzheimer's disease (AD). This review examines how chemokine systems transition from tightly regulated homeostatic signals to drivers of chronic neuroinflammation in AD. We describe the major chemokine families (CC, CXC, CX3C) and their dominant central nervous system (CNS) receptors (CCR2, CXCR3, CX3CR1), which activate canonical inflammatory pathways including NF-κB, JAK/STAT and PI3K-AKT. In AD, chemokine dysregulation occurs in a coordinated manner across multiple functional modules, including recruitment-associated (CCL2, CXCL1), interferon-inducible (CXCL10), loss-of-restraint (CX3CL1) and vascular-associated chemokines. These alterations shift the network from regulated immune communication to self-sustaining inflammatory circuits perpetuating chronic neuroinflammation. These networks reprogram microglia and astrocytes into disease-associated phenotypes, amplify peripheral immune cell infiltration and destabilise synaptic function. Biological sex profoundly influences neuroinflammatory trajectories, with females exhibiting enhanced microglial senescence and interferon signalling, while males show accelerated complement activation. Viral pathogens, particularly neurotropic viruses (HSV-1, HHV-6, VZV) and SARS-CoV-2, actively reprogram chemokine networks, linking infection to amyloid-β accumulation, tau pathology and neurodegeneration. Therapeutically, chemokine axes represent precision targets requiring stage-matched, sex-stratified interventions rather than broad anti-inflammatory approaches. Understanding chemokine network dynamics offers mechanistic insights into AD pathogenesis and could provide pointers for therapeutic strategies.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
Female
Humans
Male
*Alzheimer Disease/immunology/metabolism
Brain/immunology/metabolism
*Chemokines/metabolism/immunology
Neuroinflammatory Diseases/immunology
Receptors, Chemokine/metabolism
Sex Characteristics
Sex Factors
Signal Transduction
Virus Diseases/immunology
▼ ▼ LOAD NEXT 100 CITATIONS
RJR Experience and Expertise
Researcher
Robbins holds BS, MS, and PhD degrees in the life sciences. He served as a tenured faculty member in the Zoology and Biological Science departments at Michigan State University. He is currently exploring the intersection between genomics, microbial ecology, and biodiversity — an area that promises to transform our understanding of the biosphere.
Educator
Robbins has extensive experience in college-level education: At MSU he taught introductory biology, genetics, and population genetics. At JHU, he was an instructor for a special course on biological database design. At FHCRC, he team-taught a graduate-level course on the history of genetics. At Bellevue College he taught medical informatics.
Administrator
Robbins has been involved in science administration at both the federal and the institutional levels. At NSF he was a program officer for database activities in the life sciences, at DOE he was a program officer for information infrastructure in the human genome project. At the Fred Hutchinson Cancer Research Center, he served as a vice president for fifteen years.
Technologist
Robbins has been involved with information technology since writing his first Fortran program as a college student. At NSF he was the first program officer for database activities in the life sciences. At JHU he held an appointment in the CS department and served as director of the informatics core for the Genome Data Base. At the FHCRC he was VP for Information Technology.
Publisher
While still at Michigan State, Robbins started his first publishing venture, founding a small company that addressed the short-run publishing needs of instructors in very large undergraduate classes. For more than 20 years, Robbins has been operating The Electronic Scholarly Publishing Project, a web site dedicated to the digital publishing of critical works in science, especially classical genetics.
Speaker
Robbins is well-known for his speaking abilities and is often called upon to provide keynote or plenary addresses at international meetings. For example, in July, 2012, he gave a well-received keynote address at the Global Biodiversity Informatics Congress, sponsored by GBIF and held in Copenhagen. The slides from that talk can be seen HERE.
Facilitator
Robbins is a skilled meeting facilitator. He prefers a participatory approach, with part of the meeting involving dynamic breakout groups, created by the participants in real time: (1) individuals propose breakout groups; (2) everyone signs up for one (or more) groups; (3) the groups with the most interested parties then meet, with reports from each group presented and discussed in a subsequent plenary session.
Designer
Robbins has been engaged with photography and design since the 1960s, when he worked for a professional photography laboratory. He now prefers digital photography and tools for their precision and reproducibility. He designed his first web site more than 20 years ago and he personally designed and implemented this web site. He engages in graphic design as a hobby.
RJR Picks from Around the Web (updated 11 MAY 2018 )
Old Science
Weird Science
Treating Disease with Fecal Transplantation
Fossils of miniature humans (hobbits) discovered in Indonesia
Paleontology
Dinosaur tail, complete with feathers, found preserved in amber.
Astronomy
Mysterious fast radio burst (FRB) detected in the distant universe.
Big Data & Informatics
Big Data: Buzzword or Big Deal?
Hacking the genome: Identifying anonymized human subjects using publicly available data.